

® THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



CLINITECH LABORATORY LIMITED
Corporate Identification Number: U85195MH2010PLC201078

Our Company was incorporated as Clinitech Laboratory Private Limited on March 19, 2010 under the Companies Act, 1956 with the Registrar of Companies, Mumbai bearing Registration number 201078. The status of the Company was changed to public limited and the name of our Company was changed to Clinitech Laboratory Limited vide Special Resolution dated July 24, 2023 pursuant to conversion of the Company into public limited Company. The fresh certificate of incorporation consequent to conversion was issued on August 25, 202 by the Registrar of Companies, Mumbai. For further details of our Company, see "General Information" and "History and Certain Other Corporate Matters" on pages 36 and 92, respectively.

Registered Office: AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India; **Tel No.:** +91 22 27792281 / +91 9004072223; **Email:** ipo@clinitechlab.com; **Website:** www.ctllab.in; **Contact Person:** Bharat Kumar Bohra, Company Secretary and Compliance Officer

ADDENDUM TO THE DRAFT PROSPECTUS DATED JANUARY 23, 2024: NOTICE TO INVESTORS (THE "ADDENDUM")

OUR PROMOTERS: JAGDISH UMAKANT NAYAK , JYOTI JAGDISH NAYAK AND ASHUTOSH JAGDISH NAYAK

INITIAL PUBLIC OFFERING OF UP TO 6,02,400 EQUITY SHARES OF ₹10 EACH ("EQUITY SHARES") OF CLINITECH LABORATORY LIMITED ("CLINITECH" OR THE "COMPANY") FOR CASH AT A PRICE OF ₹ 96 PER EQUITY SHARE (THE "OFFER PRICE"), AGGREGATING TO ₹ 578.30 LAKHS ("THE OFFER"). OF THE OFFER, 31,200 EQUITY SHARES AGGREGATING TO ₹29.95 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION I.E. OFFER OF 5,71,200 EQUITY SHARES OF FACE VALUE OF ₹ 10.00 EACH AT AN OFFER PRICE OF ₹ 96.00 PER EQUITY SHARE AGGREGATING TO ₹548.35 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 26.39% AND 25.02%, RESPECTIVELY OF THE POST OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, SEE "TERMS OF THE OFFER" ON PAGE 169 OF THE DRAFT PROSPECTUS.

This is with reference to the Draft Prospectus filed by the Company with the BSE Limited ("BSE"). Potential Applicants/Bidders may note the followings:

- 1) Under the heading titled "Summary of the Offer Document" beginning from page 12 of the Draft Prospectus, certain information shall be amended and/ or updated and/ or added, as provided beginning on page 4 of the Addendum.
- 2) Under the heading titled "Risk Factor" beginning from page 17 of the Draft Prospectus, certain risk factors shall be amended and/ or updated and/ or added, as provided beginning on page 5 of the Addendum.
- 3) Under the heading titled "General Information" beginning from page 36 of the Draft Prospectus, certain risk factors shall be amended and/ or updated and/ or added, as provided beginning on page 10 of the Addendum.
- 4) Under the heading titled "Capital Structure" beginning from page 43 of the Draft Prospectus and accordingly, certain information shall be amended and/ or updated and/ or added, as provided beginning on page 11 of the Addendum.
- 5) Under the heading titled "Objects of the Issue" beginning from page 53 of the Draft Prospectus and accordingly, certain information shall be amended and/ or updated and/ or added, as provided beginning on page 15 of the Addendum.
- 6) Under the heading titled "Business Overview" beginning from page 77 of the Draft Prospectus and accordingly, certain information shall be amended and/ or updated and/ or added, as provided beginning on page 16 of the Addendum.
- 7) Under the heading titled "Our Promoters and Promoter Group" beginning from page 106 of the Draft Prospectus and accordingly, certain information shall be amended and/ or updated and/ or added, as provided beginning on page 18 of the Addendum.
- 8) Under the heading titled "Government and Other Approvals" beginning from page 154 of the Draft Prospectus and accordingly, certain information shall be amended and/ or updated and/ or added, as provided beginning on page 19 of the Addendum.
- 9) The consequent changes and/ or additions as made in the respective above sections shall be accordingly disclosed in the Draft Prospectus wherever applicable.

The above additions and/ or amendments are to be read in conjunction with the Draft Prospectus, unless indicated otherwise, and accordingly their references in the Draft Prospectus stand amended pursuant to the Addendum to the Draft Prospectus. The information in the Addendum supplements the Draft Prospectus and updates the information in the Draft Prospectus, as applicable. However, please note that the Addendum does not reflect all the changes that have occurred between the date of filing of the Draft Prospectus and the date thereof, and the information included in the Draft Prospectus will be suitably updated, including to the extent stated in the Addendum to the Draft Prospectus, as may be applicable in the Prospectus, as and when filed with ROC and the Stock Exchange.

The Addendum is filed with BSE and shall be made the respective websites NSE i.e. www.bseindia.com; Lead Manager at www.inventuremerchantbanker.com and the Issuer Company at www.ctllab.in.

All capitalized terms used in the Addendum shall, unless the context otherwise requires, have the meaning ascribed to them in the Draft Prospectus.



The Equity Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S and the applicable laws of each jurisdictions where such offers and sales are made.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

**For Clinitech Laboratory Limited
On behalf of the Board of Directors
Sd/-**

**Place: Mumbai
Date: June 10, 2024**

**Jagdish Umakant Nayak
Managing Director**

LEAD MANAGER TO THE OFFER		REGISTRAR TO THE OFFER	
 <p>INVENTURE MERCHANT BANKER SERVICES PVT. LTD. Enhancing Fortunes. Enriching Lives.</p>	<p>INVENTURE MERCHANT BANKER SERVICES PRIVATE LIMITED 2ndFloor, Viraj Towers, Near Andheri Flyover (North End), Western Express Highway, Andheri (East), Mumbai – 400069, Maharashtra Tel No: +91 22 4075 1500 Fax No: +91 22 4075 1511 Email: compliance@inventurermerchantbanker.com Investor Grievance Email: redressal@inventurermerchantbanker.com Website: www.inventurermerchantbanker.com Contact Person: Arvind Gala SEBI Registration No: INM000012003</p>	 <p>BIGSHARE SERVICES PRIVATE LIMITED S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves Road, Next to Ahura Centre, Andheri East, Mumbai - 400 093, Maharashtra, India Tel. No.: +91 22 6263 8200 Email: ipo@bigshareonline.com Investor Grievance Email: investor@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Vinayak Morbale SEBI Registration No.: INR000001385</p>	

Clinitech Laboratory Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has been filed the Draft Prospectus dated January 23, 2024 with BSE. The Draft Prospectus and the Addendum to the Draft Prospectus shall be available on the respective websites BSE i.e. www.bseindia.com; Lead Manager at www.inventurermerchantbanker.com and the Issuer Company at www.ctllab.in. Potential Applicants/Bidders should note that investment in equity shares involves a high degree of risk and details relating to such risk, please see the section entitled "Risk Factors" beginning on page 17 of the Draft Prospectus. Potential Applicants/Bidders should not reply on the Draft Prospectus filed with BSE for making any investment decision.

Table of Contents

SUMMARY OF THE OFFER DOCUMENT	4
RISK FACTORS	5
GENERAL INFORMATION.....	10
CAPITAL STRUCTURE	11
OBJECTS OF THE ISSUE.....	15
BUSINESS OVERVIEW	16
OUR PROMOTERS AND PROMOTER GROUP	18
GOVERNMENT AND OTHER APPROVALS	19
DECLARATION	20

SUMMARY OF THE OFFER DOCUMENT

The following disclosure shall be amended and/ or updated and/or added under the chapter titled “Summary of Offer Document” beginning from page 12 of the Draft Prospectus:

B. Promoters:

Jagdish Umakant Nayak, Jyoti Jagdish Nayak and Ashutosh Jagdish Nayak are the Promoters of our Company.

E. Pre-Offer Shareholding of Promoters, Promoter Group:

Sr.	Particulars	Pre-Offer	
		No. of Shares	% Holding
a)	Promoters		
	Jagdish Umakant Nayak	6,74,500	40.15
	Jyoti Jagdish Nayak	6,75,000	40.18
	Ashutosh Jagdish Nayak	100	0.006
	Total - A	13,49,600	80.33
b)	Promoter Group		
	Ananya Jagdish Nayak	100	0.006
	Anant Umakant Nayak	100	0.006
	Eshwari Anant Nayak	100	0.006
	Siddhesh Anant Nayak	55500	3.30
	Total – B	55800	3.32
	Grand Total (A+B)	14,05,400	83.65

M. Weighted Average Price of the Equity Shares acquired by the Promoter in the last one year preceding the date of this Draft Prospectus:

Name of the Promoters	No. of Equity Shares held	Average cost of Acquisition (in ₹)
Jagdish Umakant Nayak	4,16.667	Nil*
Jyoti Jagdish Nayak	4,16.667	Nil*
Ashutosh Jagdish Nayak	100	10.00

*Cost of acquisition of equity shares is NIL as the shares acquired by way of bonus shares

For further details please refer to chapter titled “Capital Structure” on page 43.

N. Average cost of acquisition of shares for promoter:

Name of the Promoters	No. of Equity Shares held	Average cost of Acquisition (in ₹)
Jagdish Umakant Nayak	6,74,500	Nil*
Jyoti Jagdish Nayak	6,75,000	Nil*
Ashutosh Jagdish Nayak	100	10.00

*Cost of acquisition of equity shares is NIL as the shares acquired by way of bonus shares and net of selling consideration for the shares sold.

RISK FACTORS

The following Risk Factors shall be amended and/ or updated and/or added under the section titled “Risk Factors” beginning from page 17 of the Draft Prospectus:

3) *We do not own our Registered Office and corporate office from which we operate.*

Our Company’s registered office is situated at AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India is taken on leave & license basis for a period of 5 years from April 01, 2023. However, there can be no assurance that our Company will be able to successfully renew the above leave and license agreement in a timely manner or at all and that we may be continue to use the office in case of termination of agreement. Further there can be no assurance that we will not face any disruption of our rights as a licensee and that such leave and license agreement will not be terminated prematurely by the licensor. Any such non-renewal or early termination or any disruption of our rights as licensee may require us to vacate the premises and relocate to a new premises on terms that may not be favourable to us thereby adversely affecting our business, financial conditions and results of operations. If the owner of the premises, revoke this agreement or impose terms and conditions that are unfavorable to us, we may suffer a disruption in our operations or have to pay increased rent, which could have a material adverse effect on our business, prospects, results of operations and financial condition. For further details of our office premises please refer to the section titled "Our Business" on pages 77 of the Draft Prospectus.

4) *We have in the past entered into related party transactions and may continue to do so in the future, which may potentially involve conflicts of interest with the equity shareholders.*

We have entered into related party transactions with our Promoters, Promoter Group, Group Entities and Directors in compliance with the Companies Act 2013 and other applicable regulations. Further, our RPT transactions, i.e., the rent deposits as 21% of total deposit and Partnership Investment as 100% of total investment as on September 30, 2023; none of the other RPT transactions are exceeding 20% of the corresponding amounts as at September 30, 2023. For details of these transactions, please refer "Related Party Transactions" on page 112. While our Company believes that all such transactions have been conducted on an arm’s length basis and are accounted as per AS 18 and are in compliance with the provisions of the Companies Act, 2013 and other applicable laws, however there can be no assurance that we could not have achieved more favourable terms had such transactions not been entered into with related parties.

We cannot assure you that we will be able to maintain the terms of such transactions or in the event that we enter future transactions with related parties, that the terms of the transactions will be favourable to us. Additionally, while it is our belief that all our related party transactions have been conducted on an arm’s-length basis, we cannot provide assurance that we could have achieved more favourable terms had such transactions been entered with third parties. We may also enter related party transactions in the future, which could involve conflicts of interest, although going forward, all related party transactions that we may enter will be subject to audit committee or board or shareholder approval, as applicable, as under the Companies Act, 2013 and the SEBI (LODR) Regulations. As such, we can provide no assurance that these transactions will not adversely affect our business, results of operation, cash flows and financial condition.

5) *We have experienced negative cash flows in the past. Any such negative cash flows in the future could adversely affect our business, results of operations and prospects.*

The following table sets forth our cash flow for the periods indicated:

(₹ in lakhs)

Particulars	Period ended September 30, 2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Net Cash from Operating Activities	-13.48	124.75	95.57	37.62
Net cash from Investing Activities	-4.85	-65.32	-146.56	54.37
Net cash flow from financing activities	-24.85	8.56	29.32	-87.79

Cash flow of a company is a key indicator to show the extent of cash generated from operations to meet its capital expenditure, pay dividends, repay loans, and make new investments without raising finance from external resources. Such negative cash flows lead to a net decrease in cash and cash equivalents. Any negative cash flow in future could adversely affect our operations and financial conditions and the trading price of our Equity Shares. For further

details, please refer “Financial Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” on pages 114 and 140, respectively.

6) We depend on skilled personnel and if we are unable to recruit and retain skilled personnel, our ability to operate or grow our business could be affected.

Our services are skilled and creative manpower intensive and we engage a considerable number of skilled personnel every year to sustain our growth. Our services are majorly dependent on Lab Staff/ Employees which includes Pathologists, Radiologists, X-Ray Technicians, Phlebotomist and Lab Technicians. Further, we spend significant time and resources in training the manpower we hire. Further, our company’s has tied up with 5 Doctors who act as Consultants for our Company. We have written arrangements them and accordingly we pay professional fees to them as agreed upon. These Doctor Consultants overlook the process of testing at our various centres before they sign the patients report. For further details, please refer to page no. 82 of the Draft Prospectus. Our success is substantially dependent on our ability to recruit, train and retain skilled manpower. High attrition and competition for manpower may limit our ability to attract and retain the skilled manpower necessary for our future growth requirements. We cannot assure you that skilled manpower will continue to be available in sufficient numbers suitable to our requirements or that we will be able to grow our workforce in a manner consistent with our growth objectives, which may affect our business, financial condition, results of operations and prospects.

The diagnostics industry in India is highly competitive with several companies present in the market, and therefore it is challenging to improve market share and profitability. Our competitors include diagnostic healthcare service providers in India, hospital-based laboratories, independent clinical laboratories, other smaller-scale providers of diagnostic services (with more established local and regional presence in certain geographies) such as pathology, radiology laboratories and preventive care providers as well as international service providers, which may establish and expand their operations in future. We compete on the breadth of our test offerings, the geographical reach of our network, our ability to accurately process specimens and report data in a timely manner and our customer relationships. Some of our competitors may have greater financial, research and development, marketing and other resources, broader service offerings, more experience in obtaining regulatory approvals or greater geographic reach or economies of scale. Further, the diagnostics industry is highly fragmented, the lack of regulations and low entry barriers allow a multitude of organised and unorganised players to compete in the market.

Also, the pricing-related competition may intensify in the near future which may have an adverse effect on the results of our operations, including our profit margins. Increase in the number of comparable diagnostic healthcare facilities may exert additional pricing pressure on some or all of our services. The manufacturers of laboratory equipment and test kits may also enter the diagnostic industry by marketing point-of-care laboratory equipment to physicians and by selling self-test kits, which may be more convenient to the patients and cheaper than our services. If we are unable to compete effectively, our business could decline or contract and our business, results of operations and financial condition could be adversely affected.

8) Substantial portion of our purchases has been dependent upon limited number of vendors/ suppliers.

Purchases from our top 10 vendors/suppliers constituted 80.31%, 79.76%, 92.75% and 88.19% of our purchases for the period ended September 30, 2023 and financial years ending March 31, 2023, 2022 and 2021, respectively. The details of our top 5 vendors/ suppliers is as follows:

For the period ended September 30, 2023

Sr. No.	Name of vendors/ suppliers	Amount (in Rs.)	% of purchases
1	Reliable Corporation	1,696,128	26.34%
2	Analog Healthcare Private Limited	1,225,141	19.02%
3	Neolife Diagnostic	570,174	8.85%
4	Neelesh Agency	539,694	8.38%
5	Medvision Biomedicals Pvt Ltd	301,395	4.68%

For FY 2022-23

Sr. No.	Name of vendors/ suppliers	Amount (in Rs.)	% of purchases
1	Reliable Corporation	2,777,065	24.12%
2	Analog Healthcare Private Limited	2,307,824	20.04%
3	Neolife Diagnostic	1,109,257	9.63%
4	Elderbeery Diagnostics LLP	852,058	7.40%
5	Premier Biomed Services Pvt Ltd	741,523	6.44%

For FY 2021-22

Sr. No.	Name of vendors/ suppliers	Amount (in Rs.)	% of purchases
1	Analog Healthcare Private Limited	2,858,447	18.88%
2	Reliable Corporation	2,489,272	16.44%
3	Medvision Biomedicals Pvt Ltd	2,015,545	13.31%
4	Neolife Diagnostic	1,578,285	10.42%
5	Elderbeery Diagnostics LLP	1,143,000	7.55%

For FY 2020-21

Sr. No.	Name of vendors/ suppliers	Amount (in Rs.)	% of purchases
1	Reliable Corporation	3,345,053	35.64%
2	Neolife Diagnostic	1,625,455	17.32%
3	Medvision Biomedicals Pvt Ltd	917,350	9.77%
4	Aster Scientific	619,213	6.60%
5	Midas Diagnostics	518,707	5.53%

Further, we have not entered into any service agreements with most of our suppliers and loss of any significant vendor would have a material effect on our financial results. We cannot assure you that we would be able maintain the historical levels of business from these suppliers or that we will be able to replace them in case we lose any of them. While we are constantly striving to increase our supplier base and reduce dependence on any particular vendor, there is no assurance that we will be able to do so in any future periods or that our business or results of operations will not be adversely affected by cessation of our relationship with any of our major vendors.

9) Our Company has allotted Equity Shares during the preceding one year from the date of the Draft Prospectus which are lower than the Issue Price.

Our Company has allotted the following Equity Shares during the preceding one year from the date of the Draft Prospectus which are lower than the Issue Price:

Date of allotment	No. of Equity Shares Allotted	Face Value (Rs.)	Issue Price (Rs.)	Nature / Reason of Allotment
December 22, 2023	1,80,000	10.00	38.00	Further Issue (preferential basis)

The above Equity Shares were issued by our Company on preferential basis and at that time our Company being an unlisted Company. This initial capital growth gave us the opportunity to grow our business operations till our Initial Public Offer is completed. Further, the said shares will be locked in for 1 year from the allotment date and there will be no exit till that date. Further details of equity shares issued, please refer to the section titled "Capital Structure" beginning on page no. 52 of this Draft Prospectus. Further, the basis for the Offer Price of Rs. 96.00 is determined by our Company in consultation with the Lead Manager. For details, please refer to the section titled "Basis for Offer Price" beginning on page no. 58 of this Draft Prospectus.

12) If we are unable to attract new clients or retain our existing clients or default in payments, the growth of our business and cash flows will be adversely affected.

Our revenue from operations is earned from individual customers and business customers. For details on the revenue earned from our B2C and B2B clients, please refer to page 77 of the Draft Prospectus. Any default or delays in payments by significant portion of our customers may have an adverse effect on cash flows, results of operations and financial condition. Our B2C (individual consumer business) contributed to 79.07%, 68.84%, 66.07% and 68.04% of our revenue from operations for September 30, 2023 and last three financial years,

respectively. Our top 5 B2B customers contributed 20.39%, 31.16%, 33.93% and 31.96% of our revenues from operations for September 30, 2023 and last three financial years, respectively. However, we have entered into an agreement/ contract with few of our B2B customers. Due to the patient sensitive information related to our individual walk-in customers, information related to them is not disclosed in the Draft Prospectus. However, the details of our top 5 B2B customers is as follows:

For the period ended September 30, 2023

Sr. No.	Name of B2B Customers	Amount (in Rs.)	% of revenue from Operations
1	Avadhoot Hospital	1979572.00	6.47
2	Sitec Labs	902050.00	2.95
3	Sachi Hospital	529279.00	1.73
4	Genecht Research Pvt Ltd	511522.00	1.67
5	Anuja Daagnostics	352192.00	1.15

For FY 2022-23

Sr. No.	Name of B2B Customers	Amount (in Rs.)	% of revenue from Operations
1	Enem Nosrtum Remedies Pvt Ltd	7840330.00	12.35
2	Avadhoot Hospital	3436420.00	5.41
3	Sitec Labs	1596980.00	2.52
4	Sachi Hospital	962545.00	1.52
5	Kharghar Hospital	911746.00	1.44

For FY 2021-22

Sr. No.	Name of B2B Customers	Amount (in Rs.)	% of revenue from Operations
1	Avadhoot Hospital	4509421.00	7.06
2	Good Lab Diagnostic	3097686.00	4.85
3	Kharghar Hospital	3035445.00	4.75
4	Reliance Industries Ltd	2792550.00	4.37
5	Clinitech Lab LLP	1738050.00	2.72

For FY 2020-21

Sr. No.	Name of B2B Customers	Amount (in Rs.)	% of revenue from Operations
1	Avadhoot Hospital	3683336.00	8.09
2	Kharghar Hospital	2094562.00	4.60
3	Clinitech Lab LLP	1828163.00	4.01
4	Vision Healthcare	1790797.00	3.93
5	Sitec Labs	961190.00	2.11

Further, to increase our revenue and cash flows, we must regularly add new clients. If we are unable to generate sufficient sales leads through our marketing programs, or if our existing or new clients do not perceive our services to be of sufficiently high value and quality, we may not be able to increase sales and our operating results would be adversely affected. In addition, our existing clients have no obligation to repeat order / new orders with us due to various factors including clients satisfaction with our services, collection of data and information as desired by our clients, our prices and the prices of competing service providers. If we fail to achieve repetitive orders from existing clients or to add new clients, our operating results will suffer, and our revenue growth, cash flows and profitability may be materially and adversely affected.

13) Failure to establish and comply with appropriate quality standards when testing and diagnostics services could result in litigation and liability for us and could materially and adversely affect its reputation and results of operations.

We, as an operator of the diagnostic centre's and providing diagnostics tests that we perform and services we provide, are intended to supply healthcare professionals with information to help them establish or support diagnoses and prescribe medication and treatment for patient care. Inaccuracies or negligence in performing the testing and imaging services, for example through the misreading of test results, overdose of drugs, the

contamination of samples or errors caused by testing equipment, could lead to incorrect diagnoses by doctors, adverse reactions by patients to the substances used in diagnostic testing, prescriptions of inappropriate treatment or decisions by doctors and other healthcare professionals not to prescribe treatment *when* treatment is required. While there have not been any instances of inaccuracies or negligence in the past that resulted in material liabilities, any such instances in the future, may lead to illness, harm, death or other adverse effects or liabilities, which could in turn subject us to malpractice claims from patients. Further, we are also generally exposed to liabilities relating to its employees' contact with hazardous samples and waste. Claims and litigation or any negative publicity against us by either patients or employees may result in liability for the harm or other adverse effects caused. Payments related to such liabilities may adversely affect our financial position and results of operations. The process of defending such cases, including the malpractice claims discussed above, even when we may be successful in their defence, is costly, could distract management from executing our strategy and could result in substantial damage to our Company's reputation in the medical community and adverse publicity leading to substantial damage to our reputation in the general public, each of which could materially and adversely affect our business. To the extent we are held liable for negligence, it could have a material adverse effect on our business, results of operations, financial condition and prospects.

21) *We may be subject to customer complaints and to litigation relating to our diagnostic healthcare services, which could have a material and adverse effect on our reputation and our business.*

We may be subject to customer complaints in the course of providing our diagnostic healthcare services on various grounds, including alleged delays in providing test results and incorrect results or misdiagnoses. In addition, we may also be subject to complaints based on malicious rumors regarding our services or testing results. Such events may generate negative publicity about our business, reduce customer confidence in the quality of our diagnostic healthcare services and negatively impact our reputation. While we have established systems to help minimize errors that can arise during the collection of samples and the testing and the delivery of reports, any failure in those systems may lead to the delivery of inaccurate or untimely results to the customers, and in serious cases, may expose us to civil and criminal charges. Although, during last 3 years, we have not received any customer complaint or any of our customer have initiated any legal proceedings against our Company. However, in the future, if any customer complaints or litigation is filed against us as a result of our services or otherwise may damage our reputation and brand, result in our incurring material legal expenses, result in substantial damage awards against us and divert the attention of our management from our operations, any of which would have a material and adverse effect on our business.

27) *Our ability to attract individual patients is largely dependent on the disposable income and increasing general health awareness of India's general population, which could decline due to a variety of factors.*

Our key source of income is from individual patients. Our individual consumer business contributed to 79.07%, 68.84%, 66.07% and 68.04% of our revenue from operations for September 30, 2023 and last three financial years, respectively. The growth of these types of customers is dependent on brand recognition, wider acceptance of our business in the communities in which we operate and our ability to compete effectively within our industry, all of which we may be negatively affected by a wide variety of reasons. For example, individual decisions regarding when to access healthcare services may be impaired by the absence of a developed health insurance sector or the lack of appropriate government programs to cover the costs of healthcare. Moreover, given the small proportion of people in India presently with health insurance, customers in India generally are responsible for all or part of the cost of diagnostic healthcare services, which means that a decrease in disposable income that can be allocated for healthcare services, or even the perception thereof, such as during times of economic downturn, can lead to a reduction in individuals' expenditures for healthcare services. In addition, we cannot assure you that the current increasing trend in health awareness and demand for preventive healthcare services will continue, and it may even reverse. Any of the above reasons may affect our ability to maintain or increase growth in walk-in customers, which may adversely affect our business, financial condition, results of operations and cash flows.

GENERAL INFORMATION

The following disclosure shall be amended and/ or updated and/or added under the chapter titled “General Information” beginning from page 36 of the Draft Prospectus:

LEAD MANAGER TO THE COMPANY

Name : **INVENTURE MERCHANT BANKER SERVICES PRIVATE LIMITED**
Registered Office : 2ndFloor, Viraj Towers, Near Andheri Flyover (North End), Western Express Highway, Andheri (East), Mumbai – 400069, Maharashtra
Tel No. : +91 22 4075 1500
Email Id : compliance@inventuremerchantbanker.com
Contact Person : Mr. Arvind Gala
Website : www.inventuremerchantbanker.com
SEBI Registration No. : INM000012003

Changes in Auditors for last three years

M/s. Kale Malde & Co., Chartered Accountants, were appointed as Statutory Auditors of our Company for 1 year for FY 2023-24 at Board of Directors meeting held on January 29, 2024 subject to the approval of the shareholders in the upcoming Annual General Meeting. The previous auditors of our company were M/s. E. A. Patil & Associates LLP, Chartered Accountants, for a period of 5 years, i.e. from FY 2019 to FY 2023. Beside this, there has been no change in Auditors during last 3 years.

CAPITAL STRUCTURE

The following disclosure shall be amended and/ or updated and/or added under the chapter titled “Capital Structure” beginning from page 43 of the Draft Prospectus:

2. History of Issued and Paid-Up Share Capital of our Company

2. Allotment of 2,45,000 Equity Shares to Jagdish Umakant Nayak and 2,45,000 Equity Shares to Jyoti Jagdish Nayak as a Bonus issue in the ratio of 49 equity share for 1 equity share held.
3. Allotment of 83,333 Equity Shares to Jagdish Umakant Nayak and 83,333 Equity Shares to Jyoti Jagdish Nayak as a Bonus issue in the ratio of 1 equity share for 3 equity share held.
4. Allotment of 4,16,667 Equity Shares to Jagdish Umakant Nayak and 4,16,667 Equity Shares to Jyoti Jagdish Nayak as a Bonus issue in the ratio of 5 equity share shares for 4 equity share held.

a) Build-up of our Promoters’ shareholding in our Company

Date of Allotment / Transfer	Nature of acquisition (Allotment/ Acquired/ transfer)	Number of Equity Shares	Face Value per Equity Share (in ₹)	Issue Price /Acquisition Price / Transfer price per Equity Share (in ₹)	Nature of Consideration	Percentage of Pre-Issue Equity Share Capital (%)	Percentage of Post-Issue Equity Share Capital (%)
Ashutosh Jagdish Nayak							
July 17, 2023	Transfer from Jagdish Umakant Nayak	100	10	10	Cash	0.01	0.00

b) Details of Promoter’s Contribution Locked-in for Three Years

Pursuant to Regulations 236 and 238 of the SEBI (ICDR) Regulations, an aggregate of at least 20% of the fully diluted post-Offer Equity Share capital of our Company held by our Promoters shall be provided towards minimum promoters’ contribution and locked-in for a period of three years from the date of Allotment (“**Minimum Promoters’ Contribution**”). Details of the Equity Shares (eligible for inclusion in the Minimum Promoters’ Contribution, in terms of Regulation 33 of the SEBI (ICDR) Regulations) forming part of Minimum Promoters’ Contribution as 20.15% and proposed to be locked-in for a period of three years are as follows:

Date of Allotment / Transfer	Nature of acquisition (Allotment/ Acquired/ transfer)	Number of Equity Shares	Face Value per Equity Share (in ₹)	Issue Price /Acquisition Price / Transfer price per Equity Share (in ₹)	Nature of Consideration	Percentage of Pre-Offer Equity Share Capital (%)	Percentage of Post-Offer Equity Share Capital (%)
Jagdish Umakant Nayak							
March 28, 2022	Bonus Issue	3,40,000	10	Nil	Nil	20.24	14.90
Jyoti Jagdish Nayak							
March 28, 2022	Bonus Issue	1,20,000	10	Nil	Nil	7.14	5.26
Total		4,60,000				27.38	20.154

c) *Equity Shares locked-in for one year*

In addition to Minimum Promoters' Contribution which shall be locked-in for three years, the balance Equity Shares held by Promoters and Others shall be locked in for a period of one year from the date of allotment in the Initial Public Offer as provided in clause (b) of Regulation 238 of the SEBI (ICDR) Regulations, 2018. The details are as follows:

Date of Allotment / Transfer	Nature of acquisition (Allotment/ Acquired/ transfer)	Number of Equity Shares	Face Value per Equity Share (in ₹)	Issue Price /Acquisition Price / Transfer price per Equity Share (in ₹)	Nature of Consideration	Percentage of Pre-Offer Equity Share Capital (%)	Percentage of Post-Offer Equity Share Capital (%)
Jagdish Umakant Nayak							
March 10, 2010	Subscribers to MOA	5,000	10	10	Cash	0.30	0.22
March 31, 2018	Bonus Issue	245,000	10	Nil	Nil	14.58	10.73
March 01, 2019	Bonus Issue	83,333	10	Nil	Nil	4.96	3.65
March 28, 2022	Bonus Issue	1,167	10	Nil	Nil	0.07	0.05
		3,34,500				19.91	14.66
Jyoti Jagdish Nayak							
March 10, 2010	Subscribers to MOA	5,000	10	10	Cash	0.30	0.22
March 31, 2018	Bonus Issue	245,000	10	Nil	Nil	14.58	10.73
March 01, 2019	Bonus Issue	83,333	10	Nil	Nil	4.96	3.65
March 28, 2022	Bonus Issue	221,667	10	Nil	Nil	13.19	9.71
		555,000				33.04	24.32
Ashutosh Jagdish Nayak							
July 17, 2023	Transfer from Jagdish Umakant Nayak	100	10	10	Cash	0.01	0.00
Total		8,89,600				52.95	38.97

12. The shareholding pattern of our Promoters and Promoter Group before and after the Offer is set forth below:

Sr.	Particulars	Pre-Offer		Post-Offer	
		No. of Shares	% Holding	No. of Shares	% Holding
a)	Promoters				
	Jagdish Umakant Nayak	6,74,500	40.15	6,74,500	29.55
	Jyoti Jagdish Nayak	6,75,000	40.18	6,75,000	29.57
	Ashutosh Jagdish Nayak	100	0.006	100	0.004
	Total - A	13,49,600	80.33	13,49,600	59.13
b)	Promoter Group				
	Ananya Jagdish Nayak	100	0.006	100	0.004
	Anant Umakant Nayak	100	0.006	100	0.004

Sr.	Particulars	Pre-Offer		Post-Offer	
		No. of Shares	% Holding	No. of Shares	% Holding
	Eshwari Anant Nayak	100	0.006	100	0.004
	Siddhesh Anant Nayak	55500	3.30	55500	2.43
	Total – B	55800	3.32	55800	2.44
	Grand Total (A+B)	14,05,400	83.65	14,05,400	61.57

13. The average cost of acquisition of or subscription to Equity Shares by our Promoters is set forth in the table below:

Name of the Promoters	No. of Equity Shares held	Average cost of Acquisition (in ₹)
Jagdish Umakant Nayak	6,74,500	Nil*
Jyoti Jagdish Nayak	6,75,000	Nil*
Ashutosh Jagdish Nayak	100	10.00

*Cost of acquisition of equity shares is NIL as the shares acquired by way of bonus shares and net of selling consideration for the shares sold.

11. Our shareholding pattern

Pursuant to Regulation 31 of the SEBI (LODR) Regulations, the holding of specified securities is divided into the following three categories: (a) Promoter and Promoter Group; (b) Public; and (c) Non-Promoter - Non-Public.

Category (I)	Category of shareholder (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV) + (V) + (VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) As a % of (A+B+C2) (VIII)	Number of Voting Rights held in each class of securities (XI)				No. of Shares Underlying convertible securities (including Warrants) (X)	Shareholding as a % assuming full conversion of convertible securities (as a % of diluted share capital) As a % of (A+B+C2) (XI) = (VII) + (X)	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialized form (XIV)
								No of Voting Rights			Total as a % of (A+B+C)			No. (a)	As a % of total Shares held (b)	No. (a)	As a % of total Shares held (b)	
								Class : Equity	Class : preference	Total								
(A)	Promoter & Promoter Group	7	14,05,400	-	-	14,05,400	83.65	14,05,400	-	14,05,400	83.65	-	-	-	-	-	14,05,400	
(B)	Public	19	2,74,600	-	-	2,74,600	16.34	2,74,600	-	2,74,600	16.34	-	-	-	-	-	2,74,600	
(C)	Non-Promoter-Non-Public	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
(C1)	Shares underlying DRs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
(C2)	Shares held by Employee Trusts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Total	26	16,80,000	-	-	16,80,000	100.00	16,80,000	-	16,80,000	100.00	-	-	-	-	-	16,80,000	

OBJECTS OF THE ISSUE

The following disclosure shall be amended and/ or updated and/or added under the chapter titled “Objects of the Issue” beginning from page 53 of the Draft Prospectus:

Schedule of implementation

The entire amount of Fresh Issue Proceeds, other than Issue Expenses, will be utilised during FY 2025.

Estimated Time lines for Schedule of implementation is as under:

Particulars	Month of Commencement	Month of Completion
Expansion of Diagnostic Centres		
Security Deposit for Lease Property	July 2024	September 2024
Rent for 12 months	August 2024	August 2025
Interiors, Furniture and Electronic Equipments	July 2024	November 2024
Employee cost and other operational costs	July 2024	August 2025

Deployment of Funds in the Objects

Our Company has not incurred Rs. 17.92 Lakhs towards Issue Expenses till June 04, 2024 from the internal accruals of the Company. The same is certified by M/s. Kale Malde & Co., Chartered Accountants, vide their certificate dated June 04, 2024 (UDIN No.: 24138034BKDAYT6135).

Details of balance fund deployment

(₹ in Lakhs)

Sr. No.	Particulars	Expenses Already Incurred till 04-06-2024	FY 2025	Total
1	Expansion of Diagnostic Centres	Nil	400.00	498.67
2	General Corporate Purposes	Nil	41.33	41.33
3	Issue Related Expenses	17.92	20.38	38.30
	Total	17.92	566.99	578.30

Details of balance fund deployment

(₹ in Lakhs)

Sr. No.	Particulars	Expenses Already Incurred till 04-06-2024	FY 2025	Total
1	Expansion of Diagnostic Centres	Nil	400.00	498.67
2	General Corporate Purposes	Nil	41.33	41.33
3	Issue Related Expenses	17.92	20.38	38.30
	Total	17.92	566.99	578.30

BUSINESS OVERVIEW

The following disclosure shall be amended and/ or updated and/or added under the chapter titled “Business Overview” beginning from page 77 of the Draft Prospectus:

The revenue from our B2B and B2C customers during last 3 years and for the period ended September 30, 2023:

(₹ in lakhs, except for percentage)

Particulars	01.04.2023 to 30.09.2023		Fiscal 2023		Fiscal 2022		Fiscal 2021	
	Amount	% #	Amount	% #	Amount	% #	Amount	% #
B2B *	63.99	20.93	197.77	31.16	216.62	33.93	145.55	31.96
B2C **	241.82	79.07	436.97	68.84	421.81	66.07	309.86	68.04
Total	305.81	100.00	634.75	100.00	638.43	100.00	455.40	100.00

*includes Hospitals and CRO (Contract Research Organization)

**includes individual walk-in customers

as a percentage of revenue from operations

The revenue from each of the above tests during last 3 years and for the period ended September 30, 2023:

(₹ in lakhs, except for percentage)

Particulars	01.04.2023 to 30.09.2023		Fiscal 2023		Fiscal 2022		Fiscal 2021	
	Amount	% #	Amount	% #	Amount	% #	Amount	% #
Biochemistry	84.47	27.62	171.45	27.01	186.24	29.17	164.9	36.21
Immunology	62.4	20.40	132.72	20.91	148.44	23.25	124.06	27.24
Hematology	75.62	24.73	135.06	21.28	126.61	19.83	104.32	22.91
Molecular Biology	8.59	2.81	44.45	7.00	69.49	10.88	0	0.00
Serology	12.64	4.13	33.71	5.31	31.34	4.91	25.87	5.68
Microbiology	10.58	3.46	21.74	3.42	17.41	2.73	14.21	3.12
Clinical Pathology	8.84	2.89	14.76	2.33	12.79	2.00	11.16	2.45
Histopathology	2.37	0.77	4.7	0.74	5.24	0.82	4.80	1.05
Other tests	40.3	13.18	76.16	12.00	40.87	6.40	6.08	1.34
Total	305.81	100.00	634.75	100.00	638.43	100.00	455.40	100.00


as a percentage of revenue from operations

Insurance

Sr. No.	Name Of the Insurance	Type Of Policy	Risk Covered for	Insurance Amount (Rs.)	Period of Insurance
1	The New India Assurance Company Limited	New India Bharat Sookshma Udyam Suraksha Policy	Building, Furniture & other Equipments, Plant & Machinery	23,00,000	From 28/02/2024 To 27/02/2025

Process flow chart

Process flow chart for our services is as under:



1. **Patient Registration:** The process begins with patient registration, where the patient provides their personal information, list of test to be done as per their requirements and insurance details.
2. **Sample Collection:** A healthcare professional collects the patient's sample, which could be blood, urine, tissue, or other bodily fluids, depending on the type of test.
3. **Sample Labelling:** Each sample is carefully labelled with the patient's information to ensure accuracy.
4. **Transport to the Laboratory:** Samples collected and labelled are then transported to the pathology laboratory under appropriate conditions to preserve their integrity.
5. **Quality Control:** Quality control checks are performed to ensure the accuracy and reliability of the test results.
6. **Sample Processing:** In the lab, our technicians process the patients sample, which may involve centrifugation, separation, or other procedures depending on the test.
7. **Analysis:** The patients sample undergoes analysis using various techniques and equipment's, such as microscopes, chemical assays, or molecular testing etc.
8. **Data Recording:** The results of the analysis are recorded by our Lab Staff in a laboratory information system (LIS) or electronic health record (EHR) along with patient details.
9. **Interpretation:** An Pathologist or a Microbiology or Medical Technologist interprets the results based on established criteria.
10. **Report Generation:** A formal pathology report is generated, which includes the test results, interpretation, and any relevant comments or recommendations.
11. **Result Delivery:** The pathology report is sent to the ordering physician or healthcare provider, who communicates the results to the patient.
12. **Data Storage:** The results are securely stored in the patient's medical record for future reference.

Human Resource

We believe that a motivated and empowered employee base is the key to our operations and business strategy. We source our human resources locally and the same is available easily.

The detailed break-up of our full-time employees as on December 31, 2023 is summarized as under:

Sr. No.	Category	Number
1.	Senior Management	4
2.	Middle Level Management	13
3	Lab staff *	40
3.	Other Employees **	17
Total		74

*includes Pathologists, Radiologists, X-Ray Technicians, Phlebotomist, Lab Technicians and Logistics.

** includes Receptionist, Sonography, X-Ray typist and Administrative.

We have tied up with 5 Doctors who act as Consultants for our Company. These Doctor Consultants overlook the process of testing at our various centres. Also, before they sign the patients report, they analyse and interpret the reports/ testing papers as prepared by our Lab Staff. We have written arrangements them and accordingly we pay professional fees to them as agreed upon.

We do not have any employees on contract basis at our offices or Diagnostic Centres.

OUR PROMOTERS AND PROMOTER GROUP

The following disclosure shall be amended and/ or updated and/or added under the chapter titled “Our Promoters and Promoter Group” beginning from page 106 of the Draft Prospectus:

Individual Promoter:

3. Ashutosh Jagdish Nayak



Ashutosh Jagdish Nayak, aged 25 years is the Promoter Non-Executive Director on the board of the Company since 2022 and is redesignated as Non-Executive Director w.e.f. September 30, 2023. He is a MBBS Bachelor of Medicine, Bachelor of Surgery from Maharashtra University of Health Sciences. He has around 2 years of experience with multi specialty hospitals in the field of patient treatment. At Clinitech, he is currently responsible as Public Relationship Officer explaining reports etc. to patients.

For a complete profile of Ashutosh Jagdish Nayak, and other directorships, please refer “*Our Management*” on page 95.

As on date of the Draft Prospectus, Ashutosh Jagdish Nayak holds 100 Equity Shares representing 0.01% of the pre-issue paid-up share capital of our Company.

A. Individuals forming part of Promoter Group:

Relationship	Ashutosh Jagdish Nayak
Father	Jagdish Umakant Nayak
Mother	Jyoti Jagdish Nayak
Spouse	-
Brother	-
Sister	Ananya Nayak
Son	-
Daughter	-
Spouse’s Father	-
Spouse’s Mother	-
Spouse’s Brother	-
Spouse’s Sister	-

GOVERNMENT AND OTHER APPROVALS

The following disclosures shall be amended and/ or updated and/or added under the chapter titled “Government and Other Approvals” beginning from page 154 of the Draft Prospectus:

C) APPROVALS/ LICENSES IN RELATION TO THE BUSINESS OF OUR COMPANY

Sr. No.	Authorisation Granted	Issuing Authority	Registration No. / Reference No. / License No.	Applicable Act/ Regulation	Valid up to
11.	Maharashtra Shop and Establishment License- Registered Office	Maharashtra Shop & Establishment (Regulation of Employment and Condition of Service) Act, 2018	104759671803	Maharashtra Shop & Establishment (Regulation of Employment and Condition of Service) Act, 2018	Valid until cancelled

DECLARATION

We hereby declare that, all the relevant provisions Companies Act, 2013 and the rules, guidelines and regulations issued by the Government of India or the regulations/ guidelines issued by Securities and Exchange Board of India, as the case may be, have been complied with and no statement made in this Draft Prospectus is contrary to the provisions of the Companies Act, 2013 (to the extent notified), the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/ guidelines issued, as the case may be. We further certify that all statements in this Draft Prospectus are true and correct.

Signed by all the Directors of Clinitech Laboratory Limited

Name and designation	Signature
Jagdish Umakant Nayak <i>Chairman & Managing Director</i>	Sd/-
Jyoti Jagdish Nayak <i>Whole Time Director</i>	Sd/-
Ashutosh Jagdish Nayak <i>Non-Executive Director</i>	Sd/-
Balu Laxman Kumbharkar <i>Non-Executive Independent Director</i>	Sd/-
Smita Arjun Patil <i>Non-Executive Independent Director</i>	Sd/-
Ravikant Moreshwar Mhatre <i>Non-Executive Independent Director</i>	Sd/-
Signed by the – Chief Financial Officer	
Rahul Motilal Patil	Sd/-

Place: Mumbai

Date: June 10, 2024



CLINITECH LABORATORY LIMITED

Corporate Identification Number: U85195MH2010PLC201078

Our Company was incorporated as Clinitech Laboratory Private Limited on March 19, 2010 under the Companies Act, 1956 with the Registrar of Companies, Mumbai bearing Registration number 201078. The status of the Company was changed to public limited and the name of our Company was changed to Clinitech Laboratory Limited vide Special Resolution dated July 24, 2023 pursuant to conversion of the Company into public limited Company. The fresh certificate of incorporation consequent to conversion was issued on August 25, 2023 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U85195MH2010PLC201078. For further details of our Company, see "General Information" and "History and Certain Other Corporate Matters" on pages 36 and 92, respectively.

Registered Office: AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India; **Tel No.:** +91 22 27792281 / +91 9004072223; **Email:** ipo@clinitechlab.com; **Website:** www.cltlab.in; **Contact Person:** Bharat Kumar Bohra, Company Secretary and Compliance Officer

OUR PROMOTERS: JAGDISH UMAKANT NAYAK AND JYOTI JAGDISH NAYAK

"The Issue is being made in accordance with Chapter IX of the SEBI ICDR Regulations (IPO of Small and Medium Enterprises) and the Equity Shares are proposed to be listed on the SME Platform of BSE India. ("BSE")."

THE ISSUE

INITIAL PUBLIC OFFERING OF UP TO 6,02,400 EQUITY SHARES OF ₹10 EACH ("EQUITY SHARES") OF CLINITECH LABORATORY LIMITED ("CLINITECH" OR THE "COMPANY") FOR CASH AT A PRICE OF ₹ 96 PER EQUITY SHARE (THE "OFFER PRICE"), AGGREGATING TO ₹ 578.30 LAKHS ("THE OFFER"). OF THE OFFER, 31,200 EQUITY SHARES AGGREGATING TO ₹29.95 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION I.E. OFFER OF 5,71,200 EQUITY SHARES OF FACE VALUE OF ₹ 10.00 EACH AT AN OFFER PRICE OF ₹ 96.00 PER EQUITY SHARE AGGREGATING TO ₹548.35 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 26.39% AND 25.02%, RESPECTIVELY OF THE POST OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, SEE "TERMS OF THE OFFER" ON PAGE 169 OF THE DRAFT PROSPECTUS.

ATTENTION INVESTORS- CORRIGENDUM TO THE DRAFT PROSPECTUS DATED JANUARY 23, 2024

In Section I and Section IV-chapter titled "General Information" of the Draft Prospectus on page nos. 4 and 37 respectively, the name of the Lead Manager to the Issuer Company is to be read as "Investment Merchant Banker Services Private Limited" instead of "First Overseas Capital Limited". All consequential changes with regards to the change in Lead Manager to the Issuer Company as mentioned above will be made in the Prospectus as applicable.

Please note that capitalized terms used and not defined herein shall have the respective meaning ascribed to them in the Draft Prospectus dated January 23, 2024.

INVESTORS MAY PLEASE NOTE THE DRAFT PROSPECTUS SHALL BE READ IN CONJUNCTION WITH THIS CORRIGENDUM.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Prospectus dated January 23, 2024.

For CLINITECH LABORATORY LIMITED

On behalf of the Board of Directors

Sd/-

Jagdish Umakant Nayak

Managing Director

DIR:00646672

Date: April 13, 2024

Place: Mumbai

Clinitech Laboratory Limited is proposing, subject to market conditions and other considerations, public issue of its Equity Shares and has filed the Draft Prospectus with the BSE Limited on January 23, 2024. The Draft Prospectus is available on the website of the Lead Manager at www.investmentmerchantbanker.com the website of the BSE Limited i.e. www.bseindia.com and website of the Issuer Company at www.cltlab.in

Investor should read the Draft Prospectus carefully, including the Risk Factors on page 17 of the Draft Prospectus before making any investment decision.

The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be issued and sold (i) in the United States only to "qualified institutional buyers", as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.



Please scan this QR Code to view the Draft Prospectus

Draft Prospectus
Dated: January 23, 2024
Fixed Price Offer

Please read section 26 of the Companies Act, 2013



CLINITECH LABORATORY LIMITED

Corporate Identification Number: U85195MH2010PLC201078

Registered Office	Corporate Office	Contact Person	Email and Telephone	Website
AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India	N.A.	Mr. Bharat Kumar Bohra, Company Secretary and Compliance Officer	E-mail: ipo@clinitechlab.com Tel: +91 22 27792281 / +91 9004072223	www.ctllab.in

PROMOTER: JAGDISH UMAKANT NAYAK AND JYOTI JAGDISH NAYAK

DETAILS OF ISSUE TO PUBLIC

Type of Issue	Fresh Issue Size	Offer For Sale Size	Total Offer Size	Eligibility
Fresh Issue	6,02,400 Equity Shares at the Offer Price of ₹ 96 each aggregating ₹ 578.30 Lakhs	N.A.	6,02,400 Equity Shares at the Offer Price of ₹ 96 each aggregating ₹ 578.30 Lakhs	This Offer is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended. The Offer is being made pursuant to Regulation 229 (2) of SEBI (ICDR) Regulations, as the Company's post Offer paid up capital is more than ₹ 10.00 Cr.

RISKS IN RELATION TO FIRST OFFER

This being the first Public Offer of our Company, there has been no formal market for the Equity Shares of our Company. The face value of the Equity Shares is ₹ 10/- each and the Offer Price of ₹ 96 is 9.60 TIMES of the face value of the Equity Shares. The Offer Price (determined and justified by our Company in consultation with the Lead Manager) as stated under "Basis for Offer Price" beginning on page no. 58 of this Draft Prospectus should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 17.

ISSUER'S ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Draft Prospectus contains all information with regard to our Company and the Offer, which is material in the context of the Offer, that the information contained in this Draft Prospectus is true and correct in all material aspects and is not misleading in any material respect, that opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Draft Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect.

LISTING

The Equity Shares offered through this Draft Prospectus are proposed to be listed on the SME Platform of BSE Limited ("BSE"). For the purposes of this Offer, BSE is the Designated Stock Exchange.

BOOK RUNNING LEAD MANAGER TO THE OFFER

REGISTRAR TO THE OFFER

Name of Book Running Lead Manager to the Offer: First Overseas Capital Limited	Name of Contact Person: Mala Soneji Tel No.: +91 22 4050 9999 Email: mb@focl.in	Name of Registrar to the Offer: Bigshare Services Private Limited	Name of Contact Person: Babu Rapheal C. Tel. No.: +91 22 6263 8200 Email: ipo@bigshareonline.com

OFFER PROGRAMME

OFFER OPENS ON:	●
OFFER CLOSES ON:	●



CLINITECH LABORATORY LIMITED

Our Company was incorporated as Clinitech Laboratory Private Limited on March 19, 2010 under the Companies Act, 1956 with the Registrar of Companies, Mumbai bearing Registration number 201078. The status of the Company was changed to public limited and the name of our Company was changed to Clinitech Laboratory Limited vide Special Resolution dated July 24, 2023 pursuant to conversion of the Company into public limited Company. The fresh certificate of incorporation consequent to conversion was issued on August 25, 2023 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U85195MH2010PLC201078. For further details of our Company, see "General Information" and "History and Certain Other Corporate Matters" on pages 36 and 92, respectively.

Registered Office: AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India

Tel No.: +91 22 27792281 / +91 9004072223; **Email:** ipo@clinitechlab.com; **Website:** www.ctlab.in

Contact Person: Bharat Kumar Bohra, Company Secretary and Compliance Officer.

PROMOTER: JAGDISH UMAKANT NAYAK AND JYOTI JAGDISH NAYAK

INITIAL PUBLIC OFFERING OF UP TO 6,02,400 EQUITY SHARES OF ₹10 EACH ("EQUITY SHARES") OF CLINITECH LABORATORY LIMITED ("CLINITECH" OR THE "COMPANY") FOR CASH AT A PRICE OF ₹ 96 PER EQUITY SHARE (THE "OFFER PRICE"), AGGREGATING TO ₹ 578.30 LAKHS ("THE OFFER"). OF THE OFFER, 31,200 EQUITY SHARES AGGREGATING TO ₹29.95 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION I.E. OFFER OF 5,71,200 EQUITY SHARES OF FACE VALUE OF ₹ 10.00 EACH AT AN OFFER PRICE OF ₹ 96.00 PER EQUITY SHARE AGGREGATING TO ₹548.35 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 26.39% AND 25.02%, RESPECTIVELY OF THE POST OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, SEE "TERMS OF THE OFFER" ON PAGE 169 OF THE DRAFT PROSPECTUS.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10.00 EACH AND THE OFFER PRICE OF ₹ 96.00 IS 9.60 TIMES OF THE FACE VALUE

THIS OFFER IS BEING MADE IN TERMS OF CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 (THE "SEBI (ICDR) REGULATIONS"), AS AMENDED. IN TERMS OF RULE 19(2)(b) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED, THIS IS AN OFFER FOR AT LEAST 25% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THIS OFFER IS A FIXED PRICE OFFER AND ALLOCATION IN THE NET OFFER TO THE PUBLIC WILL BE MADE IN TERMS OF REGULATION 253 OF THE SEBI (ICDR) REGULATIONS, AS AMENDED. FOR FURTHER DETAILS, SEE "OFFER PROCEDURE" ON PAGE 178 OF THE DRAFT PROSPECTUS.

All potential investors shall participate in the Offer only through an Application Supported by Blocked Amount ("ASBA") process including through UPI mode (as applicable) by providing details of the irrevocable bank accounts and / or UPI IDs, in case of RIIs, if applicable, which will be blocked by the Self Certified Syndicate Banks ("SCSBs") for the same. A copy will be delivered for registration to the Registrar of Companies as under Section 26 of the Companies Act, 2013. For details in this regard, specific attention is invited to "Offer Procedure" on page 178. A copy of the Prospectus will be delivered for registration to the Registrar of Companies as required under Section 26 of the Companies Act, 2013.

RISKS IN RELATION TO FIRST OFFER

This being the first Offer of the Issuer, there has been no formal market for the securities of our Company. The face value of the Equity Shares of our Company is ₹10.00. The Offer Price should not be taken to be indicative of the market price of the Equity Shares after such Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares of our Company nor regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of the Issuer and this Offer, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Prospectus. **Specific attention of the investors is invited to 'Risk Factors' on page 17.**

ISSUER'S ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Draft Prospectus contains all information with regard to our Company and the Offer, which is material in the context of the Offer, that the information contained in this Draft Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Draft Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.

LISTING

The Equity Shares offered through this Draft Prospectus are proposed to be listed on the SME Platform of BSE Limited ("BSE"). Our Company has received the approval letter dated [●], 2022 from BSE for using its name in the offer document for listing of our shares on the SME Platform of BSE. For the purpose of this Offer, the Designated Stock Exchange will be BSE.

LEAD MANAGER TO THE OFFER

REGISTRAR TO THE OFFER



FIRST OVERSEAS CAPITAL LIMITED

1-2 Bhupen Chambers, Dalal Street, Fountain,
Mumbai – 400 001, Maharashtra, India.

Tel No.: +91 22 4050 9999

Fax No.: +91 22 4050 9900

Email: mb@focl.in

Investor Grievance Email: investorcomplaints@focl.in

Website: www.focl.in

SEBI Registration No.: INM000003671

Contact Person: Mala Soneji



BIGSHARE SERVICES PRIVATE LIMITED

S6-2, 6th Floor, Pinnacle Business Park,
Mahakali Caves Road, Next to Ahura Centre,
Andheri East, Mumbai - 400 093, Maharashtra, India

Tel. No.: +91 22 6263 8200

Email: ipo@bigshareonline.com

Website: www.bigshareonline.com

Investor Grievance Email: investor@bigshareonline.com

SEBI Registration No.: INR000001385

Contact Person: Babu Rapheal C.

OFFER PROGRAMME

OFFER OPENS ON: [●]

OFFER CLOSES ON: [●]

INDEX

SECTION I – GENERAL	1
DEFINITIONS AND ABBREVIATIONS	1
CERTAIN CONVENTIONS, USE OF FINANCIAL INFORMATION AND MARKET DATA AND	
CURRENCY OF PRESENTATION	10
FORWARD-LOOKING STATEMENTS	11
SECTION II - SUMMARY OF THE OFFER DOCUMENT	12
SECTION III - RISK FACTORS	17
SECTION IV – INTRODUCTION	32
THE OFFER	32
SUMMARY FINANCIAL INFORMATION	33
GENERAL INFORMATION	36
CAPITAL STRUCTURE	43
OBJECTS OF THE OFFER	53
BASIS FOR OFFER PRICE	58
STATEMENT OF TAX BENEFITS	64
SECTION V: ABOUT THE COMPANY	67
INDUSTRY OVERVIEW	67
INTRODUCTION	67
MARKET SIZE	67
RECENT DEVELOPMENTS	68
GOVERNMENT INITIATIVES	69
ROAD AHEAD	69
OUR BUSINESS	77
HISTORY AND CERTAIN CORPORATE MATTERS	92
OUR MANAGEMENT	95
OUR PROMOTERS AND PROMOTER GROUP	106
OUR GROUP COMPANIES	110
RELATED PARTY TRANSACTIONS	112
DIVIDEND POLICY	113
SECTION VI – FINANCIAL INFORMATION	114
FINANCIAL STATEMENTS	114
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF	
OPERATIONS	140
FINANCIAL INDEBTEDNESS	150
SECTION VII – LEGAL AND OTHER INFORMATION	151
OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS	151
GOVERNMENT AND OTHER APPROVALS	154
OTHER REGULATORY AND STATUTORY DISCLOSURES	156
SECTION VIII – ISSUE RELATED INFORMATION	169
TERMS OF THE OFFER	169
ISSUE STRUCTURE	174
ISSUE PROCEDURE	178
RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES	198
SECTION IX – MAIN PROVISIONS OF THE ARTICLES OF ASSOCIATION	199
SECTION X – OTHER INFORMATION	211
MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION	211
DECLARATION	213

THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

SECTION I – GENERAL DEFINITIONS AND ABBREVIATIONS

This Draft Prospectus uses certain definitions and abbreviations which, unless the context otherwise indicates or implies, or unless otherwise specified, shall have the meaning as provided below. References to any legislation, act, regulation, rules, guidelines or our Articles of Association, Memorandum of Association, policies shall be to such legislation, act or regulation, as amended from time to time and any reference to a statutory provision shall include any subordinate legislation made from time to time under that provision.

The words and expressions used in this Draft Prospectus but not defined herein, shall have, to the extent applicable, the meaning ascribed to such terms under the Companies Act, the SEBI Regulations, the SCRA, the Depositories Act or the rules and regulations made thereunder.

Notwithstanding the foregoing in ‘Main Provisions of the Articles of Association’, ‘Summary of Our Business’, ‘Our Business’, ‘Risk Factors’, ‘Industry Overview’, ‘Key Regulations and Policies in India’, ‘Financial Information’, ‘Outstanding Litigation and Material Developments’ and ‘Part B’ of ‘Offer Procedure’, defined terms, will have the meaning ascribed to such terms in these respective sections.

Company Related Terms

Term	Description
“Clinitech Laboratory Limited”, “CLINITECH”, “We” or “us” or “our Company” or “the Issuer”	Unless the context otherwise requires, refers to Clinitech Laboratory Limited, a Company incorporated under the Companies Act, 1956 and having its registered office at AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India.
“we”, “us”, or “our”	Unless the context otherwise indicates or implies, our Company.
“you”, “your” or “yours”	Prospective investors in this Offer
AOA/Articles / Articles of Association	Unless the context otherwise requires, refers to the Articles of Association of our Company, as amended from time to time.
Audit Committee	The committee of the Board of Directors constituted as the Company’s Audit Committee in accordance with Regulation 18 of the SEBI (LODR) Regulations and Section 177 of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014
Board/ Board of Directors / Our Board	The Board of Directors of our Company, including all duly constituted Committees thereof.
Compliance Officer	The Company Secretary of our Company, being Bharat Kumar Bohra, Company Secretary and Compliance Officer.
Director(s)	Director(s) on the Board of our Company, as appointed from time to time, unless otherwise specified.
Equity Shareholders	The holders of the Equity Shares
Equity Shares/Shares	The equity shares of our Company of a face value of ₹10.00 each unless otherwise specified in the context thereof
Group Companies / Group Entities	Such companies as covered under the applicable accounting standards, being Accounting Standard 18 or other entities as considered material in accordance with the Materiality Policy, as described in “ <i>Our Group Entities</i> ” on page 109.
Key Management Personnel / KMP	Key management personnel of our Company in terms of Regulation 2(1)(s) of the SEBI (ICDR) Regulations, Section 2(51) of the Companies Act, 2013. For details, please refer “ <i>Our Management</i> ” on page 95.
Materiality Policy	A policy adopted by our Company, in its Board meeting held on January 01, 2024 for identification of group companies, material creditors and material litigations.
MoA / Memorandum of Association	The Memorandum of Association of our Company, as amended from time to time.
Peer Reviewed Auditor / Statutory Auditor	The independent peer reviewed Statutory Auditor of our Company M/s. E. A. Patil & Associates LLP, Chartered Accountants
Promoter Group	Persons and entities constituting the promoter group of our Company, pursuant to Regulation 2(1)(zb) of the SEBI (ICDR) Regulations.

Promoter	Jagdish Umakant Nayak and Jyoti Jagdish Nayak
Registered Office	The registered office of our Company situated at AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India.
Registrar of Companies / ROC	Registrar of Companies, Mumbai, Maharashtra
Restated Summary Statements	Audited restated summary statements of assets and liabilities for the period ended September 30, 2023 and as at March 31, 2023; 2022 and 2021 and audited restated summary statements of profits and losses and cash flows for the period ended September 30, 2023 and for the financial years ended March 31, 2023; 2022 and 2021 of the Company.

Offer Related Terms

Term	Description
Acknowledgement Slip	The slip, document or counter foil issued by the Designated Intermediary to an Applicant as proof of having accepted the Application Form.
Allot / Allotment /Allotted	Unless the context otherwise requires, allotment of the Equity Shares pursuant to the Offer of Equity Shares to the successful Applicants.
Allottee	A successful Applicant to whom the Equity Shares are Allotted.
Applicant	Any prospective investor who makes an application pursuant to the terms of the Prospectus and the Application Form.
Application	An indication to make an offer during the Offer Period by an Applicant, pursuant to submission of Application Form, to subscribe for or purchase our Equity Shares at the Offer Price including all revisions and modifications thereto, to the extent permissible under the SEBI (ICDR) Regulations.
Application Amount	The number of Equity Shares applied for and as indicated in the Application Form multiplied by the price per Equity Share payable by the Applicants on submission of the Application Form.
Application Form	The form in terms of which an Applicant shall make an Application and which shall be considered as the application for the Allotment pursuant to the terms of the Prospectus.
Application Supported by Blocked Amount/ ASBA	An application, whether physical or electronic, used by an Applicant authorizing a SCSB to block the application amount in the ASBA Account maintained with the SCSB and will include amounts blocked by SCSB upon acceptance of UPI Mandate Request by UPI Applicants using the UPI Mechanism
ASBA Account	A bank account maintained with an SCSB and specified in the ASBA Form submitted by ASBA Applicants for blocking the Bid Amount mentioned in the ASBA Form and will include amounts blocked by SCSB upon acceptance of UPI Mandate Request by UPI Applicants using the UPI Mechanism.
ASBA Applicant(s)	Any prospective investors in this Offer who applies for Equity Shares of our Company through the ASBA process in terms of the Prospectus.
Bankers to the Offer/ Public Offer Bank	The banks which are clearing members and registered with SEBI as Banker to an Offer with whom the Public Offer Account will be opened and in this case being [●].
Banker to the Offer Agreement	Agreement to be entered into amongst the Company, LM, the Registrar, Sponsor Bank, and the Banker of the Offer.
Basis of Allotment	The basis on which the Equity Shares will be Allotted to successful Applicants under the Offer, described in “Offer Procedure” on page 178.
Broker Centres	Broker centres notified by the Stock Exchange, where the Applicants can submit the Application Forms to a Registered Broker. The details of such broker centres, along with the name and contact details of the Registered Brokers, are available on the website of BSE on the following link www.bseindia.com .
Broker to the Offer	All recognized members of the stock exchange would be eligible to act as the Broker to the Offer.
BSE SME	The SME Platform of BSE, approved by SEBI as an SME Exchange for listing of equity shares Issued under Chapter IX of the SEBI (ICDR) Regulations, 2018.
CAN / Allotment Advice	The note or advice or intimation of Allotment, sent to each successful Applicant who has been or is to be Allotted the Equity Shares after approval of the Basis of Allotment by the Designated Stock Exchange.
Client ID	Client identification number of the Applicant’s beneficiary account.

Term	Description
Collecting Depository Participant or CDP	A depository participant as defined under the Depositories Act, 1996, registered with SEBI and who is eligible to procure Applications at the Designated CDP Locations in terms of circular no. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI.
Collection Centres	Centres at which the Designated Intermediaries shall accept the ASBA Forms.
Controlling Branches of the SCSBs	Such branches of the SCSBs which coordinate with the Lead Manager, the Registrar to the Offer and the Stock Exchange and a list of which is available at www.sebi.gov.in or at such other website as may be prescribed by SEBI from time to time.
Demographic Details	The details of the Applicants including the Applicants' address, names of the Applicants' father/husband, investor status, occupations, and bank account details.
Depository /Depositories	A depository registered with SEBI under the SEBI (Depositories and Participant) Regulations, 1996.
Depository Participant / DP	A depository participant as defined under the Depositories Act.
Designated CDP Locations	Such locations of the CDPs where Applicants can submit the Application Forms to Collecting Depository Participants. The details of such Designated CDP Locations, along with names and contact details of the Collecting Depository Participants eligible to accept Application Forms are available on the website of the Stock Exchange (www.nseindia.com).
Designated Date	The date on which the amounts blocked by the SCSBs are transferred from the ASBA Accounts to the Public Offer Account or unblock such amounts, as appropriate in terms of the Prospectus.
Designated Intermediaries / Collecting Agent	An SCSB with whom the bank account to be blocked, is maintained, a syndicate member (or sub-syndicate member), a Registered Broker, Designated CDP Locations for CDP, a registrar to an Offer and share transfer agent (RTA) (whose names is mentioned on website of the stock exchange as eligible for this activity).
Designated Market Maker / Market Maker	In our case, BHH Securities Private Limited.
Designated RTA Locations	Such locations of the RTAs where Applicants can submit the Application Forms to RTAs. The details of such Designated RTA Locations, along with names and contact details of the RTAs eligible to accept Application Forms are available on the website of the Stock Exchange (www.nseindia.com).
Designated SCSB Branches	Such branches of the SCSBs which collected the ASBA Application Form from the applicants and a list of which is available on the website of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes or at such other website as may be prescribed by SEBI from time to time.
Designated Stock Exchange	BSE Limited
Draft Prospectus / DP	The Draft Prospectus dated January 23, 2024, filed with BSE Limited.
Eligible NRI	A non-resident Indian, resident in a jurisdiction outside India where it is not unlawful to make an offer or invitation under the Offer and in relation to whom the Prospectus constitutes an invitation to subscribe for the Equity Shares.
Equity Shares	Equity Shares of our Company of face value Rs. 10/- each
Electronic Transfer of Funds	Refunds through NACH, NEFT, Direct Credit or RTGS as applicable.
Eligible QFI	Qualified Foreign Investors from such jurisdictions outside India where it is not unlawful to make an offer or invitation under the Offer and in relation to whom the Prospectus constitutes an invitation to purchase the Equity Shares offered thereby and who have opened dematerialised accounts with SEBI registered qualified depository participants as QFIs and are deemed as FPIs under the SEBI FPI Regulations.
First Applicant	The Applicant whose name appears first in the Application Form or the Revision Form.
General Information Document	The General Information Document for investing in public issues prepared and issued in accordance with the circulars (CIR/CFD/DIL/12/2013) dated October 23, 2013, notified by SEBI and updated pursuant to the circular (CIR/CFD/POLICYCELL/11/2015) dated November 10, 2015 and (SEBI/HO/CFD/DIL/CIR/P/2016/26) dated January 21, 2016 notified by the SEBI and (SEBI/HO/CFD/DIL2/CIR/P/2018/22) dated February 15, 2018.
Offer / Issue / Public Offer/ Offer size / Initial Public Offer/ Initial Public Offering / IPO	Initial Public Offering of up to 6,02,400 Equity Shares of ₹10 each ("Equity Shares") of Clinitech Laboratory Limited ("CLINITECH" or the "company") for cash at a price of ₹ 96 per equity share (the "Offer price"), aggregating to ₹ 578.30 lakhs ("the Offer"). Of the Offer, 31,200 Equity Shares aggregating to ₹29.95 lakhs will be reserved for subscription by

Term	Description
	Market Maker (“Market Maker Reservation Portion”). The Offer less the Market Maker Reservation Portion i.e. Offer of 5,71,200 Equity Shares of face value of ₹ 10.00 each at an Offer price of ₹ 96.00 per Equity Share aggregating to ₹548.35lakhs is hereinafter referred to as the “Net Offer”.
Offer Agreement / MoU	The agreement dated January 23, 2024 entered into amongst our Company and the Lead Manager, pursuant to which certain arrangements are agreed to in relation to the Offer.
Offer Closing Date	The date on which the Offer closes for subscription. In this case being [●], 2024
Offer Opening Date	The date on which the Offer opens for subscription. In this case being [●], 2024
Offer Period	The period between the Offer Opening Date and the Offer Closing Date, inclusive of both days during which prospective Applicants can submit their applications, including any revisions thereof.
Offer Price	The price at which Equity Shares are being offered by our Company being ₹ 96 per Equity Share.
Lead Manager / LM	The lead manager to the Offer, in this case being First Overseas Capital Limited.
Listing Agreement	Unless the context specifies otherwise, this means the Equity Listing Agreement to be signed between our Company and the BSE.
Market Maker Reservation Portion	31,200 Equity Shares of ₹10.00 each at ₹ 96 per Equity Share aggregating to ₹29.95 lakhs reserved for subscription by the Market Maker.
Net Offer	The Offer (excluding the Market Maker Reservation Portion) of 5,71,200 Equity Shares of face value of ₹10.00 each at an Offer Price of ₹ 96.00 per equity share aggregating to ₹548.35 lakhs.
Net Proceeds	Proceeds of the Offer that will be available to our Company, which shall be the gross proceeds of the Offer less the Offer expenses.
Non-Institutional Investors / NIIs	All Applicants, including Category III FPIs that are not QIBs or Retail Individual Investors who have made Application for Equity Shares for an amount of more than ₹2,00,000 (but not including NRIs other than Eligible NRIs).
Prospectus	The Prospectus to be filed with the RoC for this Offer in accordance with the provisions of Section 26 of the Companies Act, 2013 and the SEBI (ICDR) Regulations, including any addenda or corrigenda thereto.
Public Offer Account	The account to be opened with the Banker to the Offer under Section 40 of the Companies Act, 2013 to receive monies from the ASBA Accounts on the Designated Date.
Qualified Institutional Buyers or QIBs	A qualified institutional buyer as defined under Regulation 2(1)(ss) of the SEBI (ICDR) Regulations.
Refund Account(s)	Accounts to which the monies to be refunded to the Applicants is transferred from the Public Offer Account in case listing of the Equity Shares does not occur.
Registered Brokers	Stock brokers registered with the stock exchanges having nationwide terminals.
Registrar Agreement	The Agreement between the Registrar to the Offer and the Issuer Company dated January 23, 2024, in relation to the responsibilities and obligations of the Registrar to the Issue pertaining to the Issue.
Registrar and Share Transfer Agents or RTAs	Registrar and share transfer agents registered with SEBI and eligible to procure Applications at the Designated RTA Locations in terms of circular no. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI.
Registrar to the Offer	The Registrar to the Offer being Bigshare Services Private Limited.
Retail Individual Investors/ RIIs	Applicants (including HUFs, in the name of Karta and Eligible NRIs) whose Application Amount for Equity Shares in the Offer is not more than ₹2,00,000/-.
Revision Form	The form used by the Applicants to modify the quantity of Equity Shares or the Application Amount in any of their Application Forms or any previous Revision Form(s), as applicable.
Self Certified Syndicate Banks or SCSBs	Banks registered with SEBI, offering services in relation to ASBA, a list of which is available on the website of SEBI at www.sebi.gov.in and updated from time to time and at such other websites as may be prescribed by SEBI from time to time.
SME Platform of BSE / SME Exchange / Stock Exchange	The SME Platform of BSE, approved by SEBI as an SME Exchange for listing of equity shares offered under Chapter IX of the SEBI (ICDR) Regulations.
Sponsor Bank	[●], being a Banker to the Offer, appointed by our Company to act as a conduit between the Stock Exchanges and NPCI in order to push the mandate collect requests and / or payment instructions of the RIBs into the UPI, and carry out other responsibilities, in terms of the SEBI

Term	Description
	circular bearing number SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018 issued by SEBI
Underwriters	First Overseas Capital Limited
Underwriting Agreement	The agreement dated January 23, 2024 entered into among the Underwriter and our Company.
UPI	Unified payments interface, which is an instant payment mechanism, developed by NPCI
UPI Applicants	Collectively, individual investors applying as Retail Individual Inventors in the Retail Portion, and Other than retail individual investors applying with an application size of more than ₹ 200,000 and up to ₹ 500,000 in the Other than Retail Investors category and applying under the UPI Mechanism. Pursuant to Circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/45 dated April 5, 2022 issued by SEBI, all individual investors applying in public issues where the application amount is up to ₹ 500,000 shall use UPI and shall provide their UPI ID in the application form submitted with: (i) a stock broker registered with a recognized stock exchange (whose name is mentioned on the website of the stock exchange as eligible for such activity), (ii) a depository participant (whose name is mentioned on the website of the stock exchange as eligible for such activity), and (iii) a registrar to an issue and share transfer agent (whose name is mentioned on the website of the stock exchange as eligible for such activity)
UPI ID	ID created on the UPI for single-window mobile payment system developed by NPCI
UPI ID Linked Bank Account	Account of the RIIs, applying in the Offer using the UPI mechanism, which will be blocked upon accepting the UPI mandate to the extent of the appropriate application amount and subsequent debit of funds in the case of allotment.
UPI Mandate Request	A request (intimating the UPI Applicants by way of a notification on the UPI application and by way of a SMS directing the RIB to such UPI mobile application) to the UPI Applicants initiated by the Sponsor Bank to authorise blocking of funds on the UPI application equivalent to application Amount and subsequent debit of funds in case of Allotment
UPI mechanism	The mechanism using UPI that may be used by UPI Applicants to make an application in the Offer in accordance with the SEBI Circulars
UPI PIN	Password to authenticate UPI transaction
Wilful Defaulter(s)	Wilful defaulter as defined under Regulation 2(1)(III) of the SEBI Regulations.
Working Day(s)	“Working Day” means all days on which commercial banks in Mumbai are open for business. However, in respect of - (a) announcement of Price Band; and (b) Offer period, working day shall mean all days, excluding Saturdays, Sundays, and public holidays, on which commercial banks in Mumbai are open for business; (c) the time period between the Offer Closing Date and the listing of the Equity Shares on the Stock Exchange, working day shall mean all trading days of the Stock Exchange, excluding Sundays and bank holidays, as per circulars issued by SEBI.

Technical and Industry Related Terms

TERM	DESCRIPTION
ANDA	Abbreviated New Drug Application
CCI	Competition Commission Of India
CT	Computed Tomography
DPIIT	Department For Promotion Of Industry And Internal Trade
MRI	Magnetic Resonance Imaging
NABL	National Accreditation Board Of Laboratories
NBCFDC	National Backward Classes Finance And Development Corporation
OPD	Outpatient Department
PHCs	Primary Healthcare Centres
Reagent	Test kits and other material used for various tests
Specimens	Blood and other samples collected for tests

Explanation for KPI metrics

KPI	Explanations
Revenue from Operations	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps assess the overall financial performance of the Company and size of our business.
Total Revenue	Total Revenue is used by the management to track revenue from operations and other income.
EBITDA	EBITDA provides information regarding the operational efficiency of the business.
EBITDA Margin (%)	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business.
Net Debt	Non-current borrowing + current borrowing - Cash and cash equivalent, Bank balance, and Investment in Mutual Funds
PAT	Profit after tax provides information regarding the overall profitability of the business.
PAT Margin (%)	PAT Margin (%) is an indicator of the overall profitability and financial performance of our business.
Net Worth	Net worth is used by the management to ascertain the total value created by the entity and provides a snapshot of current financial position of the entity.
RoNW (%)	RoNW provides how efficiently the Company generates profits from shareholders' funds.

Conventional and General Terms and Abbreviations

Term	Description
A/c	Account
AGM	Annual General Meeting
AIF(s)	Alternative Investment Funds
Air Act	Air (Prevention and Control of Pollution) Act, 1981
AS	Accounting Standards as issued by the Institute of Chartered Accountants of India
ASBA	Applications Supported by Blocked Amount
Authorised Dealers	Authorised Dealers registered with RBI under the Foreign Exchange Management (Foreign Currency Accounts) Regulations, 2000
AY	Assessment Year
B. A.	Bachelor of Arts
B. Com.	Bachelor of Commerce
Banking Regulation Act	Banking Regulation Act, 1949
Bn	Billion
BSE	BSE Limited (formerly known as Bombay Stock Exchange Limited)
CAGR	Compounded Annual Growth Rate
Category I Foreign Portfolio Investor(s)	FPIs registered as Category I Foreign Portfolio Investors under the SEBI FPI Regulations.
Category II Foreign Portfolio Investor(s)	An FPI registered as a category II foreign portfolio investor under the SEBI FPI Regulations
Category III Foreign Portfolio Investor(s)	FPIs registered as category III FPIs under the SEBI FPI Regulations, which shall include all other FPIs not eligible under category I and II foreign portfolio investors, such as endowments, charitable societies, charitable trusts, foundations, corporate bodies, trusts, individuals and family offices
CBEC	Central Board of Excise and Customs
CDSL	Central Depository Services (India) Limited
Central Sales Tax Act	Central Sales Tax Act, 1956
CEO	Chief Executive Officer
CFO	Chief Financial Officer
CIN	Company Identification Number
CIT	Commissioner of Income Tax

Term	Description
Companies Act	Companies Act, 1956 (without reference to the provisions thereof that have ceased to have effect upon notification of the Notified Sections) and the Companies Act, 2013, to the extent in force pursuant to the notification of the Notified Sections, read with the rules, regulations, clarifications and modifications thereunder
Companies Act 1956	Companies Act, 1956 (without reference to the provisions thereof that have ceased to have effect upon notification of the Notified Sections)
Companies Act 2013	Companies Act, 2013, to the extent in force pursuant to the notification of the Notified Sections, read with the rules, regulations, clarifications, and modifications thereunder
Consolidated FDI Policy	The current consolidated FDI Policy, effective from June 7, 2016, issued by the Department of Industrial Policy and Promotion, Ministry of Commerce and Industry, Government of India, and any modifications thereto or substitutions thereof, issued from time to time
Copyright Act	The Copyright Act, 1957
CSR	Corporate Social Responsibility
Depositories Act	Depositories Act, 1996
Depository	A depository registered with the SEBI under the Securities and Exchange Board of India (Depositories and Participants) Regulations, 1996
DIN	Director Identification Number
DIPP	Department of Industrial Policy and Promotion, Ministry of Commerce and Industry, GoI
DP	Depository Participant
DP ID	Depository Participant's identity number
DTC	Direct Tax Code, 2013
ECS	Electronic Clearing System
EGM	Extraordinary General Meeting
Environment Protection Act	Environment Protection Act, 1986
EPF Act	Employees' Provident Funds and Miscellaneous Provisions Act, 1952
EPS	Earnings per share
ESI Act	Employees' State Insurance Act, 1948
F&NG	Father and Natural Guardian
F&O	Futures and Options
FCNR Account	Foreign Currency Non-Resident (Bank) account established in accordance with the FEMA
FDI	Foreign Direct Investment
FEMA	The Foreign Exchange Management Act, 1999 read with rules and regulations thereunder
FEMA 20	The Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2000
FII(s)	Foreign Institutional Investors as defined under SEBI FPI Regulations
Financial Year / Fiscal / Fiscal Year / FY	The period of 12 months commencing on April 1 of the immediately preceding calendar year and ending on March 31 of that particular calendar year
FIPB	Foreign Investment Promotion Board
FMC	Forward Market Commission
FOB	Free on Board
Foreign Portfolio Investor or FPIs	A foreign portfolio investor, as defined under the SEBI FPI Regulations and registered with SEBI under applicable laws in India.
FTA	The Foreign Trade (Development and Regulation) Act, 1992
FVCI	Foreign Venture Capital Investors (as defined under the Securities and Exchange Board of India (Foreign Venture Capital Investors) Regulations, 2000) registered with SEBI
GDP	Gross Domestic Product
GIR Number	General Index Registry Number
GoI/Government	Government of India
Hazardous Wastes Rules	Hazardous Wastes (Management, Handling and Transboundary Movement) Rules, 2008
HUF(s)	Hindu Undivided Family(ies)
I.T. Act	Income Tax Act, 1961, as amended from time to time
ICAI	Institute of Chartered Accountants of India
ICSI	Institute of Company Secretaries of India
IFRS	International Financial Reporting Standards
IFSC	Indian Financial System Code

Term	Description
Income Tax Act	Income Tax Act, 1961
Indian GAAP	Generally Accepted Accounting Principles in India
INR or Rupee or ₹ or Rs.	Indian Rupee, the official currency of the Republic of India
Insider Trading Regulations	The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended.
IPO	Initial Public Offering
ISIN	International Securities Identification Number
ISO	International Standards Organization
KMP	Key Managerial Personnel
KW	Kilo Watt
LIBOR	London interbank offered rate
Ltd.	Limited
M. A	Master of Arts
M. Com.	Master of Commerce
M.B.A	Master of Business Administration
MAPIN	Market Participants and Investors' Integrated Database
Maternity Benefit Act	Maternity Benefit Act, 1961
MCA	The Ministry of Corporate Affairs, GoI
MCI	Ministry of Commerce and Industry, GoI
Minimum Wages Act	Minimum Wages Act, 1948
Mn	Million
MoEF	Ministry of Environment and Forests
MoF	Ministry of Finance, Government of India
MOU	Memorandum of Understanding
Mutual Funds	Mutual funds registered with the SEBI under the Securities and Exchange Board of India (Mutual Funds) Regulations, 1996
NA	Not Applicable
NAV	Net asset value
NIFTY	National Stock Exchange Sensitive Index
NLEM 2011	National List of Essential Medicines – 2011
No.	Number
Non-Resident	A person resident outside India, as defined under FEMA Regulations
Non-Resident Indian/ NRI	A person resident outside India, who is a citizen of India or a Person of Indian Origin as defined under FEMA Regulations, as amended
Notified Sections	The sections of the Companies Act, 2013 that have been notified by the MCA and are currently in effect
NPV	Net Present Value
NR/ Non-resident	A person resident outside India, as defined under the FEMA and includes a Non-resident Indian
NRE Account	Non-Resident External Account established and operated in accordance with the FEMA
NRO Account	Non-Resident Ordinary Account established and operated in accordance with the FEMA
NSDL	National Securities Depository Limited
NSE	National Stock Exchange of India Limited
OCB	Overseas Corporate Bodies
Overseas Corporate Body / OCB	A company, partnership, society or other corporate body owned directly or indirectly to the extent of at least 60% by NRIs, including overseas trusts in which not less than 60% of beneficial interest is irrevocably held by NRIs directly or indirectly as defined under the Foreign Exchange Management (Deposit) Regulations, 2000. OCBs are not allowed to invest in this Offer.
p.a.	per annum
P/E Ratio	Price/Earnings Ratio
PAC	Persons Acting in Concert
PAN	Permanent account number
PAT	Profit after tax
Patents Act	Patents Act, 1970
Payment of Bonus Act	Payment of Bonus Act, 1965

Term	Description
Payment of Gratuity Act	Payment of Gratuity Act, 1972
PCA Act	Prevention of Cruelty to Animals Act, 1960
PIL	Public Interest Litigation
PPP	Public private partnership
Pvt./(P)	Private
QFI(s)	Qualified Foreign Investor(s) as defined under the SEBI FPI Regulations
RBI	The Reserve Bank of India
RoC or Registrar of Companies	The Registrar of Companies, Maharashtra at Mumbai
ROE	Return on Equity
RONW	Return on Net Worth
RTGS	Real Time Gross Settlement
SCRA	Securities Contract (Regulation) Act, 1956, as amended from time to time
SCRR	Securities Contracts (Regulation) Rules, 1957, as amended from time to time.
SEBI	The Securities and Exchange Board of India constituted under the SEBI Act
SEBI (ICDR) Regulations	The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, including instructions and clarifications issued by SEBI from time to time
SEBI (LODR) Regulations	Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including instructions and clarifications issued by SEBI from time to time
SEBI (Venture Capital) Regulations	Securities and Exchange Board of India (Venture Capital) Regulations, 1996 as amended from time to time.
SEBI Act	Securities and Exchange Board of India Act, 1992
SEBI FPI Regulations	Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2014
SEBI FVCI Regulations	Securities and Exchange Board of India (Foreign Venture Capital Investors) Regulations, 2000
SEBI Takeover Regulations	The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended from time to time.
Sec.	Section
SENSEX	Bombay Stock Exchange Sensitive Index
SICA	Sick Industrial Companies (Special Provisions) Act, 1985
SITP	Scheme for integrated textile parks
SME	Small and Medium Enterprise
SSI	Small Scale Industry
STT	Securities Transaction Tax
TPH	Tonnes per hour
Trademarks Act	The Trademarks Act, 1999
U.S. GAAP	Generally Accepted Accounting Principles in the United States of America
U.S. Securities Act	The United States Securities Act, 1933
US\$ or USD or US Dollar	United States Dollar, the official currency of the United States of America
USA or U.S. or US	United States of America
VCF	Venture Capital Funds
VCFs	Venture capital funds as defined in and registered with the SEBI under the Securities and Exchange Board of India (Venture Capital Fund) Regulations, 1996 or the Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012, as the case may be
Wages Act	Payment of Wages Act, 1936
Workmen's Compensation Act	Workmen's Compensation Act, 1923

CERTAIN CONVENTIONS, USE OF FINANCIAL INFORMATION AND MARKET DATA AND CURRENCY OF PRESENTATION

Certain Conventions

In this Draft Prospectus, the terms “we”, “us”, “our”, the “Company”, “our Company”, “Clinitech Laboratory Limited” and “CLINITECH”, unless the context otherwise indicates or implies, refers to Clinitech Laboratory Limited. All references in this Draft Prospectus to “India” are to the Republic of India. All references in this Draft Prospectus to the “U.S.”, “USA” or “United States” are to the United States of America.

Financial Data

Unless stated otherwise, the financial data in this Draft Prospectus is derived from our audited financial years ended March 31, 2023, 2022 and 2021 and for the period ended September 30, 2023, prepared in accordance with Indian GAAP, the Companies Act and restated in accordance with the SEBI (ICDR) Regulations which are included in this Draft Prospectus, and set out in *‘Financial Statements’* on page 114. Our Company’s financial year commences on April 1 of the immediately preceding calendar year and ends on March 31 of that particular calendar year, so all references to a particular financial year are to the 12 month period commencing on April 1 of the immediately preceding calendar year and ending on March 31 of that particular calendar year.

There are significant differences between the Indian GAAP, the International Financial Reporting Standards (the “IFRS”) and the Generally Accepted Accounting Principles in the United States of America (the “U.S. GAAP”). Accordingly, the degree to which the financial statements included in this Draft Prospectus will provide meaningful information is entirely dependent on the reader’s level of familiarity with Indian accounting practices. Any reliance by persons not familiar with Indian accounting practices, the Indian GAAP, the Companies Act and the SEBI (ICDR) Regulations on the financial disclosures presented in this Draft Prospectus should accordingly be limited. We have not attempted to quantify the impact of the IFRS or the U.S. GAAP on the financial data included in this Draft Prospectus, nor do we provide a reconciliation of our financial statements to those under the U.S. GAAP or the IFRS and we urge you to consult your own advisors regarding such differences and their impact on our financial data.

Certain figures contained in this Draft Prospectus, including financial information, have been subject to rounding adjustments. All decimals have been rounded off to two decimal points, except for figures in percentage. In certain instances, (i) the sum or percentage change of such numbers may not conform exactly to the total figure given; and (ii) the sum of the numbers in a column or row in certain tables may not conform exactly to the total figure given for that column or row. However, where any figures that may have been sourced from third-party industry sources are rounded off to other than two decimal points in their respective sources, such figures appear in this Draft Prospectus as rounded-off to such number of decimal points as provided in such respective sources.

Currency and units of presentation

In this Draft Prospectus, unless the context otherwise requires, all references to (a) ‘Rupees’ or ‘₹’ or ‘Rs.’ or ‘INR’ are to Indian rupees, the official currency of the Republic of India; (b) ‘US Dollars’ or ‘US\$’ or ‘USD’ or ‘\$’ are to United States Dollars, the official currency of the United States of America. All references to the word ‘Lakh’ or ‘Lac’ or ‘Lacs’, means ‘One hundred thousand’ and the word ‘Million’ means ‘Ten lakhs’ and the word ‘Crore’ means ‘Ten Million’ and the word ‘Billion’ means ‘One thousand Million’. Any percentage amounts, as set forth in *“Risk Factors”*, *“Our Business”*, *“Management’s Discussion and Analysis of Financial Conditions and Results of Operation”* and elsewhere in this Draft Prospectus, unless otherwise indicated, have been calculated based on our Restated Financial Statement.

Industry and Market Data

Unless stated otherwise, industry and market data used throughout this Draft Prospectus has been obtained or derived from internal Company reports and industry and government publications, publicly available information and sources. Industry publications generally state that the information contained in those publications has been obtained from sources believed to be reliable but that their accuracy and completeness are not guaranteed, and their reliability cannot be assured. Although, our Company believes that industry data used in this Draft Prospectus is reliable, it has not been independently verified. Further, the extent to which the industry and market data presented in this Draft Prospectus is meaningful depends on the reader’s familiarity with and understanding of, the methodologies used in compiling such data. There are no standard data gathering methodologies in the industry in which we conduct our business, and methodologies and assumptions may vary widely among different industry sources.

FORWARD-LOOKING STATEMENTS

All statements contained in this Draft Prospectus that are not statements of historical facts constitute ‘forward-looking statements. All statements regarding our expected financial condition and results of operations, business, objectives, strategies, plans, goals, and prospects are forward-looking statements. These forward-looking statements include statements as to our business strategy, our revenue and profitability, planned projects and other matters discussed in this Draft Prospectus regarding matters that are not historical facts. These forward looking statements and any other projections contained in this Draft Prospectus (whether made by us or any third party) are predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or other projections.

These forward-looking statements can generally be identified by words or phrases such as “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. Important factors that could cause actual results to differ materially from our expectations include but are not limited to:

- general economic and business conditions in the markets in which we operate and in the local, regional, and national and international economies;
- our ability to successfully implement strategy, growth and expansion plans and technological initiatives;
- our ability to respond to technological changes;
- our ability to attract and retain qualified personnel;
- the effect of wage pressures, hiring patterns and the time required to train and productively utilize new employees;
- general social and political conditions in India which have an impact on our business activities or investments;
- potential mergers, acquisitions restructurings and increased competition;
- occurrences of natural disasters or calamities affecting the areas in which we have operations;
- market fluctuations and industry dynamics beyond our control;
- changes in the competition landscape;
- our ability to finance our business growth and obtain financing on favourable terms;
- our ability to manage our growth effectively;
- our ability to compete effectively, particularly in new markets and businesses;
- changes in laws and regulations relating to the industry in which we operate changes in government policies and regulatory actions that apply to or affect our business;
- developments affecting the Indian economy; and
- Inability to meet our obligations, including repayment, financial and other covenants under our debt financing arrangements.

For a further discussion of factors that could cause our current plans and expectations and actual results to differ, please refer “*Risk Factors*”, “*Our Business*” and “*Management’s Discussion and Analysis of Financial Condition and Results of Operations*” on page 17, 77 and 140 respectively.

Forward looking statements reflects views as of the date of this Draft Prospectus and not a guarantee of future performance. By their nature, certain market risk disclosures are only estimates and could be materially different from what actually occurs in the future. As a result, actual future gains or losses could materially differ from those that have been estimated. Neither our Company / our directors nor the Lead Manager, nor any of its affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after the date hereof or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. In accordance with SEBI requirements, our Company and the Lead Manager will ensure that investors in India are informed of material developments until such time as the listing and trading permission is granted by the Stock Exchange.

SECTION II - SUMMARY OF THE OFFER DOCUMENT

A. Summary of Business & Industry:

Summary of Business:

We are a provider of diagnostic and healthcare tests and services through chain of 8 diagnostic centers in and around Thane and Navi Mumbai. Our Promoters have 30+ years of experience in diagnostic business. We conduct more than 3 Lakh tests per year in our NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited labs equipped with modern technology and high-end equipment.

We conduct more than 150 tests at our centres which are classified under various heads as under:

- Biochemistry tests
- Immunology tests
- Hematology tests
- Molecular Biology tests
- Serology tests
- Microbiology tests
- Histopathology tests

For more details on above tests, please refer to paragraph titled “**Our Products and Services**” on page 78.

Summary of Industry:

DIAGNOSTIC SECTOR

The diagnostic industry has emerged as an attractive play in India's growing healthcare sector and is one of the fastest growing services in the country. The domestic diagnostic industry is estimated at USD9bn (around INR 675bn) and is expected to grow at a compounded annual growth rate (CAGR) of ~10% over the next 5 years. Growth will be primarily driven by change in demographics, increase in lifestyle diseases, and higher income levels across all strata of society, rise in preventive testing, deeper penetration with asset-light expansion, and spread of healthcare services and insurance.

The diagnostic segment is a critical component of the healthcare sector. Globally, ~80% of physician diagnoses are a result of laboratory tests. There are mainly 3 types of tests: Routine, clinical lab and specialty tests.

- Routine tests: Common tests like sugar, cholesterol, HIV, pap, pregnancy, etc.
- Clinical lab tests to monitor diseases and drug treatments
- Specialty tests: Genetics, immunology, oncology, endocrinology and other critical segments

The Indian diagnostic industry is highly fragmented and under-penetrated despite the presence of over 1 lakh labs. Diagnostic chains command ~16% market share. The 4 major players – Dr Lal PathLabs (DLPL), Metropolis Healthcare (METROHL), SRL Diagnostics (SRL) and Thyrocare Technologies – have a share of ~6%. So, there is a huge opportunity for national players to consolidate and for organic expansion. We believe organized players with national presence would grow at 15-17% CAGR over the next five years and continue to garner market share, led by asset light models and strong cash flows. The growth of these diagnostics would be majorly volume-driven, given the high level of competition and government-imposed regulations. Attracted by historically high growth rates (20-25%) lucrative returns, and low entry barriers, most players compete on pricing to garner volumes quickly and move up the cost curve, supported by PE investors. To capture the increasingly important shift towards the consumer, industry leaders have started to implement initiatives such as retailer partnering, offering home testing, and enhancing engagement with patients through digital presence, in addition to maintaining their basic testing services as a safety net. A faster shift of unorganized business to organized players, potential consolidation, likely increase in preventive check-ups and sizeable scale would benefit large organized

players with strong balance sheets.

The industry is broadly segregated into pathology testing and imaging diagnostic services. Pathology testing (in-vitro diagnosis) includes sample collection in the form of blood, urine and stool. This is followed by the sample's analysis using laboratory equipment and technology to derive useful clinical information for assisting in patient treatment. The imaging diagnostic segment consists of more complex tests like computed tomography (CT) scans and magnetic resonance imaging (MRI) and other highly specialised tests like positron emission tomography (PET)-CT scans. As per estimates, the pathology segment contributes ~58% of total market revenue.

With private diagnostic chains taking the lead with superior and quality services, highly accurate and wider test menu -- resulting in market share gains -- we expect consolidation in the sector going forward. Currently, only 1% of labs are National Accreditation Board of Laboratories (NABL) and/or College of American Pathologists (CAP) accredited. Only a few large national players like SRL, DLPL, METROHL, Thyrocare, Max Healthcare and Apollo Clinic have accredited labs.

B. Promoters:

Jagdish Umakant Nayak and Jyoti Jagdish Nayak are the Promoter of our Company.

C. Offer Size:

This is Initial public offering of up to 6,02,400 equity shares of ₹10 each of the Company for cash at a price of ₹ 96 per equity share (including share premium of ₹ 86 per equity share), aggregating to ₹ 578.30 lakhs.

D. Objects of the Offer:

The proposed utilisation of the Proceeds from fresh issue is set forth below:

Sr. No.	Object	Amount Proposed to be Utilised from the Offer Proceeds (₹ in lakhs)
1.	Expansion of Diagnostic Business	498.67
2.	General Corporate Purposes	41.33
3.	Issue Related Expenses	38.30
	Total	578.30

E. Pre-Offer Shareholding of Promoters, Promoter Group:

Sr.	Particulars	Pre-Offer	
		No. of Shares	% Holding
a)	Promoters		
	Jagdish Umakant Nayak	6,74,500	40.15%
	Jyoti Jagdish Nayak	6,75,000	40.18%
	Total	13,49,500	80.33%
b)	Promoter Group		
	Ashutosh Jagdish Nayak	100	Negligible
	Ananya Jagdish Nayak	100	Negligible
	Anant Umakant Nayak	100	Negligible
	Eshwari Anant Nayak	100	Negligible
	Siddhesh Anant Nayak	55,500	3.30%
	Total	55,900	3.30%
	Grand Total	14,05,400	83.63%

F. Summary of Financial Information:

Particulars	(₹ in Lakhs)			
	30.09.23	31.03.23	31.03.22	31.03.21
Share Capital	150.00	150.00	150.00	66.66
Net Worth	244.86	238.08	184.81	139.03

Total Revenue	308.12	636.34	645.70	459.63
Profit After Tax	6.78	61.31	51.26	40.24
Basic and Diluted Earnings per Equity Share (in ₹)	0.45	4.09	3.42	6.04
Net Asset Value/Book Value per Equity share (in ₹)	16.32	15.87	12.32	20.85
Total Borrowings	81.59	102.91	88.61	53.67

Our Annual Reports and financial statements are also available on our website at: www.ctllab.in.

G. Auditor qualifications which have not been given effect to in the Restated Financial Information:

There are no auditor qualifications which would require adjustments in the Restated Financial Information and for which no such effect has been given.

H. Summary of Outstanding Litigations:

For further details regarding the same, please refer to the chapter titled ‘Outstanding Litigations and Material Developments’ beginning on page 151 of the Draft Prospectus.

I. Risk Factors:

Please see ‘Risk Factors’ beginning on page 17.

J. Summary of Contingent Liabilities of our Company:

We do not have any contingent liabilities as on September 30, 2023.

K. Summary of Related Party Transactions:

Please find below summary of Related Party Transactions:

	(₹ in Lakhs)			
Particulars	30.09.23	31.03.23	31.03.22	31.03.21
<u>Remuneration and Salaries</u>				
Jagdish Nayak	12.00	24.00	20.00	12.00
Jyoti Nayak	12.00	24.00	20.00	12.00
Ashutosh Nayak	-	-	5.31	7.08
Rahul Motilal Patil	1.26	-	-	-
<u>Remuneration outstanding at the end of year</u>				
Jagdish Nayak	1.49	3.59	0.06	0.06
Jyoti Nayak	12.12	3.59	0.14	4.54
<u>Unsecured Loans taken / repaid</u>				
<u>Acceptance of Loan</u>				
Jagdish Nayak	35.06	28.56	52.88	3.00
Jyoti Nayak	3.50	35.14	19.50	7.34
<u>Repayment of Loan</u>				

Jagdish Nayak	35.64	33.00	45.76	19.82
Jyoti Nayak	35.49	11.56	9.59	-
<u>Loans Outstanding at the year end - (Receivable) / Payable</u>				
Jagdish Nayak	2.54	3.07	7.51	0.39
Jyoti Nayak	1.50	33.50	9.91	-
<u>Rent paid</u>				
Jagdish Nayak	1.20	1.20	2.40	1.62
Jyoti Nayak	1.20	1.20	2.40	1.62
<u>Rent outstanding at the year end</u>				
Jagdish Nayak	0.05	0.10	0.60	3.38
Jyoti Nayak	1.30	0.10	0.59	3.38
<u>Rent Deposit</u>				
Jagdish Nayak	9.00	9.00	9.00	-
Jyoti Nayak	9.00	9.00	9.00	-
<u>Clinitech Lab, Prtnership Firm</u>				
Investment / (Withdrawal)	-	-1.65	4.90	-3.50
Income from Firm	-	-	1.10	1.20
Closing Balance of Investment at the end of year	12.79	12.79	14.00	14.61
Sales to Firm	1.39	3.41	17.02	17.20
Trade Receivable at the end of year	5.37	4.19	4.21	1.88

For further details please refer “Annexure V- Related Party Transaction” on page 136, under the section titled “Financial Information” beginning on page 114 of this Draft Prospectus.

L. Financing Arrangements:

There are no financing arrangements wherein the Promoters, Promoter Group, the Directors of our Company and their relatives, have financed the purchase by any other person of securities of our Company other than in the normal course of the business of the financing entity during the period of six months immediately preceding the date of the Draft Prospectus.

M. Weighted Average Price of the Equity Shares acquired by the Promoter in the last one year preceding the date of this Draft Prospectus:

Name of the Promoters	No. of Equity Shares held	Average cost of Acquisition (in ₹)
Jagdish Umakant Nayak	4,16,667	Nil*
Jyoti Jagdish Nayak	4,16,667	Nil*

*Cost of acquisition of equity shares is NIL as the shares acquired by way of bonus shares

For further details please refer to chapter titled “Capital Structure” on page 43.

N. Average cost of acquisition of shares for promoter:

Name of the Promoters	No. of Equity Shares held	Average cost of Acquisition (in ₹)
Jagdish Umakant Nayak	6,74,500	Nil*
Jyoti Jagdish Nayak	6,75,000	Nil*

*Cost of acquisition of equity shares is NIL as the shares acquired by way of bonus shares and net of selling consideration for the shares sold.

O. Pre-IPO Placement:

The Company does not intend to undertake Pre-IPO Placement in the Offer.

P. Issue of equity shares made in last one year for consideration other than cash

Other than as mentioned below, our Company has not issued any Equity Shares for consideration other than cash in the one year preceding the date of this Draft Prospectus:

Date of Allotment	No. of Equity Shares	Face Value (₹)	Issue Price (₹)	Nature / Reason of Allotment	Nature of Consideration
March 28, 2022	8,13,334	10	Nil	Bonus Issue	Other than Cash

Q. Split / Consolidation of Equity Shares in the last one year

There was no split / consolidation of the Equity Shares of our Company since incorporation.

R. Exemption from complying with any provisions of Securities Laws granted by SEBI

Our company has not applied or received any exemption from complying with any provisions of securities laws by SEBI.

SECTION III - RISK FACTORS

An investment in the Equity Shares involves a high degree of risk. You should carefully consider all the information in this Draft Prospectus, including the risks and uncertainties summarised below, before making an investment in our Equity Shares. The risks described below are relevant to, the industries our Company is engaged in, our Company and our Equity Shares. To obtain a complete understanding of our Company, you should read this section in conjunction with 'Our Business' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' on page 77 and 140 respectively, of this Draft Prospectus as well as the other financial and statistical information contained in this Draft Prospectus. Prior to making an investment decision, prospective investors should carefully consider all of the information contained in 'Financial Statements' on page 114 of this Draft Prospectus. Unless stated otherwise, the financial data in this section is as per our financial statements prepared in accordance with Indian GAAP, as restated.

If any one or more of the following risks as well as other risks and uncertainties discussed in this Draft Prospectus were to occur, our business, financial condition and results of our operation could suffer material adverse effects, and could cause the trading price of our Equity Shares and the value of investment in the Equity Shares to materially decline which could result in the loss of all or part of your investment.

This Draft Prospectus also contains forward looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors, including the considerations described below and elsewhere in this Draft Prospectus.

These risks are not the only ones that our Company face. Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations. Unless specified or quantified in the relevant risk factors below, we are not in a position to quantify financial or other implication of any risks mentioned herein.

Materiality

The Risk factors have been determined on the basis of their materiality. The following factors have been considered for determining the materiality.

- 1. Some events may not be material individually but may be material when considered collectively.*
- 2. Some events may have an impact which is qualitative though not quantitative.*
- 3. Some events may not be material at present but may have a material impact in the future.*

INTERNAL RISKS

- 1. Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.***

Since we primarily derive all of our revenues from walk-in customers, our brand and reputation are critical for the success of our business and operations. Our ability to maintain and improve our brand name and brand image is dependent on factors such as quality, accuracy and efficiency of our diagnostic tests, turnaround time and patient trust and satisfaction, the performance of our service network, the introduction of new tests and services. Further, as we expand into new geographic markets within India, and as the market becomes increasingly competitive, maintaining and enhancing our brand may become costly and difficult.

Our services are designed to diagnose and detect early symptoms of diseases and to help prevent diseases and other health conditions by monitoring a variety of health indicators. While there have not been any past material incidences of errors, users of healthcare services have a greater sensitivity to errors than users of services or products that are not intended for the diagnosis, treatment and prevention of diseases. We train our medical personnel, including physicians, radiologists, technicians and other staff to provide accurate and timely test results. However, any delays or inaccuracies in the results we provide, including due to inherent limitations in the technology and equipment used or due to wrong interpretation of test results by doctors, may result in the wrong treatment being prescribed to a patient, which may cause potential harm to such patient and may induce negative publicity and cause other harm to our brand and reputation. In addition, if our personnel make errors in the handling and labelling of patient specimens, or in the operation of our complex medical equipment, or if they inadequately or improperly extract specimens from patients causing bodily harm, our test results may not be accurate and we may become liable under healthcare or other laws

for acts or omissions by our employees, which may adversely affect our brand and reputation and in turn our operations and financials will be adversely impacted.

2. *Any inability on our part to maintain quality standards could adversely impact our business, results of operations and financial condition.*

Quality of services is a vital element for our sector. We provide distinguished services to a variety of customers which provides us a safeguard against the change of trend with any type of customer as our operational cash influges get balanced with other type of our customer base. Any rapid change in our customers' expectation on account of changes in technology or introduction of new kind of services or service standards or hygiene expectations of our staff and centres by our customers or any other reason and failure on our part to meet their expectation could adversely affect our business, results of operations and financial condition. Any failure on our part to successfully meet customer demand or preference may negatively affect our business, results of operation and financial condition.

3. *Negative publicity with respect to our services or the industry in which we operate could adversely affect our business, financial condition and results of operations.*

Our business is dependent on the trust our clients have in the quality of our services and tests conducted by our diagnostic centres. Any negative publicity regarding our Company, services, brand, our staff behavior or our diagnostic centres and industry including those arising from a drop in quality of our services, or any other unforeseen events could affect our reputation and our results from operations. Any damage to our brand or our reputation may result in withdrawal of business by our existing clients as well as loss of new business. Furthermore, negative publicity may result in an increase in regulatory scrutiny of industry practices as well as an increase in claims litigation, which may further increase our costs of doing business and affect our profitability. Accordingly, any adverse effect on our brand and reputation may have an adverse effect on our business, financial condition and results of our operations.

Further, any failure or defect in our services could result in a claim against us for damages, regardless of our responsibility for such a failure or defect. We currently carry no services liability insurance with respect to our services. Although we attempt to maintain quality standards, we cannot assure that all our services would be of uniform quality, which in turn could adversely affect the value of our brand, and our sales could be diminished if we are associated with negative publicity which in turn will negatively affect our results of operation and financial condition.

4. *Our operations are concentrated in Thane and Navi Mumbai, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.*

All our diagnostic centres are located in Thane and Navi Mumbai region, 100% of our operations are concentrated in these regions. We have derived 100% of our revenues for the period ended September 30, 2023 and for the financial years ended March 31, 2023, 2022 and 2021, respectively. Our expansion is also planned in Thane, Navi Mumbai and Raigad district, which subjects us to various risks, including but not limited to the following risks:

- regional natural disasters;
- vulnerability to change of policies, laws and regulations or the political and economic environment of Western India;
- constraints on our ability to diversify across states;
- perception by our potential clients, that we are a regional player, which hampers us from competing against other large companies at a national level.

Further, any political disruptions, natural calamities or civil disruptions, opposition and protests, particularly in locations where we operate, could adversely affect our business operations or strategy.

5. *We have not entered into long-term contracts with our customers and typically operate on the basis of orders from our walk-in customers, any loss of customers could adversely impact our revenues and profitability.*

We generate sales generally by our continuing relationships with our customers as well as walk-in customers. We do not enter in any long- term contract with any of our customers. We offer range of diagnostic tests which are being offered by our diagnostic centres operating at various locations. For more details of our diagnostic centres and tests offered by our Company, please refer to section titled "Our Business" beginning on page 77.

We have not entered into any agreements with any of our customers and loss of any significant customers would have a material effect on our financial results. We cannot assure you that the customers would continue to give new business or we would be able maintain the historical levels of business from these customers or that we will be able to replace these customers in case we lose any of them. While we are constantly striving to increase our customer base and reduce dependence on any particular customer, there is no assurance that we will be able to broaden our customer base in any future periods or that our business or results of operations will not be adversely affected by a reduction in demand or cessation of our relationship with any of our major customers.

Our existing client relationships help us to get repeat business from our customers. This has helped us maintain a relationship with our customers and improve our customer retention strategy. We combine our expertise with an understanding of the diagnostic market developed through market feedback and extensive interaction with various customers. We constantly try to address customer needs with a variety of customized packages. However, any change in the customer preferences can adversely affect our business and in turn our financial performance.

6. *Substantial portion of our purchases has been dependent upon limited number of customers.*

Purchases from our top 10 vendors constituted 80.31%, 79.76%, 92.75% and 88.19% of our Purchases for the period ended September 30, 2023 and financial years ending March 31, 2023, 2022 and 2021, respectively. We have not entered into any service agreements with most of our suppliers and loss of any significant vendor would have a material effect on our financial results. We cannot assure you that we would be able maintain the historical levels of business from these suppliers or that we will be able to replace them in case we lose any of them. While we are constantly striving to increase our supplier base and reduce dependence on any particular vendor, there is no assurance that we will be able to do so in any future periods or that our business or results of operations will not be adversely affected by cessation of our relationship with any of our major vendors.

7. *Our Promoters and Executive Directors, Jagdish Umakant Nayak and Jyoti Jagdish Nayak plays key role in our functioning and we heavily rely on their knowledge and experience in operating our business and therefore, it is critical for our business that our Promoters remain associated with us. Our success also depends on our key managerial personnel and our ability to attract and retain them. Any loss of our key person could adversely affect our business, operations and financial condition.*

The success of our business operations is attributable to our Promoters and Executive Directors and the key managerial team. We believe that our relation with our Promoters, who has rich experience in markets, managing customers and handling overall businesses, has enabled us to experience growth and profitability. Both our Promoters have individual industry experience of more than 30 years. They have been actively involved in the day-to-day operations and management since the incorporation of the Company. Further, our Promoters/ Directors have also promoted other companies/ firms/ ventures and may continue to do so. If they divert their attention to the other companies or businesses, we may not be able to function as efficiently and profitably as before. We may have to incur substantial additional costs to replace the services of our Promoters or we may not be able to do so at all, which could adversely affect our business operations and affect our ability to continue to manage and expand our business. The loss of service of the Promoters and other senior management could seriously impair the ability to continue to manage and expand the business efficiently. If we are unable to retain qualified employees at a reasonable cost, we may be unable to execute our growth strategy. For further details of our Directors and key managerial personnel, please refer to Section “Our Management” on page 103 of this Draft Prospectus.

8. *Our business requires us to obtain and renew certain registrations, licenses and permits from government and regulatory authorities and the failure to obtain and renew them in a timely manner may adversely affect our business operations.*

We deal in healthcare services and results of our services decide the road map for treatment of our customers accordingly our business is highly regulated. Our business operations require us to obtain and renew from time to time, certain approvals, licenses, registrations and permits, some of which may expire in the normal course of business and for which we may have to make an application for obtaining the approval or its renewal. We will be applying for certain approvals relating to our business. If we fail to maintain such registrations and licenses or comply with applicable conditions, or a regulatory authority claims we have not complied, with these conditions, our certificate of registration for carrying on a particular activity may be suspended and/or cancelled and we will not then be able to carry on such activity. This could materially and adversely affect our business, financial condition, and results of operations. We cannot assure you that we will be able to obtain approvals in respect of such applications or any application made by us in the future. For more information about the licenses required in our business and the licenses and approvals applied

for, please refer “Government and Other Approvals” on page 154 of this Draft Prospectus, respectively.

9. *Because we operate in a highly competitive industry, our revenues, profits or market share could be harmed if we are unable to compete effectively.*

The segments of the industry in which we operate are subject to intense competition. Our principal competitors are other service providers of the similar services, including other major well-established and recognized brands. We also compete against smaller, independent and local diagnostic labs. If we are unable to compete successfully, our revenues or profits may decline or our ability to maintain or increase our market share may be diminished.

We compete primarily on brand name recognition and reputation, customer trust & satisfaction, quality of service etc. Some of our competitors are larger than we are in terms of size of operations and nation-wide presence and our competitors may also have greater financial and marketing resources than we do, which could allow them to improve their properties and expand and improve their marketing efforts in ways that could affect our ability to compete effectively. In addition, industry consolidation may exacerbate these risks. In all these conditions where we fail to compete effectively with our competitors, our business and in turn our financial performance will be impacted.

10. *We are subject to risks arising from interest rate fluctuations, which could adversely affect our results of operations, planned expenditures and cash flows.*

As of September 30, 2023, we have total borrowing of Rs. 81.60 Lakhs which is subject to risk of fluctuation in interest rates. If the interest rates of our existing or future borrowings increase significantly, our cost of funds will increase. A further increase in interest rates (or the current high interest rate environment not changing) may have an adverse effect on our results of operations and financial condition. While we could consider refinancing the loan or hedging interest rate risks in appropriate cases, there can be no assurance that we will be able to do so on commercially reasonable terms, that our counterparties will perform their obligations, or that these agreements, if entered into, will protect us adequately against interest rate risks. Further, if such arrangements do not protect us adequately against interest rate risks, they would result in higher costs.

11. *We have referred to the data derived from third party industry data aggregators and government publications, publicly available information, and sources.*

Unless stated otherwise, industry and market data used throughout this Draft Prospectus has been obtained or derived from industry data aggregators and government publications, publicly available information, and sources. Industry publications generally state that the information contained in those publications has been obtained from sources believed to be reliable but that their accuracy and completeness are not guaranteed, and their reliability cannot be assured. Although, our Company believes that industry data used in this Draft Prospectus is reliable, it has not been independently verified. Further, the extent to which the industry and market data presented in this Draft Prospectus is meaningful depends on the reader's familiarity with and understanding of, the methodologies used in compiling such data. There are no standard data gathering methodologies in the industry in which we conduct our business, and methodologies and assumptions may vary widely among different industry sources.

12. *We depend on third-parties to provide us our testing equipment and reagents, and any failure to continue to do so or recall of existing testing equipment and reagents could adversely affect our business, results of operations and financial condition.*

We depend on third-party vendors and suppliers to procure our testing equipment and reagents. Certain of these suppliers require us to purchase minimum quantity or value of purchases. We cannot assure you that we will be able to continue to obtain adequate supplies of equipment, reagents and test kits, in a timely manner and without any defects, in the future. Any disruption in our business may also result in us not meeting our minimum purchase obligations, leading to potential disruption to our supply of equipment or reagents. Any such reductions or interruptions in the supply of equipment or reagents, defects in reagent and test kits and any inability on our part to find alternate sources for the procurement of such items, may have an adverse effect on our ability to provide our services in a timely or cost-effective manner. Further, the procurement cost of testing equipment and reagents produced outside India may increase due to depreciation of Indian Rupee, and the suppliers may therefore demand to re-negotiate the supply contracts with us. In the event of an increase in the price of such items, we cannot assure you that we will be able to correspondingly increase the price of our services. Any such disruption in supply or increase in costs, can adversely affect our business, results of operations and financial condition.

13. Any inadequacy in collection of, or failure or delay in the delivery of, specimens to our processing laboratories could compromise or destroy the integrity of such specimens, which could adversely affect our business, results of operations and financial condition.

The process of collecting specimens is highly dependent on the skill and performance of our front-end employees. Any losses, errors or delays in the specimen collection, preparation, labelling and storage process could result in us not being able to effectively provide our services and adversely affect our business and reputation.

The timely pickup, transportation and delivery of specimens depend on several factors beyond our control, including weather and road conditions. Any disruptions in transportation services on account of natural disasters, strikes, lock-outs, terrorism, inadequacies in the road or air infrastructure, weather related problems, or other events could affect our ability to receive specimens and generate test results in a timely manner. For example, the lockdown due to the outbreak of COVID-19 has marginally affected the process and timeliness of collection and delivery of specimens. While most of our diagnostic centres are serviced through our in-house logistics team, we also rely on the services of third-party phlebotomists and logistics providers for specialized tests including for collection of COVID-19 samples. As a result, we may experience loss of specimens, delays and inefficiencies, including mislabeling of specimen, which are not within our control. If we are unable to deliver or receive specimens at our processing laboratories in a timely manner, their integrity as well as the outcome of results may be compromised, or the reporting of results of tests to patients may be delayed, which could adversely affect our reputation. Further, specimens may be lost, damaged or contaminated due to mishandling while in transit. In the event specimens are lost, destroyed, damaged or contaminated, we may incur additional costs, such as the cost of re-administering tests or from delays in the generation of critical test results. The occurrence of any such events could adversely affect our reputation, business, results of operations and financial condition.

14. Implementation of pricing policies by the Government or other authorities could adversely affect our business, results of operations and financial condition.

The prices that we charge for our services could become subject to recommended or maximum fees set by the Government or other authorities. For example, the government could introduce “price lists” for services that could be mandatory or, even if not mandatory, result in guidance for the prices we charge for our diagnostic healthcare services. Further, we are not empaneled diagnostic centre under the Central Government Health Scheme (“CGHS”) and hence we are not entitled to enjoy our services at CGHS rates and/or CGHS recommended rates. However, in future, if we get our diagnostic centres empaneled, then we may enjoy the benefits at a future date. The implementation of such policies and the restriction under CGHS affecting the prices we charge could, in effect, limit our ability to charge customers higher prices for our services, which may have an adverse effect on our business, results of operations and financial condition.

15. Failure to introduce new tests, services and technologies or acquire new or improved equipment could adversely affect our business, results of operations and financial condition.

The diagnostic healthcare services industry is subject to constant innovations in, and improvements to tests and services, processes and technologies. In order to maintain our position in our industry, we must continue to anticipate and keep abreast of the demands and needs of our patients through investing in technologies and equipment to develop new tests and services and improve existing tests and services. If we fail to anticipate trends in the industry, or we are not able to introduce or develop new tests, services and technologies before or at least concurrently with our competitors and at competitive prices, we may consequently be unable to deliver our diagnostic healthcare services involving new tests, services or technologies in an efficient and effective manner. As a result, our business, results of operations and financial condition may be adversely affected.

In addition, technological advancement could lead to the development of more cost-effective technologies or non-invasive diagnostic healthcare tests which are more convenient or less expensive than the tests that we offer. The introduction of such technology and its subsequent use by our existing and potential patients could lead to a decline in the demand for our services. Advances in technology may lead to the development of more cost-effective tests that can be performed outside a commercial clinical laboratory, such as tests that can be performed by hospitals in their own laboratories, point-of-care tests that can be performed by doctors in their surgeries, or home-testing that can be performed by patients or other non-medical professionals themselves, such as pregnancy and diabetes tests. In addition, manufacturers of laboratory equipment and test kits could seek to increase their sales by marketing point-of-care laboratory equipment to physicians and by selling test kits approved for home use to both physicians and patients.

Increased testing by physicians in their offices and home use by patients could affect the market for our services and, therefore, adversely affect our business, results of operations and financial condition.

16. *Cyber threats and non-compliance with and changes in privacy laws and regulations may adversely affect our business, results of operations and financial condition and cash flows.*

We may face cyber threats such as (i) phishing and trojans - targeting constituents, wherein fraudsters send unsolicited mails to the constituents seeking account sensitive information or to infect their systems to search and attempt ex-filtration of account sensitive information; (ii) hacking – wherein attackers seek to hack into our website and portal with the primary intention of causing reputational damage to us by disrupting services; (iii) data theft – wherein cyber criminals may attempt to intrude into our network with the intention of stealing our data or information; and (iv) advanced persistent threat – a network attack in which an unauthorised person gains access to our network and remains undetected for a long period of time with an intention to steal our data or information rather than to cause damage to our network or organization. Although there have been no such instances in past, any such security breaches or compromises of technology systems in future could result in damage to our reputation, institution of legal proceedings against us and potential imposition of penalties, which may have an adverse effect on our business and results of operations.

Further, we must comply with privacy laws and regulations with respect to the use, storage and disclosure of protected patients' health information, as well as laws pertaining to the electronic transmission of such information, such as the Information Technology (Reasonable security practices and procedures and sensitive personal data on information) Rules, 2011 ("IT Rules"). In the ordinary course of our business, we receive certain personal information about our customers and their patients, including by electronic means. Under the provisions of the IT Rules, we are required to and we have ensured security of all personal data collected by us, formulated a privacy policy and subsequently published such policy on our website. Accordingly, we depend upon our internal information technology system for the storage and transmission of such confidential information. A compromise in our security systems (including systems of third-party information technology vendors) that results in customer or patient personal information being obtained by unauthorised persons or our failure to comply with security requirements for use, storage and transmission of sensitive information could adversely affect our reputation with our customers and result in litigation against us or the imposition of penalties and fines, all of which may adversely impact our business, results of operations, financial condition and liquidity. Further, new requirements for additional security and protection of the privacy of patient information could prove technically difficult, time-consuming or expensive to implement. Failure to comply with privacy laws and regulations may adversely impact our business and reputation and result in litigation.

17. *Our insurance coverage may not be sufficient or adequate in protecting us against all or certain operating hazards and from all or certain losses and this may have an adverse impact on the financial conditions of the business.*

As on the date of this Draft Prospectus, Our Company has availed of certain insurance coverage. We believe that the insurance coverage taken by us will protect our business and from any damages or losses that we may suffer in the future. Further, our insurance coverage would be reasonably adequate to cover the normal risks associated with the operation of our businesses. However, we cannot assure you that any claim under the insurance policies maintained by us will be honoured fully, in part or on time, or that we have taken out sufficient insurance to cover all our losses. In addition, our insurance coverage expires from time to time. We may or may not apply for the renewal of our insurance coverage in the normal course of our business, but we cannot assure you that such renewals will be granted in a timely manner, at acceptable cost or at all. To the extent that we suffer loss or damage, or successful assertion of one or more large claims against us for events for which we are not insured, or for which we did not obtain or maintain insurance, or which is not covered by insurance, exceeds our insurance coverage or where our insurance claims are rejected, the loss would have to be borne by us and our results of operations, financial performance and cash flows could be adversely affected.

18. *Our ability to attract individual patients is largely dependent on the disposable income and increasing general health awareness of India's general population, which could decline due to a variety of factors.*

Our key source of income is from individual patients. Our individual consumer business contributed to 100% of our revenue from operations for September 30, 2023 and last three financial years. The growth of these types of customers is dependent on brand recognition, wider acceptance of our business in the communities in which we operate and our ability to compete effectively within our industry, all of which we may be negatively affected by a wide variety of reasons. For example, individual decisions regarding when to access healthcare services may be impaired by the absence of a developed health insurance sector or the lack of appropriate government programs to cover the costs of

healthcare. Moreover, given the small proportion of people in India presently with health insurance, customers in India generally are responsible for all or part of the cost of diagnostic healthcare services, which means that a decrease in disposable income that can be allocated for healthcare services, or even the perception thereof, such as during times of economic downturn, can lead to a reduction in individuals' expenditures for healthcare services. In addition, we cannot assure you that the current increasing trend in health awareness and demand for preventive healthcare services will continue, and it may even reverse. Any of the above reasons may affect our ability to maintain or increase growth in walk-in customers, which may adversely affect our business, financial condition, results of operations and cash flows.

19. *Employee misconduct, errors or fraud could expose us to business risks or losses that could adversely affect our business prospects, results of operations and financial condition.*

Employee misconduct, errors or frauds could expose us to business risks or losses, including regulatory sanctions, penalties and serious harm to our reputation. Such employee misconduct includes breach in security requirements, misappropriation of funds, hiding unauthorized activities, failure to observe our stringent operational standards and processes, and improper use of confidential information. It is not always possible to detect or deter such misconduct, and the precautions we take to prevent and detect such misconduct may not be effective. In addition, losses caused on account of employee misconduct or misappropriation of petty cash expenses and advances may not be recoverable, which we may result in write-off of such amounts and thereby adversely affecting our results of operations. Our employees may also commit errors that could subject us to claims and proceedings for alleged negligence, as well as regulatory actions in which case, our reputation, business prospects, results of operations and financial condition could be adversely affected.

20. *Failure or malfunction of our equipment could adversely affect our ability to conduct our operations.*

Our operations are subject to risks inherent in the use of complex medical equipment. We have experienced routine breakdowns and may experience breakdowns and failures or there could be injury to our employees or others either because of defects, faulty maintenance or repair, or improper use or lack of timely servicing of our equipment. Our Company has entered into comprehensive maintenance contracts for which we pay fixed fees for maintenance of major medical equipment and have not incurred any material costs associated with repair and maintenance of medical equipment in the past three fiscal years. However, any significant malfunction or breakdown of our equipment may entail significant repair and maintenance costs and cause disruptions and delays in our operations. Any injury caused by our medical equipment in our diagnostic centres due to equipment defects, improper maintenance or improper operation could subject us to liability claims. We cannot assure you that we would be able to effectively respond to any such events, in a timely manner and at an acceptable cost, which could lead to an inability to effectively provide our services and, therefore, affect our business and reputation.

21. *Our inability to manage growth could disrupt our business and reduce our profitability.*

A principal component of our strategy is to continue to grow by expanding the size and geographical scope of our businesses. This growth strategy will place significant demands on our management, financial and other resources. It will require us to continuously develop and improve our operational, financial, and internal controls. Continuous expansion increases the challenges involved in financial management, recruitment, training and retaining high quality human resources, preserving our culture, values, and entrepreneurial environment, and developing and improving our internal administrative infrastructure. Any inability on our part to manage such growth could disrupt our business prospects, impact our financial condition, and adversely affect our results of operations.

22. *We have not made any alternate arrangements for meeting our capital requirements for the Objects of the Offer. Further we have not identified any alternate source of financing the 'Objects of the Offer'. Any shortfall in raising / meeting the same could adversely affect our growth plans, operations, and financial performance.*

As on date, we have not made any alternate arrangements for meeting our capital requirements for the objects of the Offer. We meet our capital requirements through our owned funds and internal accruals. Any shortfall in our net owned funds, internal accruals and our inability to raise debt in future would result in us being unable to meet our capital requirements, which in turn will negatively affect our financial condition and results of operations. Further we have not identified any alternate source of funding and hence any failure or delay on our part to raise money from this Offer or any shortfall in the Offer Proceeds may delay the implementation schedule and could adversely affect our growth plans. For further details please refer to the chapter titled "Objects of the Offer" beginning on page 53 of the Draft Prospectus.

23. *We do not own our Registered Office and corporate office from which we operate.*

Our Company's registered office is situated at AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India is taken on leave & license basis for a period of 5 years from April 01, 2023. However, there can be no assurance that our Company will be able to successfully renew the above leave and license agreement in a timely manner or at all and that we may be continue to use the office in case of termination of agreement. Further there can be no assurance that we will not face any disruption of our rights as a licensee and that such leave and license agreement will not be terminated prematurely by the licensor. Any such non-renewal or early termination or any disruption of our rights as licensee may require us to vacate the premises and relocate to a new premises on terms that may not be favourable to us thereby adversely affecting our business, financial conditions and results of operations. If the owner of the premises, revoke this agreement or impose terms and conditions that are unfavorable to us, we may suffer a disruption in our operations or have to pay increased rent, which could have a material adverse effect on our business, prospects, results of operations and financial condition. For further details of our office premises please refer to the section titled "Our Business" on pages 77 of the Draft Prospectus.

24. *Our results of operations are likely to vary from year to year and be unpredictable, which could cause the market price of the Equity Shares to be volatile.*

Our results of operations in any given year can be influenced by a number of factors, many of which are outside of our control and may be difficult to predict, including:

- maintaining high levels of customer satisfaction;
- costs relating to our operations;
- adhering to our high quality and process execution standards;
- pricing policies introduced by our competitors;
- the timing and nature of, and expenses incurred in, our marketing efforts;
- recruiting, training, and retaining sufficient skilled technical and management personnel;
- developing and improving our internal administrative infrastructure, particularly our financial, operational, communications, and other internal systems;

Also, please refer "*Management's Discussion and Analysis of Financial Condition and Results of Operations*" on page 140 for details on the factors affecting our financial results. All of these factors, in combination or alone could negatively impact our revenues and may cause significant fluctuations in our results of operations. This variability and unpredictability could materially and adversely affect our results of operations and financial condition.

25. *We have in the past entered into related party transactions and may continue to do so in the future, which may potentially involve conflicts of interest with the equity shareholders.*

We have entered into related party transactions with our Promoters, Promoter Group, Group Entities and Directors in compliance with the Companies Act 2013 and other applicable regulations. For details of these transactions, please refer "Related Party Transactions" on page 112.

We cannot assure you that we will be able to maintain the terms of such transactions or in the event that we enter future transactions with related parties, that the terms of the transactions will be favourable to us. Additionally, while it is our belief that all our related party transactions have been conducted on an arm's-length basis, we cannot provide assurance that we could have achieved more favourable terms had such transactions been entered with third parties. We may also enter related party transactions in the future, which could involve conflicts of interest, although going forward, all related party transactions that we may enter will be subject to audit committee or board or shareholder approval, as applicable, as under the Companies Act, 2013 and the SEBI (LODR) Regulations. As such, we can provide no assurance that these transactions will not adversely affect our business, results of operation, cash flows and financial condition.

26. *Any variation in the utilization of the Net Proceeds as disclosed in this Draft Prospectus shall be subject to certain compliance requirements, including prior Shareholders' approval.*

In accordance with Section 27 of the Companies Act, 2013, we cannot undertake any variation in the utilization of the Net Proceeds as disclosed in this Draft Prospectus without obtaining the shareholders' approval through a special resolution. In the event of any such circumstances that requires us to undertake variation in the disclosed utilisation of

the Net Proceeds, we may not be able to obtain the Shareholders’ approval in a timely manner, or at all. Any delay or inability in obtaining such Shareholders’ approval may adversely affect our business or operations. Further, our Promoters or controlling shareholders would be required to provide an exit opportunity to the shareholders who do not agree with our proposal to modify the objects of the Offer as prescribed in the SEBI (ICDR) Regulations. If our shareholders exercise such exit option, our business and financial condition could be adversely affected. Therefore, we may not be able to undertake variation of objects of the Offer to use any unutilized proceeds of the Offer, if any, even if such variation is in the interest of our Company, which may restrict our ability to respond to any change in our business or financial condition, and may adversely affect our business and results of operations.

27. Our funding requirements and deployment of the Offer Proceeds are based on management estimates and have not been independently appraised by any bank or financial institution.

Our funding requirements and the deployment of the proceeds of the Offer are based on management estimates and our current business plan. The fund requirements and intended use of proceeds have not been appraised by bank or financial institution and are based on our estimates. In view of the competitive and dynamic nature of our business, we may have to revise our expenditure and fund requirements as a result of variations including in the cost structure, changes in estimates and other external factors, which may not be within the control of our management. This may entail rescheduling, revising, or cancelling the planned expenditure and fund requirement and increasing or decreasing the expenditure for a particular purpose from its planned expenditure at the discretion of our board. In addition, schedule of implementation as described herein are based on management’s current expectations and are subject to change due to various factors some of which may not be in our control.

28. Our Company’s management will have flexibility in utilizing the Net Proceeds. There is no monitoring agency appointed by our Company and the deployment of funds is at the discretion of our Management and our Board of Directors, though it shall be monitored by our Audit Committee.

The deployment of the funds towards the objects of the Offer is entirely at the discretion of the Board of Directors/Management and is not subject to monitoring by external independent agency. As per SEBI (ICDR) Regulations, 2018, as amended, appointment of monitoring agency is required only for Offer size above ₹ 10,000.00 lakhs. Hence, we have not appointed any monitoring agency to monitor the utilization of Offer Proceeds. However, the audit committee of our Board will monitor the utilization of Offer Proceeds in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further, our Company shall inform about material deviations in the utilization of Offer Proceeds to BSE and shall also simultaneously make the material deviations / adverse comments of the audit committee public. Any inability on our part to effectively utilize the Offer Proceeds could adversely affect our financials.

29. We have experienced negative cash flows in the past. Any such negative cash flows in the future could adversely affect our business, results of operations and prospects.

The following table sets forth our cash flow for the periods indicated:

(₹ in lakhs)

Particulars	Period ended			
	September 30, 2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Net Cash from Operating Activities	-13.48	124.75	95.57	37.62
Net cash from Investing Activities	-4.85	-65.32	-146.56	54.37
Net cash flow from financing activities	-24.85	8.56	29.32	-87.79

Cash flow of a company is a key indicator to show the extent of cash generated from operations to meet its capital expenditure, pay dividends, repay loans, and make new investments without raising finance from external resources. Such negative cash flows lead to a net decrease in cash and cash equivalents. Any negative cash flow in future could adversely affect our operations and financial conditions and the trading price of our Equity Shares. For further details, please refer “Financial Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” on pages 114 and 140, respectively.

30. Our Company has availed certain unsecured loans that are callable by the lenders at any time.

As on September 30, 2023, our Company has availed certain unsecured loans from Directors that are callable on demand by our lenders. The total amount of outstanding as on September 30, 2023 is ₹ 4.04 Lakhs. For further details

of these unsecured loans, refer “*Financial Indebtedness*” on page 150. In case of any demand from our lenders for repayment of such unsecured loans, the resultant cash outgo, may adversely affect our business operations and financial position of our Company.

31. *We have not made any dividend payments in the past and our ability to pay dividends in the future will depend upon future earnings, financial condition, cash flows, working capital requirements, capital expenditures and restrictive covenants in our financing arrangements.*

In the past, we have not made dividend payments to the shareholders of our Company. The amount of our future dividend payments, if any, will depend upon various factors including our future earnings, financial condition, cash flows and requirement to fund operations and expansion of the business. There can be no assurance that we will be able to declare dividends. Any future determination as to the declaration and payment of dividends will be at the discretion of our Board of Directors. For further details, see “*Dividend Policy*” on page 113.

32. *Our Promoters and members of the Promoter Group will continue to jointly retain majority control over our Company after the Issue, which will allow them to determine the outcome of matters submitted to shareholders for approval.*

After the completion of this IPO, our Promoter and promoter group will beneficially own approximately 61.56% of our post-Issue equity share capital. As a result, the Promoters and Promoter Group may have the ability to control our business including matters relating to any sale of all or substantially all of our assets, the timing and distribution of dividends and the election or termination of appointment of our officers and directors. This control could delay, defer or prevent a change in control of the Company, impede a merger, consolidation, takeover or other business combination involving the Company, or discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company even if it is in the Company’s best interest. In addition, for so long as the Promoter Group continues to exercise significant control over the Company, they may influence the material policies of the Company in a manner that could conflict with the interests of our other shareholders. The Promoter Group may have interests that are not matching with the interests of our other shareholders and may take positions with which our other shareholders do not agree.

33. *The requirements of being a listed company may strain our resources.*

We have no experience as a listed company and have not been subjected to the increased scrutiny of our affairs by shareholders, regulators and the public that is associated with being a listed company. As a listed company, we will incur significant legal, accounting, corporate governance, and other expenses that we did not incur as an unlisted company. We will be subject to the SEBI (LODR) Regulations, which require us to file audited / unaudited reports periodically with respect to our business and financial condition. If we experience any delays, we may fail to satisfy our reporting obligations and/or we may not be able to readily determine and accordingly report any changes in our results of operations as timely as other listed companies.

As a listed company, we will need to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, for which significant resources and management overview will be required. As a result, management’s attention may be diverted from other business concerns, which could adversely affect our business, prospects, financial condition, and results of operations. Further, we may need to hire additional legal and accounting staff with appropriate and relevant experience and technical accounting knowledge and we cannot assure you that we will be able to do so in a timely manner or at all.

EXTERNAL RISKS

34. *Any downturn in the macroeconomic environment in India could adversely affect our business, results of operations, cash flows and financial condition.*

India is our key market. For Fiscal 2023, entire of our Company’s revenue from operations was from India. In addition, an increase in India’s trade deficit, a downgrading in India’s sovereign debt rating or a decline in India’s foreign exchange reserves could increase interest rates and adversely affect liquidity, which could adversely affect the Indian economy and our business, results of operations, cash flows and financial condition.

35. *Changing laws, rules and regulations and legal uncertainties, including adverse application of tax laws, in the jurisdictions in which we operate may adversely affect our business and results of operations.*

Our business is subject to various laws and regulations, which are evolving and subject to change. For details, see “Key Industrial Regulations and Policies in India” on page 86. We are also subject to corporate, taxation and other laws in effect in India, which require continued monitoring and compliance. These laws and regulations and the way in which they are implemented and enforced may change. There can be no assurance that future legislative or regulatory changes will not have any adverse effect on our business, results of operations, cash flows and financial condition.

36. *Natural disasters, fires, epidemics, pandemics, acts of war, terrorist attacks, civil unrest and other events could materially and adversely affect our business.*

Natural disasters (such as typhoons, flooding and earthquakes), epidemics, pandemics such as COVID-19, acts of war, terrorist attacks and other events, many of which are beyond our control, may lead to economic instability, including in India, or globally, which may in turn materially and adversely affect our business, financial condition and results of operations. Our operations may be adversely affected by fires, natural disasters and/or severe weather, which can result in damage to our property or inventory and generally reduce our productivity and may require us to evacuate personnel and suspend operations.

37. *Significant differences exist between Ind AS and Indian GAAP and other accounting principles, such as IFRS and US GAAP, which may be material to investors’ assessments of our financial condition, result of operations and cash flows.*

Our financial statements for Fiscals 2023, 2022 and 2021 and for the period ended September 30, 2023 included in this Draft Prospectus are prepared and presented in conformity with Indian GAAP and restated in accordance with the requirements the SEBI (ICDR) Regulations and the Guidance Note on “Reports in Company Prospectuses (Revised 2016)” issued by the ICAI. Ind AS differs from Indian GAAP and other accounting principles with which prospective investors may be familiar in other countries, such as IFRS and U.S. GAAP. Accordingly, the degree to which the Financial Statements included in this Draft Prospectus will provide meaningful information is entirely dependent on the reader’s level of familiarity with Indian accounting practices. Persons not familiar with Indian accounting practices should limit their reliance on the financial disclosures presented in this Draft Prospectus.

RISKS RELATING TO THE EQUITY SHARES AND THE OFFER

38. *Investors bear the risk of fluctuations in the price of Equity Shares and there can be no assurance that a liquid market for our Equity Shares will develop following the listing of our Equity Shares on the Stock Exchanges.*

There has been no public market for our Equity Shares prior to the Offer. The price may not necessarily be indicative of the market price of our Equity Shares after the Offer is completed. You may not be able to re-sell your Equity Shares at or above the Offer price and may as a result lose all or part of your investment.

Our Equity Shares are expected to trade on SME Platform of BSE after the Offer, but there can be no assurance that active trading in our Equity Shares will develop after the Offer, or if such trading develops that it will continue. Investors may not be able to sell our Equity Shares at the quoted price if there is no active trading in our Equity Shares.

The price at which our Equity Shares will trade at after the Offer will be determined by the marketplace and may be influenced by many factors, including:

- Our financial condition, results of operations and cash flows;
- The history of and prospects for our business;
- An assessment of our management, our past and present operations, and the prospects for as well as timing of our future revenues and cost structures; and
- The valuation of publicly traded companies that are engaged in business activities similar to ours;
- quarterly variations in our results of operations;
- results of operations that vary from the expectations of securities analysts and investors;
- results of operations that vary from those of our competitors;
- changes in expectations as to our future financial performance, including financial estimates by research analysts and investors;
- a change in research analysts’ recommendations;
- announcements by us or our competitors of significant acquisitions, strategic alliances, joint operations, or capital commitments;

- announcements of significant claims or proceedings against us;
- new laws and government regulations that directly or indirectly affect our business;
- additions or departures of Key Management Personnel;
- changes in the interest rates;
- fluctuations in stock market prices and volume; and general economic conditions.

The Indian stock markets have, from time to time, experienced significant price and volume fluctuations that have affected market prices for the securities of Indian companies. As a result, investors in our Equity Shares may experience a decrease in the value of our Equity Shares regardless of our financial performance or prospects.

39. Any future issuance of Equity Shares by us or sales of Equity Shares by the Promoters could adversely affect the trading price of our Equity Shares and in the case of the issuance of Equity Shares by us result in the dilution of our then current shareholders.

As disclosed in “Capital Structure” on page 43, an aggregate of 20% of our fully diluted post-Offer capital held by our Promoters shall be considered as minimum Promoters’ contribution and locked in for a period of three years and the balance Equity Shares held by the Promoters will be locked-in for one year from the date of Allotment. Except for the customary lock-in on our ability to issue equity or equity-linked securities discussed in “Capital Structure” on page 43, there is no restriction on our ability to issue Equity Shares. As such, there can be no assurance that our Company will not issue additional Equity Shares after the lock-in period expires or that the Promoters will not sell, pledge or encumber their Equity Shares after the lock-in periods expire. Future issuances of Equity Shares or convertible securities and the sale of the underlying Equity Shares could dilute the holdings of our Shareholders and adversely affect the trading price of our Equity Shares. Such securities may also be issued at prices below the then trading price of our Equity Shares or the Issue Price. Sales of Equity Shares by the Promoters could also adversely affect the trading price of our Equity Shares.

40. You may be subject to Indian taxes arising out of capital gains on the sale of our Equity Shares.

Previously, any gain realized on the sale of listed equity shares on or before March 31, 2018 on a stock exchange held for more than 12 months was not subject to long term capital gains tax in India if Securities Transaction Tax (“STT”) was paid on the sale transaction and additionally, as stipulated by the Finance Act, 2017, STT had been paid at the time of acquisition of such equity shares on or after October 1, 2004, except in the case of such acquisitions of Equity Shares which are not subject to STT, as notified by the Central Government under notification no. 43/2017/F. No. 370142/09/2017-TPL on June 5, 2017. However, the Finance Act, 2018, now seeks to tax on such long-term capital gains exceeding ₹ 100,000 arising from sale of equity shares on or after April 1, 2018, while continuing to exempt the unrealized capital gains earned up to January 31, 2018 on such Equity Shares. Accordingly, you may be subject to payment of long-term capital gains tax in India, in addition to payment of STT, on the sale of any Equity Shares held for more than 12 months. STT will be levied on and collected by a domestic stock exchange on which the Equity Shares are sold.

Further, any gain realized on the sale of listed equity shares held for a period of 12 months or less will be subject to short-term capital gains tax in India. Capital gains arising from the sale of the Equity Shares will be exempt from taxation in India in cases where the exemption from taxation in India is provided under a treaty between India and the country of which the seller is resident. Generally, Indian tax treaties do not limit India’s ability to impose tax on capital gains. As a result, residents of other countries may be liable for tax in India as well as in their own jurisdiction on a gain upon the sale of the Equity Shares.

41. QIBs and Non-Institutional Bidders are not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting a Bid.

Pursuant to the SEBI ICDR Regulations, QIBs and Non-Institutional Bidders are not permitted to withdraw or lower their applications (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting an application. Retail Individual Bidders can revise their applications during the Offer Period and withdraw their applications until Offer Closing Date. While we are required to complete Allotment, listing and commencement of trading pursuant to the Offer within three Working Days from the Offer Closing Date, events affecting the Bidders’ decision to invest in our Equity Shares, including adverse changes in international or national monetary policy, financial, political or economic conditions, our business, results of operations, cash flows and financial condition may arise between the date of submission of the Bid and Allotment, listing and commencement of trading. We may complete the Allotment, listing and commencement of trading of our Equity Shares even if such events occur and such events may limit the Bidders’ ability to sell our Equity Shares Allotted pursuant to the Offer or may cause the trading price of our Equity Shares to decline on listing.

42. Political, economic, or other factors that are beyond our control may have an adverse effect on our business and results of operations.

The Indian financial market and the Indian economy are influenced by economic and market conditions in other countries, particularly in emerging market in Asian countries. Financial turmoil in Asia, Europe, the U.S. and elsewhere in the world in recent years has affected the Indian economy. Although economic conditions are different in each country, investors' reactions to developments in one country can have adverse effects on the securities of companies in other countries, including India. A loss in investor confidence in the financial systems of other emerging markets may cause increased volatility in Indian financial markets and, indirectly, in the Indian economy in general. Any worldwide financial instability, including the financial crisis and fluctuations in the stock markets in China and further deterioration of credit conditions in the U.S. or European markets, could also have a negative impact on the Indian economy. Any financial disruption could have an adverse effect on our business, future financial performance, shareholders' equity, and the price of our Equity Shares.

Our performance, growth and market price of our Equity Shares are and will be dependent on the health of the Indian economy. There have been periods of slowdown in the economic growth of India. Demand for our services may be adversely affected by an economic downturn in domestic, regional, and global economies. India's economic growth is affected by various factors including domestic consumption and savings, balance of trade movements, namely export demand and movements in key imports (oil and oil products), global economic uncertainty and liquidity crisis, volatility in exchange currency rates, and annual rainfall which affects agricultural production. Consequently, any future slowdown in the Indian economy could harm our business, results of operations, cash flows and financial condition. Also, a change in the Government or a change in the economic and deregulation policies could adversely affect economic conditions prevalent in the areas in which we operate in general and our business in particular and high rates of inflation in India could increase our costs without proportionately increasing our revenues, and as such decrease our operating margins.

43. Changing laws, rules and regulations and legal uncertainties in India, including adverse application of corporate and tax laws, may adversely affect our business and financial results.

Our business and financial performance could be adversely affected by any change in laws or interpretations of existing laws, or the promulgation of new laws, rules and regulations applicable to us and our business including those relating to the industry in which we operate. There can be no assurance that the Government of India or state governments will not introduce new laws, regulations and policies which will require us to obtain additional approvals and licenses or impose onerous requirements on our business.

For example, the new Companies Act, 2013 contains significant changes to Indian company law, including in relation to the issue of capital by companies, disclosures in offer documents, related party transactions, corporate governance, audit matters, internal controls, shareholder class actions, restrictions on the number of layers of subsidiaries, prohibitions on loans to directors, insider trading and restrictions on directors and key management personnel from engaging in forward dealing. Moreover, effective April 1, 2014, companies exceeding certain net worth, revenue or profit thresholds are required to spend at least 2% of average net profits from the immediately preceding three financial years on corporate social responsibility projects, failing which an explanation is required to be provided in such companies' annual reports.

The Ministry of Finance has issued a notification dated March 31, 2015 notifying ICDS which creates a new framework for the computation of taxable income. Subsequently, the Ministry of Finance, through a press release dated July 6, 2016, deferred the applicability of ICDS from April 1, 2015 to April 1, 2016 and is applicable from FY 2017 onwards and will have impact on computation of taxable income for FY 2017 onwards. ICDS deviates in several respects from concepts that are followed under general accounting standards, including Indian GAAP and Ind AS. Such specific standards for computation of income taxes in India are relatively new, and the impact of the ICDS on our results of operations and financial condition is uncertain. There can be no assurance that the adoption of ICDS will not adversely affect our business, results of operations and financial condition going forward.

The Government of India has recently approved the adoption of a comprehensive national goods and services tax ("GST") regime that will combine taxes and levies by the Central and State Governments into a unified rate structure, with effect from July 1, 2017. Given the limited availability of information in the public domain concerning the GST, we cannot provide any assurance as to this or any other aspect of the tax regime following implementation of the GST. The implementation of this rationalized tax structure may be affected by any disagreement between certain state governments, which may create uncertainty. Any future increases or amendments may affect the overall tax efficiency of companies operating in India and may result in significant additional taxes becoming payable. If, because of a particular tax risk

materializing, the tax costs associated with certain transactions are greater than anticipated, it could affect the profitability of such transactions.

We have not determined the effect of such legislations on our business. In addition, unfavourable changes in or interpretations of existing, or the promulgation of new, laws, rules and regulations including foreign investment laws governing our business, operations and group structure could result in us being deemed to be in contravention of such laws or may require us to apply for additional approvals. We may incur increased costs and other burdens relating to compliance with such new requirements, which may also require significant management time and other resources, and any failure to comply may adversely affect our business, results of operations and prospects. Uncertainty in the applicability, interpretation or implementation of any amendment to, or change in, governing law, regulation or policy, including by reason of an absence, or a limited body, of administrative or judicial precedent may be time consuming as well as costly for us to resolve and may affect the viability of our current business or restrict our ability to grow our business in the future.

44. *Investors may have difficulty enforcing foreign judgments against us or our management.*

We are a limited liability company incorporated under the laws of India. All our directors and executive officers are residents of India and all our assets and such persons are located in India. As a result, it may not be possible for investors to effect service of process upon us or such persons outside of India, or to enforce judgments obtained against such parties outside of India.

Recognition and enforcement of foreign judgments is provided for under Section 13 of the Code of Civil Procedure, 1908 (“CPC”) on a statutory basis. Section 13 of the CPC provides that foreign judgments shall be conclusive regarding any matter directly adjudicated upon, except: (i) where the judgment has not been pronounced by a court of competent jurisdiction; (ii) where the judgment has not been given on the merits of the case; (iii) where it appears on the face of the proceedings that the judgment is founded on an incorrect view of international law or a refusal to recognise the law of India in cases to which such law is applicable; (iv) where the proceedings in which the judgment was obtained were opposed to natural justice; (v) where the judgment has been obtained by fraud; and (vi) where the judgment sustains a claim founded on a breach of any law then in force in India. Under the CPC, a court in India shall, upon the production of any document purporting to be a certified copy of a foreign judgment, presume that the judgment was pronounced by a court of competent jurisdiction, unless the contrary appears on record.

However, under the CPC, such presumption may be displaced by proving that the court did not have jurisdiction. India is not a party to any international treaty in relation to the recognition or enforcement of foreign judgments. Section 44A of the CPC provides that where a foreign judgment has been rendered by a superior court, within the meaning of that Section, in any country or territory outside of India which the Central Government has by notification declared to be in a reciprocating territory, it may be enforced in India by proceedings in execution as if the judgment had been rendered by the relevant court in India. However, Section 44A of the CPC is applicable only to monetary decrees not being of the same nature as amounts payable in respect of taxes, other charges of a like nature or of a fine or other penalty.

The United States and India do not currently have a treaty providing for reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any federal or state court in the United States on civil liability, whether or not predicated solely upon the federal securities laws of the United States, would not be enforceable in India. However, the party in whose favour such final judgment is rendered may bring a new suit in a competent court in India based on a final judgment that has been obtained in the United States. The suit must be brought in India within three years from the date of the judgment in the same manner as any other suit filed to enforce a civil liability in India.

It is unlikely that a court in India would award damages on the same basis as a foreign court if an action were brought in India. Furthermore, it is unlikely that an Indian court would enforce a foreign judgment if that court were of the view that the amount of damages awarded was excessive or inconsistent with public policy or Indian practice. It is uncertain as to whether an Indian court would enforce foreign judgments that would contravene or violate Indian law. However, a party seeking to enforce a foreign judgment in India is required to obtain approval from the RBI under the FEMA to execute such a judgment or to repatriate any amount recovered.

45. *The Equity Shares have never been publicly traded, and, after the Offer, the Equity Shares may experience price and volume fluctuations, and an active trading market for the Equity Shares may not develop. Further, the price of the Equity Shares may be volatile, and you may be unable to resell the Equity Shares at or above the Offer Price, or at all.*

Prior to the Offer, there has been no public market for the Equity Shares, and an active trading market on the SME Platform of BSE may not develop or be sustained after the Offer. Our Company and the Lead Manager have appointed BHH Securities Private Limited as Designated Market Maker for the Equity Shares of our Company. Listing and quotation does not guarantee that a market for the Equity Shares will develop, or if developed, the liquidity of such market for the Equity Shares. The Offer Price of the Equity Shares may not be indicative of the market price of the Equity Shares at the time of commencement of trading of the Equity Shares or at any time thereafter. The market price of the Equity Shares may be subject to significant fluctuations in response to, among other factors, variations in our operating results of our Company, market conditions specific to the industry we operate in, developments relating to India, volatility in the SME Platform of BSE, securities markets in other jurisdictions, variations in the growth rate of financial indicators, variations in revenue or earnings estimates by research publications, and changes in economic, legal and other regulatory factors.

SECTION IV – INTRODUCTION

THE OFFER

Following table summarises the present Offer in terms of this Draft Prospectus:

Particulars	Details of Equity Shares
Offer of Equity Shares #	Offer of 6,02,400 Equity Shares having face value of ₹10.00 each at a price of ₹ 96.00 per Equity Share (including a share premium of ₹ 86.00 per Equity share) aggregating ₹5,687.00 lakhs
Of which:	
Market Maker Reservation Portion	Offer of 31,200 Equity Shares having face value of ₹10.00 each at a price of ₹ 96.00 per Equity Share aggregating ₹29.95 lakhs
Net Offer to the Public*	Offer of 5,71,200 Equity Shares having face value of ₹10.00 each at a price of ₹ 96.00 per Equity Share aggregating ₹548.35 lakhs
	Of which:
	2,85,600 Equity Shares having face value of ₹10.00 each at a price of ₹ 96.00 per Equity Share aggregating ₹274.18 lakhs will be available for allocation to Retail Individual Investors
	2,85,600 Equity Shares having face value of ₹10.00 each at a price of ₹ 96.00 per Equity Share aggregating ₹274.18 lakhs will be available for allocation to other investors including corporate bodies or institutions, irrespective of the number of specified securities applied for.
Pre and Post Offer Share Capital of our Company	
Equity Shares outstanding prior to the Offer	16,80,000 Equity Shares
Equity Shares outstanding after the Offer	22,82,400 Equity Shares
Objects of the Offer	Please refer “ <i>Objects of the Offer</i> ” on page 53.

Public offer of 6,02,400 Equity Shares of ₹10.00 each for cash at a price of ₹ 96.00 per Equity Share of our Company aggregating to ₹ 578.30 lakhs is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. For further details see ‘Terms of the Offer’ on page 169.

The offer has been authorised by our Board pursuant to a resolution dated December 22, 2023, and by our Equity Shareholders pursuant to a resolution passed at the extraordinary general meeting held on January 16, 2024.

*As per Regulation 253(2) of the SEBI (ICDR) Regulations, as amended, as present Offer is a fixed price offer the allocation in the net offer to the public category shall be made as follows:

- a) Minimum fifty percent to retail individual investors; and
- b) Remaining to:
 - i. Other investors including corporate bodies or institutions, irrespective of the number of specified securities applied for;
- c) The unsubscribed portion in either of the categories specified in (a) or (b) above may be allocated to the applicants in the other category.

If the retail individual investor category is entitled to more than fifty per cent on proportionate basis, accordingly the retail individual investors shall be allocated that higher percentage.

SUMMARY FINANCIAL INFORMATION

STATEMENT OF ASSETS AND LIABILITIES AS RESTATED

(₹ in Lakhs)

Particulars	Note No.	30.09.2023	31.03.2023	31.03.2022	31.03.2021
Equity & Liabilities					
Shareholders Fund					
Share capital	I.1	150.00	150.00	150.00	66.66
Reserves and surplus	I.2	94.86	88.08	34.81	72.37
Total Shareholder's Fund		244.86	238.08	184.81	139.03
Non Current Liabilities					
Long Term Borrowings	I.3	25.52	28.21	35.71	48.01
Long term provisions	I.4	17.57	12.34	12.06	9.64
Other Non-Current Liabilities	I.5	0.00	149.00	0.00	0.00
Deferred Tax Liability (Net)		0.00	0.00	0.00	0.00
Total Current Liabilities		43.09	189.55	47.77	57.65
Current Liabilities					
Short Term Borrowings	I.6	56.07	74.70	52.90	5.66
Trade Payables	I.7	50.75	39.95	51.87	45.98
Other Current Liabilities	I.8	2.92	4.67	5.59	4.99
Short Term Provisions	I.9	69.74	56.38	25.80	20.02
Total Current Liabilities		179.48	175.70	136.14	76.65
Total Equity & Liability		467.43	603.34	368.74	273.32
Non-Current Assets					
a) Property Plant and Equipments					
Tangible Assets	I.10	157.62	132.16	164.81	83.75
Intangible Assets	I.10	0.94	0.78	0.28	0.28
Capital WIP / Intangible assets under development	I.10	64.22	56.00	40.50	8.25
Total Fixed Assets (a)		222.78	188.94	205.59	92.28
b) Non Current Investments	I.11	12.79	202.22	14.00	9.11
c) Long term Loans and Advances		-	0.00	0.00	0.00
d) Other Non Current Assets		-	0.00	0.00	0.00
e) Deferred Tax Assets	I.12	17.96	15.73	10.79	8.85
Total Non Current Assets		253.53	406.89	230.38	110.24
Current assets					
Current Investments		-	0.00	0.00	0.00
Inventories	I.13	20.07	14.13	15.59	8.91
Trade Receivables	I.14	66.72	48.89	36.43	55.83
Cash and Cash Equivalent balances	I.15	35.16	78.35	10.36	32.03
Short Term Loans and advances	I.16	5.67	4.32	5.62	9.21
Other Current Assets	I.17	86.27	50.75	70.36	57.11

Total Current Assets		213.90	196.44	138.36	163.09
Total Assets		467.43	603.33	368.74	273.32

STATEMENT OF PROFIT & LOSS AS RESTATED

(₹ in Lakhs)

Particulars	Note No.	30.09.2023	31.03.2023	31.03.2022	31.03.2021
Income					
Revenue from Operations	II.1	305.81	634.75	638.43	455.40
Other Income	II.2	2.31	1.59	7.27	4.23
Total Revenue		308.12	636.34	645.70	459.63
Expenditure					
Cost of Material Consumed		58.46	116.61	144.76	101.80
Laboratory testing charges	II.3	12.58	22.30	34.83	27.23
Employee Benefit Expenses	II.4	116.58	203.19	177.89	116.36
Other Expenses	II.5	90.94	157.55	174.30	127.60
Total (B)		278.56	499.65	531.78	372.99
Profit Before Interest, Depreciation and Tax		29.56	136.69	113.92	86.64
Depreciation and Amortisation Expenses		18.98	44.58	38.08	24.53
Profit Before Interest and Tax		10.58	92.11	75.84	62.11
Financial Charges	II.6	3.54	5.74	5.62	7.54
Profit before Taxation		7.05	86.37	70.22	54.57
Provision for Taxation		2.50	30.00	20.90	15.40
Provision for Deferred Tax		-2.23	-4.94	-1.94	-1.07
Total Taxes		0.27	25.06	18.96	14.33
Profit After Tax but Before Extra ordinary Items		6.78	61.31	51.26	40.24
Extraordinary Exps. / (Income)		0.00	0.00	0.00	0.00
Prior Period Items		0.00	0.00	0.00	0.00
Net Profit after adjustments		6.78	61.31	51.26	40.24
Net Profit Transferred to Balance Sheet		6.78	61.31	51.26	40.24

STATEMENT OF CASH FLOWS AS RESTATED

(₹ in Lakhs)

PARTICULARS	30.09.23	31.03.23	31.03.22	31.03.21
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit Before Tax	7.05	86.37	70.22	54.57
<i>Adjusted for :</i>				
a. Depreciation	18.98	44.58	38.08	24.53
b. Interest Expenses & Finance Cost	3.54	5.74	5.62	7.54
c. Interest & Other Income	-2.31	(1.59)	(7.27)	(4.23)
d. Other Adjustment	-	(8.03)	(5.48)	(11.31)
Operating profit before working capital changes	27.26	127.07	101.17	71.10
<i>Adjusted for :</i>				
a. Decrease /(Increase) in Inventories	-5.94	1.46	(6.68)	7.95
b. Decrease / (Increase) in trade receivable	-17.83	(12.46)	19.40	(5.34)
b. Decrease / (Increase) in Current Investments	-	0.00	0.00	0.00
c. (Increase) / Decrease in short term loans and advances	-1.35	1.30	3.59	5.56
d. Increase / (Decrease) in Trade Payables	10.80	(11.92)	5.89	(12.64)
e. Increase / (Decrease) in short term provisions	13.36	30.61	5.76	0.95
f. Increase / (Decrease) in other current liabilities	-1.75	(0.92)	0.60	(1.45)
g. (Increase) / Decrease in Other Current Assets	-35.52	19.61	(13.26)	(13.11)
Cash generated from operations	-10.98	154.75	116.47	53.02
Income Tax Paid (net of refunds)	2.50	30.00	20.90	15.40
NET CASH GENERATED FROM OPERATION	-13.48	124.75	95.57	37.62
B. CASH FLOW FROM INVESTING ACTIVITES				
a. (Purchase) / Sale of Fixed Assets	-52.82	(27.97)	(151.37)	(18.90)
b.(Purchase) / Sale of non-current investment	189.43	(188.22)	(4.88)	59.40
c. (Increase) / Decrease in Long term loans and advances	-	0.00	0.00	0.00
d. Increase / (Decrease) in Long Term Provisions	5.23	0.28	2.42	9.64
e. (Increase) / Decrease in Other Non Current Assets	-	0.00	0.00	0.00
f. Increase / (Decrease) in Other Long Term Liabilities	-149.00	149.00	0.00	0.00
g. Interest & Other Income	2.31	1.59	7.27	4.23
h. Dividend Income	-	0.00	0.00	0.00
Net cash (used) in investing activities	-4.85	(65.32)	(146.56)	54.37
C. CASH FLOW FROM FINANCING ACTIVITES				
a. Interest & Finance Cost	-3.54	(5.74)	(5.62)	(7.54)
b. Proceeds from share issued	-	0.00	0.00	0.00
c. (Repayments) / proceeds of long term borrowings	-2.69	(7.50)	(12.30)	(54.87)
d. (Repayments) / proceeds of short term borrowings	-18.63	21.80	47.24	(25.38)
Net cash generated/(used) in financing activities	-24.85	8.56	29.32	(87.79)
Net Increase / (Decrease) in cash and cash equivalents	-43.19	67.99	(21.67)	4.20
Cash and cash equivalents at the beginning of the year	78.35	10.36	32.03	27.83
Cash and cash equivalents at the end of the year	35.16	78.35	10.36	32.03

GENERAL INFORMATION

Our Company was incorporated as Clinitech Laboratory Private Limited on March 19, 2010 under the Companies Act, 1956 with the Registrar of Companies, Mumbai bearing Registration number 201078. The status of the Company was changed to public limited and the name of our Company was changed to Clinitech Laboratory Limited vide Special Resolution dated July 24, 2023 pursuant to conversion of the Company into public limited Company. The fresh certificate of incorporation consequent to conversion was issued on August 25, 2023 by the Registrar of Companies, Mumbai.

Company Identification Number	U85195MH2010PLC201078
Address of Registered office of Company	AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India
Address of Registrar of Companies	Address: Everest, 100, Marine Drive, Mumbai – 400002 Tel No: + 91 22 22812627/22020295/22846954 Fax No: +91 22 22811977
Designated Stock Exchange	BSE Limited
Listing of Shares offered in this Offer	SME Platform of BSE
Contact Person:	Bharat Kumar Bohra, Company Secretary and Compliance Officer AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India Tel: +91 22 27792281 / +91 9004072223 Fax: Not Available E-mail: ipo@clinitechlab.com Website: www.ctllab.in

For details of the changes in our Name, Registered Office and other details, please refer “*History and Certain Other Corporate Matters*” on page 92.

Our Board of Directors

Details regarding our Board of Directors as on the date of this Draft Prospectus are set forth in the table hereunder:

Sr. No.	Name and Designation	DIN	Address
1.	Jagdish Umakant Nayak <i>Chairman & Managing Director</i>	00646672	Flat No. 902, Madhuban CHS, Plot No. 25, Sector – 6, Airoli, Navi Mumbai, Thane -400708, Maharashtra, India
2.	Jyoti Jagdish Nayak <i>Whole Time Director</i>	02945625	Flat No. 902, Madhuban CHS, Plot No. 25, Sector – 6, Airoli, Navi Mumbai, Thane -400708, Maharashtra, India
3.	Ashutosh Jagdish Nayak <i>Non-Executive Director</i>	07553633	Flat No. 902, Madhuban CHS, Plot No. 25, Sector – 6, Airoli, Navi Mumbai, Thane -400708, Maharashtra, India
4.	Balu Laxman Kumbharkar <i>Non-Executive Independent Director</i>	10180137	A L 5/ 13/9, Sneh Sagar Apt, Sector-17 Airoli, Airoli Mode, Navi Mumbai, Maharashtra, India
5.	Smita Arjun Patil <i>Non-Executive Independent Director</i>	10147488	C-2-6, Room No. 2/4, Near Meghraj Tokiz, Sector -2, Vashi, Navi Mumbai - 400703, Thane, Maharashtra, India
6.	Ravikant Moreshwar Mhatre <i>Non-Executive Independent Director</i>	06362676	Mavli Prasad Niwas, H no. 30, At post Koparkhairne, Navi Mumbai - 400705, Maharashtra, India

For detailed profile of our Managing Director and other Directors, please refer “*Our Management*” and “*Our Promoters and Promoter Group*” on page 95 and 106 respectively.

Company Secretary and Compliance Officer

Our Company has appointed Bharat Kumar Bohra, the Company Secretary of our Company, as the Compliance Officer, whose contact details are set forth hereunder.

Bharat Kumar Bohra

AL-1/545, Sector 16, Airoli,
Opposite Radhikabai Meghe Vidyalaya,
Navi Mumbai, Thane - 400708,
Maharashtra, India
Tel: +91 22 27792281 / +91 9004072223
Fax: Not Available
E-mail: ipo@clinitechlab.com
Website: www.ctllab.in

Chief Financial Officer

Our Company has appointed Rahul Motilal Patil, as the Chief Financial Officer. His contact details are set forth hereunder.

Rahul Motilal Patil

AL-1/545, Sector 16, Airoli,
Opposite Radhikabai Meghe Vidyalaya,
Navi Mumbai, Thane - 400708,
Maharashtra, India
Tel: +91 22 27792281 / +91 9004072223
Fax: Not Available
E-mail: cfo@clinitechlab.com
Website: www.ctllab.in

Applicants can contact the Compliance Officer or the Lead Manager or the Registrar to the Offer in case of any pre-Offer or post-Offer related problems, such as non-receipt of letters of Allotment, credit of Allotted Equity Shares in the respective beneficiary account and refund orders, etc. All complaints, queries or comments received by Stock Exchange / SEBI shall be forwarded to the Lead Manager, who shall respond to the same.

Applicants may contact the Lead Manager for complaints, information or clarifications pertaining to the Offer.

All grievances may be addressed to the Registrar to the Offer with a copy to the relevant Designated Intermediary with whom the ASBA Form was submitted. The Applicant should give full details such as name of the sole or first Applicant, ASBA Form number, Applicant DP ID, Client ID, PAN, date of the ASBA Form, address of the Applicant, number of the Equity Shares applied for and the name and address of the Designated Intermediary where the ASBA Form was submitted by the Applicant. Further, the investor shall also enclose the Acknowledgment Slip from the Designated Intermediaries in addition to the documents/information mentioned hereinabove.

Details of Key Intermediaries pertaining to this Offer of our Company:

Lead Manager of the Offer	Registrar to the Offer
FIRST OVERSEAS CAPITAL LIMITED 1-2 Bhupen Chambers, Dalal Street, Fountain, Mumbai – 400 001, Maharashtra, India. Tel No.: +91 22 4050 9999 Fax No.: +91 22 4050 9900 Email: mb@focl.in Investor Grievance Email: investorcomplaints@focl.in Website: www.focl.in SEBI Registration No.: INM000003671 Contact Person: Mala Soneji	BIGSHARE SERVICES PRIVATE LIMITED S6-2, 6 th Floor, Pinnacle Business Park, Mahakali Caves Road, Next to Ahura Centre, Andheri East, Mumbai - 400 093, Maharashtra, India Tel. No.: +91 22 6263 8200 Email: ipo@bigshareonline.com Website: www.bigshareonline.com Investor Grievance Email: investor@bigshareonline.com SEBI Registration No.: INR000001385 Contact Person: Babu Rapheal C.

Banker to the Company	Legal Advisor to the Offer
Bank of Baroda Limited 7221, Airoli, Sector 10 Branch, Unit No. 06, Ground Floor, Signia Ocean, Sector 10A, Next to D’Mart, Airoli, Navi Mumbai – 400 708, Maharashtra, India Tel: +91 77389 51607 Email: vjairo@bankofbaroda.co.in Contact Person: Pravin Khale Website: www.bankofbaroda.in	Pabari Legal Associates Advocate & Legal Associates C2-503, 5 th Floor, Sarova, Near Thakur College, Near Samta Nagar Post Office, Kandivali East, Mumbai 400101, Maharashtra, India Tel No.: +91 9322376203 Email: pabarimukesh@gmail.com Contact Person: Mukesh J Pabari
Statutory Auditor of the Company and Peer Review Auditor	Escrow and sponsor Banker to the Offer
M/s. E. A. Patil & Associates LLP, Chartered Accountants 1301, Proxima Building (Arunachal Bhavan), Plot No. 19, Sector - 30A, Vashi, Navi Mumbai – 400 705, Maharashtra, India Tel: +91 22 4974 2721-25 Email: mohan.khebade@eaplpl.com Contact Person: CA Mohan R. Khebade Membership No.: 107639 Firm Registration No.: 117371W / W100092 Peer Review No: 013977 (valid till February 28, 2025)	[●]

Changes in Auditors for last three years

M/s. E. A. Patil & Associates LLP, Chartered Accountants, were re-appointed as Statutory Auditors of our Company for the 5 year period from FY 2019 to FY 2024 at AGM dated September 30, 2019. There has been no change in Auditors during last 3 years.

DESIGNATED INTERMEDIARIES

Self-Certified Syndicate Banks (SCSB’s)

The list of SCSBs is available at <http://www.sebi.gov.in/sebiweb/home/list/5/33/0/0/Recognised-Intermediaries> on the SEBI website, or at such other website as may be prescribed by SEBI from time to time. A list of the Designated Branches of the SCSBs with which an Applicant, not applying through Syndicate/ Sub Syndicate or through a Registered Broker, CRTA or CDP may submit the Application Forms available at <http://www.sebi.gov.in/sebiweb/home/list/5/33/0/0/Recognised-Intermediaries> on the SEBI website, or at such other website as may be prescribed by SEBI from time to time.

Registered Brokers

The list of the Registered Brokers, including details such as postal address, telephone number and e-mail address, is provided on the websites of the BSE Limited i.e. www.bseindia.com, as updated from time to time.

RTAs

The list of the RTAs eligible to accept application forms at the Designated RTA Locations, including details such as address, telephone number and e-mail address, are provided on the websites of Stock Exchange www.nseindia.com, as updated from time to time.

Collecting Depository Participants

The list of the CDPs eligible to accept application forms at the Designated CDP Locations, including details such as name and contact details, are provided on the websites of Stock Exchange www.nseindia.com as updated from time to time. The

list of branches of the SCSBs named by the respective SCSBs to receive deposits of the application forms from the Designated Intermediaries will be available on the website of the SEBI www.sebi.gov.in and updated from time to time.

Credit Rating

This being an Offer of Equity Shares, there is no requirement of credit rating for the Offer.

IPO Grading

Since the Offer is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, there is no requirement of appointing an IPO Grading agency.

Statement of Responsibility of the Lead Manager/Statement of inter se allocation of responsibilities

Since First Overseas Capital Limited is the sole Lead Manager to this Offer, a statement of *inter se* allocation of responsibilities amongst Lead Managers is not required.

Expert Opinion

Except as stated below, our Company has not obtained any expert opinions:

Our Company has received written consent dated January 19, 2024 from the Statutory Auditors, M/s. E. A. Patil & Associates LLP, Chartered Accountants to include their name as required under Section 26(1)(a)(v) of the Companies Act 2013 read with SEBI ICDR Regulations in this Prospectus as an “expert” as defined under Section 2(38) of the Companies Act 2013 to the extent and in its capacity as an independent Statutory Auditor and in respect of its (i) examination report dated December 15, 2023 on our restated financial information; and (ii) other reports and certificates issued in respect of this issue and included in this Draft Prospectus and such consent has not been withdrawn as on the date of this Draft Prospectus.

Debenture Trustees

This is an Offer of equity shares; hence appointment of debenture trustee is not required.

Appraisal and Monitoring Agency

The objects of the Offer have not been appraised by any agency.

The Objects of the Offer and means of finance, therefore, are based on internal estimates of our Company. In terms of Regulation 41 of the SEBI (ICDR) Regulations, we are not required to appoint a monitoring agency since the Offer size is not in excess of ₹10,000 lakhs.

Filing of the Offer Document

The Draft Prospectus shall not be filed with SEBI, nor shall SEBI issue any observation on the Offer Document in terms of Regulation 246(2) of SEBI (ICDR), 2018. However, pursuant to Regulation 246(5), the soft copy of Draft Prospectus has been submitted to SEBI. Pursuant to SEBI Circular Number SEBI/HO/CFD/DIL1/CIR/P/2018/011 dated January 19, 2018, a copy of the Draft Prospectus and Prospectus will be filed online through SEBI Intermediary Portal at <https://siportal.sebi.gov.in>.

Further, pursuant to SEBI Circular Number CFD/DIL1/CIR/P/2019/0000000154 dated December 11, 2019, a copy of the Draft Prospectus and Prospectus along with the with due diligence certificate including additional confirmations required to be filed under Section 26 of the Companies Act, 2013 will be filed with SEBI.

A copy of the Prospectus, along with the material contracts and documents referred elsewhere in the Prospectus, will be delivered to the RoC Office situated at Everest, 100, Marine Drive, Mumbai – 400002, Maharashtra, India.

Underwriting Agreement

This Offer is 100% Underwritten. The Underwriting agreement is dated January 23, 2024. Pursuant to the terms of the Underwriting Agreement, the obligations of the Underwriters are several and are subject to certain conditions specified therein.

The Underwriter has indicated its intention to underwrite the following number of specified securities being offered through this Offer:

Details of the Underwriter	No. of shares underwritten*	Amount Underwritten (₹in lakhs)	% of the Total Issue Size Underwritten
FIRST OVERSEAS CAPITAL LIMITED 1-2 Bhupen Chambers, Dalal Street, Fountain, Mumbai – 400 001, Maharashtra, India. Tel No.: +91 22 4050 9999 Fax No.: +91 22 4050 9900 Email: mb@focl.in Investor Grievance Email: investorcomplaints@focl.in Website: www.focl.in SEBI Registration No: INM000003671 Contact Person: Rushabh Shroff	6,02,400	578.30	100%

* Including market maker portion

In the opinion of our Board of Directors, the resources of the above-mentioned Underwriter are sufficient to enable them to discharge the underwriting obligations in full. The abovementioned Underwriter is registered with SEBI under Section 12(1) of the SEBI Act or registered as broker with the Stock Exchange.

Details of the Market Making Arrangement for this Offer

Our Company has entered into Market Making Agreement dated January 23, 2024, with the Lead Manager and Market Maker, duly registered with BSE to fulfil the obligations of Market Making:

The details of Market Maker are set forth below:

BHH Securities Private Limited
 634, Rotunda Building, Bombay Samachar Marg, Mumbai - 400023
 Tel No.:+91-22-30289783,30289874
 Email: info@bhhsecurities.com
 Contact Person: Rahul Harlalka
 SEBI Registration No: INZ000262331

The Market Maker shall fulfil the applicable obligations and conditions as specified in the SEBI (ICDR) Regulations, and its amendments from time to time and the circulars issued by BSE and SEBI regarding this matter from time to time. Following is a summary of the key details pertaining to the Market Making arrangement:

- 1) The Market Maker shall be required to provide a 2-way quote for 75% of the time in a day. The same shall be monitored by the Stock Exchange. Further, the Market Maker shall inform the Stock Exchange in advance for each and every black out period when the quotes are not being offered by the Market Maker.
- 2) The minimum depth of the quote shall be ₹1,00,000. However, the investors with holdings of value less than ₹1,00,000 shall be allowed to offer their holding to the Market Maker in that scrip provided that they sell their entire holding in that scrip in one lot along with a declaration to the effect to the selling broker.
- 3) After a period of three (3) months from the market making period, the market maker would be exempted to provide quote if the Equity Shares of market maker in our Company reaches to 25%. (Including the 5% of Equity Shares of the Offer.) Any Equity Shares allotted to Market Maker under this Offer over and above 5% of Offer Size would not be taken in to consideration of computing the threshold of 25%. As soon as the Shares of market maker in our Company reduce to 24%, the market maker will resume providing 2-way quotes.

- 4) There shall be no exemption/threshold on downside. However, in the event the market maker exhausts his inventory through market making process, the concerned stock exchange may intimate the same to SEBI after due verification.
- 5) Execution of the order at the quoted price and quantity must be guaranteed by the Market Maker, for the quotes given by him.
- 6) There would not be more than five Market Makers for a script at any point of time and the Market Makers may compete with other Market Makers for better quotes to the investors.
- 7) On the day of listing, there will be pre opening session (call auction) and there after the trading will happen as per the equity market hours. The circuits will apply from the first day of listing on the discovered price during the pre-open call auction.
- 8) There will be special circumstances under which the Market Maker may be allowed to withdraw temporarily/fully from the market – for instance due to system problems, any other problems. All controllable reasons require prior approval from the Exchange, while *force-majeure* will be applicable for non-controllable reasons. The decision of the Exchange for deciding controllable and non-controllable reasons would be final.
- 9) The Market Maker shall have the right to terminate said arrangement by giving a six-month notice or on mutually acceptable terms to the Merchant Banker, who shall then be responsible to appoint a replacement Market Maker.

In case of termination of the above mentioned Market Making agreement prior to the completion of the compulsory Market Making period, it shall be the responsibility of the Lead Manager to arrange for another Market Maker in replacement during the term of the notice period being served by the Market Maker but prior to the date of releasing the existing Market Maker from its duties in order to ensure compliance with the requirements of regulation 261 of the SEBI (ICDR) Regulations, 2018. Further the Company and the Lead Manager reserve the right to appoint other Market Maker either as a replacement of the current Market Maker or as an additional Market Maker subject to the total number of Designated Market Makers does not exceed five or as specified by the relevant laws and regulations applicable at that particular point of time. The Market Making Agreement is available for inspection at our Registered Office from 11.00 a.m. to 5.00 p.m. on working days.

- 10) **Risk containment measures and monitoring for Market Makers:** SME Platform of BSE will have all margins which are applicable on the BSE Main Board viz., Mark-to-Market, Value-At-Risk (VAR) Margin, Extreme Loss Margin, Special Margins and Base Minimum Capital etc. BSE can impose any other margins as deemed necessary from time-to-time.
- 11) **Punitive Action in case of default by Market Makers:** SME Platform of BSE will monitor the obligations on a real time basis and punitive action will be initiated for any exceptions and/or non-compliances. Penalties / fines may be imposed by the Exchange on the Market Maker in case he is not able to provide the desired liquidity in a particular security as per the specified guidelines. These penalties / fines will be set by the Exchange from time to time. The Stock Exchange will impose a penalty on the Market Maker in case he is not present in the market (offering two-way quotes) for at least 75% of the time. The nature of the penalty will be monetary as well as suspension in market making activities / trading membership.

The Department of Surveillance and Supervision of the Exchange would decide and publish the penalties / fines / suspension for any type of misconduct/ manipulation/ other irregularities by the Market Maker from time to time.

- 12) **Price Band and Spreads:** SEBI Circular bearing reference no: CIR/MRD/DP/ 02/2012 dated January 20, 2012, has laid down that for Offer size up to ₹250 crores, the applicable price bands for the first day shall be:
 - (a) In case equilibrium price is discovered in the Call Auction, the price band in the normal trading session shall be 5% of the equilibrium price.
 - (b) In case equilibrium price is not discovered in the Call Auction, the price band in the normal trading session shall be 5% of the Offer price.

Additionally, the trading shall take place in TFT segment for first 10 days from commencement of trading. The following spread will be applicable on the SME Platform of BSE.

Sr. No.	Market Price Slab (in ₹)	Proposed spread (in % to sale price)
1	Up to 50	9

2	50 to 75	8
3	75 to 100	6
4	Above 100	5

- 13) Pursuant to SEBI Circular number CIR/MRD/DSA/31/2012 dated November 27, 2012, limits on the upper side for market maker(s) during market making process has been made applicable, based on the Offer size, and as follows:

Offer Size	Buy quote exemption threshold (including mandatory initial inventory of 5% of the Offer Size)	Re-Entry threshold for buy quote (including mandatory initial inventory of 5% of the Offer Size)
Up to ₹20 Crores	25%	24%
₹20 to ₹50 Crores	20%	19%
₹50 to ₹80 Crores	15%	14%
Above ₹80 Crores	12%	11%

All the above-mentioned conditions and systems regarding the Market Making Arrangement are subject to change based on changes or additional regulations and guidelines from SEBI and Stock Exchange from time to time.

CAPITAL STRUCTURE

The Equity Share capital of our Company, as on the date of this Draft Prospectus and after giving effect to the Offer is set forth below:

No.	Particulars	Amount (₹ in lakhs)	
		Aggregate nominal value	Aggregate value at Offer Price
A.	Authorised Share Capital		
	50,00,000 Equity Shares of face value of ₹10 each	500.00	-
B.	Issued, Subscribed and Paid-Up Share Capital before the Offer		
	16,80,000 Equity Shares of face value of ₹10.00 each	168.00	-
C.	Present Offer in terms of this Draft Prospectus		
	<i>Consisting of:</i>		
	Fresh Issue of up to 6,02,400 Equity Shares for cash at a price of ₹ 96.00 per Equity Share	602.40	578.30
	<i>Which comprises:</i>		
	31,200 Equity Shares of ₹10.00 each at a price of ₹ 96.00 per Equity Share reserved as Market Maker portion	3.12	29.95
	Net Offer to the Public of 5,71,200 Equity Shares of ₹10.00 each at a price of ₹ 96.00 per Equity Share	571.20	548.35
	<i>Of which:</i>		
	2,85,600 Equity Shares of ₹10.00 each at a price of ₹ 96.00 per Equity Share will be available for allocation to Retail Individual Investors upto ₹2,00,000/-	285.60	274.18
	2,85,600 Equity Shares of ₹10.00 each at a price of ₹ 96.00 per Equity Share will be available for allocation to Other than Retail Individual Investors above ₹2,00,000/-	285.60	274.18
D.	Issued, Subscribed and Paid-up Share Capital after the Offer		
	22,82,400 Equity Shares of ₹10.00 each	228.24	-
E.	Securities Premium Account		
	Before the Offer		50.40
	After the Offer		568.46

The Offer has been authorised by our Board pursuant to a resolution dated December 22, 2023, and by our Equity Shareholders pursuant to a resolution passed at the extraordinary general meeting held on January 16, 2024.

Class of Shares

The company has only one class of shares i.e. Equity shares of ₹ 10/- each only and all Equity Shares are ranked pari-passu in all respects.

All Equity Shares issued are fully paid-up as on date of the Draft Prospectus. Our Company has not issued any partly paid-up equity shares since its incorporation nor it does have any partly paid-up equity shares as on the date of the Draft Prospectus.

Our Company does not have any outstanding convertible instruments as on the date of the Draft Prospectus.

Notes to the Capital Structure

1. Details of changes in authorised Share Capital:

The authorised share capital of our Company has been altered in the manner set forth below:

Particulars of Change		Date of Members Meeting	AGM/EGM
From	To		
₹1,00,000 consisting of 10,000 Equity shares of ₹10.00 each.		On incorporation	-
₹1,00,000 consisting of 10,000 Equity shares of ₹10.00 each.	₹1,00,00,000 consisting of 10,00,000 Equity shares of ₹10.00 each.	March 26, 2018	EGM
₹1,00,00,000 consisting of 10,00,000 Equity shares of ₹10.00 each.	₹1,50,00,000 consisting of 15,00,000 Equity shares of ₹10.00 each.	February 28, 2019	EGM
₹1,50,00,000 consisting of 15,00,000 Equity shares of ₹10.00 each.	₹5,00,00,000 consisting of 50,00,000 Equity shares of ₹10.00 each.	August 26, 2023	EGM

2. History of Issued and Paid-Up Share Capital of our Company

The history of the equity share capital of our Company is set forth below:

Date of Allotment	No. of Equity Shares	Face Value (₹)	Issue Price (₹)	Nature / Reason of Allotment	Nature of Consideration	Cumulative No. of Equity Shares	Cumulative Paid Up Share Capital (₹)	Cumulative Share Premium (₹)
On Incorporation	10,000	10	10	Cash	Subscription to MOA ⁽¹⁾	10,000	1,00,000	Nil
March 31, 2018	4,90,000	10	Nil	Other than Cash	Bonus Issue ⁽²⁾	5,00,000	50,00,000	Nil
March 01, 2019	1,66,666	10	Nil	Other than Cash	Bonus Issue ⁽³⁾	6,66,666	66,66,660	Nil
March 28, 2022	8,33,334	10	Nil	Other than Cash	Bonus Issue ⁽⁴⁾	15,00,000	1,50,00,000	Nil
December 22, 2023	1,80,000	10	38	Cash	Further Issue ⁽⁵⁾	16,80,000	1,68,00,000	50,40,000

- Initial allotment of 5,000 Equity Shares to Jagdish Umakant Nayak and 5,000 Equity Shares to Jyoti Jagdish Nayak, being the subscribers to the MoA of our Company.
- Allotment of 2,45,000 Equity Shares to Jagdish Umakant Nayak and 2,45,000 Equity Shares to Jyoti Jagdish Nayak as a Bonus issue.
- Allotment of 83,333 Equity Shares to Jagdish Umakant Nayak and 83,333 Equity Shares to Jyoti Jagdish Nayak as a Bonus issue.
- Allotment of 4,16,667 Equity Shares to Jagdish Umakant Nayak and 4,16,667 Equity Shares to Jyoti Jagdish Nayak as a Bonus issue.
- Allotment of 1,000 Equity Shares to Vishakka Vijay Shete; 1,000 Equity Shares to Pramod Gandhi HUF; 20,000 Equity Shares to Kripananda Chidambaram; 55,400 Equity Shares to Siddhesh Anant Nayak; 500 Equity Shares to Velvina Lancy Dcunha; 2,000 Equity Shares to Sangieta Maanoj Harisinghani; 15,000 Equity Shares to Lancy Leo Dcunha; 2,000 Equity Shares to Bhagwat Jagannath Tatya Mane; 5,000 Equity Shares to Rashmi Prabhu; 2,000 Equity Shares to Ravindra Vasant Shete; 2,000 Equity Shares to Tasneem Abdul Sattar Shaikh; 2,000 Equity Shares to Pravina Shrikant Desai; 2,000 Equity Shares to Jay Vinod Goyal; 5,000 Equity Shares to Swetapadma Mohanty; 50,000 Equity Shares to Ajit Sakharam Kandar; 26,600 Equity Shares to Mukesh Thumar and 2,000 Equity Shares to Nitin Shashikant Powale on a preferential basis.

3. Issue of Equity Shares for Consideration other than Cash.

- Other than the Bonus issue of Equity Shares as mentioned in point no. 2 above, our Company has not allotted any Equity Shares for consideration other than cash, since its incorporation.
- No Equity Shares have been allotted pursuant to any scheme approved under Sections 391-394 of the Companies Act, 1956 or Section 230-233 of the Companies Act, 2013.

5. We have not issued any equity share (including bonus shares) by capitalizing any revaluation reserves.
6. **Issue of Shares in the preceding two years**

Following Equity Shares were issued by our Company in the preceding two years:

Date of Allotment	No. of Equity Shares	Face Value (₹)	Issue Price (₹)	Nature / Reason of Allotment	Nature of Consideration
March 28, 2022	8,33,334	10	Nil	Bonus Issue	Other than Cash
December 22, 2023	1,80,000	10	38	Further Issue	Cash

7. **Issue of Equity Shares in the last one year at a Price lower than the Offer Price:**

Other than as mentioned below, No Equity Shares were issued in last one year immediately preceding the date of the Draft Prospectus at a price which is lower than the Offer Price.

Date of Allotment	No. of Equity Shares	Face Value (₹)	Issue Price (₹)	Nature / Reason of Allotment	Nature of Consideration
March 28, 2022	8,33,334	10	Nil	Bonus Issue	Other than Cash
December 22, 2023	1,80,000	10	38	Further Issue	Cash

8. Our Company does not have any Employee Stock Option Scheme / Employee Stock Purchase Scheme for our employees and we do not intend to allot any shares to our employees under Employee Stock Option Scheme / Employee Stock Purchase Scheme from the proposed issue. As and when, options are granted to our employees under the Employee Stock Option Scheme, our Company shall comply with the SEBI (Share Based Employee Benefits) Regulations, 2014.
9. As on the date of the Draft Prospectus, our Company does not have any preference share capital.
10. **Build Up of our Promoters' Shareholding, Promoters' Contribution and Lock-In**

As on the date of this Draft Prospectus, our Promoters hold 13,49,500 Equity Shares, constituting 80.33% of the pre-issued, subscribed, and paid-up Equity Share capital of our Company.

- a) **Build-up of our Promoters' shareholding in our Company**

Date of Allotment / Transfer	Nature of acquisition (Allotment/ Acquired/ transfer)	Number of Equity Shares	Face Value per Equity Share (in ₹)	Issue Price /Acquisition Price / Transfer price per Equity Share (in ₹)	Nature of Consideration	Percentage of Pre-Issue Equity Share Capital (%)	Percentage of Post-Issue Equity Share Capital (%)
Jagdish Umakant Nayak							
Incorporation	Subscribers to MOA	5,000	10	10	Cash	0.30	0.22
March 31, 2018	Bonus Issue	2,45,000	10	Nil	Other than Cash	14.58	10.73
March 01, 2019	Bonus Issue	83,333	10	Nil	Other than Cash	4.96	3.65
March 28, 2022	Bonus Issue	4,16,667	10	Nil	Other than Cash	24.80	18.26

July 17, 2023	Transfer *	-500	10	10	Cash	(0.03)	(0.02)
December 20, 2023	Transfer to Santosh Gopalkrishna Kudva	-75,000	10	13	Cash	(4.46)	(3.29)
	Total – A	6,74,500				40.15	29.55
Jyoti Jagdish Nayak							
Incorporation	Subscribers to MOA	5,000	10	10	Cash	0.30	0.22
March 31, 2018	Bonus Issue	2,45,000	10	Nil	Other than Cash	14.58	10.73
March 01, 2019	Bonus Issue	83,333	10	Nil	Other than Cash	4.96	3.65
March 28, 2022	Bonus Issue	4,16,667	10	Nil	Other than Cash	24.80	18.26
December 20, 2023	Transfer to Santosh Gopalkrishna Kudva	-75,000	10	13	Cash	(4.46)	(3.29)
	Total - B	6,75,000				40.18	29.58
	Grand Total – (A+B)	13,49,500				80.33	59.13

* Transfer of 100 Equity Shares each to Ashutosh Jagdish Nayak, Ananya Jagdish Nayak, Anant Umakant Nayak, Eshwari Anant Nayak and Siddhesh Anant Nayak to meet with requirements of 7 shareholders for conversion of the Company to Limited Company.

Our Promoters have confirmed to the Company and the Lead Manager that the acquisition of the Equity Shares forming part of the Promoters' Contribution has been financed from personal funds/internal accruals and no financial assistance from any banks or financial institution has been availed by our Promoters for this purpose. All the Equity Shares held by our Promoters were fully paid-up on the respective dates of acquisition of such Equity Shares. As on the date of this Draft Prospectus, none of the Equity Shares held by our Promoters are pledged.

b) *Details of Promoter's Contribution Locked-in for Three Years*

Pursuant to Regulations 236 and 238 of the SEBI (ICDR) Regulations, an aggregate of at least 20% of the fully diluted post-Offer Equity Share capital of our Company held by our Promoters shall be provided towards minimum promoters' contribution and locked-in for a period of three years from the date of Allotment (“**Minimum Promoters' Contribution**”). Details of the Equity Shares (eligible for inclusion in the Minimum Promoters' Contribution, in terms of Regulation 33 of the SEBI (ICDR) Regulations) forming part of Minimum Promoters' Contribution and proposed to be locked-in for a period of three years are as follows:

Date of Allotment / Transfer	Nature of acquisition (Allotment/ Acquired/ transfer)	Number of Equity Shares	Face Value per Equity Share (in ₹)	Issue Price /Acquisition Price / Transfer price per Equity Share (in ₹)	Nature of Consideration	Percentage of Pre-Offer Equity Share Capital (%)	Percentage of Post-Offer Equity Share Capital (%)
Jagdish Umakant Nayak							
March 18, 2022	Bonus Issue	4,30,000	10	Nil	Nil	13.69	10.077
Jagdish Umakant Nayak							
March 18, 2022	Bonus Issue	4,30,000	10	Nil	Nil	13.69	10.077
	Total	4,60,000				27.38	20.154

Our Promoters have granted written consent to include such number of Equity Shares held by him as may constitute at least 20% of the post Offer Equity Share capital of our Company as Minimum Promoters' Contribution and have agreed not to sell or transfer or pledge or otherwise dispose of in any manner, the Minimum Promoters' Contribution from the date of filing of this Draft Prospectus until the commencement of the lock-in period specified above, or for such other time as required under SEBI (ICDR) Regulations, except as may be permitted, in accordance with the SEBI (ICDR) Regulations.

In terms of Regulation 237 of the SEBI (ICDR) Regulations, 2018, we confirm that the Minimum Promoters' Contribution of 20% of the Post Offer Capital of our Company as mentioned above does not consist of;

- Equity Shares acquired during the preceding three years for;
 - consideration other than cash and revaluation of assets or capitalization of intangible assets is involved in such transaction;
 - resulting from a bonus issue by utilization of revaluation reserves or unrealized profits of the company or from bonus issue against equity shares which are ineligible for minimum Promoters' contribution;
- The Equity Shares held by the Promoters and offered for Minimum Promoters' contribution which are subject to any pledge with any creditor;
- Equity Shares acquired by Promoters during the preceding one year at a price lower than the price at which equity shares are being offered to public in the Initial Public offer;
- No Equity shares have been issued to our promoters upon conversion of a partnership firm during the preceding one year at a price less than the issue price, against funds brought in by them during that period, in case of an issuer formed by conversion of one or more partnership firms or limited liability partnerships, where the partners of the erstwhile partnership firms or limited liability partnerships are the promoters of the issuer and there is no change in the management are ineligible for Minimum Promoters' Contribution.

c) *Equity Shares locked-in for one year*

In addition to Minimum Promoters' Contribution which shall be locked-in for three years, the balance Equity Shares held by Promoters and Others shall be locked in for a period of one year from the date of allotment in the Initial Public Offer as provided in clause (b) of Regulation 238 of the SEBI (ICDR) Regulations, 2018.

d) *Other requirements in respect of 'lock-in'*

In terms of Regulation 239 of the SEBI (ICDR) Regulations, 2018, the entire pre-Offer capital held by the Persons other than the Promoters shall be locked in for a period of one year from the date of allotment in the Initial Public Issue.

In terms of Regulation 241 of the SEBI (ICDR) Regulations, 2018, our Company confirms that certificates of Equity Shares which are subject to lock in shall contain the inscription "Non-Transferable" and specify the lock-in period and in case such equity shares are dematerialized, the Company shall ensure that the lock-in is recorded by the Depository.

In terms of Regulation 242 of the SEBI (ICDR) Regulations, 2018, the Equity Shares held by our Promoters and locked in may be pledged as a collateral security for a loan granted by a scheduled commercial bank or public financial institution or a systemically important non-banking finance company or housing finance company, subject to following;

- In case of Minimum Promoters' Contribution, the loan has been granted to the issuer company or its subsidiary (ies) for the purpose of financing one or more of the Objects of the Offer and pledge of equity shares is one of the terms of sanction of the loan.
- In case of Equity Shares held by Promoters in excess of Minimum Promoters' contribution, the pledge of equity shares is one of the terms of sanction of the loan.

However, lock in shall continue pursuant to the invocation of the pledge and such transferee shall not be eligible to transfer the equity shares till the lock in period stipulated has expired.

Transferability of Locked in Equity Shares:

In terms of Regulation 243 of the SEBI (ICDR) Regulations, 2018 and subject to provisions of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as applicable;

- The Equity Shares held by our Promoters and locked in as per Regulation 238 of the SEBI (ICDR) Regulations, 2018 may be transferred to another Promoters or any person of the Promoters' Group or to a new promoter(s) or persons in control of our Company, subject to continuation of lock-in for the remaining period with transferee and such transferee shall not be eligible to transfer them till the lock-in period stipulated has expired.

The equity shares held by persons other than promoters and locked in as per Regulation 239 of the SEBI (ICDR) Regulations, 2018 may be transferred to any other person (including Promoter and Promoters' Group) holding the equity shares which are locked-in along with the equity shares proposed to be transferred, subject to continuation of lock-in for the remaining period with transferee and such transferee shall not be eligible to transfer them till the lockin period stipulated has expired.

11. Our shareholding pattern

Pursuant to Regulation 31 of the SEBI (LODR) Regulations, the holding of specified securities is divided into the following three categories: (a) Promoter and Promoter Group; (b) Public; and (c) Non-Promoter - Non-Public.

Category (I)	Category of shareholder (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV) + (V) + (VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) As a % of (A+B+C2) (VIII)	Number of Voting Rights held in each class of securities (XI)			No. of Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding as a % assuming full conversion of convertible securities (as a % of diluted share capital) As a % of (A+B+C2) (XI) = (VII) + (X)	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialized form (XIV)	
								No of Voting Rights					Total as a % of (A+B + C)	No. (a)	As a % of total Shares held (b)	No. (a)		As a % of total Shares held (b)
								Class Equity	Class :preference	Total								
(A)	Promoter & Promoter Group	7	14,05,000	-	-	14,05,000	83.63	14,05,000	-	14,05,000	83.63	-	-	-	-	14,05,000		
(B)	Public	17	2,75,000	-	-	2,75,000	16.37	2,75,000	-	2,75,000	16.37	-	-	-	-	2,75,000		
(C)	Non-Promoter-Non-Public	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
(C1)	Shares underlying DRs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
(C2)	Shares held by Employee Trusts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Total	24	16,80,000	-	-	16,80,000	100.00	16,80,000	-	16,80,000	100.00	-	-	-	-	16,80,000		

Note: The term “Encumbrance” has the same meaning as assigned under regulation 28(3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

- Our Company will file the shareholding pattern of our Company in the form prescribed under Regulation 31 of SEBI (LODR) Regulations, one day prior to the listing of the Equity Shares. The shareholding pattern will be uploaded on the website of BSE before commencement of trading of our Equity Shares.
- There are no Equity Shares against which depository receipts have been issued.
- Other than the Equity Shares, there is no other class of securities issued by our Company.

We confirm that the public shareholders of the Company are not connected to the Company or its directors or its promoter or its promoter group or its group companies in any manner.

12. The shareholding pattern of our Promoters and Promoter Group before and after the Offer is set forth below:

Sr.	Particulars	Pre-Offer		Post-Offer	
		No. of Shares	% Holding	No. of Shares	% Holding
a)	Promoters				
	Jagdish Umakant Nayak	6,74,500	40.15	6,74,500	29.55
	Jyoti Jagdish Nayak	6,75,000	40.18	6,75,000	29.58
	Total - A	13,49,500	80.33	13,49,500	59.13
b)	Promoter Group				
	Ashutosh Jagdish Nayak	100	Negligible	100	Negligible
	Ananya Jagdish Nayak	100	Negligible	100	Negligible
	Anant Umakant Nayak	100	Negligible	100	Negligible
	Eshwari Anant Nayak	100	Negligible	100	Negligible
	Siddhesh Anant Nayak	55500	3.30	55500	2.43
	Total – B	55900	3.30	55900	2.43
	Grand Total (A+B)	14,05,000	83.63	14,05,000	61.56

13. The average cost of acquisition of or subscription to Equity Shares by our Promoters is set forth in the table below:

Name of the Promoters	No. of Equity Shares held	Average cost of Acquisition (in ₹)
Jagdish Umakant Nayak	6,74,500	Nil*
Jyoti Jagdish Nayak	6,75,000	Nil*

*Cost of acquisition of equity shares is NIL as the shares acquired by way of bonus shares and net of selling consideration for the shares sold.

14. None of our Directors or Key Managerial Personnel hold Equity Shares in our Company.

15. Major shareholders

The list of our major shareholders and the number of Equity Shares held by them is provided below:

a. List of Shareholders holding 1.00% or more of the Paid-up Capital of the Company as on date of the Draft Prospectus:

Sr. No.	Name of shareholder	No. of Equity Shares	% of Pre-Issue Capital
1.	Jagdish Umakant Nayak	6,74,500	29.55
2.	Jyoti Jagdish Nayak	6,75,000	29.58
3.	Santosh Gopalkrishna Kudva	1,50,000	8.93
4.	Siddhesh Anant Nayak	55,500	3.30
5.	Ajit Sakharam Kandar	50,000	2.98
6.	Mukesh Thumar	26,600	1.58
7.	Kripananda Chidambaram	20,000	1.19

b. List of Shareholders holding 1.00% or more of the Paid-up Capital of the Company as on date two years prior to the date of the Draft Prospectus:

Sr. No.	Name of shareholder	No. of Equity Shares	% of Pre-Issue Capital
1.	Jagdish Umakant Nayak	3,33,333	50.00%
2.	Jyoti Jagdish Nayak	3,33,333	50.00%

- c. List of Shareholders holding 1.00% or more of the Paid-up Capital of the Company as on date one year prior to the date of the Draft Prospectus:

Sr. No.	Name of shareholder	No. of Equity Shares	% of Pre-Issue Capital
1.	Jagdish Umakant Nayak	7,50,000	50.00%
2.	Jyoti Jagdish Nayak	7,50,000	50.00%

- d. List of Shareholders holding 1.00% or more of the Paid-up Capital of the Company as on date ten days prior to the date of the Draft Prospectus:

Sr. No.	Name of shareholder	No. of Equity Shares	% of Pre-Issue Capital
1.	Jagdish Umakant Nayak	6,74,500	29.55
2.	Jyoti Jagdish Nayak	6,75,000	29.58
3.	Santosh Gopalkrishna Kudva	1,50,000	8.93
4.	Siddhesh Anant Nayak	55,500	3.30
5.	Ajit Sakharam Kandar	50,000	2.98
6.	Mukesh Thumar	26,600	1.58
7.	Kripananda Chidambaram	20,000	1.19

16. There will be no further issue of capital, whether by way of issue of bonus shares, preferential allotment, rights issue or in any other manner during the period commencing from the date of this Draft Prospectus until the Equity Shares have been listed. Further, our Company presently does not have any intention or proposal to alter our capital structure for a period of six months from the date of opening of this Offer, by way of split / consolidation of the denomination of Equity Shares or further issue of Equity Shares (including issue of securities convertible into exchangeable, directly or indirectly, for our Equity Shares) whether preferential or otherwise, except that if we enter into acquisition(s) or joint venture(s), we may consider additional capital to fund such activities or to use Equity Shares as a currency for acquisition or participation in such joint ventures.
17. None of our Promoters, members of our Promoter Group or our Directors or their immediate relatives have sold or purchased Equity Shares by any other person during the six months immediately preceding the date of this Draft Prospectus, except as under:

Date of Transaction	Nature of Transaction (Acquired/ transfer)	Number of Equity Shares	Face Value per Equity Share (in ₹)	Acquisition Price / Transfer price per Equity Share (in ₹)	Nature of Consideration
Jagdish Umakant Nayak					
December 20, 2023	Transfer*	75,000	10	13	Cash
Jyoti Jagdish Nayak					
December 20, 2023	Transfer*	75,000	10	13	Cash

* Transfer of Equity Shares to Santosh Gopalkrishna Kudva.

18. There have been no financial arrangements whereby our Promoters, Promoter Group, our Directors and their relatives have financed the purchase by any other person of securities of our Company, during a period of six months preceding the date of this Draft Prospectus, other than in the normal course of business of the financing entity.
19. Our Company, our Promoters, our Directors and the Lead Manager to this Offer have not entered into any buy-back and/or standby or similar arrangements with any person for purchase of our Equity Shares issued by our Company through this Draft Prospectus.
20. There are no safety net arrangements for this public Offer.
21. An oversubscription to the extent of 10% of the Net Offer can be retained for the purposes of rounding off to the minimum allotment lot and multiple of one share thereafter, while finalizing the Basis of Allotment. Consequently, the actual allotment may go up by a maximum of 10% of the Net Offer as a result of which, the post-Offer paid up capital after the Offer would also increase by the excess amount of allotment so made. In such an event, the Equity

Shares held by the Promoters and subject to lock- in shall be suitably increased so as to ensure that 20% of the Post Offer paid-up capital is locked in for 3 years.

22. Under-subscription in the net Offer, if any, in any category, would be allowed to be met with spill over from any other category or a combination of categories at the discretion of our Company in consultation with the Lead Manager and the BSE.
23. As on the date of filing of this Draft Prospectus, there are no outstanding warrants, options, or rights to convert debentures, loans, or other financial instruments into our Equity Shares.
24. All the Equity Shares of our Company are fully paid up as on the date of this Draft Prospectus. Further, since the entire money in respect of the Offer is being called on application, all the successful applicants will be issued fully paid-up equity shares.
25. As per RBI regulations, OCBs are not allowed to participate in this Offer.
26. Our Company has not raised any bridge loan against the proceeds of this Offer. However, depending on business requirements, we might consider raising bridge financing facilities, pending receipt of the Net Proceeds.
27. Our Company undertakes that at any given time, there shall be only one denomination for our Equity Shares, unless otherwise permitted by law.
28. Our Company shall comply with such accounting and disclosure norms as specified by SEBI from time to time.
29. No payment, direct or indirect in the nature of discount, commission, allowances or otherwise shall be made either by us or our Promoters to the persons who receive allotments, if any, in this Offer.
30. We have 24 (Twenty-Four) Shareholders as on the date of this Draft Prospectus.
31. Our Promoters and the members of our Promoter Group will not participate in this Offer.
32. Our Promoter and members of our Promoter Group will not receive any proceeds from the Offer.
33. Our Company has not made any public issue since its incorporation.
34. As on the date of this Draft Prospectus, the Lead Manager and their respective associates (determined as per the definition of 'associate company' under Section 2(6) of the Companies Act, 2013) do not hold any Equity Shares in our Company. The Lead Manager and their respective affiliates may engage in transactions with and perform services for our Company in the ordinary course of business or may in the future engage in commercial banking and investment banking transactions with our Company, for which they may in the future receive customary compensation.
35. Our Company shall ensure that transactions in the Equity Shares by the Promoters and the Promoter Group between the date of filing this Draft Prospectus and the Offer Closing Date shall be reported to the Stock Exchange within twenty-four hours of such transaction.
36. For the details of transactions by our Company with our Promoter Group, Group Companies please refer to paragraph titled "*Statement of Transactions with Related Parties, as Restated*" in '*Financial Statements*' on page 114.

OBJECTS OF THE OFFER

The Offer comprises of a Fresh Issue by our Company.

Fresh Issue

Our Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:

1. Expansion of Diagnostic Centres;
2. General Corporate Purposes

We believe that listing will enhance our corporate image and visibility of brand name of our Company. We also believe that our Company will receive the benefits from listing of Equity Shares on the SME Platform of BSE. It will also provide liquidity to the existing shareholders and will also create a public trading market for the Equity Shares of our Company.

The main object clause of Memorandum of Association of our Company enables us to undertake the activities for which the funds are being raised by us through the Issue. Further, we confirm that the activities which we have been carrying out till date are in accordance with the object clause of our Memorandum of Association. For the main objects clause of our Memorandum of Association, see “*History and Certain Corporate Matters*” on page 92.

Net Proceeds

The details of the proceeds of the Fresh Issue are summarized in the table below:

S. No.	Particulars	Amount (₹ in lakhs)
1.	Gross Proceeds from the Fresh Issue	578.30
2.	Issue related Expenses	38.30
	Net Proceeds of the Fresh Issue (“Net Proceeds”)	540.00

Utilisation of Net Proceeds and Means of Finance

The proposed utilisation of the Net Proceeds is set forth below:

S. No.	Object	Amount Proposed to be Utilised from the Net Proceeds (₹ in lakhs)
1.	Expansion of Diagnostic Centres	498.67
3.	General Corporate Purposes	41.33
	Total	540.00

Since the entire fund requirement are to be funded from the proceeds of the Fresh Issue, there is no requirement to make firm arrangements of finance under Regulation 230(1)(e) of the SEBI ICDR Regulations through verifiable means towards at least 75% of the stated means of finance, excluding the amounts to be raised through the proposed Issue.

Requirement of Funds and Means of Finance

The fund requirements, the deployment of funds and the intended use of the Net Proceeds as described herein are based on our current business plan and management estimates and have not been appraised by any bank, financial institution or any other external agency. Given the dynamic nature of our business, we may have to revise our business plan from time to time and consequently our funding requirements and deployment on account of variety of factors such as our financial condition, business and strategy, including external factors such as market conditions, competitive environment, costs of commodities and interest/ exchange rate fluctuations which may not be within the control of our management.

In case of variations in the actual utilisation of funds earmarked for the purpose set forth above or shortfall in the Net Proceeds, increased fund requirement may be financed by our internal accruals and/ or debt, as required. If the actual utilisation towards the said Object is lower than the proposed deployment such balance will be used for general corporate purposes to the extent that the total amount to be utilised towards general corporate purposes will not exceed 25% of the gross proceeds from the Issue.

Details of the Objects of the Fresh Issue

1. Expansion of Diagnostic Centres

Our company intends to utilize approximately Rs. 498.67 Lakhs towards the setting up of 15 New Diagnostic Centres. Our Company has identified Navi Mumbai to Panvel as its focus area for expansion and it proposes to open new centres in and around this area. The estimated cost break-up for setting up Diagnostic Centre is as follows:

(₹ in lakhs)			
Sl. No.	Particulars	Estimated amount per store	Estimated amount for 15 stores
A.	Security Deposit for Lease Property	Rs. 3-8 Lakhs	66.50
B.	Rent for 12 months/ per property ranging from Rs. 30,000 to Rs. 80,000 p.m.	Rs. 6.65 Lakhs p.m.	79.80
C.	Interiors, Furniture and Electronic Equipments	Rs. 10 Lakhs	150.00
D.	Employee cost and other operational costs per centre for 12 months	-	202.37
	Total		498.67

A & B. Security Deposit and Rent for 15 Centres

We have identified 15 locations for setting up new diagnostic centres at various locations around Raigad, Navi Mumbai and Thane district, as disclosed in the quotation described below. Based on the Quotation dated January 11, 2024 provided by Kush Jagdish Tiwari Estate Agency (RERA registration no. A51700038528) estimated Rent and Security Deposit for an average property size of 300 square feet for these locations are as under:

(₹ in lakhs)			
Sl. No.	Area	Estimated Rent p.m. / per Centre	Security Deposit
1	Old Panvel	0.35	3.50
2	Khanda Colony	0.35	3.50
3	Kamothe	0.35	3.50
4	Taloja	0.35	3.50
5	CBD Belapur	0.60	6.00
6	Nerul	0.55	5.50
7	Sanpada	0.55	5.50
8	Vashi	0.80	8.00
9	KoparKhairane	0.40	4.00
10	Ghansoli	0.40	4.00
11	Ulwe	0.35	3.50
12	Dronagiri	0.30	3.00
13	Pushpak Nagar	0.30	3.00
14	Dombivli	0.50	5.00
15	Kalyan	0.50	5.00
	Total	6.65	66.50

As per above estimates, our Company proposes to deploy total of Rs. 146.30 Lakhs towards payment of Security Deposits to Land lords from whom we will take properties on lease basis and rentals for 1 year for 15 Centres.

C. Interiors, Furniture and Electronic Equipments

As per the quotation dated January 21, 2024 provided by M/s. The J Studio (Architect Juhi Garg – Registration No. CA/2019/109630), following is the estimated breakup of interiors, furniture and office equipment per Centre:

(₹ in lakhs)			
Sl. No.	Type of Work	Description	Amount per Centre
1	Painting	Lambi Putti Primer + 2 coats of paints (Luster Dana) considered in Asian Paints	0.55

2	Electricals	Light fittings + Labour + Material Lights- Philips and Jainsons Fans – Havells or Equivalent Switch Boards – GM, Anchor or Equivalent Pipes – Pressfit or Equivalent Wires – Polycab or Equivalent	0.40
3	Furniture	Material + Labour (includes 3 work desks for staff operating in shifts + waiting area sofa and table + glass partition and door + examination bed) In Laminate – Royal Touche, Royal Crown or Equivalent Plywood – Greenply commercial grade Hardware – Ebco or Equivalent Adhesive – Fevicol or Equivalent	3.00
4	AC ducting work	Material + Labour Ducting and drainage piping work	0.15
5	Toilet	Providing and fixing tiles Providing and fixing sanitayware, mixers, faucet and other supplementary materials Civil and plumbing work Sanitaryware – Jaguar or Equivalent Fittings – Jaguar or Equivalent	3.00
6	False Ceiling	In Gyproc sheet and Ultra-GI sections	0.30
7	Electronic Equipments	Providing AC, Fridge, Water Purifier, Computers	2.60
	Total – Per Centre		10.00

As per above estimate of Rs. 10 Lakh per centre, our Company proposes to deploy total of Rs. 150 Lakhs towards interiors, furniture and Equipments for 15 Centres.

D. Employee cost and other Operational Costs

We have estimated an amount of Rs. 202.37 Lakhs to be deployed towards 12 months employee cost and operational costs of these 15 centres out of the issue proceeds. The same is estimated based on our actual cost of Airoli Centre, details of which is given below:

Airoli Centre Staff details

Sl. No.	Name of the Employee	Department	Salary p.m. (₹)
1	Rupali Solkar	Pathology	12,000
2	Abhijit Awale	Pathology	12,000
3	Roshani Matal	Pathology	12,000
4	Yogita Patil	Pathology	12,000
5	Vijay Jadhav	Sales	40,000
	Total		88,000
	Estimated employee cost of 15 centres for 12 months (₹ in lakhs)		158.40

Airoli Centre – Other Operational Cost

Sl. No.	Particular	Amount p.m. (₹)
1	Electricity Expenses	8,600
2	Printing & Stationery	3,580
3	Blood Test kit (Syringe, needle, Sugar tube, EDTA, collection tube)	9,000
4	Staff Welfare (Tea etc.)	3,250
	Total	24,430
	Estimated Other Operational cost of 15 centres for 12 months (₹ in lakhs)	43.97

Accordingly total estimated investment out of Issue proceeds for other operational cost for 15 stores will be Rs. 202.37 (158.40 + 43.97) Lakhs.

2. General Corporate Purposes

Our Company proposes to deploy the balance Net Proceeds aggregating to ₹ 41.33 lakhs towards general corporate purposes. The general corporate purposes for which our Company proposes to utilise the Net Proceeds include but are not limited to funding growth opportunities, strategic initiatives, joint-ventures, partnerships, marketing and business development expenses, expansion of facilities and meeting exigencies and expenses incurred by our Company in the ordinary course of business. In addition to the above, our Company may utilise the Net Proceeds towards other expenditure (in the ordinary course of business) considered expedient and as approved periodically by the Board, subject to compliance with necessary provisions of the Companies Act. The quantum of utilisation of funds towards each of the above purposes will be determined by our Board based on the business requirements of our Company, from time to time. Our Company's management, in accordance with the policies of the Board, shall have flexibility in utilising surplus amounts, if any. However, we confirm that the amount for general corporate purposes, as mentioned in objects of the issue, shall not exceed twenty five per cent of the fresh issue amount raised by our Company.

Offer Related Expenses

The total expenses of the Offer are estimated to be approximately ₹38.30 lakhs. The expenses of this Offer include, among others, underwriting and management fees, printing and distribution expenses, advertisement expenses and legal fees, if applicable. The estimated Offer expenses are as follows:

(₹ in lakhs)

Activity	Estimated expenses*	As a % of the total estimated Offer expenses	As a % of the total Offer size
Payment to Merchant Banker including, underwriting, and selling commissions, brokerages, Advisors to the Company, payment to other intermediaries such as Legal Advisors, Registrars etc. and other out of pocket expenses, Brokerage and selling commission ⁽¹⁾	26.30	68.67%	4.55%
Advertising and marketing expenses	3.00	7.83%	0.52%
Printing and stationery expenses, distribution, and postage	2.00	5.22%	0.35%
Regulatory and other expenses including Listing Fee	7.00	18.28%	1.21%
Total estimated Issue expenses	38.30	100.00%	6.62%

⁽¹⁾The SCSBs and other intermediaries will be entitled to processing fees of ₹ 10 per Application form for which the shares are allotted,

Schedule of implementation

- The entire amount of Fresh Issue Proceeds, other than Issue Expenses, will be utilised during FY 2025.

Estimated Time lines for Schedule of implementation is as under:

Particulars	Month of Commencement	Month of Completion
Expansion of Diagnostic Centres		
Security Deposit for Lease Property	May 2024	July 2024
Rent for 12 months	May 2024	July 2025
Interiors, Furniture and Electronic Equipments	June 2024	October 2024
Employee cost and other operational costs	May 2024	July 2025

Deployment of Funds in the Objects

Our Company has not incurred Rs. 11.31 Lakhs towards Issue Expenses till December 31, 2023 from the internal accruals of the Company. The same is certified by M/s. E. A. Patil & Associates LLP, Chartered Accountants, vide their certificate dated January 20, 2024 (UDIN No.: 24107639BKBEAY2929).

Details of balance fund deployment

(₹ in Lakhs)

Sr. No.	Particulars	Expenses Already Incurred till December 31, 2023	FY 2025	Total
1	Expansion of Diagnostic Centres	Nil	400.00	498.67
2	General Corporate Purposes	Nil	41.33	41.33
3	Issue Related Expenses	11.31	26.99	38.30
	Total	11.31	566.99	578.30

Interim Use of Funds

Pending utilization for the purposes described above, we undertake to temporarily deposit the funds from the Net Proceeds only in the scheduled commercial banks included in the Second Schedule of the Reserve Bank of India Act, 1934, for the necessary duration. In accordance with Section 27 of the Companies Act, 2013, our Company confirms that it shall not use the Net Proceeds for buying, trading or otherwise dealing in the equity shares of any other listed company.

Appraisal Report

None of the objects for which the Net Proceeds from the Issue will be utilised have been appraised by any financial institutions/banks.

Bridge Loan

As of the date of this Draft Prospectus, our Company has not raised any bridge loans which are required to be repaid from the Net Proceeds. However, depending on its business requirements, our Company may consider raising bridge financing facilities, pending receipt of the Net Proceeds.

Monitoring of Utilization of Funds

As the size of the Offer will not exceed Rs.10,000 Lakhs, the appointment of Monitoring Agency would not be required as per Regulation 262(1) of the SEBI ICDR Regulations. Our Board and the management will monitor the utilization of the Net Offer Proceeds through our audit committee. Pursuant to Regulation 32 of the SEBI Listing Regulations, our Company shall on half-yearly basis disclose to the Audit Committee the Application of the proceeds of the Issue. On an annual basis, our Company shall prepare a statement of funds utilized for purposes other than stated in this Draft Prospectus and place it before the Audit Committee. Such disclosures shall be made only until such time that all the proceeds of the Issue have been utilized in full.

Variation in Objects

In accordance with Section 13(8) and Section 27 of the Companies Act, 2013, our Company shall not vary the Objects of the Issue without our Company being authorized to do so by the shareholders by way of a special resolution. In addition, the notice issued to the shareholders in relation to the passing of such special resolution shall specify the prescribed details and be published in accordance with the Companies Act 2013.

Pursuant to the Companies Act 2013, the Promoters or controlling shareholders will be required to provide an exit opportunity to the shareholders who do not agree to such proposal to vary the Objects of the Issue at the fair market value of the Equity Shares as on the date of the resolution of our Board recommending such variation in the terms of the contracts or the objects referred to in the Draft Prospectus, in accordance with such terms and conditions as may be specified on this behalf by SEBI.

Other Confirmations

No part of the Net Proceeds of the Issue will be utilized by our Company as consideration to our Promoters, members of the Promoter Group, Directors, Group Entities, or key management personnel. Our Company has not entered into or is not planning to enter into any arrangement/ agreements with Promoters, Directors, key management personnel, associates, or Group Entities in relation to the utilization of the Net Proceeds of the Issue.

BASIS FOR OFFER PRICE

The Offer Price is determined by our Company in consultation with the Lead Manager. The financial data presented in this section are based on our Company's restated financial statements. Investors should also refer to the sections titled 'Risk Factors' and 'Financial Information' on pages 17 and 114, respectively, to get a more informed view before making the investment decision.

Qualitative Factors

For details of Qualitative factors please refer to the paragraph "Our Competitive Strengths" in "Our Business" beginning on page 77.

Quantitative Factors (Based on Standalone Financial Statements)

1. Basic & Diluted Earnings Per Share (EPS):

Period	Basic and Diluted EPS (₹)	Weights
FY 2023	4.09	3
FY 2022	3.42	2
FY 2021	6.04	1
Weighted Average	4.19	

Notes:

1. Basic EPS and Diluted EPS calculations are in accordance with Accounting Standard 20 (AS-20) 'Earnings per Share', notified under Section 133 of Companies Act, 2013 read together along with paragraph 7 of the Companies (Accounts) Rules, 2014.

2. Basic Earnings per share = Net profit/ (loss) after tax, as restated attributable to equity shareholders /Weighted average number of shares outstanding during the year/ period.

3. Diluted Earnings per share = Net profit after tax, as restated / Weighted average number of diluted equity shares outstanding during the year/ period.

4. The figures disclosed above are based on the Restated Consolidated Financial Statements of our Company.

2. Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 96.00:

- a. Based on the basic and diluted EPS of ₹4.09 as per restated financial statements for the FY 2023, the P/E ratio is 23.49.
- b. Based on the weighted average EPS of ₹4.19 as per restated financial statements the P/E ratio is 22.92.
- c. Industry P/E

Particulars	Industry P/E
▪ Highest	84.26
▪ Lowest	35.85
▪ Average	58.42

Notes:

(1) The industry high and low has been considered from the industry peer set in Diagnostics - Healthcare Services sector, provided later in this section. The industry average has been calculated as the arithmetic average P/E of the industry peer set disclosed in this section. For further details, please see the paragraph entitled "Peer Competitors – Comparison of Accounting Ratios" at point 6 below.

3. Return on Net Worth

Period	Return on Net Worth (%)	Weights
FY 2023	25.75%	3
FY 2022	27.74%	2
FY 2021	28.94%	1
Weighted Average	26.95%	

4. Minimum Return on increased Net Worth required to maintain pre-Issue EPS.

The minimum return on increased net worth required maintaining pre-Issue EPS:

A) Based on weighted average EPS of ₹4.19

At the Issue Price of ₹ 96: 11.71% based on restated financial statements.

B) Based on Basic and Diluted EPS for the FY 2023 of ₹4.09

At the Issue Price of ₹ 96: 11.43% based on restated financial statements.

5. Net Asset Value per Equity Share

- FY 2023 ₹ 15.87
- 30.09.2023 ₹ 16.32
- NAV per Equity Share after the Issue is : ₹ 35.77
- Issue Price per Equity Share is: ₹ 96.00

6. Peer Competitors - Comparison of Accounting Ratios

Since we are the Company engaged in Diagnostics - Healthcare Services sector, hence we have selected the Companies from the same sector. Most of the listed Companies in the sector are very large compared to us and may have product portfolio larger than ours, hence we have considered the listed Companies which are in the similar line of business as ours is considered above for comparison.

Name of the Company	CMP* (₹)	Face Value (₹)	EPS (₹)	P/E# Ratio	EBIDTA (Rs. In Lakhs)	Mcap / EBIDTA Multiple	RONW (%)	NAV (₹)	Price / NAV	Total Revenue (₹ crore)	M Cap (₹ crore)	Mcap / Total Revenue
Clinitech***	96.00	10	4.09	23.49	16.30	134.42	27.74%	15.87	6.05	6.36	21.91	3.44
Dr Lalpath Labs**	2453.70	10	29.12	84.26	53160.00	38.53	715.53%	203.91	12.03	2058.60	20,482.96	9.95
Thyrocare**	670.75	10	12.16	55.16	12847.00	27.65	12.02%	101.12	6.63	635.09	3,551.80	5.59
Krsnaa Diagnostics**	709.10	5	19.78	35.85	14168.00	16.16	8.41%	235.28	3.01	506.50	2,289.67	4.52

* Source: Issue Price for Clinitech and closing market price on January 10, 2024 on BSE for Others.

P/E Ratio is computed by dividing the Issue Price / closing market price on September 20, 2023 on BSE by EPS

** Source: Data for these Companies are sourced from Annual Report based on Consolidated financials for FY 2023 / FY 2022 / FY 2021 and RHP for Krsnaa Diagnostics for FY 2021. RONW / EPS / NAV etc. is adjusted for face value

***Clinitech financials are based on March 31, 2023 Restated Financials.

7. Key Operational and Financial Performance Indicators:

The KPIs disclosed below have been used historically by our Company to understand and analyze the business performance, which in result, help us in analyzing the growth of our Company in comparison to our peers.

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated January 01, 2024 and the members of the Audit Committee have verified the details of all KPIs pertaining to our Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of this Draft Prospectus. Further, the KPIs herein have been certified by M/s. E. A. Patil & Associates LLP, Chartered Accountants, by their certificate dated January 20, 2024.

The KPIs of our Company have been disclosed in the sections titled “Our Business” on page 77. We have described and defined the KPIs, as applicable, in “Definitions and Abbreviations” beginning on page 1.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilisation of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI ICDR Regulations. Further, the ongoing KPIs will continue to be certified by a member of an expert body as required under the SEBI ICDR Regulations.

Financial KPIs of our Company

(₹ in lakhs, except for percentage)

Particulars	30.09.2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Total Revenue	308.12	636.34	645.7	459.63
EBITDA ⁽¹⁾	29.56	136.69	113.92	86.64
EBITDA margin (%) ⁽²⁾	9.59%	21.48%	17.64%	18.85%
PAT	6.78	61.31	51.26	40.24
PAT Margin (%)	2.20%	9.63%	7.94%	8.75%
Net Debt ⁽³⁾	46.43	24.56	78.25	21.64
Total Equity	150.00	150.00	150.00	66.66
Networth	244.86	238.08	184.81	139.03
RONW (%) ⁽⁴⁾	2.77%	25.75%	27.74%	28.94%
EPS (Basic & Diluted) ⁽⁵⁾	0.45 & 0.45	4.09 & 4.09	3.42 & 3.42	6.04 & 6.04

⁽¹⁾EBITDA = Profit before tax + depreciation & amortization expense + finance cost.

⁽²⁾EBITDA Margin = EBITDA/ Total Revenue.

⁽³⁾Net Debt = Current Debts (Long Term Borrowings) as well as Non Current Debt (Short term Borrowings) less Cash and Bank balance (Cash and Cash Equivalents balances).

⁽⁴⁾RONW = Profit after tax / Networth

⁽⁵⁾EPS = Net Profit after tax, as restated, attributable to equity shareholders divided by weighted average no. of equity shares outstanding during the year/ period.

Explanation for KPI metrics

KPI	Explanations
Revenue from Operations	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps assess the overall financial performance of our Company and size of our business.
Total Revenue	Total Revenue is used by the management to track revenue from operations and other income.
EBITDA	EBITDA provides information regarding the operational efficiency of the business.
EBITDA Margin (%)	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business.
PAT	Profit after tax provides information regarding the overall profitability of the business.
PAT Margin (%)	PAT Margin (%) is an indicator of the overall profitability and financial performance of our business.
Net Debt	Net Debt is used to know the position of Companies indebtedness vs. liquid balances available in balance sheet
Net Worth	Net worth is used by the management to ascertain the total value created by the entity and provides a snapshot of current financial position of the entity.
RONW (%)	RONW provides how efficiently our Company generates earnings for the equity shareholders of the Company.

8. Set forth below are the details of comparison of key performance of indicators with our listed industry peers:

Dr. Lal Pathlabs

(₹ in lakhs, except for percentage)

Particulars	30.09.2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Total Revenue	1,17,480.00	2,05,860.00	2,13,995.40	1,63,259.90
EBITDA ⁽¹⁾	35,650	53,155.30	61,327.10	48,761.00
EBITDA margin (%) ⁽²⁾	30.35%	25.82%	28.66%	29.87%
PAT	19,430	24,107.70	35,029.10	29,647.90
PAT Margin (%)	16.54%	11.71%	16.37%	18.16%
Net Debt ⁽³⁾	-66,140	-42,874.10	-27,194.10	-92,590.90
Total Equity	8,350	8,336.80	8,334.50	8,334.50
Networth	180,610	169,954.50	153,706.80	127,601.50
RONW (%) ⁽⁴⁾	10.76%	14.18%	22.79%	23.23%
EPS (Basic & Diluted) ⁽⁵⁾	23.11 & 23.05	28.82 & 28.74	41.70 & 41.57	35.33 & 35.25

Thyrocare

(₹ in lakhs, except for percentage)

Particulars	30.09.2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Total Revenue	28,604.00	53,509.00	61,811.00	50,705.00
EBITDA ⁽¹⁾	7,518.00	12,847.00	26,414.00	18,369.00
EBITDA margin (%) ⁽²⁾	26.28%	20.23%	42.73%	36.23%
PAT	3,758.00	6,436.00	17,614.00	11,315.00
PAT Margin (%)	13.14%	10.13%	28.50%	22.32%
Net Debt ⁽³⁾	-85.00	-2,847.00	-1,391.00	-1,573.00
Total Equity	5,293.00	5,293.00	5,290.00	5,287.00
Networth	48,764.00	53,522.00	52,657.00	42,728.00
RONW (%) ⁽⁴⁾	7.71%	12.02%	33.45%	26.48%
EPS (Basic & Diluted) ⁽⁵⁾	7.10 & 7.09	12.16 & 12.14	33.30 & 33.25	21.41 & 21.37

Krsnaa Diagnostics

(₹ in lakhs, except for percentage)

Particulars	30.09.2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Total Revenue	30,340.80	50,650.20	47,036.10	66,147.60
EBITDA ⁽¹⁾	7,153.30	14,168.00	14,638.70	35,883.10
EBITDA margin (%) ⁽²⁾	23.58%	27.97%	31.12%	54.25%
PAT	2,513.90	6,211.10	6,871.30	18,492.90
PAT Margin (%)	8.29%	12.26%	14.61%	27.96%
Net Debt ⁽³⁾	-13,260.70	-9,229.60	-21,625.10	4,978.64
Total Equity	1,569.90	1,569.90	1,569.90	649.50
Networth	75,525.00	73,873.60	68,440.90	23,186.50
RONW (%) ⁽⁴⁾	3.33%	8.41%	10.04%	79.76%
EPS (Basic & Diluted) ⁽⁵⁾	8.01 & 7.75	19.78 & 19.26	22.89 & 22.88	160.36 & 12.25#

Source: All the financial information for listed industry peers mentioned above is sourced from the regulatory filings made by aforesaid companies to stock exchanges for the respective years / period to compute the corresponding financial ratios.

⁽¹⁾ EBITDA = Profit before tax + depreciation & amortization expense + finance cost.

⁽²⁾ EBITDA Margin = EBITDA/ Total Revenue.

⁽³⁾ Net debt = Non-current borrowing + current borrowing - Cash and Cash Equivalent and Bank Balance.

⁽⁴⁾ RONW = Profit after tax / Networth

*Capital employed = Total Equity + Non-current borrowing + current Borrowing – Intangible Assets

⁽⁵⁾ EPS = Net Profit after tax, as restated, attributable to equity shareholders divided by weighted average no. of equity shares outstanding during the year/ period.

after Split of face value

9. Weighted average cost of acquisition

- a) The price per share of our Company based on the primary/ new issue of shares (equity / convertible securities)

Other than as mentioned below, there has been no issuance of Equity Shares or convertible securities, during the 18 months period preceding the date of this Draft Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company.

Date of allotment	No. of equity shares allotted	Face value per equity share (₹)	Issue price per equity share (₹)	Nature of allotment	Nature of consideration	Total Consideration (in ₹ lakhs)
March 28, 2022	8,33,334	10	Nil	Bonus Issue	Other than Cash	Nil
December 22, 2023	1,80,000	10	38	Further Issue	Cash	68.40
Weighted average cost of acquisition (WACA)						₹ 6.62

- b) The price per share of our Company based on the secondary sale / acquisition of shares (equity / convertible securities)

Other than as mentioned below, there have been no secondary sale / acquisitions of Equity Shares or any convertible securities, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this certificate, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-Offer capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

Dates of Allotment / Transfer	Nature of acquisition (Allotment/ Acquired/ transfer)	Number of Equity Shares	Face Value per Equity Share (in ₹)	Issue Price / Acquisition Price / Transfer price per Equity Share (in ₹)	Nature of Consideration	Percent age of Pre Issue Equity Share Capital (%)	Percent age of Post Issue Equity Share Capital (%)
Jagdish Umakant Nayak							
December 20, 2023	Transfer	75,000	10	13	Cash	4.46	3.29
Jyoti Jagdish Nayak							
December 20, 2023	Transfer	75,000	10	13	Cash	4.46	3.29
Total		1,50,000		13		8.92	6.58

c) Weighted average cost of acquisition, issue price

Types of transactions	Weighted average cost of acquisition (₹ per Equity Share)	Issue price (i.e. ₹ 96)
Weighted average cost of acquisition of primary / new issue as per paragraph 8(a) above.	6.62	14.50 times
Weighted average cost of acquisition for secondary sale / acquisition as per paragraph 8(b) above.	13.00	7.38 times

The face value of Equity Shares of our Company is ₹10 per Equity Share and the Issue price of ₹ 96 is 9.60 TIMES of the face value.

The Issue Price of ₹ 96.00 is determined by our Company, in consultation with the Lead Manager is justified based on the above accounting ratios. For further details, please refer to the section titled 'Risk Factors', and chapters titled 'Our Business' and 'Financial Information' beginning on page 17, 77 and 114, respectively of the Draft Prospectus.

STATEMENT OF TAX BENEFITS

STATEMENT OF POSSIBLE TAX BENEFITS AVAILABLE TO CLINITECH LABORATORY LIMITED AND ITS SHAREHOLDERS UNDER THE APPLICABLE LAWS IN INDIA

To,
The Board of Directors
Clinitech Laboratory Limited
AL-1/545, Sector 16, Airoli,
Opposite Radhikabai Meghe Vidyalaya,
Navi Mumbai, Thane - 400708,
Maharashtra, India

Dear Sirs,

Sub: Statement of Possible Special Tax Benefits ('the Statement') available to Clinitech Laboratory Limited and its Shareholders prepared in accordance with the requirements under Schedule VI-Clause 9L of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended (the 'Regulations')

We hereby confirm that the enclosed annexure, prepared by the Company states the possible special tax benefits available to the Company and the shareholders of the Company under the Income – tax Act, 1961 ("The Act") as amended time to time, presently in force in India. Several of these benefits are dependent on the Company or its shareholders fulfilling the conditions prescribed under the relevant provisions of the Act. Hence, the ability of the Company or its shareholders to derive the tax benefits is dependent upon fulfilling such conditions, which based on the business, the company may or may not choose to fulfil.

The benefits discussed in the enclosed Annexure cover only special tax benefits available to the Company and its Shareholders and do not cover any general tax benefits. Further, these benefits are neither exhaustive nor conclusive and the preparation of the contents stated is the responsibility of the Company's Management. We are informed that this statement is only intended to provide general information to the investors and hence is neither designed nor intended to be a substitute for professional tax advice. In view of the individual nature of the tax consequences, the changing tax laws, each investor is advised to consult his or her own tax consultant with respect to the specific tax implications arising out of their participation in the issue. We are neither suggesting nor are we advising the investor to invest money or not to invest money based on this statement.

Our views are based on the existing provisions of the Act and its interpretations, which are subject to change or modification by subsequent legislative, regulatory, administrative or judicial decisions. Any such change, which could also be retroactive, could have an effect on the validity of our views stated herein. We assume no obligation to update this statement on any events subsequent to its issue, which may have a material effect on the discussions herein.

We do not express any opinion or provide any assurance as to whether:

- The Company or its Shareholders will continue to obtain these benefits in future; or
- The conditions prescribed for availing the benefits, where applicable have been/would be met.

The contents of this annexure are based on information, explanations and representations obtained from the Company and on the basis of our understanding of the business activities and operations of the Company and the provisions of the tax laws.

No assurance is given that the revenue authorities / courts will concur with the views expressed herein. The views are based on the existing provisions of law and its interpretation, which are subject to change from time to time. We would not assume responsibility to update the view, consequence to such change.

We shall not be liable to Company for any claims, liabilities or expenses relating to this assignment except to the extent of fees relating to this assignment, as finally judicially determined to have resulted primarily from bad faith of intentional misconduct.

The enclosed Annexure is intended solely for your information and for inclusion in the Draft Prospectus/Prospectus or any other issue related material in connection with the proposed issue of equity shares and is not to be used, referred to or distributed for any other purpose without our prior written consent.

**Signed in terms of our separate report of even date
For E. A. Patil & Associates LLP
Chartered Accountants**

SD/-

**CA Mohan R. Khebade
Partner
Membership No: 107639
FRN: 117371W/W100092**

**Date: January 19, 2024
Place: Navi Mumbai**

UDIN:24107639BKBEAW3335

Annexure

STATEMENT OF POSSIBLE SPECIAL TAX BENEFITS AVAILABLE TO THE COMPANY AND ITS SHAREHOLDERS

Outlined below are the possible Special tax benefits available to the Company and its shareholders under the Income Tax Act, 1961 presently forced in India. It is not exhaustive or comprehensive and is not intended to be a substitute for professional advice. Investors are advised to consult their own tax consultant with respect to the tax implications of an investment in the Equity Shares particularly in view of the fact that certain recently enacted legislation may not have a direct legal precedent or may have different interpretation on the benefits, which an investor can avail.

YOU SHOULD CONSULT YOUR OWN TAX ADVISORS CONCERNING THE INDIAN TAX IMPLICATIONS AND CONSEQUENCES OF PURCHASING, OWNING AND DISPOSING OF EQUITY SHARES IN YOUR PARTICULAR SITUATION.

A. SPECIAL TAX BENEFITS TO THE COMPANY UNDER THE INCOME TAX ACT, 1961 (THE “ACT”)

The Company is entitled to tax benefit under section 35(1)(iv) in respect of any expenditure of a capital nature on scientific research in the field of information technology.

B. SPECIAL TAX BENEFITS TO THE SHAREHOLDERS UNDER THE INCOME TAX ACT, 1961 (THE “ACT”)

The Shareholders of the Company are not entitled to any special tax benefits under the Act.

Notes:

- All the above benefits are as per the current tax laws and will be available only to the sole / first name holder where the shares are held by joint holders.
- The above statement covers only certain relevant direct tax law benefits and does not cover any indirect tax law benefits or benefit under any other law.

No assurance is given that the revenue authorities/courts will concur with the views expressed herein. Our views are based on the existing provisions of law and its interpretation, which are subject to changes from time to time. We do not assume responsibility to update the views consequent to such changes. We do not assume responsibility to update the views consequent to such changes. We shall not be liable to any claims, liabilities or expenses relating to this assignment except to the extent of fees relating to this assignment, as finally judicially determined to have resulted primarily from bad faith or intentional misconduct. We will not be liable to any other person in respect of this statement.

SECTION V: ABOUT THE COMPANY INDUSTRY OVERVIEW

The information in this section has been extracted from reports publicly available documents and information, including, but not limited to, materials issued or commissioned by the Government of India and certain of its ministries, trade and industry-specific publications and other relevant third-party sources.

Industry websites and publications generally state that the information contained therein has been obtained from sources believed to be reliable, but their accuracy and completeness are not guaranteed, and their reliability cannot be assured. While the Company has exercised reasonable care in relying on such government, industry, market and other relevant data in this document, it has not been independently verified by the Company or any of its advisors, nor the Lead Manager or any of its respective advisors, and should not be relied on as if it had been so verified.

INDIAN ECONOMY OVERVIEW

<https://www.ibef.org/economy/indian-economy-overview>

INTRODUCTION

Strong economic growth in the first quarter of FY 2022-23 helped India overcome the UK to become the fifth-largest economy after it recovered from repeated waves of COVID-19 pandemic shock. Real GDP in the first quarter of 2022-23 is currently about 4% higher than its corresponding 2019-20, indicating a strong start for India's recovery from the pandemic. Given the release of pent-up demand and the widespread vaccination coverage, the contact-intensive services sector will probably be the main driver of development in 2022-2023. Rising employment and substantially increasing private consumption, supported by rising consumer sentiment, will support GDP growth in the coming months.


Future capital spending of the government in the economy is expected to be supported by factors such as tax buoyancy, the streamlined tax system with low rates, a thorough assessment and rationalisation of the tariff structure, and the digitization of tax filing. In the medium run, increased capital spending on infrastructure and asset-building projects is set to increase growth multipliers, and with the revival in monsoon and the Kharif sowing, agriculture is also picking up momentum. The contact-based services sector has largely demonstrated promise to boost growth by unleashing the pent-up demand over the period of April-December 2022. The sector's success is being captured by a number of HFIs (High-Frequency Indicators) that are performing well, indicating the beginnings of a comeback.

India has emerged as the fastest-growing major economy in the world and is expected to be one of the top three economic powers in the world over the next 10-15 years, backed by its robust democracy and strong partnerships. India's appeal as a destination for investments has grown stronger and more sustainable as a result of the current period of global unpredictability and volatility, and the record amounts of money raised by India-focused funds in 2022 are evidence of investor faith in the "Invest in India" narrative.

MARKET SIZE

India's nominal gross domestic product (GDP) at current prices is estimated to be at Rs. 301.75 trillion (US\$ 3.62 trillion) in 2023-24. Additionally, the Nominal GDP at current prices in Q1 of 2023-24 was Rs. 70.67 trillion (US\$ 848.92 billion), as against Rs. 65.42 trillion (US\$ 785.85 billion) in 2022-23, estimating a growth of 8%. With 115 unicorns valued at more than US\$ 350 billion, as of February 2023, India presently has the third-largest unicorn base in the world. The government is also focusing on renewable sources by achieving 40% of its energy from non-fossil sources by 2030. India is committed to achieving the country's ambition of Net Zero Emissions by 2070 through a five-pronged strategy, 'Panchamrit'. Moreover, India ranked 3rd in the renewable energy country attractive index.

India's Gross Domestic Production



According to the McKinsey Global Institute, India needs to boost its rate of employment growth and create 90 million non-farm jobs between 2023 and 2030 in order to increase productivity and economic growth. The net employment rate needs to grow by 1.5% per annum from 2023 to 2030 to achieve 8-8.5% GDP growth between 2023 and 2030. India's current account deficit (CAD) decreases to US\$ 9.2 billion in Q1 of 2023-24 from US\$ 17.9 billion in Q1 of 2022–2023.

Exports fared remarkably well during the pandemic and aided recovery when all other growth engines were losing steam in terms of their contribution to GDP. Going forward, the contribution of merchandise exports may waver as several of India's trade partners witness an economic slowdown. According to Mr. Piyush Goyal, Minister of Commerce and Industry, Consumer Affairs, Food and Public Distribution and Textiles, Indian exports are expected to reach US\$ 1 trillion by 2030.

RECENT DEVELOPMENTS

India is primarily a domestic demand-driven economy, with consumption and investments contributing to 70% of the economic activity. With an improvement in the economic scenario and the Indian economy recovering from the Covid-19 pandemic shock, several investments and developments have been made across various sectors of the economy. According to World Bank, India must continue to prioritise lowering inequality while also putting growth-oriented policies into place to boost the economy. In view of this, there have been some developments that have taken place in the recent past. Some of them are mentioned below:

- As of August 2023, India's foreign exchange reserves stood at US\$ 594.90 billion.
- In the first half of 2023-24, India saw a total of US\$ 21 billion in PE-VC investments.
- Merchandise exports in September 2023 stood at US\$ 34.47 billion, with total merchandise exports of US\$ 211.40 billion during the period of April-September (2023-24).
- India was also named as the 48th most innovative country among the top 50 countries, securing 40th position out of 132 economies in the Global Innovation Index 2023. India rose from 81st position in 2015 to 40th position in 2023. India ranks 3rd position in the global number of scientific publications.
- PMI Services remained comfortably in the expansionary zone at 62.3 in the month of June 2023.
- In September 2023, the gross Goods and Services Tax (GST) revenue collection stood at Rs. 1,62,712 crore (US\$ 19.54 billion), of which CGST is Rs. 29,818 crore (US\$ 3.58 billion), SGST is Rs. 37,657 crore (US\$ 4.52 billion), IGST is Rs. 83,623 crore (US\$ 10.04 billion).
- Between April 2000–June 2023, cumulative FDI equity inflows to India stood at US\$ 937.58 billion.
- In August 2023, the overall IIP (Index of Industrial Production) stood at 145.1. The Indices of Industrial Production for the mining, manufacturing and electricity sectors stood at 111.9, 143.5 and 220.5, respectively, in August 2023.
- According to data released by the Ministry of Statistics & Programme Implementation (MoSPI), India's Consumer Price Index (CPI) based retail inflation reached 5.02% in September 2023.
- Foreign Institutional Investors (FII) inflows between April-July (2023-24) were close to Rs. 80,500 crore (US\$ 9.67 billion), while Domestic Institutional Investors (DII) sold Rs. 4,500 crore (US\$ 540.56 million) in the same period. As per depository data, Foreign Portfolio Investors (FPIs) invested Rs. 22,000 crore (US\$ 2.67 billion) in India during the first week of July 2023.

- The wheat procurement during RMS 2023-24 (till May) was estimated to be 262 lakh metric tonnes (LMT) and the rice procured in KMS 2023-24 was 385 LMT. The combined stock position of wheat and rice in the Central Pool is over 579 LMT (Wheat 312 LMT and Rice 267 LMT).

GOVERNMENT INITIATIVES

Over the years, the Indian government has introduced many initiatives to strengthen the nation's economy. The Indian government has been effective in developing policies and programmes that are not only beneficial for citizens to improve their financial stability but also for the overall growth of the economy. Over recent decades, India's rapid economic growth has led to a substantial increase in its demand for exports. Besides this, a number of the government's flagship programmes, including Make in India, Start-up India, Digital India, the Smart City Mission, and the Atal Mission for Rejuvenation and Urban Transformation, are aimed at creating immense opportunities in India.

ROAD AHEAD

In the second In the second quarter of FY24, the growth momentum of the first quarter was sustained, and high-frequency indicators (HFIs) performed well in July and August of 2023. India's comparatively strong position in the external sector reflects the country's generally positive outlook for economic growth and rising employment rates. India ranked 5th in foreign direct investment inflows among the developed and developing nations listed for the first quarter of 2022.

India's economic story during the first half of the current financial year highlighted the unwavering support the government gave to its capital expenditure, which, in 2023-24, stood 37.4% higher than the same period last year. In the budget of 2023-24, capital expenditure took lead by steeply increasing the capital expenditure outlay by 37.4 % in BE 2023-24 to Rs.10 lakh crore (US\$ 120.12 billion) over Rs. 7.28 lakh crore (US\$ 87.45 billion) in RE 2022-23. The ratio of revenue expenditure to capital outlay increased by 1.2% in the current year, signaling a clear change in favour of higher-quality spending. Stronger revenue generation because of improved tax compliance, increased profitability of the company, and increasing economic activity also contributed to rising capital spending levels.

Since India's resilient growth despite the global pandemic, India's exports climbed at the second-highest rate with a year-over-year (YoY) growth of 8.39% in merchandise exports and a 29.82% growth in service exports till April 2023. With a reduction in port congestion, supply networks are being restored. The CPI-C inflation reduction from June 2022 already reflects the impact. In September 2023 (Provisional), CPI-C inflation was 5.02%, down from 7.01% in June 2022. With a proactive set of administrative actions by the government, flexible monetary policy, and a softening of global commodity prices and supply-chain bottlenecks, inflationary pressures in India look to be on the decline overall.

Diagnostic Sector

The diagnostic industry has emerged as an attractive play in India's growing healthcare sector and is one of the fastest growing services in the country. The domestic diagnostic industry is estimated at USD9bn (around INR 675bn) and is expected to grow at a compounded annual growth rate (CAGR) of ~10% over the next 5 years. Growth will be primarily driven by change in demographics, increase in lifestyle diseases, and higher income levels across all strata of society, rise in preventive testing, deeper penetration with asset-light expansion, and spread of healthcare services and insurance.

The diagnostic segment is a critical component of the healthcare sector. Globally, ~80% of physician diagnoses are a result of laboratory tests. There are mainly 3 types of tests: Routine, clinical lab and specialty tests.

- Routine tests: Common tests like sugar, cholesterol, HIV, pap, pregnancy, etc.
- Clinical lab tests to monitor diseases and drug treatments
- Specialty tests: Genetics, immunology, oncology, endocrinology and other critical segments

The Indian diagnostic industry is highly fragmented and under-penetrated despite the presence of over 1 lakh labs. Diagnostic chains command ~16% market share. The 4 major players – Dr Lal PathLabs (DLPL), Metropolis Healthcare (METROHL), SRL Diagnostics (SRL) and Thyrocare Technologies – have a share of ~6%. So, there is a huge opportunity for national players to consolidate and for organic expansion. We believe organized players with national presence would grow at 15-17% CAGR over the next five years and continue to garner market share, led by asset light models and strong cash flows. The growth of these diagnostics would be majorly volume-driven, given the high level of competition and government-imposed regulations. Attracted by historically high growth rates (20-25%) lucrative returns, and low entry barriers, most players compete on pricing to garner volumes quickly and move up the cost curve, supported by PE investors. To capture the increasingly important shift towards the consumer, industry leaders have started to implement initiatives such as retailer partnering, offering home testing, and enhancing engagement with patients through digital presence, in

addition to maintaining their basic testing services as a safety net. A faster shift of unorganized business to organized players, potential consolidation, likely increase in preventive check-ups and sizeable scale would benefit large organized players with strong balance sheets.

The industry is broadly segregated into pathology testing and imaging diagnostic services. Pathology testing (in-vitro diagnosis) includes sample collection in the form of blood, urine and stool. This is followed by the sample's analysis using laboratory equipment and technology to derive useful clinical information for assisting in patient treatment. The imaging diagnostic segment consists of more complex tests like computed tomography (CT) scans and magnetic resonance imaging (MRI) and other highly specialised tests like positron emission tomography (PET)-CT scans. As per estimates, the pathology segment contributes ~58% of total market revenue.

With private diagnostic chains taking the lead with superior and quality services, highly accurate and wider test menu -- resulting in market share gains -- we expect consolidation in the sector going forward. Currently, only 1% of labs are National Accreditation Board of Laboratories (NABL) and/or College of American Pathologists (CAP) accredited. Only a few large national players like SRL, DLPL, METROHL, Thyrocare, Max Healthcare and Apollo Clinic have accredited labs.

Indian diagnostic industry – Market structure


The market share is categorized as: unorganized (47%), hospital-based lab (37%) while the remaining (~16%) is with the organized players. Doctor referrals constitute a large part of this business. This includes commission payments to doctors in lieu of referring a diagnostic lab. Further, currently, the illness diagnosis segment is more prevalent than wellness segment in India.


Services:

Pathology testing or invitro diagnosis involves the collection of samples in the form of blood, urine, stool, etc., and analyzing them using laboratory equipment and technology to arrive at useful clinical information that assists in treatment of diseases. It includes biochemistry, immunology, hematology, urine analysis, molecular diagnosis, and microbiology.

Imaging diagnosis or radiology involves imaging procedures such as X-rays and ultrasounds that help determine anatomical or physiological changes inside a patient’s body, thus assisting doctors in diagnosing. It includes more complex tests such as CT scans, MRIs, and highly specialized PET-CT scans.

Wellness and preventive diagnostic services aim at identifying pre-existing diseases or the likely risk of particular diseases before the onset of symptoms. It is expected that wellness and preventive diagnostic services will assist people more accurately identify risks so that they can take corrective or precautionary measures before any chronic condition develops. Wellness and preventive tests are generally aligned to either specifically screen for a chronic disease or contain a series of tests to ascertain the overall health condition of an individual.





The diagnostic sector in India is highly fragmented with large chains, standalone centres and hospital-based laboratories. The lack of regulatory framework and minimum standard requirements led to low-entry barriers. However, limited test menu/offerings by regional standalone laboratories and partial coverage of hospital-based laboratories have resulted in higher opportunities for diagnostic chain players.

Diagnostic chains have the advantage of years of experience, brand trust and recall, global quality standards and accreditations, brand experience, expansive test menu, patient touch-points to service patients locally, value-added offerings for patients and the ability to sustainably grow into newer markets. Pan India diagnostic players have been gaining market share continuously over the past few years on account of expanding collection centres and laboratory networks, which has helped them improve their asset utilisation. National diagnostic players would gain market share in coming years, especially post the COVID-19 pandemic, which would further lead to industry growth.

Asset Light Model for Growth:

Hub and spoke model: Most organized diagnostic chains operate on hub and spoke business model, which brings economies of scale benefits. To gain a competitive advantage, reap scale economy benefits and control operating costs, these diagnostic chains constantly endeavor to increase their network rapidly. They do so by adding satellite laboratories and collection centers (majorly on a franchisee model).

Reagent rental model: Suppliers sell their equipment to lab testing companies at almost zero capital costs. Lab testing companies agree to buy reagent batches (batch of testing chemicals) exclusively from the company whose equipment is installed in their lab and pay a periodic rental (given a lease rental type agreement), which is booked as an operating expense.

Shop in Shop model: Diagnostic players are entering into outsourcing contracts with hospitals, whereby they would handle the entire diagnostic operations for them. Such models of outsourcing clinical tests to private laboratories are expected to rise to streamline and increase efficiency.

Home collection: Home sample collection and testing has been on the rise, provided by almost all organized players and some unorganized ones as well. Phlebotomist collects the sample and transports it in a specially designed transportation box (cold box) to the designated processing center. Home sample collection is one of the key reasons for the success of diagnostic chains and their rapid penetration in the urban market.

Formalization of Diagnostic Industry:

The diagnostics industry is highly fragmented with large chains, standalone centers, and hospital-based laboratories. Owing to low entry barriers, the industry is fragmented and is witnessing a lot of small and medium sized players; however, very few are able to scale in a profitable manner. Regional Standalone Laboratories have a limited test menu and, hence, lack the capacity needed to expand in terms of service offerings and perceived quality of testing, which may not be as good as that of an established chain's. Hospital-based laboratories are restricted to the hospital's inpatients, with a limited test menu

and charges that are higher than diagnostic chains. Diagnostic chains, on the other hand, have an advantage of years of experience, brand trust and recall, global quality standards and accreditations, brand experience, expansive test menus, patient touch points to service patients locally, value added offerings for patients and the ability to sustainably grow in new markets.

Diagnostic chains have managed rapid growth through opening more collection centers, which has improved their asset utilization. Moreover, large chains have greater bargaining power that allows them to keep their input costs (bulk purchase of reagents) lower than standalone centers. Standalone ones also tend to lose out on some business as they are unable to carry out complex tests and customers hold the perception that their quality does not match that of branded chains'. Hence, we can say diagnostic chains would continue to eat into standalone centers' market share.

Their situation is further strengthened after the COVID-19 breakout, with the shift from unorganized to organized players expected to happen at a faster rate now, as patients prefer visiting branded and recognized labs that give better quality and enhanced safety. Organized players are also likely to benefit from rise in home collection, given their strong brand recognition, reliability and quality services. The unorganized and smaller labs offer a chance to the bigger players to expand their reach and presence through acquisitions and franchisee operation model.

Positive Impact of COVID-19:

The current health scare of COVID-19 is set to change the mindset of Indian customers. An increasing number of customers will now evaluate and label diagnostics chains as 'COVID-19 capable' and 'non-COVID-19 capable'. With these tests becoming the new norm, a higher market share is expected to shift towards the labs offering COVID-related tests. The pandemic is helping the organized players build their brand value and goodwill, which will help attract patients.

Customers are now anticipated to place quality over pricing when it comes to diagnostics. Higher quality standards, authentic reports, after sales service, and doctor engagement will be the key deciding factors in the lab selection process. Unorganized and standalone labs were facing severe cost pressures due to lockdown. The faster adoption of quality standards, partly enforced by the Government and partly forced upon by customers, indirectly, could result in the closure of operations for many unorganized standalone labs. A faster consolidation in the industry, along with changes in the regulatory framework, is also anticipated soon. Diagnostics chains with a lean balance sheet, strong consumer-connect, high brand recall, and following global quality standards will gain market share. We believe that the current disruption led by COVID-19 will help the industry leaders in absorbing the small and mid-sized labs, which are facing operational challenges.

Challenges faced by industry:

Lower/no entry barrier: One of the key reasons for the industry to be fragmented is low entry barrier. The historically high growth rates (20-25%) had attracted quite a few PE investors into this setup. Private equity (PE) players were very active in this space during 2011-15; but the number of deals has gone down on the back of high competition. Also, limited test menu/offerings by regional standalone laboratories and partial coverage of hospital-based laboratories have resulted in higher opportunities for diagnostic chain players.

Challenge in entering new geographies: India is a vast country with diverse cultures and disease profiles across its various regions. The diversity in demographics, disease profiles, and healthcare systems present big challenges. Large diagnostic players face competition from local players who have an edge due to their familiarity with local market dynamics. Also, most players have substantial presence in metros and Tier I. However, the Tier II, III and IV cities are something that has not been tapped aggressively and is largely run by local standalone players offering basic tests. Nevertheless, companies have now started to tap the interiors in order to drive volumes by partnering with local players, which is driving consolidation. National diagnostics players, after having set up centers in new locations, take time to engage with doctors (as referrals contribute high share in this sector) who have long relationships with regional players. Doctors take their own time, which also depends on how much visibility the national players have created of their services in local areas. These national players garnering higher market share from unorganized counterparts take time to scale up their operations.

Pricing pressures: India's diagnostics industry is highly competitive with unorganized players still garnering approximately 84% market share. This increases competition among organized and unorganized diagnostic chains in terms of volumes of patients' samples and pricing of diagnostic tests.

Vulnerability to technological advancements: Medical devices and analyzers are constantly undergoing technological advancements. To stay ahead of the competition, diagnostics centers have to constantly upgrade their technology. However, these upgrades not only involve significant capital investments, but also increase maintenance costs. This is critical, especially for smaller players who face a paucity of funds.

Recent Trends:


Focus on Preventive and Wellness services: Organized players are increasingly targeting healthy individuals with sedentary lifestyles, who are more prone to lifestyle diseases such as cardiovascular ailments and diabetes. Bulk business from employer schemes is a key driver of this market. Emerging trend of precision medicine and focus on preventive care and walk-in/direct-to-customer diagnostic services are expected to drive growth in the diagnostics arena.

Consolidation, shift from unorganized to organized: India’s diagnostics industry is highly fragmented. With emergence of pan-India diagnostic chains, the sector has seen more and more consolidation via mergers and acquisitions and increased market share of organized chains.

Brand building initiatives: All the major diagnostic players are investing in brand building and creating online and offline marketing campaigns to differentiate their offerings, quality, and test accuracy from their competitors. They are launching advertising campaigns, healthcare camps, and various wellness and preventive test packages under their own brands. Their focus on repeat sales and conversion of referral customers into owned ones is the path they are following in this competitive market.

Emergence of Online Aggregators: Online aggregators provide a robust website platform for customers to the most suitable diagnostic packages. They also provide a feature for choosing the service provider along with display of the price it offers. Individual health check-up providers suggest various packages to customers based on their requirements and handle the booking of packages at designated service providers. These facilities are bringing diagnostic and testing services to the fingertips of customers, offering them a number of available options almost instantly.

Indian diagnostic industry – Major growth drivers



Source: <https://www.edelweiss.in/ewwebimages/WebFiles/Research/a8b96f38-8192-4fc1-8bf8-de1b28d900f2.pdf>

National players have majority of accredited labs in the country, focus on quality


National diagnostic players focus on quality through their accredited lab network has helped them establish a brand for themselves in their core market of operation. There are around 1,216 NABL accredited labs, which is ~1% of total labs in India and works out to less than 1 lab per million. The top 4 players have the maximum number of NABL accredited labs. Though the number of accredited labs in India have been growing at 16% CAGR to 1,216 in 2020 from 576 in 2015, there is still a long way to go to reach the numbers of peer nations such as the UK, US and Australia, which have more than 10 labs per million. Quality will be the key future growth driver for the diagnostic industry, where national players are ahead of sector peers.

Exhibit 22: NABL accredited labs state-wise

States	No	States	No
Maharashtra	116	Gujarat	54
Karnataka	90	Haryana	44
Delhi	156	Jharkhand	12
Tamil Nadu	73	Kerala	36
MP	12	Manipur	7
UP	70	Meghalaya	3
Kolkata	90	Mizoram	2
Rajasthan	33	Nagaland	2
Himachal Pradesh	2	Odisha	9
Andhra Pradesh	36	Punjab	24
Telangana	65	Sikkim	1
Assam	23	Tripura	1
Bihar	10	Uttarakhand	12
Chhattisgarh	1	Chandigarh	11
Goa	3	Jammu & Kashmir	2
		Puducherry	2
		Others	214

Source: Edelweiss Professional Investor Research

Exhibit 24: Major cities have higher number of NABL accredited labs



National diagnostic players poised to gain market share

Diagnostic players, with revenue above INR 100 crore, are profitable with better operating margins as the benefits of scale in test coverage and market penetration brings operating leverage.

Benefits of scale:

1. Diagnostic companies procure their main raw material of chemicals/reagents from equipment manufacturers. Moreover, machines are supplied to them free of cost, lowering their upfront capex requirement for expansion. This arrangement is available to scaled up players only as they can procure reagents in bulk.
2. Large organised diagnostic chains are in a position to perform high revenue generating complex tests.
3. Their strong brand visibility and widespread network of labs and patient service centres attracts more B2C revenue.
4. Doctors' associations play a crucial role in growth, which is driven by a strong brand
5. The hub and spoke model ushers cost efficiencies with bulk testing and increased penetration.
6. Their efficient IT infrastructure, centralised operations and streamlined pan India processes help them gain market share.

Expected increase in health insurance coverage

Most diagnostic testings in India is still an out of pocket expense and is hardly covered by any of the prevailing insurance schemes in the market.

While the Insurance Regulatory and Development Authority of India (IRDAI) pegs the health insurance opportunity size at INR 3 lakh crore, the market size as on FY19-end stands under INR 50,000 crore. This highlights the industry's strong growth potential going forward. Life insurers mostly provide benefit policies for health protection, attached as riders to the base policy, although standalone policies have also been offered.

As per IRDAI, only 36 crore individuals had health insurance coverage, of which only 20% was via commercial insurance providers in the life and non-life space, as bulk of it comes from Central and state government-sponsored schemes. Private health expenditure is expected to rise significantly as life expectancy continues to increase. Till date, the lion's share of healthcare expenditure has come from out-of-pocket expenditure, which is the highest in India compared to its regional peers.


A multitude of factors — under-penetration, low government share of expenditure, rising life expectancy and higher healthcare cost — will be the key growth drivers in this segment.

Inclusion of diagnostic tests under insurance coverage could act as a booster shot

Besides the under-penetration of health insurance, India trails the world in outpatient department (OPD) and diagnostic tests coverage. As per various industry estimates, ~20% of total diagnostic services are being reimbursed via insurance claims, the rest is met by out of pocket expense. This is resulting in a significant section of the population opting for cheaper alternatives. The inclusion of OPD and diagnostic tests in insurance coverage in many Western countries had led to an inflection in the growth rate of the diagnostic industry. We expect a similar trends to emerge in India if such tests are covered by insurance policies.

National players gain market share through the inorganic route

National players are driving growth through acquisitions, business mix, by offering high end complex tests and competitive pricing. This inorganic expansion is the result of competitive pricing, lower scale of business and slowdown in PE investments. This mode of growth is one of the major vectors of market share gains for national players in this fragmented market. Global players like LabCorp and Quest Diagnostics in the US have also grown through acquisitions and this model is being followed by Indian diagnostic players. National players are more focused on Tier II, III cities for inorganic expansion.



Conclusion:

The diagnostic industry has emerged as an attractive play in India's growing healthcare sector and is one of the fastest growing service segments in the country. Diagnostic is a business of economies of scale and the most important metric is the cost of processing a sample. The existing players are still in the nascent stages of their growth cycles and have a long runway ahead. We are positive on the national diagnostic chains in India, given their advantages of many years of experience, brand trust and recall, global quality standards and accreditations, wide test menus, extensive patient touchpoints to service patients locally, value-added offerings, and ability to sustainably grow in new markets. Potential consolidation in the industry, organic and inorganic expansion, complemented by their strong balance sheets and return ratios, would provide tailwinds to their growth in the medium term.

The large listed Indian diagnostic chains - Dr. Lal, Metropolis, Thyrocare - remain beneficiaries of what we view as attractive long-term industry growth story. Given the outbreak of COVID-19 and its impact on people mindset about healthcare and preventive measures over the next one to two years; we are giving higher valuation to these stocks. We see the potential for increased inclusion of diagnostic testing in health insurance and ample runway for higher market penetration as standards of living increase and preventive healthcare awareness rises.

Source: <https://www.edelweiss.in/ewwebimages/WebFiles/Research/a8b96f38-8192-4fc1-8bf8-de1b28d900f2.pdf> and <https://www.hdfcsec.com/hsl.research.pdf/Diagnostics%20Sector%20-%20Initiating%20Coverage%20v2%20-%2030.03.2021.pdf>

OUR BUSINESS

Following information is qualified in its entirety by, and should be read together with, the more detailed financial and other information included in the Draft Prospectus, including the information contained in the section titled ‘Risk Factors’, beginning on page 17 of the Draft Prospectus.

This section should be read in conjunction with, and is qualified in its entirety by, the more detailed information about our Company and its financial statements, including the notes thereto, in the sections titled ‘Risk Factors’ and ‘Financial Information’ and chapter titled ‘Management Discussion and Analysis of Financial Condition and Results of Operations’ beginning on page 17, 114 and 140, respectively, of the Draft Prospectus.

Unless the context otherwise requires, in relation to business operations, in this section of the Draft Prospectus, all references to “we”, “us”, “our” and “our Company” are to our promoters, Clinitech Laboratory Limited and Group Entities as the case may be.

Overview

We are a provider of diagnostic and healthcare tests and services through chain of 8 diagnostic centers in and around Thane and Navi Mumbai. Our Promoters have 30+ years of experience in diagnostic business. We conduct more than 3 Lakh tests per year in our NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited labs equipped with modern technology and high-end equipment.

We conduct more than 150 tests at our centres which are classified under various heads as under:

- Biochemistry tests
- Immunology tests
- Hematology tests
- Molecular Biology tests
- Serology tests
- Microbiology tests
- Histopathology tests

For more details on above tests, please refer to paragraph titled “**Our Products and Services**” on page 78.

We give below details of number of patients handled by us and tests conducted during last 3 years and upto September 30, 2023:

Particulars	01.04.2023 to 30.09.2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Patient count	49,119	1,08,038	84,583	61,087
Tests conducted	176,660	3,47,502	2,68,370	2,22,842

The financial performance of our Company for the Fiscals 2023, 2022 and 2021 and upto September 30, 2023, is as follows:
(₹ in lakhs, except for percentage)

Particulars	30.09.2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Total Revenue	308.12	636.34	645.7	459.63
EBITDA ⁽¹⁾	29.56	136.69	113.92	86.64
EBITDA margin (%) ⁽²⁾	9.59%	21.48%	17.64%	18.85%
PAT	6.78	61.31	51.26	40.24
PAT Margin (%)	2.20%	9.63%	7.94%	8.75%

Net Debt ⁽³⁾	46.43	24.56	78.25	21.64
Total Equity	150.00	150.00	150.00	66.66
Networth	244.86	238.08	184.81	139.03
RONW (%) ⁽⁴⁾	2.77%	25.75%	27.74%	28.94%
EPS (Basic & Diluted) ⁽⁵⁾	0.45	4.09	3.42	6.04

⁽¹⁾EBITDA = Profit before tax + depreciation & amortization expense + finance cost.

⁽²⁾EBITDA Margin = EBITDA/ revenue from operations.

⁽³⁾Net debt = non-current borrowing + current borrowing - Cash and Cash Equivalent, Bank Balance, and Investment in Mutual Funds.

⁽⁴⁾RONW = Net profit after tax /Networth

⁽⁵⁾EPS = Net Profit after tax, as restated, attributable to equity shareholders divided by weighted average no. of equity shares outstanding during the year/ period.

OUR COMPETITIVE STRENGTHS

1. NABL Accreditation

Our Company has been awarded Certificate of Accreditation by NABL (National Accreditation Board for Testing and Calibration Laboratories) in accordance with ISO 15189:2012 for its facilities in the medical testing at Airoli, Navi Mumbai. The certificate enables us to maintain quality of services and it reposes confidence of our customers in us.

2. Chain of Diagnostic Centers

We provide diagnostic and healthcare tests and services through chain of 8 diagnostic centers in and around Thane, Raigad and Navi Mumbai. Our 30+ years of experience has created a trust amongst our customers. Our Promoters inspirational leadership has led Clinitech to be recognised as one of the trusted pathology lab in our region.

3. Experienced Promoter and management team with strong industry expertise and successful track record

The Promoters of our Company, Jagdish Umakant Nayak and Jyoti Jagdish Nayak, established Nayak Clinical Laboratory in 1990 and later on in 1996 renamed as Nayak Pathology Laboratory. During 2010, our promoters corporatized the business and established our Company by name Clinitech Laboratory Private Limited. Our 30+ years of experience has created a trust amongst our customers. Our vision is to make available affordable and holistic healthcare to every individual. Our Promoters inspirational leadership has led Clinitech to be recognised as one of the trusted pathology lab in our region over the years. Further our Company is managed by a team of experienced personnel. The team comprises of personnel having technical, customer relationship, operational, marketing and business development experience. We believe that our management team's experience and their understanding of the needs of our customers will enable us to continue to take advantage of both current and future market opportunities.

For further details regarding the experience and qualifications of our management team please see "Our Management" on page 103 of this Draft Prospectus. We believe that the knowledge and experience of our promoter and management will enables us to identify new opportunities, rapidly respond to market conditions, adapt to changes in the business landscape and competitive environment and enhance the growth in the business.

4. Strong and long-standing customer relationships

Our three-decade long experience and client relationships help us to get repeat business from our customers. Our client relationships also help us to cross sell our other products and services to them. Further we have been mutually value creating, stable and long-term association with our customers through products & services offered by us. This has helped us maintain a long-term relationship with our customers and improve our customer retention strategy. Through these efforts, we aim to become the "first choice service provider" for all our customers for the services we offer.

OUR STRATEGIES

1. Leveraging our existing products / services portfolio

Our Company has developed various products to meet the needs of healthcare requirements of customers. Our promoters long standing experience of diagnostic services has helped us in building products most suiting our customers. We have retained our customers and have been receiving repeat orders over last many years.

2. Leveraging our Infrastructure

We provide diagnostic and healthcare tests and services through chain of 8 diagnostic centers in and around Thane, Raigad and Navi Mumbai. We leverage our infrastructure by keeping abreast of latest diagnostic technologies like sensors, IoT devices, and predictive analytics to get better results at least cost. We further integrate these tools to enhance monitoring and diagnosis capabilities, which helps us serve our customers better.

3. Collaboration and continuous Training

We encourage collaboration among experts within and outside the center. We keep regular training sessions and knowledge sharing, which can enhance the team's skills and keep them updated on the latest industry practices. Further we have established a culture of continuous improvement in our systems and for that we regularly evaluate the center's processes, technologies, and methodologies to adapt to evolving infrastructure needs.

4. Inorganic Growth

In addition to increasing the existing capabilities and leveraging existing product/ service portfolio, we also intend to explore acquisition of businesses, entering into joint ventures in new geographies / verticals where considerable business opportunities would be available to grow our business. Strategic acquisitions/ joint ventures targeted to increase product / services portfolio and penetrate newer markets will be the focus of our Company going forward.

Our Products and Services

Clinical pathology is a medical specialty that focuses on the diagnosis of diseases and conditions through the analysis of bodily fluids and tissues. It includes various laboratory tests and techniques such as blood tests, urine analysis, and tissue biopsies to help healthcare professionals understand the underlying causes of a patient's symptoms and guide treatment decisions. Clinical pathologists play a crucial role in interpreting test results and providing valuable information to aid in patient care.

Brief description of various tests conducted at our diagnostic centres:

- Biochemistry plays a crucial role in pathology, the study of disease processes. It helps us understand the molecular and biochemical mechanisms underlying diseases.
- A serology test is a blood test that analyzes serum, which is the clear liquid portion of blood. This test is often used to detect antibodies in the blood, which are produced by the immune system in response to infections or other foreign substances. Serology tests can be used to diagnose various infectious diseases, including viral infections like HIV, Hepatitis, and COVID-19.
- Microbiology tests in pathology involve the study of microorganisms such as bacteria, viruses, fungi, and parasites to diagnose infectious diseases and understand their characteristics. These tests are crucial for identifying the causative agents of infections, determining their susceptibility to antibiotics, and monitoring treatment efficacy. Test like (Bacterial Culture, Viral Culture, Tuberculosis (TB), Molecular Tests etc.) is done under microbiology.
- Hematology tests in pathology are diagnostic procedures that involve the examination of blood samples to assess various aspects of blood and blood-related disorders. These tests are crucial for diagnosing and monitoring conditions such as anemia, leukemia, clotting disorders.

- Molecular biology plays a crucial role in pathology by helping us understand the molecular mechanisms underlying diseases. It involves studying the structure and function of biomolecules like DNA, RNA, and proteins to uncover the molecular basis of diseases.
- Immunology tests in pathology are a set of diagnostic tests that assess the immune system's function and its response to various conditions. These tests are crucial for diagnosing and monitoring a wide range of diseases, including autoimmune disorders, allergies, infections, and certain cancers.
- Histopathology is a branch of pathology that involves the microscopic examination of tissue samples to diagnose diseases. It's a crucial tool in medical diagnosis, allowing pathologists to study the structure and cellular makeup of tissues to identify abnormalities.


We give below our revenue from each of the above tests during last 3 years and for the period ended September 30, 2023:

(₹ in lakhs, except for percentage)

Particulars	01.04.2023 to 30.09.2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Biochemistry	84.47	171.45	186.24	164.90
Immunology	62.40	132.72	148.44	124.06
Hematology	75.62	135.06	126.61	104.32
Molecular Biology	8.59	44.45	69.49	0.00
Serology	12.64	33.71	31.34	25.87
Microbiology	10.58	21.74	17.41	14.21
Clinical Pathology	8.84	14.76	12.79	11.16
Histopathology	2.37	4.7	5.24	4.79
Other tests	40.30	76.16	40.87	6.08
Total	305.81	634.75	638.43	455.39

Process flow chart

Process flow chart for our services is as under:



1. Patient Registration: The process begins with patient registration, where the patient provides their personal information and insurance details.
2. Sample Collection: A healthcare professional collects the patient's sample, which could be blood, urine, tissue, or other bodily fluids, depending on the type of test.
3. Sample Labelling: Each sample is carefully labelled with the patient's information to ensure accuracy.
4. Transport to the Laboratory: Samples are transported to the pathology laboratory under appropriate conditions to preserve their integrity.
5. Quality Control: Quality control checks are performed to ensure the accuracy and reliability of the test results.
6. Sample Processing: In the lab, technicians process the sample, which may involve centrifugation, separation, or other procedures depending on the test.

7. Analysis: The sample undergoes analysis using various techniques and equipment, such as microscopes, chemical assays, or molecular testing.
8. Data Recording: The results of the analysis are recorded in a laboratory information system (LIS) or electronic health record (EHR) along with patient details.
9. Interpretation: A pathologist or a medical technologist interprets the results based on established criteria.
10. Report Generation: A formal pathology report is generated, which includes the test results, interpretation, and any relevant comments or recommendations.
11. Result Delivery: The pathology report is sent to the ordering physician or healthcare provider, who communicates the results to the patient.
12. Data Storage: The results are securely stored in the patient's medical record for future reference.

Plant and Machinery & Technology

The major Equipment owned by us for our services are as under:

Sl. No.	Name of the Equipment	Number of Equipment
1	Electrolyte Analyzer	3
2	Fully automated 5-part differential Haematology Analyzer	3
3	Fully automated Immunology Analyzer	3
4	Fully automated Microbiology System	2
5	Fully automated Glycohemoglobin Analyzer	1
6	Fully automated PCR Analyzer	1
7	Fully automated 6-part differential Haematology Analyzer	1
8	Biochemistry Analyzer	4
9	Coagulometer	4
10	ABG Analyzer	4

Collaborations

We have not entered into any technical or other collaboration.

Infrastructure Facilities / Utilities

Power

Our Company has no special power load requirements for carrying out our business activities. Our power requirements are met from connection available from Maharashtra State Electricity Distribution Company Limited. The available power supply in our premises is adequate to carry our existing as well proposed activities.

Fuel

Our Company do not have any special requirement of fuel to carry out the present activities.

Water

We do not have any special need of water for our business. We require water for normal sanitation and the same is available in the premises we occupy.

Effluent Treatment Plant (ETP)

We are engaged in the industry there is no effluent generated from the present/ proposed activities, ETP is not required.

Bio Waste Management

Any waste generated in the Laboratory is bifurcated in different categories. Then given to the Bio Waste collector daily. They do the needful for disposal of this waste in accordance with govt guidelines.

Bio waste segregation in path labs is essential for the safety of personnel, compliance with regulations, protection of the environment and to achieve following:

1. Infection Control: Pathology labs handle biological specimens, which may contain infectious agents. Proper segregation ensures that potentially contaminated materials are handled separately, reducing the risk of infection for lab personnel and the public.
2. Regulatory Compliance: Government has strict regulations governing the disposal of bio waste. Proper segregation helps labs comply with these regulations, avoiding legal issues and penalties.
3. Environmental Protection: Bio waste can contain hazardous chemicals or substances harmful to the environment. Segregating bio waste from other waste streams helps prevent contamination
4. Safety: Segregation minimizes the chances of accidental exposure to biohazardous materials. It also simplifies waste management.

For further details, please see “Government and other Key Approvals” on page 159 of this Draft Prospectus.

Raw Material

We require reagent as raw material. Major reagents are glucose kit, creatinine kit, cholesterol kit, bilirubin total kit, alkaline kit, gamma GT kit, sgot, sgpt, uric acid kit etc. Our major requirements for all this reagent are met through local vendors.

Human Resource

We believe that a motivated and empowered employee base is the key to our operations and business strategy. We source our human resources locally and the same is available easily.

The detailed break-up of our full-time employees as on December 31, 2023 is summarized as under:

Sr. No.	Category	Number
1.	Senior Management	4
2.	Middle Level Management	13
3	Lab staff	40
3.	Other Employees	17
Total		74


We do not have any employees on contract basis at our offices or Diagnostic Centres.

Export Possibilities & Export Obligation

Currently, we do not have any outstanding export obligations.

Intellectual Property

As on the date of this Draft Prospectus, Our Company has registered following trademarks with the Registrar of Trademarks.

Particulars of the Mark	TM Registration No.	Date of Issue / Renewal	Issuing Authority	Class	Status	TM in respect of
	3447787	21/06/2017	Trade Marks Registry	44	Registered	Medical Services, Medical Clinic Services, Medical Assistance

For further details, please see “Government and other Key Approvals” on page 159 of this Draft Prospectus and for the information in relation to the risk relating to our intellectual property; please refer to the chapter titled “Risk Factors” on page 19 of this Draft Prospectus.

Competition

We operate in a competitive market and competition is based primarily on quality of service, timely delivery and pricing of such products & services. To remain competitive in the market we strive to improve our sales & marketing efforts, reduce cost and improve operating efficiencies. If we fail to maintain our strengths, our competitors will gain an advantage over us, which would adversely affect our market share and results of operation. We face competition from those who may be better capitalized, have longer operating history, have greater brand presence, and better management than us. If we are unable to manage our business it might impede our competitive position and profitability. We intend to continue competing vigorously to capture more market share and adding more management personnel to manage our growth in an optimal way.

In the future, we may also face competition from new entrants in the segment. Some of these players may already have robust business networks, which could eat into our market share. Some of our competitors are larger than we are, have greater financial resources than we do, and may be able to deliver products and services on more attractive terms or to invest larger amounts of capital into their businesses, including expenditure for better and more efficient marketing and delivery.

Immovable Property

Our Company does not own any immovable properties.

Our Company has taken the following immovable properties on leave & license basis:

Address / Description of Premises	Name of Licensor	Term	Purpose
AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India Area – 174 Sq. ft.	Jagdish Umakant Nayak Agreement dated July 21, 2023	60 months from April 01, 2023 Interest free refundable deposit of Rs. 9,00,000/- Rent of Rs. 20,000/- p.m. for first 12 months and to be increased by Rs. 5,000/- p.m. thereafter every year	Registered office
AL-1/546, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India Area – 174 Sq. ft.	Jyoti Jagdish Nayak Agreement dated July 21, 2023	60 months from April 01, 2023 Interest free refundable deposit of Rs. 9,00,000/- Rent of Rs. 20,000/- p.m. for first 12 months and to be increased by Rs. 5,000/- p.m. thereafter every year	Diagnostic Centre, Airoli
Office No. 2, First Floor, Superior Micron Heights CHS Ltd., Plot No. 21, Sector - 7, Airoli, Navi Mumbai, Thane - 400708, Maharashtra, India Area – 150 Sq. ft.	Pande Prabhakar Balkrishnarai and Pande Madhuri Prabhakar Agreement dated December 09, 2021	60 months from December 15, 2021 Interest free refundable deposit of Rs. 51,000/- Rent of Rs. 22,000/- p.m. for first 12 months and 10% increase thereafter every year	Diagnostic Centre, Airoli

<p>Row House No. U-03, Group – I, Sub Sector - U, Plot No. U-03, Sector – 4, Airoli, Navi Mumbai, Thane - 400708, Maharashtra, India</p> <p>Area – 108 Sq. Meter</p>	<p>Sawant Sandhya Shantaram and Sawant Shantaram Sahadeo</p> <p>Agreement dated May 07, 2021</p>	<p>60 months from June 01, 2021</p> <p>Interest free refundable deposit of Rs. 2,00,000/-</p> <p>Rent of Rs. 52,000/- p.m. for first 12 months and 10% increase thereafter every year</p>	<p>Diagnostic Centre, Airoli</p>
<p>Shop No.9, Bebika Darshan Apartment, Opp. Aadarsh School, Badlapur East - 421503, Maharashtra, India</p> <p>Area – 260 sq. ft.</p>	<p>Ravindra Dharmaji Jadhav</p> <p>Agreement dated December 28, 2023</p>	<p>24 months from December 18, 2023</p> <p>Interest free refundable deposit of Rs. 50,000/-</p> <p>License fees of Rs. 14,000/- p.m.</p>	<p>Diagnostic Centre, Badlapur</p>
<p>Shop No. 6, Ground Floor, Millennium Empire, Plot No. 47, Sector 15, Near D-Mart, Kharghar – 410210, Navi Mumbai, Dist. Raigad, Maharashtra, India</p> <p>Area – 400 Sq. ft.</p>	<p>Vikas Sajaram Choudhary</p> <p>Agreement dated November 11, 2021</p>	<p>33 months from December 01, 2021</p> <p>Interest free refundable deposit of Rs. 2,50,000/-</p> <p>Rent of Rs. 47,000/- p.m. for first 11 months, Rs. 50,000/- p.m. for next 11 months and Rs. 53,000/- p.m. for last 11 months</p>	<p>Diagnostic Centre, Kharghar</p>
<p>FF-19, First Floor, Murbad Municipal Council, Commercial Complex, Murbad, Thane - 421401, Maharashtra, India</p> <p>Area – 210 Sq. ft.</p>	<p>Chetan Rajnikant Shah and Vaishali Chetan Shah</p> <p>Agreement dated August 01, 2023</p>	<p>11 months from August 01, 2023</p> <p>Interest free refundable deposit of Rs. 75,000/-</p> <p>Rent of Rs. 9,000/- p.m.</p>	<p>Diagnostic Centre, Murbad</p>
<p>Shop No. 31, First Floor, Hiranandani Fortune City, Village Bhokarpada, Panvel, Raigad - 410221, Maharashtra, India</p> <p>Area – 280 sq. ft.</p>	<p>Bandana Singh</p> <p>Agreement dated September 17, 2023</p>	<p>36 months from September 17, 2023</p> <p>Interest free refundable deposit of Rs. 90,000/-</p> <p>Rent of Rs. 18,000/- p.m. for first 12 months, Rs. 19,800 p.m. for next 12 months and Rs. 21,750 p.m. for last 12 months</p>	<p>Diagnostic Centre, Panvel</p>
<p>Shop No. 119, First Floor, Laxmi Market, Pokharan Road No. 1, Vartak Nagar, Thane West - 400606, Maharashtra, India</p> <p>Area – 450 Sq. ft.</p>	<p>Mahendra Dattatreya Kelkar and Sanhita Mahendra Kelkar</p> <p>Agreement dated July 12, 2023</p>	<p>60 months from July 12, 2023</p> <p>Interest free refundable deposit of Rs. 50,000/-</p> <p>License fees of Rs. 40,000/- p.m.</p>	<p>Diagnostic Centre, Thane</p>

Insurance

Our company has taken New India Bharat Sookshma Udyam Suraksha Policy for our fixed assets at AL-1/545 & 546, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India from The New India Assurance Company Limited. The details of the insurance policy obtained are set forth below:

Sr. No.	Name Of the Insurance	Type Of Policy	Risk Covered for	Insurance Amount (Rs.)	Valid upto
1	The New India Assurance Company Limited	New India Bharat Sookshma Udyam Suraksha Policy	Building, Furniture & other Equipments, Plant & Machinery	23,00,000	27-02-2024

KEY INDUSTRIAL REGULATIONS AND POLICIES IN INDIA

The following description is a summary of certain sector-specific laws currently in force in India, which are applicable to our Company. The information detailed in this chapter has been obtained from publications available in the public domain. The description below may not be exhaustive and is only intended to provide general information to investors, and is neither designed as, nor intended to substitute, professional legal advice. Judicial and administrative interpretations are subject to modification or clarification by subsequent legislative, judicial, or administrative decisions. The information detailed in this chapter has been obtained from various legislations, including rules and regulations promulgated by the regulatory bodies that are available in the public domain.

The Company may be required to obtain licenses and approvals depending upon the prevailing laws and regulations as applicable. For information on regulatory approvals obtained by us, please refer “Government and Other Approvals” on page 154. We are required to obtain and regularly renew certain licenses / registrations / sanctions / permissions required statutorily under the provisions of various Central and State Government regulations, rules, bye laws, acts, and policies. Additionally, the projects undertaken by us require, at various stages, the sanction of the concerned authorities under the relevant central and state legislations and local byelaws.

Following is an overview of some of the important laws and regulations, which are relevant to our business.

INDUSTRY-SPECIFIC REGULATIONS

The Clinical Establishments (Registration and Regulation) Act, 2010 (“CERR Act”)

The CERR Act provides for registration and regulation of clinical establishments and prescribes minimum standards for facilities and services provided by them. Currently, the CERR Act is in effect in the States of Arunachal Pradesh, Himachal Pradesh, Mizoram, Sikkim, Uttar Pradesh, Rajasthan, Bihar, Uttarakhand and Jharkhand and all Union Territories except Delhi (“Notified Areas”). Additionally, the States of Bihar, Jharkhand, Uttarakhand, Himachal Pradesh, Arunachal Pradesh and Sikkim, and Union Territories of Puducherry, Dadra & Nagar Haveli, Daman & Diu and Andaman & Nicobar Islands have framed rules applicable to their respective states under the CERR Act prescribing inter alia the powers of registration authority, procedure for registration of clinical establishments and applicable fee.

The CERR Act defines a “clinical establishment” to include inter alia a place established in connection with the diagnosis or treatment of diseases where pathological, bacteriological, genetic, radiological, chemical, biological investigations or other diagnostic or investigative services with the aid of laboratory or other medical equipment, are usually carried.

While draft minimum standards under the CERR Act for various services to be provided by, and application formats for permanent registration of, clinical establishments have been made publicly available, these are yet to be notified in the Official Gazette. In the interim, clinical establishments in Notified Areas are required to apply for provisional registration under the CERR Act within six months of establishment, irrespective of prior registration under any other applicable laws, which would be valid for an initial period of 12 months, subject to renewal for time periods as prescribed under the CERR Act. Permanent registration shall only be applied for and granted if the clinical establishment meets the prescribed standards for registration under the CECG Rules, once notified. Unless revoked on account of contravention of any provisions of the CERR Act or CECG Rules, such registration would be valid for a period of five years and may be renewed pursuant to an application made within six months before the expiry of the permanent registration.

The Clinical Establishments (Central Government) Rules 2012 (“CECG Rules”)

The Ministry of Health and Family Welfare, Government of India by a notification dated May 23, 2012 brought into force the CECG Rules, which are applicable to the states wherein the CERR Act is in operation. The CECG Rules inter alia, provide conditions for registration and continuation of clinical establishments. In terms of CECG Rules, clinical establishments are required to display the rates for each type of services in vernacular and English language, the rates to be charged are ought to be within the range as determined by the Central Government, the clinical establishments are required to ensure compliance with standard treatment guidelines as determined and issued by the Central Government or the State Governments as the case may be, clinical establishments are required to maintain electronic records of every patient. Additionally, clinical establishments are also required to maintain information and statistics in accordance with the CECG Rules.

Additionally, States of Bihar, Jharkhand, Uttarakhand, Himachal Pradesh, Arunachal Pradesh and Sikkim, and Union Territories of Puducherry, Dadar & Nagar Haveli, Daman & Diu and Andaman & Nicobar Islands have framed rules applicable to their respective states under the CERR Act, prescribing inter alia the powers of registration authority,

procedure for registration of clinical establishments and applicable fee.

Certain states/union territories which are governed by other legislations for regulation of clinical establishments or nursing homes, wherein the CERR Act is not applicable, are as follows:

- i) Haryana Clinical Establishments (Registration and Regulation) Act, 2014;
- ii) The Andhra Pradesh Private Medical Care Establishments (Registration and Regulation) Act, 2002;
- iii) The Bombay Nursing Homes Registration Act, 1949;
- iv) The Delhi Nursing Homes Registration Act, 1953;
- v) The Jammu and Kashmir Nursing Homes and Clinical Establishment (Registration and Licensing) Act, 1963;
- vi) The Madhya Pradesh Upcharya Griha Tatha Rujopchar Sanbabdu Sthapamaue (Ragistrikaran Tatha Anugyapan) Adhiniyam, 1973;
- vii) The Manipur Homes and Clinics Registration Act, 1992;
- viii) The Nagaland Health Care Establishments Act, 1997;
- ix) The Orissa Clinical Establishments (Control and Regulation) Act, 1990;
- x) The Punjab State Nursing Home Registration Act, 1991; and
- xi) The West Bengal Clinical Establishments Act, 1950.

The Preconception and Pre-Natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994 as amended (“PCPNDT Act”)

The PCPNDT Act prohibits sex selection, before or after conception; regulates use of pre-natal diagnostic techniques for the purposes of detecting genetic abnormalities or metabolic disorders or chromosomal abnormalities or certain congenital malformations or sex-linked disorders; and provide for prevention of their misuse for sex determination leading to female foeticide. The PCPNDT Act prohibits any person, organisation, genetic counseling centre, laboratory or clinic from issuing, publishing or distributing any advertisement regarding availability of facilities of pre-natal determination of sex and from employing any person who does not possess the prescribed qualifications. The PCPNDT Act mandates genetic counselling centres, genetic laboratories or genetic clinics to be registered failing which penal action could be initiated against them. The central supervisory board constituted under the PCPNDT Act is authorised to lay down a code of conduct for persons working in any genetic counselling centre, laboratory or clinic. Appropriate authority appointed by Central and respective State Government are conferred powers inter alia to grant, suspend or cancel the registration of a genetic counselling centre, laboratory or clinic, enforce standards, investigate complaints and take necessary legal action.

The Preconception and Pre-Natal Diagnostic Techniques (Prohibition of Sex Selection) Rules, 1996 as amended (“PCPNDT Rules”)

The PCPNDT Rules prescribe minimum qualifications of employees, equipment and places for a genetic counseling centre, laboratory and clinic. The PCPNDT Rules stipulate the format in which an application for registration should be made by such centre, laboratory or clinic before the appropriate authority appointed under the PNC PDT Act and lays down the manner in which records are to be maintained and preserved by such genetic counselling centre, laboratory or clinic. The PCPNDT Rules provide for code of conduct and conditions to be followed by owners, employees or any other persons associated with a genetic counselling centre, laboratory and clinic registered under the PCPNDT Act. The PCPNDT Rules further require every genetic counselling centre, laboratory and clinic to intimate every change of employee, place, address and equipment installed, to the appropriate authority within the time prescribed and preserve such information as permanent records.

The Atomic Energy Act, 1962 as amended (“AE Act”)

The AE Act aims to ensure safe disposal of radioactive waste and secure public safety, including that of persons handling radioactive substances. The AE Act empowers the Central Government to inter alia:

- i) Prohibit the manufacture, possession, use, and transfer by sale or otherwise, export and import and in any emergency, transport and disposal, of any radioactive substances without its written consent;
- ii) require any person to make periodical returns or other such statements as regards any prescribed substance in a person’s possession or control that can be a source of atomic energy; and
- iii) In order to prevent radiation hazards, secure public safety and safety of persons handling radioactive substances or radiation generating plants, ensure safe disposal of radioactive wastes at such premises.

The Atomic Energy (Radiation Protection) Rules, 2004 (“AERP Rules”)

The AERP Rules stipulate that every person intending to use any radioactive material for any purpose, in any location and in any quantity has to comply with the requirements of AE Act. The AERP Rules mandate every person handling radioactive material to apply for a license which may be subsequently modified, revoked or withdrawn at the discretion of the competent authority which is the Atomic Energy Regulatory Board (“AERB”) unless exempted under AERP Rules. The license shall be valid for a period of five years from the date of its issue. The power of AERB extends to notifying appropriate radiation surveillance procedures, requisitioning medical records of workers and ensuring rehabilitation of affected workers. The AERP Rules lay down various compliance measures inter alia as regards maintenance of radiation protection equipment and health surveillance of workers. AERP Rules also prescribe certain general safety guidelines, directives for emergency preparedness and accidents. The AERP Rules require radiation symbol or warning sign to be conspicuously and prominently displayed at all times on the radiation equipment and at the entrance of the room housing such equipment. The AERP Rules confer power upon the AERB to issue safety codes, safety standards and prescribe the requirements for radiation installation, sealed sources, radiation generating equipment and equipment containing radioactive sources, and transportation of radioactive material. The licensee has to ensure compliance with such standards and requirements. Every employer with the written approval of AERB is required to appoint a radiological safety officer who would ensure the safety of workers, safe storage and movement of radioactive material and report the loss or leakage of any radioactive material to the competent authority. The AERB has been vested with wide powers under AERP Rules for conducting inspections of premises, radiation installations and conveyances. Violations of either AERP rules or the terms of license shall be punishable with imprisonment or fine or both.

The Atomic Energy (Safe Disposal of Radioactive Wastes) Rules, 1987 (“AE Rules”)

The AE Rules have been framed to ensure safe disposal of radioactive wastes. A person can dispose radioactive wastes only after obtaining authorisation from the competent authority as per the procedure laid down in the AE Rules and in accordance with the terms and conditions including location and quantity of disposable as specified in such authorisation. The competent authority constituted under AE Act can suspend, cancel authorisation in event when the authorised person fails to comply with conditions of the authorisation or with any provisions of the AE Act or the AE Rules. The AE Rules lay down specific duties for the authorised person and various safety measures to be adhered to discharging radioactive waste and procedure to be followed in the event of accidental release.

Atomic Energy Regulatory Board – Safety Code for Medical Diagnostic X-Ray Equipment and Installation dated October 5, 2001 as amended (“X-ray Code”)

The X-ray Code governs radiation safety in design, installation and operation of x-ray generating equipment for medical diagnostic purposes. Pursuant to the X-ray Code medical diagnostic x-ray equipment and protective devices are required to be operated in accordance with the requirements outlined and it is the responsibility of the employer/owner of medical X-ray installation equipment to ensure compliance with the statutory provisions. The X-ray Code mandates that only medical X-ray equipment which is of the type approved by AERB is to be installed for use. The purchase, transfer, gift, leasing or loan of X-ray equipment shall be registered with AERB by the person acquiring the equipment. Further, no diagnostic X-ray equipment shall be operated unless the licensee obtains license and/or registration from AERB. Non-compliance with the regulatory requirement set forth in the X-ray Code shall be punishable with imprisonment or fine or both.

Atomic Energy Regulatory Board –Safety code on Nuclear Medicine Facilities dated November 4, 2010 (“Nuclear Medicine Code”)

The Nuclear Medicine Code stipulates requirements of radiation safety in handling of radioactive materials for nuclear medicine facilities. Pursuant to the Nuclear Medicine Code, diagnostic and therapeutic procedures using unsealed radioisotopes are to be carried out only in facilities approved by the AERB and such facilities cannot be commissioned until approval to commence is received from AERB. The Nuclear Medicine Code mandates that nuclear medicine facilities should not be located in residential buildings and such facilities are to ensure compliance with specified regulatory requirements. The Nuclear Medicine Code requires active rooms, wards and areas of source storage and handling to be marked with radiation symbol and to provide a legend denoting active area and presence of a radiation hazard. The Nuclear Medicine Code mandates employers to designate with the approval of a competent authority, a person having prescribed qualifications to function as a radiological safety officer, who shall be a full time employee. The Nuclear Medicine Code embeds requirement of emergency preparedness plan outlining emergency response actions.

Atomic Energy Regulatory Board- Safety Code on Safe Transport of Radioactive Material AERB/NRF-TS/SC-1, 2015 (“Transport Code”)

The Transport Code which is based on the International Atomic Energy Agency regulations, regulates the transport of radioactive material in public domain. The basic requirement for the transport of radioactive material is that the package containing the material shall be designed and prepared in such a way that during the whole process of transport, the radioactive material remains contained to prevent contamination and remains shielded to avoid radiation exposure to cargo handlers and the public. The prime responsibility for ensuring compliance with the regulations lies with the consignor. Once the package is prepared as per the prescribed procedures, it can be transported by any mode.

Aircraft (Carriage of Dangerous Goods) Rules, 2003

The Aircraft (Carriage of Dangerous Goods) Rules, 2003, issued by the Directorate General of Civil Aviation, Ministry of Civil Aviation govern the carriage of dangerous goods, namely articles or substances which are capable of posing a risk to health, safety, property or the environment and which are listed as such under the Technical Instructions for the Safe Transport of Dangerous Goods by Air issued by the International Civil Aviation Organisation (the “**Technical Instructions**”). Carriage of dangerous goods in any aircraft and delivery for loading on an aircraft has to be in accordance with the Technical Instructions. For the carriage of radioactive material in any aircraft, the operator is required to ensure that the consignor and consignee has the written consent of the Central Government under Section 16 of the Atomic Energy Act. The packaging, labelling, marking and classification of dangerous goods also have to be in accordance with Technical Instructions.

Radiation Surveillance Procedures for Medical Applications, 1989 (“RSPM Notification”)

The RSPM Notification was promulgated under rule 15 of the Radiation Protection Rules, 1971 to ensure that procedures and installations involving radiation, radiation equipment and radioactive material are conducted in a manner that provide adequate protection against the hazards of radiation. In the light of the RSPM Notification, any person desirous of handling any radioactive material or radiation equipment has to approach the competent authority for prior permission in the form of either a license or an authorisation. The RSPM Notification provide safety guidelines as regard to certain key aspects such as the design safety of equipment, planning of radiation instalments, commissioning of radiation equipment and isolation and disposal of radioactive effluents or damaged radioactive material. The RSPM Notification stipulates adherence to working conditions in a medical radiation installation formulated by the competent authority in this regard. The RSPM Notification holds an employer directly responsible for effective implementation of surveillance procedures. However, the RSPM notification is yet to be issued under the Atomic Energy (Radiation Protection) Rules, 2004.

National Accreditation Board for Testing and Calibration Laboratories (“NABL”)

The NABL is an autonomous body established under the aegis of Department of Science and Technology, Government of India. NABL provides government, regulators and the diagnostic industry with a scheme of laboratory accreditation through third-party assessment for formally recognizing the quality and technical competence of the testing and calibration of laboratories in accordance with International Organisation for Standardization Standards. NABL certification is a mandatory eligibility condition for diagnostic centres empanelment under the Central Government Health Scheme. Diagnostic laboratories which are not accredited by NABL may also participate in application and get empanelled under the Central Government Health Scheme but their empanelment shall be provisional till they are inspected by Quality Council of India or NABL, and are recommended for continuation of empanelment under the Central Government Health Scheme; however there is no legal obligation to obtain certification from the NABL.

Guidelines relating to import of blood samples

The “Guidelines for Exchange of Human Biological Material for Biomedical Research Purposes” issued by the Central Government on November 19, 1997 authorises the Indian Council of Medical Research (“ICMR”) to set up a committee for consideration of proposals relating to import of biological materials, such as blood samples, for commercial purposes. Pursuant to these guidelines, ICMR has issued the “Guidance on Transfer of Human Biological Material for Commercial Purposes” (“**ICMR Guidance**”). In accordance with the ICMR Guidance, applications for import of blood samples are required to be made to the ICMR for onward consideration by a committee. Applicant companies are required to comply with inter alia the “Guidance on Regulations for the Transport of Infectious Substances (2013-2014)” and “Laboratory Biosafety Manual – 2004”, issued by the World Health Organization, United Nations, class (6.2) specifications for packing instructions, and the Environment Protection Act, 1986, along with the rules framed thereunder.

The Drugs and Cosmetics Act, 1940 (the “Drugs and Cosmetics Act”)

The Drugs and Cosmetics Act regulates the import, manufacture, distribution and sale of drugs in India and provides for

labelling, packing, testing and licensing of drugs. The manufacture, sale and distribution of drugs are primarily governed by relevant state authorities. Drugs manufactured/sold/distributed/imported have to meet the standards of quality set out in the Second Schedule to the Drugs and Cosmetics Act. Central Government can prohibit the import of drugs in public interest. The Central Government has issued the Drugs and Cosmetics Rules, 1945 (the “**Drugs and Cosmetics Rules**”) which mandate an import licence in the prescribed form for import of drugs. Such import licence will be valid for a period of three years from the date of its issue unless it is suspended or cancelled sooner. The imported drug has to meet the standard of strength, quality and purity. The Drugs and Cosmetics Rules also require a licence to sell, stock, exhibit or offer for sale or distribute drugs. This licence will be valid for a period of five years from the date of grant or renewal unless suspended or cancelled sooner.

The Consumer protection Act, 2019 as amended (“CPA”)

The Consumer Protection Act, 2019 came into effect from 20th July, 2020 will empower consumers and help them in protecting their rights through its various notified rules and provisions like Consumer Protection Councils, Consumer Disputes Redressal Commissions, Mediation, Product Liability and punishment for manufacture or sale of products containing adulterant / spurious goods. It will be empowered to conduct investigations into violations of consumer rights and institute complaints / prosecution, order recall of unsafe goods and services, order discontinuance of unfair trade practices and misleading advertisements, impose penalties on manufacturers/endorsers/publishers of misleading advertisements. It introduces the concept of product liability and brings within its scope, the product manufacturer, product service provider and product seller, for any claim for compensation. The new Act provides for simplifying the consumer dispute adjudication process in the consumer commissions, which include, among others, empowerment of the State and District Commissions to review their own orders, enabling a consumer to file complaints electronically and file complaints in consumer Commissions that have jurisdiction over the place of his residence, videoconferencing for hearing and deemed admissibility of complaints if the question of admissibility is not decided within the specified period of 21 days.

Environmental laws and regulations

Environment Protection Act, 1986 as amended (“Environment Act”)

The Environment Act is an umbrella legislation designed to provide a framework for the Central Government to coordinate activities of various state and central authorities established under previous environmental laws. The Environment Act specifies that no person carrying on any industry, operation or process shall discharge or emit or permit to be discharged or emitted any environment pollutants in excess of such standards as may be prescribed. The Environment Act empowers the Central Government to make rules for various purposes viz., to prescribe:

- (i) the standards of quality of air, water or soil for various areas;
- (ii) the maximum allowable limits of concentration of various environmental pollutants for different areas;
- (iii) the procedures and safeguards for the prevention of accidents which may cause environmental pollution and remedial measures for such accidents.

Environment (Protection) Rules, 1986, as amended, (“Environment Rules”)

In the exercise of powers conferred under Environment Act, the Central Government has framed the Environment Rules. Pursuant to Environment Rules, every person who carries on an industry, operation or process requiring consent under Water Act or Air Act or shall submit to the concerned SPCB, an environmental statement for that financial year in the prescribed form.

Bio-Medical Waste (Management and Handling) Rules, 1998, as amended (“BMW Rules”)

The Central Government has framed the BMW Rules, pursuant to the rule making power conferred under the Environment Act. The BMW Rules apply to persons generating, collecting, receiving, storing, transporting, treating, disposing or handling bio-medical waste in any form including hospitals, clinics and pathological laboratories. The BMW requires an occupant of an institution generating bio-medical waste to take steps to ensure that such waste is handled without any adverse effect to human health and the environment. The BMW Rules regulates modes of treatment and disposal of “bio-medical waste” which is defined as any waste generated during diagnosis, treatment or immunization of human beings or animals or in research activities pertaining thereto or in the production or testing of animals, as defined in the BMW Rules. The BMW Rules require every occupier of an institution handling bio-medical waste in any form and providing services to more than 1000 patients per month, to obtain an authorization from the prescribed authority. The BMW Rules require such authorized person to submit an annual report and an accident report to the prescribed authority and maintain relevant

records. However, the prescribed authority may cancel, suspend or refuse to renew an authorisation, if for reasons to be recorded in writing, the occupier/ operator has failed to comply with any of the provisions of Environment Act or BMW Rules.

Laws relating to taxation

The tax related laws along with their respective rules that may be applicable to the operations of our Company include:

1. the Income Tax Act 1961, as amended by the Finance Act in respective years
2. Central Goods and Services Tax Act, 2017, (along with the various state-wise legislations issued thereunder);
3. The Integrated Goods and Service Tax Act, 2017; and
4. Professional Tax state-wise legislations.

Overseas Direct Investment ("ODI")

In terms of the Master Direction No. 15/2015-16 on “Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary Abroad” issued by the RBI, dated January 1, 2016, as amended, an Indian entity is allowed to make ODI under the automatic route up to limits prescribed by the RBI, which currently should not exceed 400% of its net worth. ODI can be made by investing in either joint ventures or wholly owned subsidiaries outside India. Any financial commitment exceeding USD one billion (or its equivalent) in a financial year would require the prior approval of the RBI.

Laws relating to Employment

Certain other laws and regulations that may be applicable to our Company in India include the following:

- EPFMP Act;
- Employees’ State Insurance Act, 1948;
- Equal Remuneration Act, 1976;
- The Maternity Benefit Act, 1961;
- Minimum Wages Act, 1948;
- Payment of Bonus Act, 1965;
- Payment of Gratuity Act, 1972;
- Code of Wages, 2019; and
- Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

Indian Contract Act, 1872

The Indian Contract Act, 1872 provides for seeking data protection under contract law and common law, by incorporating confidentiality and data protection clauses in contracts. According to this Act, when a party commits a breach of contract, the other party is entitled to receive compensation for any loss or damage caused to it. Specific performance of the contract is also a remedy under the Act. Thus companies acting as ‘data importers’ may enter into contracts with ‘data exporters’ to adhere to a high standard of data protection.

The Specific Relief Act, 1963

The Specific Relief Act is complimentary to the provisions of the Contract Act and the T.P. Act, as the Act applies both to movable property and immovable property. The Act applies in cases where the Court can order specific performance of a contract. Specific relief can be granted only for purpose of enforcing individual civil rights and not for the mere purpose of enforcing a civil law. ‘Specific performance’ means Court will order the party to perform his part of agreement, instead of imposing on him any monetary liability to pay damages to other party.

Other Laws and Regulations

In addition to the above, our Company is also required to comply with the provisions of the Companies Act, and other applicable statutes imposed by the Centre or the State for its day-to-day operations. Our Company is also amenable to various central and state tax laws.

HISTORY AND CERTAIN CORPORATE MATTERS

Brief History of our Company

Our Company was incorporated as Clinitech Laboratory Private Limited on March 19, 2010 under the Companies Act, 1956 with the Registrar of Companies, Mumbai bearing Registration number 201078. The status of the Company was changed to public limited and the name of our Company was changed to Clinitech Laboratory Limited vide Special Resolution dated July 24, 2023 pursuant to conversion of the Company into public limited Company. The fresh certificate of incorporation consequent to conversion was issued on August 25, 2023 by the Registrar of Companies, Mumbai.

Our corporate identification number is U85195MH2010PLC201078.

The Promoters of our Company are Jagdish Umakant Nayak and Jyoti Jagdish Nayak.

Names of signatories to the Memorandum of Association of the Company and the number of Equity Shares subscribed by them:

The names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association: 5,000 Equity Shares each by Jagdish Umakant Nayak and Jyoti Jagdish Nayak.

Changes in our Registered Office:

Date of Change	Changed From	Change to	Reason for change
August 31, 2018	AL-1/545 & 546, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India	Flat No. 902, Madhuban CHS, Plot No. 25, Sector – 6, Airoli, Navi Mumbai, Thane -400708, Maharashtra, India	Administrative Reasons
June 01, 2022	Flat No. 902, Madhuban CHS, Plot No. 25, Sector – 6, Airoli, Navi Mumbai, Thane -400708, Maharashtra, India	AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India	Administrative Reasons

Major Events and Milestones

The table below sets forth some of the key events in the history of our Company:

Financial Year	Event
2010	Incorporation of our Company.
2012	Established new Lab at Kalyan
2016	NABL Accreditation at Airoli Centre
2018	Established new Lab at Thane
2021	NABL Accreditation for SARS-COV-2 testing Signed up agreements for Diagnostic Centre at Kharghar
2022	Signed up agreements for Diagnostic Centre at Panvel / Badlapur
2023	Converted Company to Limited Established new Lab at Murbad

Significant financial and strategic partners

As on the date of the Draft Prospectus, our Company does not have any significant financial or strategic partners.

Time and cost overrun

Our Company has not experienced any significant time and cost overrun in its business.

Launch of Key Products or services

For details of key products or services launched by our Company, entry into new geographies or exit from existing markets, facility creation, location of our facilities, see “Our Business” beginning on page 77.

Defaults or rescheduling of borrowings with financial institutions/ banks and conversion of loans into equity

There have been no defaults or rescheduling of borrowings with financial institutions in respect of our current borrowings from lenders.

Material Acquisitions or Divestments of Business/Undertakings, Mergers, Amalgamations or Revaluation of Assets, in the last ten years

Our Company has not undertaken any material acquisitions or divestments of business/undertakings, mergers, amalgamations, or revaluation of assets in the last ten years.

Main Objects of our Company:

The main objects of our Company, as contained in our Memorandum of Association, are as set forth below:

1. To run, own, manage, administer, pathological testing laboratories, diagnostic centers, scan centers, nursing homes, hospitals, clinics, dispensaries, maternity homes, child welfare and family planning centers, clinical, X-ray and ECG clinics, to act as consultant and advisors providing technical knowhow, technical services for establishment, operation and improvement of nursing homes, hospitals, clinics, medical institutions, medical centers, diagnostic centers and laboratories in India and Abroad.

The main objects as contained in the Memorandum of Association enable our Company to carry on the business presently being carried out as well as to carry on the activities for which the funds are being raised in the Issue.

Amendments to the Memorandum of Association

The following changes have been made in the Memorandum of Association of our Company since inception:

Particulars of Change		Date of Members Meeting	AGM/EGM
From	To		
₹1,00,000 consisting of 10,000 Equity shares of ₹10.00 each.		On incorporation	-
₹1,00,000 consisting of 10,000 Equity shares of ₹10.00 each.	₹1,00,00,000 consisting of 10,00,000 Equity shares of ₹10.00 each.	March 26, 2018	EGM
₹1,00,00,000 consisting of 10,00,000 Equity shares of ₹10.00 each.	₹1,50,00,000 consisting of 15,00,000 Equity shares of ₹10.00 each.	February 28, 2019	EGM
₹1,50,00,000 consisting of 15,00,000 Equity shares of ₹10.00 each.	₹5,00,00,000 consisting of 50,00,000 Equity shares of ₹10.00 each.	August 26, 2023	EGM

Date of Shareholders' Resolution	Nature of Other Amendment
July 24, 2023	Our Company was converted into a public limited company and the name of our Company was changed to 'Clinitech Laboratory Limited'

Changes in the Management

There has been no change in the management of our Company since incorporation.

Defaults or rescheduling of borrowings from financial institutions/ banks and conversion of loans into equity

No defaults have been called by any financial institution or bank in relation to borrowings from financial institutions or banks. For details of our financing arrangements, please refer “Financial Indebtedness” on page 150. Further, except as stated in the section “Capital Structure” beginning on page 43, none of our loans have been rescheduled or been converted into Equity Shares.

Lock outs and strikes

There have been no lock outs or strikes at any of the offices of our Company.

Time and cost overruns

Our Company has not experienced any time or cost overrun in relation to any of the projects implemented.

Details regarding acquisition of business/undertakings, mergers, amalgamations, and revaluation of assets

Our Company has not acquired any business or undertaking, and has not undertaken any merger, amalgamation, or revaluation of assets.

Holding Company of our Company

As of the date of the Draft Prospectus, our Company does not have any holding Company.

Subsidiary of our Company

As of the date of the Draft Prospectus, our Company does not have a subsidiary company.

Collaboration Agreements

As on the date of the Draft Prospectus, our Company is not a party to any collaboration agreements.

Shareholders' Agreements

As on the date of the Draft Prospectus, our Company has not entered into any shareholders' agreements.

Material Agreements

We have not entered into any material contract, not being a contract entered into in the ordinary course of business carried on or intended to be carried on by us or contract entered into more than two years before the filing of the Draft Prospectus.

Number of Shareholders

Our Company has 24 (Twenty-Four) shareholders as on date of the Draft Prospectus.

OUR MANAGEMENT

Board of Directors

Under our Articles of Association, we are required to have not less than three directors and not more than 15 Directors. As on the date of this Draft Prospectus, we have 6 Directors on our Board.

Set forth below are details regarding our Board as on the date of this Draft Prospectus:

Name, Designation, Address, Date of Birth, Age, Occupation, Term, Period of Directorship and DIN	Other Directorships
<p>Jagdish Umakant Nayak</p> <p><i>Designation: Chairman & Managing Director</i></p> <p><i>Address: Flat No. 902, Madhuban CHS, Plot No. 25, Sector – 6, Airoli, Navi Mumbai, Thane -400708, Maharashtra, India</i></p> <p><i>Date of Birth: March 15, 1967</i></p> <p><i>Age: 56 years</i></p> <p><i>Occupation: Business</i></p> <p><i>Term: Redesignated as Chairman and Managing Director w.e.f. September 30, 2023 for a period of Five years.</i></p> <p><i>Period of Directorship: Director since incorporation</i></p> <p><i>DIN: 00646672</i></p>	<ul style="list-style-type: none"> • <u>Companies</u> • Sine Automation and Integration Private Limited • Pathnet Clinical Testings (India) Private Limited • <u>LLPs</u> • Hitech Technopower India LLP • CTL Wellnz LLP
<p>Jyoti Jagdish Nayak</p> <p><i>Designation: Whole Time Director</i></p> <p><i>Address: Flat No. 902, Madhuban CHS, Plot No. 25, Sector – 6, Airoli, Navi Mumbai, Thane -400708, Maharashtra, India</i></p> <p><i>Date of Birth: December 17, 1970</i></p> <p><i>Age: 52 years</i></p> <p><i>Occupation: Business</i></p> <p><i>Term: Redesignated as Whole Time Director w.e.f. September 30, 2023 for a period of Five years.</i></p> <p><i>Period of Directorship: Director since incorporation</i></p> <p><i>DIN: 02945625</i></p>	<ul style="list-style-type: none"> • <u>Companies</u> • Nil • <u>LLPs</u> • Nil
<p>Ashutosh Jagdish Nayak</p> <p><i>Designation: Non-Executive Director</i></p> <p><i>Address: Flat No. 902, Madhuban CHS, Plot No. 25, Sector – 6, Airoli, Navi Mumbai, Thane -400708, Maharashtra, India</i></p> <p><i>Date of Birth: April 28, 1998</i></p>	<ul style="list-style-type: none"> • <u>Companies</u> • Nil • <u>LLPs</u> • Sine Vibro LLP • CTL Wellnz LLP

<p>Age: 25 years</p> <p>Occupation: Business</p> <p>Term: Redesignated as Non- Executive Director w.e.f. September 30, 2023.</p> <p>Period of Directorship: Director since January 31, 2022</p> <p>DIN: 07553633</p>	
<p>Balu Laxman Kumbharkar</p> <p>Designation: Non-Executive and Independent Director</p> <p>Address: A L 5/ 13/9, Sneh Sagar Apt, Sector-17 Airoli, Airoli Mode, Navi Mumbai, Maharashtra, India</p> <p>Date of Birth: August 07, 1956</p> <p>Age: 66 years</p> <p>Occupation: Service</p> <p>Term: Appointed as Non-Executive Independent Director for a period of Five years w.e.f. September 30, 2023 and is not liable to retire by rotation</p> <p>Period of Directorship: Director since June 19, 2023</p> <p>DIN: 10180137</p>	<p>Companies:</p> <ul style="list-style-type: none"> • Nil <p>LLPs</p> <ul style="list-style-type: none"> • Nil
<p>Smita Arjun Patil</p> <p>Designation: Non-Executive and Independent Director</p> <p>Address: C-2-6, Room No. 2/4, Near Meghraj Tokiz, Sector -2, Vashi, Navi Mumbai - 400703, Thane, Maharashtra, India</p> <p>Date of Birth: July 18, 1981</p> <p>Age: 41 years</p> <p>Occupation: Service</p> <p>Term: Appointed as Non-Executive Independent Director for a period of Five years w.e.f. September 30, 2023 and is not liable to retire by rotation</p> <p>Period of Directorship: Director since June 19, 2023</p> <p>DIN: 10147488</p>	<p>Companies:</p> <ul style="list-style-type: none"> • Nil <p>LLPs</p> <ul style="list-style-type: none"> • Nil
<p>Name: Ravikant Moreshwar Mhatre</p> <p>Designation: Non Executive and Independent Director</p> <p>Address: Mavli Prasad Niwas, H no. 30, At post Koparkhairne, Navi Mumbai – 400705, Maharashtra, India</p>	<p>Companies:</p> <ul style="list-style-type: none"> • Virtuous Capital Limited • BEW Engineering Limited • Shanthala FMCG Products Limited • Shree OSFM E-Mobility Limited

<p>Date of Birth: June 25, 1971</p> <p>Age: 49 years</p> <p>Occupation: Business</p> <p><i>Term:</i> Appointed as Non-Executive Independent Director for a period of Five years w.e.f. September 30, 2023 and is not liable to retire by rotation</p> <p><i>Period of Directorship:</i> Director since June 19, 2023</p> <p>DIN: 06362676</p>	<p>LLPs</p> <p>Nil</p>
---	------------------------

Relationship between our Directors

Except as stated below, none of the Directors of our Company are related to each other as per Section 2(77) of the Companies Act, 2013:

- Jyoti Jagdish Nayak is spouse of Jagdish Umakant Nayak.
- Ashutosh Jagdish Nayak is son of Jyoti Jagdish Nayak and Jagdish Umakant Nayak.

Brief Profile of our Directors

Jagdish Umakant Nayak, aged 56 years is the founding promoter and director on the board of the Company since incorporation is redesignated as Chairman and Managing Director w.e.f. September 30, 2023. He has graduated in science with microbiology subject from University of Bombay in 1987. He has also done Diploma in Medical Laboratory Technology from Somaiya Vidyavihar in 1989. He has more than 30 years of experience in the field of diagnostic healthcare industry. At Clinitech, he is currently responsible for formulating business growth strategies, maintaining customer relationships, marketing of the Company’s products & services and overseeing of day-to-day functioning of the Company. He also looks after new product development and applications that are designed to address the health issues of the customers.

Jyoti Jagdish Nayak, aged 52 years is the founding promoter and director on the board of the Company since incorporation is redesignated as Whole Time Director w.e.f. September 30, 2023. She has graduated in science with microbiology subject from University of Bombay in 1991. She has also done Post Graduate Diploma course in Medical Laboratory Technology from Board of Technical Education, Maharashtra State in 1993. She has done masters in in science with microbiology subject from Apex Professional University, Arunachal Pradesh in 2018. She has more than 30 years of experience in the field of diagnostic healthcare industry. At Clinitech, she is currently responsible for managing diagnostic centers and day-to-day functioning of the Company.

Ashutosh Jagdish Nayak, aged 25 years is the director on the board of the Company since 2022 and is redesignated as Non-Executive Director w.e.f. September 30, 2023. He is a MBBS Bachelor of Medicine, Bachelor of Surgery from Maharashtra University of Health Sciences. He has around 2 years of experience with multi specialty hospitals in the field of patient treatment. At Clinitech, he is currently responsible as Public Relationship Officer explaining reports etc. to patients.

Balu Laxman Kumbharkar aged 66 years, is the Non-Executive Independent Director of the Company. He has completed his Bachelor’s degree in Arts from University of Bombay. He is having over 35 years of experience in the field of store management, vendor development and handling purchases for hospital. He has been appointed as independent director w.e.f. June 19, 2023 to comply with corporate governance requirements.

Smita Arjun Patil aged 42 years, is the Non-Executive Independent Director of the Company. She has completed her Bachelor of Education from University of Mumbai. She has also done her M. A. from University of Mumbai. She is having 5 years of experience in the field of teaching Hindi and Marathi. She has been appointed as independent director w.e.f. June 19, 2023 to comply with corporate governance requirements.

Ravikant Moreshwar Mhatre, aged 51 years, is an Independent Director of our Company. He has completed his B. Com. from University of Bombay in October 1998. He has experience of more than 20 years in supply of sports merchandising. He is a sports person and keen follower of cricket since his college days and has turned his passion in to

a business by sensing need for quality sports merchandising by the education institute. He has his own business of sourcing quality sports merchandising from the manufacturers and supplying them to education institutes. He has been on our Board of Directors since June 19, 2023 to comply with Corporate Governance requirements.

Further Confirmations:

- There are no arrangements or understanding with major shareholders, customers, suppliers, or others, pursuant to which any of the Directors were selected as a Director.
- There is no service contracts entered into by the Directors with our Company providing for benefits upon termination of employment.
- None of the Directors is declared as wilful defaulters by the RBI or any bank or financial institution or consortium thereof.
- None of our Promoters or Directors of our Company are declared Fugitive Economic Offenders under Section 12 of the Fugitive Economic Offenders Act, 2018.
- None of our Directors is or was a director of any listed company during the last five years preceding the date of this Draft Prospectus, whose shares have been or were suspended from being traded on the Stock Exchange(s), during the term of their directorship in such company.
- None of our Directors is or was a director of any listed company during the last five years preceding the date of this Draft Prospectus, whose shares have been or were suspended from being traded on the Stock Exchange(s), during the term of their directorship in such company.
- None of the Promoters, Persons forming part of our Promoter Group, Directors or persons in control of our Company, has been or is involved as a promoter, director or person in control of any other company, which is debarred from accessing the capital market under any order or directions made by SEBI or any other regulatory authority.
- No consideration in cash or shares or otherwise has been paid or agreed to be paid to any of our Directors or to the firms of companies in which they are interested by any person either to induce him to become or to help him qualify as a Director, or otherwise for services rendered by him or by the firm or company in which he is interested, in connection with the promotion or formation of our Company.
- No proceedings/ investigations have been initiated by SEBI against any company, the board of directors of which also comprises any of the Directors of our Company. No consideration in cash or shares or otherwise has been paid or agreed to be paid to any of our Directors or to the firms of companies in which they are interested by any person either to induce him to become or to help him qualify as a Director, or otherwise for services rendered by him or by the firm or company in which he is interested, in connection with the promotion or formation of our Company.

Compensation of our Directors

Terms of Appointment of the Managing Director

Jagdish Umakant Nayak has been appointed as the Chairman and Managing Director (MD) of our Company for a period of 5 years with effect from September 30, 2023 *vide* Shareholders resolution passed at AGM dated September 30, 2023. The significant terms of his employment are as under:

Terms of Appointment	5 years
Remuneration	Upto maximum of Rs. 30 Lakhs p.a. or such higher amount as may be decided by the Board of Directors of the Company from time to time
Perquisites and Allowances	House Rent Allowance as per the Income Tax Rules, 1962 Medical Reimbursement / Allowance as per the Income Tax Rules Provision for Driver / driver’s salary allowance as per the rules of the Company Personal Accident Insurance as per the rules of the Company

Earned/ privilege leave as per the rules of the Company

Encashment of Leave as per the rules of the Company

Other reimbursements	The MD shall be entitled to use the Company’s car, all the expenses for maintenance and running of the same including the salary of Driver to be borne by the Company
	Reimbursement of any other expenses properly incurred by him in accordance with rules of the Company
	Reimbursement of Medical expenses & LTC as per the rules of the Company
	Other perquisites, allowances, benefits and amenities as per the service rules of the Company as applicable from time to time

Terms of Appointment of the Whole Time Director

Jyoti Jagdish Nayak has been appointed as the Whole Time Director (WTD) of our Company for a period of 5 years with effect from September 30, 2023 *vide* Shareholders resolution passed at AGM dated September 30, 2023. The significant terms of her employment are as under:

Terms of Appointment	5 years
Basic Salary	Upto maximum of Rs. 30 Lakhs p.a.
Sitting Fees	The WTD shall not be entitled to sitting fees for attending meetings of the Board or committees thereof
Perquisites and allowances	<ol style="list-style-type: none"> Contribution to PF and super annuation / Annuity fund as per scheme of the Company Gratuity payable shall be at the rate not exceeding 15 days salary for each completed year of service or part there of in excess of 6 months as per scheme of the Company Encashment of unavailed leaves at the end of the tenure or at specified intervals will be as per the rules of the Company House Rent Allowance as per the Income Tax Rules, 1962 Medical Reimbursement / Allowance as per the Income Tax Rules Provision for Driver / driver’s salary allowance as per the rules of the Company Personal Accident Insurance as per the rules of the Company Travelling allowance as per Company rules Entertainment allowance as per Company rules Telephone & Mobile allowance as per Company rules Vehicle running (Petrol, Toll, Car Insurance, Car Repairing) allowance as per Company rules

Remuneration to Executive Directors

Details of remuneration paid to the Executive Directors in FY 2023 is as under:

Name of the Director	Amount (Rs. In Lakhs)
Jagdish Umakant Nayak	24.00
Jyoti Jagdish Nayak	24.00
Ashutosh Jagdish Nayak	Nil

Remuneration details of our Non-Executive and Independent Directors

Our Non- Executive and Independent Directors are entitled to sitting fees for attending meetings of the Board, or of any committee of the Board, existing or new or such other meeting attended as member. Currently, the sitting fees payable by our Company to our Directors is ₹ 2,00,000/- p.a. plus applicable GST on reverse charge mechanism basis w.e.f. June 19, 2023.

We have not paid any sitting fees to any of our Directors in the Financial Year 2023.

Bonus or Profit-Sharing Plan of the Directors

None of our Directors are party to any bonus or profit-sharing plan of our Company.

Shareholding of Directors in our Company

Our Articles of Association do not require our directors to hold qualification shares. As on date of the Draft Prospectus, our Directors hold the following number of Equity Shares of our Company:

Name of Directors	Number of Equity Shares Held (Pre-Issue)	Percentage of pre-Issue capital
Jagdish Umakant Nayak	6,74,500	40.15
Jyoti Jagdish Nayak	6,75,000	40.18
Ashutosh Jagdish Nayak	100	Negligible

Interest of Directors

- Our Non-Executive Non-Independent Directors and Independent Directors may be deemed to be interested to the extent of sitting fees payable to them for attending meetings of our Board and Committees thereof and reimbursement of expenses available to them and commission payable to them as approved by our Board. All our Executive Directors may be deemed to be interested to the extent of other remuneration and reimbursement of expenses payable to them.
- Our Promoters may be deemed to be interested in the promotion or formation of our Company. Our Directors may also be regarded as interested in the Equity Shares held by them, if any (together with dividends and any other distributions in respect of such Equity Shares).
- None of our Directors have any interest in any property acquired or proposed to be acquired of our Company or by our Company in the preceding three years.
- Further, none of our Directors have any interest in any transaction by our Company for acquisition of land, construction of building or supply of machinery.
- No consideration in cash or shares or otherwise has been paid or agreed to be paid to any of our Directors or to the firms or companies in which any of our Directors are interested, by any person, either to induce him to become, or to qualify him as, as a Director, or otherwise for services rendered by our Directors or by the firm or company in which they are interested, in connection with the promotion or formation of our Company.
- Except as disclosed in “Financial Statements” beginning on page 114 and as disclosed in this section, none of our Directors have any interest in our business.
- Further, except as disclosed in “Financial Statements” beginning on page 114, no loans have been availed by our Directors from our Company.

Changes in our Board during the Last Three Years

Except as disclosed below, there have been no changes in our Board during the last three years:

Name of Director	Date of change	Reason
Jagdish Umakant Nayak	September 30, 2023	Re-designation as Chairperson & Managing Director
Jyoti Jagdish Nayak	September 30, 2023	Redesignation as Whole Time Director
Ashutosh Jagdish Nayak	September 30, 2023	Redesignation as Non-Executive Director
Balu Laxman Kumbharkar	June 19, 2023	Appointment as Independent Director
Smita Arjun Patil	June 19, 2023	Appointment as Independent Director
Ravikant Moreshwar Mhatre	June 19, 2023	Appointment as Independent Director

Borrowing Powers of our Board

Our Articles of Association, subject to applicable law, authorize our Board to raise or borrow money or secure the payment of any sum of money for the purposes of our Company. Pursuant to a resolution passed by our shareholders at their meeting held on September 30, 2023, our shareholders have authorized our Board to borrow any sum of money from time to time notwithstanding that the sum or sums so borrowed together with the monies, if any, already borrowed by the company

(apart from temporary loans obtained from the Company’s bankers in the ordinary course of business) exceed the paid up capital and free reserves of the Company provided such amount does not exceed ₹1,00,00,00,000 (Rupees Hundred Crores Only) in excess of its paid up capital and free reserves which may have not been set apart for any purpose.

Corporate Governance

The provisions of the SEBI (LODR) Regulations with respect to corporate governance will also be applicable to our Company immediately upon the listing of our Equity Shares with the Stock Exchange. Our Company is in compliance with the requirements of the applicable regulations, including the SEBI (LODR) Regulations, the SEBI (ICDR) Regulations and the Companies Act, 2013 in respect of corporate governance including constitution of the Board and committees thereof.

Our Board has been constituted in compliance with the Companies Act and SEBI (LODR) Regulations, to the extent applicable. Our Board functions either as a full board or through various committees constituted to oversee specific functions. In compliance with the requirements of the Companies Act and the SEBI (LODR) Regulations, to the extent applicable our Board of Directors consists of 4 (four) Directors (including one woman Director) of which three are non-executive Independent Directors which is in compliance with the requirements of Regulation 17 of SEBI (LODR) Regulations.

Committees of our Board

Our Board has constituted the following committees including those for compliance with corporate governance requirements:

a. *Audit Committee*

Our Audit Committee was constituted pursuant to a resolution of our Board dated January 01, 2024. The Audit Committee comprises:

Name of Director	Status in Committee	Nature of Directorship
Ravikant Mhatre	Chairman	Non-Executive Independent Director
Balu Kumbharkar	Member	Non-Executive Independent Director
Smita Patil	Member	Non-Executive Independent Director

The Company Secretary of the Company shall act as the Secretary of the Audit Committee.

Set forth below are the scope, functions, and the terms of reference of our Audit Committee, in accordance with Section 177 of the Companies Act, 2013 and Regulation 18 of the SEBI (LODR) Regulations.

A. *Powers of Audit Committee*

The Audit Committee shall have powers, including the following:

- To investigate any activity within its terms of reference;
- To seek information from any employee;
- To obtain outside legal or other professional advice; and
- To secure attendance of outsiders with relevant expertise if it considers necessary.

B. *Role of Audit Committee*

The role of the Audit Committee shall include the following:

- Oversight of our Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient, and credible;
- Recommendation for appointment, re-appointment and replacement, remuneration and terms of appointment of auditors of our Company;
- Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:

- Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-section 3 of section 134 of the Companies Act, 2013;
- Changes, if any, in accounting policies and practices and reasons for the same;
- Major accounting entries involving estimates based on the exercise of judgment by management;
- Significant adjustments made in the financial statements arising out of audit findings;
- Compliance with listing and other legal requirements relating to financial statements;
- Disclosure of any related party transactions; and
- Modified opinion(s) in the draft audit report.
- Reviewing, the quarterly financial statements with the management before submission to the Board for approval;
- Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;
- Review and monitor the auditor's independence and performance, and effectiveness of audit process;
- Approval or any subsequent modification of transactions of our Company with related parties;
- Scrutiny of inter-corporate loans and investments;
- Valuation of undertakings or assets of our Company, wherever it is necessary;
- Evaluation of internal financial controls and risk management systems;
- Monitoring the end use of funds raised through public offers and related matters;
- Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
- Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- Discussion with internal auditors of any significant findings and follow up there on;
- Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;
- Discussion with statutory auditors before the commencement of the audit, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- To establish and review the functioning of the whistle blower mechanism;
- Approval of appointment of the chief financial officer (*i.e.*, the whole-time finance director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience, and background, etc. of the candidate;
- Carrying out any other terms of reference as may be decided by the Board or specified/ provided under the Companies Act, 2013 or the SEBI (LODR) Regulations or by any other regulatory authority; and
- Review of (1) management discussion and analysis of financial condition and results of operations; (2) statement of significant related party transactions (as defined by the audit committee), submitted by management; (3) management letters / letters of internal control weaknesses issued by the statutory auditors; (4) internal audit reports relating to internal control weaknesses; (5) the appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee; (6) statement of deviations including (a) quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1) of the SEBI (LODR) Regulations; (b) annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7) of the SEBI (LODR) Regulations.

As required under Regulation 18 of the SEBI (LODR) Regulations, the Audit Committee shall meet at least four times in a year, and not more than four months shall elapse between two meetings. The quorum shall be two members present, or one-third of the members, whichever is greater, provided that there should be a minimum of two independent members present.

b. Stakeholders' Relationship Committee

The Stakeholders' Relationship Committee was constituted by a resolution of our Board dated January 01, 2024. The Stakeholders' Relationship Committee comprises:

Name of Director	Status in Committee	Nature of Directorship
Smita Patil	Chairperson	Non-Executive Independent Director
Balu Kumbharkar	Member	Non-Executive Independent Director
Ravikant Mhatre	Member	Non-Executive Independent Director
Jagdish Umakant Nayak	Member	Executive Managing Director

The Company Secretary of the Company shall act as the Secretary of the Stakeholders' Relationship Committee.

Set forth below are the terms of reference of our Stakeholders' Relationship Committee.

- To look into the redressal of grievances of shareholders, debenture holders and other security holders;
- To investigate complaints relating to allotment of shares, approval of transfer or transmission of shares;
- To consider and resolve the grievances of the security holders of the company including complaints related to transfer of shares, non-receipt of balance sheet, non-receipt of declared dividends; and
- To carry out any other function as prescribed under the SEBI (LODR) Regulations as and when amended from time to time.

c. Nomination and Remuneration Committee

The Nomination and Remuneration Committee was constituted by our Board on January 01, 2024. The scope and function of the Nomination and Remuneration Committee is in accordance with Section 178 of the Companies Act, 2013 and the SEBI (LODR) Regulations. The Nomination and Remuneration Committee include the following:


Name of Director	Status in Committee	Nature of Directorship
Balu Kumbharkar	Chairman	Non-Executive Independent Director
Smita Patil	Member	Non-Executive Independent Director
Ravikant Mhatre	Member	Non-Executive Independent Director

The Company Secretary of the Company shall act as the Secretary of the Nomination and Remuneration Committee.

The scope, functions and the terms of reference of the Nomination and Remuneration Committee is in accordance with the Section 178 of the Companies Act, 2013 read with Regulation 19 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Set forth below are the terms of reference of our Nomination and Remuneration Committee.

- Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy, relating to the remuneration of the directors, key managerial personnel, and other employees. The Nomination and Remuneration Committee shall, while formulating such policy ensure that (a) the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate directors of the quality required to run the company successfully; (b) relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and (c) remuneration to directors, key managerial personnel and senior management involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;
- Devising a policy on diversity of board of directors;
- Identify persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, recommend to the Board their appointment and removal and shall carry out evaluation of every director's performance;
- To extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.

ORGANIZATION STRUCTURE



OUR KEY MANAGERIAL PERSONNEL

Set forth below are the details of our key managerial personnel in addition to our Managing Director, Whole-time Director as on the date of the Draft Prospectus. For details of our Managing Director, Whole-time Director please refer “*Our Management*” on page 95.

Rahul Motilal Patil, aged 31 Years, is the Chief Financial Officer of our Company. He has completed her bachelors in commerce from University of Mumbai in 2014. Further he has also done two year Post graduate diploma in Management (Finance Management) Hybrid program from S. P. Mandali’s We School (Welingkar Education) in 2020. He has experience of over 8 years in accounts and finance including direct indirect taxation and audit. He has been associated with our Company since October 2019 and has been promoted to the Chief Financial Officer position with effect from June 19, 2023. The remuneration paid to him during fiscal ended March 31, 2023 was 4.90 Lakhs.

Bharat Kumar Bohra, aged 38 years, is the Company Secretary & Compliance Officer of our Company. He has completed his bachelors in commerce from MDS University, Ajmer in 2004 and Company Secretary from ICSI in 2015. He is a qualified Company Secretary. He has worked as independent professional having experience of over 10 years in the field of Company Law and secretarial compliances. He has been associated with our Company since January 01, 2024. No remuneration has been paid to him during fiscal ended March 31, 2023.

Shareholding of KMP

None of the above mentioned key managerial personnel hold any Equity Shares in our Company. For details of shareholding of our directors and key managerial personnel, please refer “*Capital Structure*” on page 43.

Status of Key Managerial Personnel

All our key managerial personnel are permanent employees of our Company.

Nature of family relationship

None of the above mentioned key managerial personnel are related to each other and neither are they related to our Promoters or Directors.

Arrangements and Understanding with Major Shareholders

None of our key managerial personnel or Directors has been appointed pursuant to any arrangement or understanding with our major shareholders, customers, suppliers, or others. For more information, refer “*History and Certain Other Corporate Matters*” on page 92.

Bonus or Profit-Sharing Plan for our Key Managerial Personnel

As on the date of this Draft Prospectus our Company does not have any performance linked bonus or profit-sharing plan with any of our key managerial personnel.

Loans to Key Managerial Personnel

There is no loan outstanding against any of the key managerial personnel as on date of this Draft Prospectus.

Interest of Key Managerial Personnel

Except as disclosed in “*Interest of Directors*” on page 100 in respect of Directors, no other Key Managerial Personnel of our Company has any interest in our Company other than to the extent of the remuneration or benefits to which they are entitled to as per their terms of appointment and reimbursement of expenses incurred by them during the ordinary course of business. There is no contingent or deferred compensation accrued for the year payable to the Key Managerial Personnel, even if the compensation is payable at a later date.

Further, the Key Managerial Personnel may be regarded as interested in the Equity Shares held by them, if any, (together with dividends and any other distributions in respect of such Equity Shares). No loans have been availed by our Key Managerial Personnel from our Company.

Employees Stock Option Scheme

Our Company does not have any Employee Stock Option Scheme/ Employee Stock Purchase Scheme as on the date of filing of the Draft Prospectus.

Payment or Benefit to officers of our Company

Except as disclosed in this Draft Prospectus, no amount or benefit has been paid or given or is intended to be paid or given to any of our Company’s employees including the Key Management Personnel within the two years preceding the date of filing of this Draft Prospectus, except for the payment of remuneration or commission for services rendered as an officer of our Company.

Changes in our Company’s Key Managerial Personnel during the last three years

Except as disclosed below, there have been no changes in our Key Managerial Personnel during the last three years

Name of Employee	Date of appointment	Date of cessation	Reason
Rahul Motilal Patil	June 19, 2023	-	Appointed as CFO
Bharat Kumar Bohra	January 01, 2024	-	Appointed as company Secretary and Compliance Officer

OUR PROMOTERS AND PROMOTER GROUP

Individual Promoter:

1. Jagdish Umakant Nayak
2. Jyoti Jagdish Nayak

Details of our Promoters



Jagdish Umakant Nayak, aged 56 years is the founding promoter and director on the board of the Company since incorporation is redesignated as Chairman and Managing Director w.e.f. September 30, 2023. He has graduated in science with microbiology subject from University of Bombay in 1987. He has also done Diploma in Medical Laboratory Technology from Somaiya Vidyavihar in 1989. He has more than 30 years of experience in the field of diagnostic healthcare industry. At Clinitech, he is currently responsible for formulating business growth strategies, maintaining customer relationships, marketing of the Company's products & services and overseeing of day-to-day functioning of the Company. He also looks after new product development and applications that are designed to address the health issues of the customers.

For a complete profile of Jagdish Umakant Nayak, and other directorships, please refer "*Our Management*" on page 95.

As on date of the Draft Prospectus, Jagdish Umakant Nayak holds 6,74,500 Equity Shares representing 40.15% of the pre-issue paid-up share capital of our Company.



Jyoti Jagdish Nayak, aged 52 years is the founding promoter and director on the board of the Company since incorporation is redesignated as Whole Time Director w.e.f. September 30, 2023. She has graduated in science with microbiology subject from University of Bombay in 1991. She has also done Post Graduate Diploma course in Medical Laboratory Technology from Board of Technical Education, Maharashtra State in 1993. She has done masters in science with microbiology subject from Apex Professional University, Arunachal Pradesh in 2018. She has more than 30 years of experience in the field of diagnostic healthcare industry. At Clinitech, she is currently responsible for managing diagnostic centers and day-to-day functioning of the Company.

For a complete profile of Jyoti Jagdish Umakant Nayak, and other directorships, please refer "*Our Management*" on page 95.

As on date of the Draft Prospectus, Jyoti Jagdish Nayak holds 6,75,000 Equity Shares representing 40.18% of the pre-issue paid-up share capital of our Company.

Declaration: We confirm that the PAN, bank account number and passport number and other applicable details of our Promoters will be submitted to the SME Platform of BSE where the Equity Shares are proposed to be listed at the time of filing this Draft Prospectus.

Interest of our Promoters

Our Promoters are interested in our Company to the extent (i) that they have promoted our Company; (ii) of their shareholding and the shareholding of relatives in our Company and the dividend payable, if any and other distributions in respect of the Equity Shares held by them or the relatives; (iii) of being Chairman and Key Management Personnel of our Company and the remuneration, sitting fees and reimbursement of expenses payable by our Company to them; (iv) that she has mortgaged her personal properties and provided personal guarantees for the loans availed by our Company; (v) of being a subscriber to the Memorandum of Association of our Company; (v) of her relatives having been appointed to places of profit in our Company; and (vi) that our Company has undertaken transactions with them, or their relatives or entities in

which our Promoter hold shares. For details regarding the shareholding of our Promoter in our Company, please refer “*Capital Structure*”, “*Our Management*” and “*Related Party Transactions*” on pages 43, 95 and 136, respectively.

Our Promoter do not have any interest in any property acquired by our Company within two years of the date of this Draft Prospectus or proposed to be acquired by it or in any transaction in acquisition of land and construction of building etc. Further, our Promoter do not have any interest in any supply of machinery to our Company.

Other than as disclosed in the section “*Related Party Transaction as Restated*” on page 136, there are no sales/purchases between our Company and our Promoter and Promoter Group and Group Companies where such sales or purchases exceeding in value in the aggregate 10% of the total sales or purchases of our Company or any business interest between our Company, our Promoter, our Promoter Group and Group Entities as on the date of the last audited financial statements.

Our Promoters may also be deemed to be interested in our Company to the extent of the personal guarantees given by them for the loans availed by our Company. For further details, please see the chapter titled “*Financial Indebtedness*” beginning on page 150 of this Draft Prospectus.

Our Promoters are not members of any firm or company having any interest in the Company for which any sums are paid or agreed to be paid to either of our Promoters or to the firm or company in cash or shares or otherwise by any person either to induce our Promoters to become, or to qualify our Promoters as, a director, or otherwise for services rendered by our Promoters or by the firm or company, in connection with the promotion or formation of the Company.

Change in the management and control of our Company

There has been no change in the management and control of our Company since incorporation.

Group Company

For details of our group entities, please refer “*Our Group Entities*” on page 109 of the Draft Prospectus.

Payment of Benefit to Promoters

Except as stated above in “*Interest of Promoters*” and in “*Financial Statements- Annexure XV – Statement of Related Party Transactions*” on pages 106 and 112 of the Draft Prospectus, there has been no payment of benefits to our Promoters, members of our Promoter Group and Group Entities, during the two years preceding the filing of the Draft Prospectus.

Material Guarantees

Our Promoters have not given any material guarantees to any third parties with respect to the Equity Shares, as on the date of this Draft Prospectus.

Common Pursuits

There are no entities owned by promoters of our Company has any activities conflicting with our Business.

Litigation

For details relating to legal proceedings involving the Promoters, please refer ‘*Outstanding Litigations and Material Developments*’ on page 151 of the Draft Prospectus.

Other Confirmations

Our Promoters and their relatives have not been declared as Wilful Defaulters and there are no violations of securities laws committed by our Promoters in the past and no proceedings for violation of securities laws are pending against them.

None of our Promoters or Directors are Fugitive Economic Offenders under Section 12 of the Fugitive Economic Offenders Act, 2018.

None of the Promoters, Promoter Group entities or Group Companies have been debarred or prohibited from accessing or operating in capital markets under any order or direction passed by SEBI or any other regulatory or governmental authority.

Our Promoters and members of the Promoter Group are not and have never been promoters, directors or person in control of any other company which is debarred or prohibited from accessing or operating in capital markets under any order or direction passed by SEBI or any other regulatory or governmental authority.

There is no litigation or legal action pending or taken by any ministry, department of the Government or statutory authority during the last 5 (five) years preceding the date of the Offer against our Promoters, except as disclosed under the chapter titled “Outstanding Litigation and Material Developments” beginning on page 151 of this Draft Prospectus.

Except as disclosed in “*Related Party Transactions*” on page 136, our Promoters are not related to any of the sundry debtors or beneficiaries of loans and advances of our Company.

Our Promoters are not interested in any entity which holds any intellectual property rights that are used by our Company.

Guarantees

Our Promoters have not given any guarantee to any third party as of the date of the Draft Prospectus.

Companies with which our Promoters have disassociated in the last three years

Our Promoters have not disassociated themselves as a promoter(s) from any Company in three years preceding the date of the Draft Prospectus.

OUR PROMOTER GROUP

In addition to the Promoters named above, the following individuals and entities form part of the Promoter Group:

A. Individuals forming part of Promoter Group:

Relationship	Jagdish Umakant Nayak	Jyoti Jagdish Nayak
Father	Deceased	Deceased
Mother	Deceased	Meera Prabhu
Spouse	Jyoti Nayak	Jagdish Nayak
Brother	Anant Nayak	Ganesh Prabhu Giridhar Prabhu
Sister	N.A.	N.A.
Son	Ashutosh Nayak	Ashutosh Nayak
Daughter	Ananya Nayak	Ananya Nayak
Spouse's Father	Deceased	Deceased
Spouse's Mother	Meera Prabhu	Deceased
Spouse's Brother	Ganesh Prabhu Giridhar Prabhu	Anant Nayak
Spouse's Sister	N.A.	N.A.

B. Entities forming part of Promoter Group:

Companies

- Sine Automation and Integration Private Limited
- Pathnet Clinical Testings (India) Private Limited

LLPs

- Hitech Technopower India LLP
- CTL Wellnz LLP
- Sine Vibro LLP

Partnership Firms

- Clinitech Lab

H.U.F.

Nil

Proprietary concern

Nil

OUR GROUP COMPANIES

As per the requirements of SEBI (ICDR) Regulations, for the purpose of identification of ‘Group Companies’, our Company considered companies as covered under the applicable accounting standards, being AS 18 (as mentioned in our restated financial statements), or other companies as considered material by our Board.

Accordingly, our Board has identified following entities as our Group Companies, and other than these entities, there are no companies which are considered material by the Board to be identified as group companies. Set forth below are details of our Group Companies as on the date of this Draft Prospectus.

Clinitech Lab (CL)

Corporate Information

CL is a partnership firm formed via partnership deed dated April 01, 2018. Office of CL is located at F/11, behind Getwell Medical, Sector 3, Airoli, Navi Mumbai - 400708, Maharashtra, India

Partner’s Capital / Profit/Loss Sharing Ratio

The Fixed Capital contribution by each of the Partners and their profit/Loss sharing ratio is as under:

Sl. No.	Name of the Partner	Fixed Capital contribution (Rs.)	Profit/Loss Sharing Ratio (%)
1.	Tejprakash Ramayan Yadav	15,00,000	33.33
2.	Shirish Tulshiram Chaudhary	15,00,000	33.33
3.	Clinitech Laboratory Limited	15,00,000	33.34
	Total	45,00,000	100.00

Partners shall be entitled to interest at the rate of 12% p.a. on their fixed capital.

Nature of activities

The partnership business shall be that of to run, own, manage, administer, pathological testing laboratories, diagnostic centers, scan center, X-Ray and ECG Clinic, to act as consultant and advisors providing technical knowhow, technical services for establishment, operation and improvement of pathological testing laboratories, diagnostic centers, medical centers in India.

Financial Information

In accordance with SEBI ICDR Regulations, the financial information derived from the audited financial statements of CL for the FY 2021, FY 2022 and FY 2023 will be available on the website, www.ctllab.in

Litigation

There is no outstanding litigation involving our Group Companies which have a material impact on our Company.

Group Companies under the Insolvency and Bankruptcy Code, 2016

Neither has any winding up petition been filed under the Companies Act, 2013 against any group company nor has any corporate insolvency resolution process commenced against such group company under the Insolvency and Bankruptcy Code, 2016 or any other applicable law.

Defunct Group Companies

None of our Group Companies are defunct companies, nor has any application been made to strike off their names from the register of companies during the five years preceding the date of filing the Draft Prospectus.

Related Party Transactions and sales and purchases between our Company and Group Companies

For details of related party transactions entered into by our Company, refer “*Related Party Transactions*” on page 136.

Common Pursuits

There are no common pursuits amongst any of our Group Companies and our Company.

Interest of Group Companies

- a) None of the Group Companies have any interest in the promotion of our Company.
- (b) None of the Group Companies are interested in the properties acquired or proposed to be acquired by our Company in the preceding three years.
- (c) Except as disclosed in “*Financial Statements*” beginning on page 146, none of the Group Companies is interested in any transactions for acquisition of land, construction of building or supply of machinery.
- (d) Except in the ordinary course of business as disclosed in “*Financial Statements*” beginning on page 114, none of the Group Companies have any business interest or other interests in our Company.

Payment or Benefit to our Group Entities

Except as stated in the “*Related Party Transactions*” on page, there has been no payment of benefits to our Group Entities during the two years prior to the filing of this Draft Prospectus.

Other Confirmations

As on the date of this Draft Prospectus, none of the Group Entities: (i) are listed on any stock exchange; (ii) have completed any public or rights issue since the date of its incorporation; (iii) has received any winding up petition accepted by a court; (iv) have become defunct; (v) have made an application to the relevant registrar of companies (in India), for striking off its name (vi) have been identified as wilful defaulters, as defined under the SEBI (ICDR) Regulations and there are no violations of securities laws committed by them in the past and no proceedings pertaining to such penalties are pending against them (vii) have been refused listing of any of the securities issued by such entity by any stock exchange, in India or abroad (viii) had negative net worth as of the date of their last audited financial statements.

RELATED PARTY TRANSACTIONS

For details of related party transactions of our Company as per the requirements under Accounting Standard 18 “*Related Party Disclosures*” issued by the Institute of Chartered Accountants of India and as reported in the Restated Financial Statements, please refer “*Statement of Related Parties & Transactions*” on page 136.

DIVIDEND POLICY

The declaration and payment of dividends will be recommended by the Board of Directors and approved by the Shareholders, at their discretion, subject to the provisions of the Articles of Association and applicable law, including the Companies Act, 2013. The dividend, if any, will depend on a number of factors, including but not limited to the earnings, capital requirements, contractual obligations, applicable legal restrictions, and overall financial position of our Company. Our Company has not declared any dividend in last three financial years.

Our Company has no formal dividend policy. Our Board may also, from time to time and in accordance with applicable laws, pay interim dividends from the profits of the Financial Year in which such interim dividend is sought to be declared.

**SECTION VI – FINANCIAL INFORMATION
FINANCIAL STATEMENTS**

RESTATED FINANCIAL STATEMENTS

INDEPENDENT AUDITOR’S REPORT

(As required by Section 26 of Companies Act, 2013 read with Rule 4 of Companies (Prospectus and Allotment of Securities) Rules, 2014)

Report of Independent Auditor on examination of the Restated Statement of Asset and Liabilities as at September 30, 2023, March 31, 2023, March 31, 2022 and March 31, 2021 and Profit and Losses and cash Flow for the interim period ended September 30, 2023, and each of the years ended March 31, 2023, 2022 and 2021

To,
The Board of Directors,
Clinitech Laboratory Limited
(Formerly known as ‘Clinitech Laboratory Private Limited’)
AL-1/545, Sector-16
Airoli, Navi Mumbai,
Thane, Maharashtra-400708

Dear Sirs/ Madams,

1. We, E.A. Patil & Associates LLP, Chartered Accountants, have examined the attached Restated Financial Information of Clinitech Laboratory Limited (the “Company”) comprising the Restated Statement of Asset and Liabilities as at September 30, 2023, March 31, 2023, 2022 and 2021, the Statements of Profit and Loss, the Restated Cash Flow Statement for the six month period ended September 30, 2023 and for the years ended March 31, 2023, 2022 and 2021, the Summary Statement of Significant Accounting Policies, and other explanatory information (collectively, the “Restated Financial Information”) for the purpose of inclusion in the Draft Prospectus prepared by the Company in connection with its proposed SME Initial Public Offer of equity shares (“SME IPO”)] prepared in terms of the requirements of:
 - a) Section 26 of Part I of Chapter III of the Companies Act, 2013 (the “Act”);
 - b) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“ICDR Regulations”); and
 - c) The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India (“ICAI”), as amended from time to time (the “Guidance Note”)

2. Management’s Responsibility for the Restated Financial Statements

The Company’s Board of Directors is responsible for the preparation of the Restated Financial Statement for the purpose of inclusion in the Draft Prospectus to be filed with BSE Limited (“BSE”) and the Registrar of Companies (“ROC”) in connection with the proposed SME IPO. The Restated Financial Information have been prepared by the management of the Company on the basis of preparation stated in **Annexure IV** to the Restated Financial Information. The Board of Directors’ responsibility includes designing, implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Financial Information. The Board of Directors of the Company are also responsible for identifying and ensuring that the Company complies with the Act, ICDR Regulations and the Guidance Note.

3. Auditor’s Responsibility

We have been subjected to the peer review process of the Institute of Chartered Accountants of India (“ICAI”) and holds the peer review certificate dated January 31, 2022 valid till February 28, 2025.

We have examined such Restated Financial Information taking into consideration:

- a) The terms of reference and terms of our engagement agreed upon with you in accordance with our engagement letter dated October 16, 2023 in connection with the proposed SME IPO of equity shares of the Company;

- b) The Guidance Note on Reports in Company Prospectus (Revised 2016) issued by ICAI. The Guidance Note also requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI;
- c) Concepts of test checks and materiality to obtain reasonable assurance based on verification of evidence supporting the Restated Financial Information; and
- d) The requirements of Section 26 of the Act and the ICDR Regulations.
- e) Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with the Act, the ICDR Regulations and the Guidance Note in connection with the SME IPO.

4. These Restated Financial Information have been compiled by the management from

- a) Audited Interim Financial Statements of the Company as at and for the six-month period ended September 30, 2023 prepared in accordance with Accounting Standard (AS) 25 "Interim Financial Reporting", specified under section 133 of the Act and other accounting principles generally accepted in India which have been approved by the Board of Directors at their meeting held on 8th December 2023.
- b) Audited Financial Statements of the Company as at and for the years ended March 31, 2023, March 31, 2022 and March 31, 2021 prepared in accordance with the Accounting Standards (referred to as "AS") as prescribed under Section 133 of the Act read with Companies (Accounting Standards) Rules, as amended, and other accounting principles generally accepted in India, which have been approved by the Board of Directors at their meeting held on September 30, 2023, September 30, 2022 and November 9, 2021 respectively.

5. For the purpose of our examination, we have relied on

- a) Auditors' reports issued by us dated 8th December 2023 on the Interim Financial Statements of the Company as at and for the six-month period ended September 30, 2023, as referred in Paragraph 4(a) above.
- b) Auditors' Report issued by us dated August 21, 2023, September 5, 2022 and November 9, 2021 on the financial statements of the Company as at and for the years ended March 31, 2023, March 31, 2022 and March 31, 2021, as referred in Paragraph 4(b) above.

6. Based on our examination and according to the information and explanations given to us, we report that:

- a) The Restated Financial Information have been prepared after incorporating adjustments for the changes in accounting policies, material errors and regrouping/reclassifications retrospectively in the financial years ended March 31, 2023, March 31, 2022 and March 31, 2021 and for the period 01 April 2023 to 30 September 2023 to reflect the same accounting treatment as per the accounting policies and grouping/classifications followed as at and for the six months period ended 30 September 2023;
- b) There are no qualifications in the Auditor's report on the financial statements of the Company as at and for the six-month period ended September 30, 2023, as at and for each of the years ended March 31, 2023, 2022 and 2021, which require any adjustments to the Restated Financial Information;
- c) There are no qualifications in the Annexure to the Auditor's reports issued under Companies (Auditor's Report) Order, 2020 and Companies (Auditor's Report) Order, 2016, as applicable, on the Financial Statements for the year ended March 31, 2023, March 31, 2022 and March 31, 2021 which requires any corrective adjustments in the Restated Financial Information.
- d) The Restated Financial Information have been prepared in accordance with the Act, ICDR Regulations and the Guidance Note.

7. In accordance with the requirements of the Act including the Rules made thereunder, ICDR Regulations, Guidance Note and Engagement Letter, we report that:

- a) The "Restated Statement of Assets and Liabilities" of the Company as at September 30, 2023 and March 31, 2023, 2022 and 2021 examined by us, as set out in **Annexure I** to this Report read with significant accounting policies in **Annexure IV** has been arrived at after making such adjustments and regrouping to the audited financial statements of the Company, as in our opinion were

- appropriate and more fully described in notes to the restated summary statements to this Report.
- b) The “Restated Statement of Profit and Loss” of the Company for the financial period/year ended September 30, 2023 and March 31, 2023, 2022 and 2021 examined by us, as set out in **Annexure II** to this Report read with significant accounting policies in **Annexure IV** has been arrived at after making such adjustments and regrouping to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in notes to the restated summary statements to this Report.
 - c) The “Restated Statement of Cash Flow” of the Company for the financial period/year ended September 30, 2023 and March 31, 2023, 2022 and 2021 examined by us, as set out in **Annexure III** to this Report read with significant accounting policies in **Annexure IV** has been arrived at after making such adjustments and regrouping to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in notes to the restated summary statements to this Report.

8. Other Financial Information

At the company’s request, we have also examined the following Other Financial Information, as restated, proposed to be included in the Draft Prospectus, prepared by the management and approved by the Board of Directors of the Company and annexed to this report relating to the Company as at September 30, 2023, March 31, 2023, March 31, 2022 and March 31, 2021.

- i. Restated Statement of Share Capital, as Annexure I.1
- ii. Restated Statement of Reserves and Surplus, as Annexure I.2
- iii. Restated Statement of Long-Term Borrowings, as Annexure I.3
- iv. Restated Statement of Long-Term Provisions, as Annexure I.4
- v. Restated Statement of Other Non-Current Liabilities, as Annexure I.5
- vi. Restated Statement of Short-Term Borrowings, as Annexure I.6
- vii. Restated Statement of Trade Payables, as Annexure I.7
- viii. Restated Statement of Other Current Liabilities, as Annexure I.8
- ix. Restated Statement of Short-Term Provisions, as Annexure I.9
- x. Restated Statement of Property, Plant and Equipment, as Annexure I.10
- xi. Restated Statement of Non-Current Investment, as Annexure I.11
- xii. Restated Statement of Deferred Tax Assets/Liabilities, as Annexure I.12
- xiii. Restated Statement of Inventories, as Annexure I.13
- xiv. Restated Statement of Trade Receivables, as Annexure I.14
- xv. Restated Statement of Cash and cash Equivalent, as Annexure I.15
- xvi. Restated Statement of Short-Term Loans and Advances, as Annexure I.16
- xvii. Restated Statement of Other Current Assets, as Annexure I.17
- xviii. Restated Statement of Revenue from Operations, as Annexure II.1
- xix. Restated Statement of Other Income, as Annexure II.2
- xx. Restated Statement of Cost of Materials Consumed, as Annexure II.3
- xxi. Restated Statement of Employee Benefit Expenses, as Annexure II.4
- xxii. Restated Statement of Other Expenses, as Annexure II.5
- xxiii. Restated Statement of Financial Charges, as Annexure II.6
- xxiv. Restated Statement of Related Party Transactions, as Annexure V
- xxv. Restated Statement of Ratio Analysis, as Annexure VI
- xxvi. Statement of Capitalization, as Annexure VII

9. The Restated Financial Information do not reflect the effects of events that occurred subsequent to the respective dates of the reports on the special purpose interim financial statements and audited financial statements mentioned in paragraph [4] above.

10. We have not audited any financial statements of the Company as at any date or for any period subsequent to September 30, 2023. Accordingly, we express no opinion on the financial position, results of operations and cash flows of the Company as at any date or for any period subsequent to September 30, 2023.

11. This report should not in any way be construed as a reissuance or re-drafting of any of the previous audit reports issued by us, nor should this report be construed as a new opinion on any of the financial statements referred to herein.
12. We have no responsibility to update our report for events and circumstances occurring after the date of the report.
13. Our report is intended solely for use of the Board of Directors for inclusion in the Draft Prospectus to be filed with BSE and ROC in connection with the proposed SME IPO. Our report should not be used, referred to, or distributed for any other purpose except with our prior consent in writing. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For E. A. Patil & Associates LLP
Chartered Accountants
Firm's ICAI Registration Number- 117371W/W100092

Sd/-

CA Mohan R. Khebade
Partner
Membership No: 107639
Date: December 15, 2023
Place: Navi Mumbai
UDIN: 23107639BGQXC1950

Annexure I

STATEMENT OF ASSETS AND LIABILITIES AS RESTATED

(₹ in Lakhs)

Particulars	Note No.	30.09.2023	31.03.2023	31.03.2022	31.03.2021
Equity & Liabilities					
Shareholders Fund					
Share capital	I.1	150.00	150.00	150.00	66.66
Reserves and surplus	I.2	94.86	88.08	34.81	72.37
Total Shareholder's Fund		244.86	238.08	184.81	139.03
Non Current Liabilities					
Long Term Borrowings	I.3	25.52	28.21	35.71	48.01
Long term provisions	I.4	17.57	12.34	12.06	9.64
Other Non-Current Liabilities	I.5	0.00	149.00	0.00	0.00
Deferred Tax Liability (Net)		0.00	0.00	0.00	0.00
Total Current Liabilities		43.09	189.55	47.77	57.65
Current Liabilities					
Short Term Borrowings	I.6	56.07	74.70	52.90	5.66
Trade Payables	I.7	50.75	39.95	51.87	45.98
Other Current Liabilities	I.8	2.92	4.67	5.59	4.99
Short Term Provisions	I.9	69.74	56.38	25.80	20.02
Total Current Liabilities		179.48	175.70	136.16	76.65
Total Equity & Liability		467.43	603.34	368.74	273.32
Non-Current Assets					
a) Property Plant and Equipments					
Tangible Assets	I.10	157.62	132.16	164.81	83.75
Intangible Assets	I.10	0.94	0.78	0.28	0.28
Capital WIP / Intangible assets under development	I.10	64.22	56.00	40.50	8.25
Total Fixed Assets (a)		222.78	188.94	205.59	92.28
b) Non Current Investments	I.11	12.79	202.22	14.00	9.11
c) Long term Loans and Advances		-	0.00	0.00	0.00
d) Other Non Current Assets		-	0.00	0.00	0.00
e) Deferred Tax Assets	I.12	17.96	15.73	10.79	8.85
Total Non Current Assets		253.53	406.89	230.38	110.24
Current assets					
Current Investments		-	0.00	0.00	0.00
Inventories	I.13	20.07	14.13	15.59	8.91
Trade Receivables	I.14	66.72	48.89	36.43	55.83
Cash and Cash Equivalents balances	I.15	35.16	78.35	10.36	32.03

Short Term Loans and advances	I.16	5.67	4.32	5.62	9.21
Other Current Assets	I.17	86.27	50.75	70.36	57.11
Total Current Assets		213.90	196.44	138.36	163.09
Total Assets		467.43	603.33	368.74	273.32

Annexure II

STATEMENT OF PROFIT & LOSS AS RESTATED

(₹ in Lakhs)

Particulars	Note No.	30.09.2023	31.03.2023	31.03.2022	31.03.2021
Income					
Revenue from Operations	II.1	305.81	634.75	638.43	455.40
Other Income	II.2	2.31	1.59	7.27	4.23
Total Revenue		308.12	636.34	645.70	459.63
Expenditure					
Cost of Material Consumed		58.46	116.61	144.76	101.80
Laboratory testing charges	II.3	12.58	22.30	34.83	27.23
Employee Benefit Expenses	II.4	116.58	203.19	177.89	116.36
Other Expenses	II.5	90.94	157.55	174.30	127.60
Total (B)		278.56	499.65	531.78	372.99
Profit Before Interest, Depreciation and Tax		29.56	136.69	113.92	86.64
Depreciation and Amortisation Expenses		18.98	44.58	38.08	24.53
Profit Before Interest and Tax		10.58	92.11	75.84	62.11
Financial Charges	II.6	3.54	5.74	5.62	7.54
Profit before Taxation		7.05	86.37	70.22	54.57
Provision for Taxation		2.50	30.00	20.90	15.40
Provision for Deferred Tax		-2.23	-4.94	-1.94	-1.07
Total Taxes		0.27	25.06	18.96	14.33
Profit After Tax but Before Extra ordinary Items		6.78	61.31	51.26	40.24
Extraordinary Exps. / (Income)		0.00	0.00	0.00	0.00
Prior Period Items		0.00	0.00	0.00	0.00
Net Profit after adjustments		6.78	61.31	51.26	40.24
Net Profit Transferred to Balance Sheet		6.78	61.31	51.26	40.24

Annexure III

STATEMENT OF CASH FLOWS AS RESTATED

(₹ in Lakhs)

PARTICULARS	30.09.23	31.03.23	31.03.22	31.03.21
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit Before Tax	7.05	86.37	70.22	54.57
<i>Adjusted for :</i>				
a. Depreciation	18.98	44.58	38.08	24.53
b. Interest Expenses & Finance Cost	3.54	5.74	5.62	7.54
c. Interest & Other Income	-2.31	(1.59)	(7.27)	(4.23)
d. Other Adjustment	-	(8.03)	(5.48)	(11.31)
Operating profit before working capital changes	27.26	127.07	101.17	71.10
<i>Adjusted for :</i>				
a. Decrease /(Increase) in Inventories	-5.94	1.46	(6.68)	7.95
b. Decrease / (Increase) in trade receivable	-17.83	(12.46)	19.40	(5.34)
b. Decrease / (Increase) in Current Investments	-	0.00	0.00	0.00
c. (Increase) / Decrease in short term loans and advances	-1.35	1.30	3.59	5.56
d. Increase / (Decrease) in Trade Payables	10.80	(11.92)	5.89	(12.64)
e. Increase / (Decrease) in short term provisions	13.36	30.61	5.76	0.95
f. Increase / (Decrease) in other current liabilities	-1.75	(0.92)	0.60	(1.45)
g. (Increase) / Decrease in Other Current Assets	-35.52	19.61	(13.26)	(13.11)
Cash generated from operations	-10.98	154.75	116.47	53.02
Income Tax Paid (net of refunds)	2.50	30.00	20.90	15.40
NET CASH GENERATED FROM OPERATION	-13.48	124.75	95.57	37.62
B. CASH FLOW FROM INVESTING ACTIVITES				
a. (Purchase) / Sale of Fixed Assets	-52.82	(27.97)	(151.37)	(18.90)
b.(Purchase) / Sale of non-current investment	189.43	(188.22)	(4.88)	59.40
c. (Increase) / Decrease in Long term loans and advances	-	0.00	0.00	0.00
d. Increase / (Decrease) in Long Term Provisions	5.23	0.28	2.42	9.64
e. (Increase) / Decrease in Other Non Current Assets	-	0.00	0.00	0.00
f. Increase / (Decrease) in Other Long Term Liabilities	-149.00	149.00	0.00	0.00
g. Interest & Other Income	2.31	1.59	7.27	4.23
h. Dividend Income	-	0.00	0.00	0.00
Net cash (used) in investing activities	-4.85	(65.32)	(146.56)	54.37
C. CASH FLOW FROM FINANCING ACTIVITES				
a. Interest & Finance Cost	-3.54	(5.74)	(5.62)	(7.54)
b. Proceeds from share issued	-	0.00	0.00	0.00
c. (Repayments) / proceeds of long term borrowings	-2.69	(7.50)	(12.30)	(54.87)
d. (Repayments) / proceeds of short term borrowings	-18.63	21.80	47.24	(25.38)
Net cash generated/(used) in financing activities	-24.85	8.56	29.32	(87.79)
Net Increase / (Decrease) in cash and cash equivalents	-43.19	67.99	(21.67)	4.20
Cash and cash equivalents at the beginning of the year	78.35	10.36	32.03	27.83
Cash and cash equivalents at the end of the year	35.16	78.35	10.36	32.03

SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO THE RESTATED FINANCIAL INFORMATION.

Note no.1: Corporate Information

Clinitech Laboratory Limited (formerly known as Clinitech Laboratory Private Limited) is a company incorporated on 19th March, 2010. The Corporate Identity Number (CIN) of the Company is U85195MH2010PTC201078. The Company has been converted from Private Limited Company to Public Limited Company vide Certificate of Incorporation dated 25th August 2023.

The company is engaged in the business of providing pathology and related healthcare services.

Note no.2: SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation of financial statements:

The restated summary statement of assets and liabilities of the Company as at September 30, 2023, March 31, 2023, 2022 and 2021 and the related restated summary statement of profits and loss and cash flow for the period/year ended September 30, 2023, March 31, 2023, 2022 and 2021 (hereinafter referred to as “Restated Financial Information”) have been compiled by the management from the audited financial statements for the period/year ended on September 30, 2023, March 31, 2023, 2022 and 2021. Restated Financial Information have been prepared to comply in all material respect with the provisions of Part-I of Chapter III of the Companies Act, 2013 (the “Act”) read with Companies (Prospectus and Allotment of Securities) Rules, 2014, Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“ICDR Regulations”) issued by SEBI and Guidance Note on Reports in Companies Prospectus (revised 2019) (“Guidance Note”). Restated Financial Information have been prepared specifically for inclusion in the Offer Document to be filed by the Company with BSE Limited in connection with its proposed SME IPO. The Company’s management has recast the Financial Statements in the form required by Schedule III of the Companies Act, 2023 for the purpose of Restated Financial Information.

The Restated Financial Information have been prepared and presented under historical cost convention and evaluated on a going-concern basis using accrual system of accounting in accordance with the accounting principles generally accepted in India (“Indian GAAP”) and the requirements of the Companies Act, 2013 including the Accounting Standards as prescribed by Section 133 of the Companies Act, 2023 (“the Act”) read with Rule 7 of Companies (Accounts), Rules, 2014.

2.2 Use of estimates

The preparation of Restated Financial Information requires the management of the company to make estimates and assumptions that affect the reported balance of assets and liabilities as at the date of the financial statement and reported amounts of income and expenses during the year. Example of such estimates includes employee benefits, provision for taxes, accounting for the useful lives of depreciable fixed assets etc.

The Company has considered internal and external information while finalizing various estimates in relation to its Restated Financial Information up to the date of the approval by the Board of Directors and has not identified any material impact on the carrying value of assets, liabilities or provisions. Since the situations are continuously evolving, the impact assessed may be different from the estimates made as at the date of approval of these financial results and management will continue to monitor any material changes arising due to the impact of this pandemic on financial and operational performance of the company and take necessary measures to address the situation.

2.3 Revenue Recognition

Revenue is recognized to the extent that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue from clinical diagnostic services is recognized on the completion of the services and is at net of reversal and discounts. Interest and other income are recognized on accrual basis.

2.4 Property Plant and Equipment

Property Plant and Equipment are stated at historical cost less depreciation. Cost also includes all expenses incurred to bring the asset to its present location and condition. Pre-operative expenses not pertaining to any specific fixed assets are allocated proportionately. Depreciation provided on Written Down Value Method ('WDV') is based on the estimated useful lives of the assets as prescribed under Part C of Schedule II of the Companies Act 2013.

2.5 Depreciation/Amortization

Depreciation provided on Written Down Value Method ('WDV') is based on the estimated useful lives of the assets as prescribed under Part C of Schedule II of the Companies Act 2013. For additions and disposals, depreciation is provided pro-rata for the period of use. However, where the useful life of any assets is exhausted on the first day of financial year, same is written off as depreciation in Statement of Profit & Loss.

The useful lives for the Property, Plant & Equipment as prescribed under Part C of Schedule II of the Companies Act 2013 is as follows:

Plant and machinery	5-15 years
Office equipment	5 years
Computer equipment and Software	3 years
Furniture and fixtures	10 years
Vehicles	10 years
Intangible Assets	3 years

2.6 Inventories

Inventory is valued at cost or net realizable value whichever is lower. Cost of inventory includes cost of purchase, cost of conversion, other cost incurred to bring the material to its present location and condition.

2.7 Leases

In accordance with Accounting Standard 19 "Accounting for leases", lease arrangements, where the risks and rewards incidental to ownership of an asset substantially vests with the lessor, are recognized as operating leases. Lease payments under operating lease are recognized as an expense in the profit and loss account.

2.8 Employee retirement and other benefits

The Company has a gratuity plan, wherein every employee who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn salary) for each completed year of service. The gratuity plan of the Company is an unfunded scheme. The Company has provided liability in the books of accounts based on the actuarial valuation performed by independent valuer.

1) Defined Contribution Plans :

Contributions to defined contribution retirement benefit schemes are recognized as an expense in the profit and loss account during the period in which the employee renders the related service. e.g. Provident fund.

2) Defined Benefit Plans :

Gratuity and leave encashment schemes are defined benefits. The present value of the obligation under such defined benefit plans is determined based on actuarial valuation carried out by an independent actuary at the balance sheet date using the Projected Unit Credit Method, which recognizes each period of service as giving rise to one additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation.

2.10 Provisions, Contingent Liabilities & Contingent Assets

A provision is recognized when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. These are reviewed at each balance sheet date and adjusted to reflect the current management estimates. Contingent Liabilities are disclosed in respect of possible obligations that arise from past events but their existence is confirmed by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company. A Contingent Asset is a possible asset that arises from past events but their existence is confirmed by the occurrence or non-occurrence of one or more uncertain future events not wholly within the

control of the entity. Contingent Assets are not recognized till the realization of the income is virtually certain. However the same are disclosed in the financial statements where an inflow of economic benefit is probable.

2.11 Taxation

Income tax expense comprises current tax expense, deferred tax expense or credit computed in accordance with the relevant provisions of the Income Tax Act, 1961. Provision for current taxes is recognized under the taxes payable method based on the estimated tax liability computed after taking credit for allowances and exemptions in accordance with the Indian Income tax Act, 1961.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to timing differences that result between the profits offered for income taxes and the profits as per the financial statements of the Company. Deferred tax assets and liabilities are measured using the tax rates and the tax laws that have been enacted or substantively enacted by the balance sheet date. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment rate. Deferred tax assets in respect of carry forward losses are recognized only to the extent that there is virtual certainty that sufficient future taxable income will be available against which such deferred tax asset can be realized. Other deferred tax assets are recognized only if there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. Deferred tax assets are reviewed as at each balance sheet date and written down or written-up to reflect the amount that is reasonably / virtually certain (as the case may be) to realized.

2.12 Earnings Per Share

The basic earnings per share is computed by dividing the net profit attributable to the equity shareholders for the year by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed using the weighted average number of equity shares and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. The dilutive potential equity shares are adjusted for the proceeds receivable, had the shares been actually issued at fair value. Dilutive potential equity shares are deemed converted as of the beginning of the year, unless they have been issued at a later date.

2.13 Previous year figures have been re-grouped and re-classified wherever necessary.

2.14 In the absence of confirmations, the entries recorded in the books of accounts have been relied upon, and therefore, such balances are as per the books of accounts of the company.

2.15 In the opinion of the board, unless otherwise stated in the Balance sheet and schedules attached thereto, the current assets and loans and advances as stated in the balance sheet are approximately of the value realizable in the ordinary course of business and provisions for all the known liabilities for the period have been made in the books of accounts of the company.

2.16 Accounting policies not specifically referred to are consistent with generally accepted accounting practices.

RATIO ANALYSIS

Sl.NO	Ration Name	30.09.2023	FY 2022-23	FY 2021-22	FY 2020-21
1	CURRENT RATIO (Current Asset/Current Liability)	1.19	1.20	1.05	2.19
2	DEBT EQUITY RATIO (Debt/Equity)	0.33	0.41	0.47	0.32
3 #	DEBT SERVICE COVERAGE RATIO (Earnings before Interest, tax, depreciation and amortization/Interest + Principal)	2.84	9.97	8.26	8.23

4 #	RETURN ON EQUITY (Net Income/Shareholder's Equity)	0.03	0.25	0.25	0.27
5 #	INVENTORY TURNOVER RATIO (Cost of Goods sold/Average Inventory)	3.42	7.85	11.82	7.9
6 #	TRADE RECEIVABLES TURNOVER RATIO (Net Annual Credit Sales/Average accounts receivable)	5.29	14.88	13.84	8.57
7 #	TRADE PAYABLES TURNOVER RATIO (Net Annual Credit Purchases/Average accounts receivable)	1.42	2.51	3.1	1.79
8 #	NET CAPITAL TURNOVER RATIO (Net Annual Sales/Working Capital)	8.89	19.87	91.78	5.17
9 #	Net Profit Ratio (Net Profit/Sales)	0.02	0.1	0.08	0.09
10 #	RETURN ON CAPITAL EMPLOYED (Earnings before interest and tax/capital Employed)	0.04	0.24	0.24	0.24
11 #	Return On Investment	0.02	0.05	0.06	0.07

Note- Ratios for the interim period ended 30th September, 2023 are not comparable with ratios of full year ended March 31, 2023.

Note on Reconciliation of Restated Net Worth

Reconciliation of Restated Net-worth is stated as follows

Particulars	For the period ended 30th Sept 2023	For the period ended 31st March 2023	For the period ended 31st March 2022	For the period ended 31st March 2021
Net Worth as per audited financials	244.86	249.3	201.60	150.34
<u>Adjustments for :</u>				
Opening Balance of Adjustments	-11.21	-16.79	-11.31	0
Less: Gratuity Restatement Adjustment. (note-1)	0.00	12.99	-2.69	-10.3
Less: Employee Benefit Expenses Restatement Adjustment. (note-2)	11.21	-7.41	-2.79	-1.01
Closing Balance of Adjustments	0.00	-11.21	-16.79	-11.31
Networth as restated	244.86	238.09	184.81	139.03

Explanatory note to the above restatements of Networth made in the audited standalone restated financial statements of the company for the respective years.

1. Gratuity Expenses- Gratuity expenses of prior years of FY 2020-21 and FY 2021-22 debited to reserves of FY 2022-23 have been adjusted in the reserves of respective years FY 2020-21, FY 2021-22 in the Restated Financial Statements.

2. Employee Benefit Expenses- Short Provision of employee benefit expenses (EPF and ESIC) of FY 2020-21, FY 2021-22 and FY 2022-23 debited to reserves of interim period ended September 30, 2023, have been adjusted in the reserves of respective years FY 2020-21, FY 2021-22 and FY 2022-23 in the Restated Financial Statements.

NOTES ON ACCOUNTS AND RESTATEMENTS MADE IN THE RESTATED FINANCIALS

1. In the opinion of the management, current assets, loans and advances have value which can be realized in the ordinary course of business at the values stated in the financial statements. The Provision for depreciation and for all known liabilities is adequately provided in the books of account.
2. Consumption of consumables have been arrived by adding purchases to opening stock and deducting closing stock there from.
3. There are no contingent liabilities reported and as such no provision has been made in these accounts for such liability.

Annexure – I.1

STATEMENT OF SHARE CAPITAL AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.2023	31.03.2022	31.03.2021
Authorised				
Equity shares of ₹ 10/- each	150.00	150.00	150.00	150.00
Issued, Subscribed & Fully Paid-up				
Equity shares of ₹ 10/- each	150.00	150.00	150.00	66.66

Note: The Company has only one class of equity shares of par value ₹ 10 each. Each equity shareholder is entitled to one vote per share held, and on liquidation entitled to receive balance of net assets remaining after settlement of all debts, creditors & preferential amounts, proportionate to their respective shareholding. No dividend is proposed.

Reconciliation of No. of Shares Outstanding at the end of the year:

Particulars	30.09.2023	31.03.2023	31.03.2022	31.03.2021
Shares outstanding at the beginning of the year	15,00,000	15,00,000	6,66,666	6,66,666
Shares issued during the year	-	0	8,33,334	0
Bonus Issued during the year	-	0	0	0
Share outstanding at the end of the year	15,00,000	15,00,000	15,00,000	6,66,666

Details of Shareholding more than 5% of the aggregate shares in the company:

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Jagdish Umakant Nayak				
No. of Shares	7,49,500	7,50,000	7,50,000	3,33,333
% Holding	49.97	50.00	50.00	50.00
Jyoti Jagdish Nayak				
No. of Shares	7,50,000	7,50,000	7,50,000	3,33,333
% Holding	50.00	50.00	50.00	50.00

Terms/rights attached to shares

The company has only one class of equity shares having par value of Rs. 10 per share. Each holder of equity share is entitled to one vote per share. The dividend, if proposed by the Board of Directors is subject to the approval of shareholders in the ensuring Annual General Meeting. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

Annexure – I.2

STATEMENT OF RESERVES AND SURPLUS AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Statement of Profit & Loss				
Opening balance	88.08	34.81	72.37	43.44
Add: Profit for the year	6.78	61.31	51.26	40.24
Less: Utilised for Bonus Issue / other adjustments	-	-0.62	-83.34	0.00
Less: Gratuity Restatement Adjustment	-	0.00	-2.69	-10.30
Less: Employee Benefit Expenses Restatement Adjustment	-	-7.41	-2.79	-1.01
Profit available for appropriation	94.86	88.08	34.81	72.37
Balance as at the end of the year	94.86	88.08	34.81	72.37

General Reserves	-	0.00	0.00	0.00
Securities Premium Account				
Opening balance	-	0.00	0.00	0.00
Add: Additions during the year	-	0.00	0.00	0.00
Less: Utilised for Bonus Issue	-	0.00	0.00	0.00
Balance as at the end of the year	-	0.00	0.00	0.00
Total Reserve & Surplus	94.86	88.08	34.81	72.37

Annexure – I.3

STATEMENT OF LONG TERM BORROWINGS AS RESTATED

(₹ in Lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Secured, Considered good				
- from Standard Chartered Bank	-	-	-	48.01
- Term Loan from Bank of Baroda	25.52	27.22	31.25	-
- Car Loan from Bank of Baroda	-	0.99	4.46	-
Total	25.52	28.21	35.71	48.01

Annexure – I.4

STATEMENT OF LONG TERM PROVISIONS AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Provision for Gratuity	17.57	12.34	12.06	9.64
Total	17.57	12.34	12.06	9.64

Annexure – I.5

STATEMENT OF SHORT TERM BORROWINGS AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Advance received against Sale of Property	-	149.00	0.00	0.00
Total	-	149.00	0.00	0.00

Annexure – I.6

STATEMENT OF SHORT-TERM BORROWINGS AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Loans from Banks & Financial Institutions				
Overdraft from Bank of Baroda	45.25	30.50	28.31	-
Current maturities of Long Term Borrowings	6.79	7.63	7.17	5.27

From Related Parties				
Jagdish Umakant Nayak	2.54	3.07	7.51	0.39
Jyoti Jagdish Nayak	1.50	33.50	9.91	0.00
Total	56.07	74.70	52.90	5.66

Annexure – I.7**STATEMENT OF TRADE PAYABLES AS RESTATED**

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Sundry Creditors	50.75	39.95	51.87	45.98
Total	50.75	39.95	51.87	45.98

Annexure – I.8**STATEMENT OF OTHER CURRENT LIABILITIES AS RESTATED**

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Directors Remuneration payable	0.00	0.00	0.20	4.60
Rent Equalisation Reserve	1.92	3.67	0.00	0.00
Other Payables	1.00	1.00	5.39	0.39
Total	2.92	4.67	5.59	4.99

Annexure – I.9**STATEMENT OF SHORT-TERM PROVISIONS AS RESTATED**

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Provision for Employee Benefits (other than gratuity)	54.98	37.71	17.69	8.66
Other Provisions	11.89	16.14	7.17	10.70
Provision for Gratuity	2.86	2.53	0.94	0.66
Total	69.74	56.38	25.80	20.02

Annexure – I.10

STATEMENT OF FIXED ASSETS AS RESTATED

(₹ in lakhs)

As at 30.09.2023

Particulars	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	As at	Additions	Deductions	Total	Provided up to	Provided up to	W/Back	Total	As at	As at
	1.4.2023				1.4.2023	30.09.2023			30.09.2023	31.03.2023
A) Tangible Assets										
Computer	31.21	1.48	-	32.70	26.17	1.31	-	27.48	5.21	5.04
Plant & Machinery	195.72	27.59	-	223.31	121.31	8.75	-	130.06	93.24	74.40
Motor Vehicles	20.09	-	-	20.09	10.96	1.18	-	12.14	7.94	9.13
General Furniture And Fittings	92.61	14.80	-	107.41	54.27	6.30	-	60.57	46.84	38.34
Office Equipments	19.35	0.31	-	19.66	14.10	1.18	-	15.28	4.38	5.25
Total - A	358.98	44.19	-	403.16	226.81	18.73	-	245.55	157.62	132.16
B) Intangible Assets	5.91	0.41	-	6.31	5.12	0.25	-	5.37	0.94	0.78
Total - B	5.91	0.41	-	6.31	5.12	0.25	-	5.37	0.94	0.78
C) Capital WIP	56.00	8.22	-	64.22	-	-	-	-	64.22	56.00
Total - C	56.00	8.22	-	64.22	-	-	-	-	64.22	56.00
GRAND TOTAL - A+B+C	420.88	52.82	-	473.70	231.94	18.98	-	250.92	222.78	188.94

(₹ in lakhs)

For FY 2022-23

Particulars	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	As at	Additions	Deductions	Total	Provided up to	Provided up to	W/Back	Total	As at	As at
	1.4.2022				1.4.2022	31.03.2023			31.03.2023	31.03.2022
A) Tangible Assets										
Computer	29.09	2.13	-	31.21	22.28	3.89	-	26.17	5.04	6.80
Plant & Machinery	192.34	3.38	-	195.72	100.15	21.16	-	121.31	74.40	92.19

Motor Vehicles	20.09	-	-	20.09	7.78	3.18	-	10.96	9.13	12.31
General Furniture And Fittings	89.01	3.60	-	92.61	41.49	12.79	-	54.27	38.34	47.53
Office Equipments	16.83	2.52	-	19.35	10.85	3.25	-	14.10	5.25	5.98
Total - A	347.36	11.62	-	358.98	182.54	44.27	-	226.81	132.16	164.81
B) Intangible Assets	5.06	0.84	-	5.91	4.81	0.31	-	5.12	0.78	0.25
Total - B	5.06	0.84	-	5.91	4.81	0.31	-	5.12	0.78	0.25
C) Capital WIP	40.50	15.50	-	56.00	-	-	-	-	56.00	40.50
Total - C	40.50	15.50	-	56.00	-	-	-	-	56.00	40.50
GRAND TOTAL - A+B+C	392.92	27.96	-	420.88	187.35	44.58	-	231.94	188.94	205.57

(₹ in lakhs)

For FY 2021-22

Particulars	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	As at	Additions	Deductions	Total	Provided up to	Provided up to	W/Back	Total	As at	As at
	1.4.2021				1.4.2021	31.03.2022			31.03.2022	31.03.2021
A) Tangible Assets										
Computer	21.30	7.79	-	29.09	18.93	3.35		22.28	6.80	2.37
Plant & Machinery	151.05	58.16	16.88	192.34	91.91	20.11	-11.87	100.15	92.19	59.15
Motor Vehicles	8.92	11.17	-	20.09	4.18	3.59		7.78	12.31	4.73
General Furniture And Fittings	48.00	41.01	-	89.01	33.10	8.38		41.49	47.53	14.90
Office Equipments	10.83	6.01	-	16.83	8.23	2.62		10.85	5.98	2.60
Total - A	240.10	124.13	16.88	347.36	156.35	38.06	-11.87	182.54	164.81	83.75
B) Intangible Assets	5.06	-	-	5.06	4.78	0.02		4.81	0.25	0.28
Total - B	5.06	-	-	5.06	4.78	0.02	-	4.81	0.25	0.28
C) Capital WIP	8.25	32.25	-	40.50					40.50	8.25
Total - C	8.25	32.25	-	40.50	-	-	-	-	40.50	8.25
GRAND TOTAL - A+B+C	253.41	156.38	16.88	392.92	161.13	38.09	-11.87	187.35	205.57	92.28

(₹ in lakhs)

For FY 2020-21

Particulars	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	As at	Additions	Deductions	Total	Provided up to	Provided up to	W/Back	Total	As at	As at
	1.4.2020				1.4.2020	31.03.2021			31.03.2021	31.03.2020
A) Tangible Assets										
Computer	20.33	0.97		21.30	17.04	1.89		18.93	2.37	3.28
Plant & Machinery	137.98	13.07		151.05	77.78	14.12		91.91	59.15	60.20
Motor Vehicles	8.92	-		8.92	2.54	1.65		4.18	4.73	6.38
General Furniture And Fittings	47.83	0.18		48.00	27.90	5.20		33.10	14.90	19.92
Office Equipments	9.89	0.93		10.83	6.67	1.56		8.23	2.60	3.22
Total - A	224.95	15.15	-	240.10	131.94	24.41	-	156.35	83.75	93.01
B) Intangible Assets	5.06	-	-	5.06	4.67	0.12		4.78	0.28	0.40
Total - B	5.06	-	-	5.06	4.67	0.12	-	4.78	0.28	0.40
C) Capital WIP	4.50	3.75	-	8.25					8.25	4.50
Total - C	4.50	3.75	-	8.25	-	-	-	-	8.25	4.50
GRAND TOTAL - A+B+C	234.51	18.90	-	253.41	136.60	24.53	-	161.13	92.28	97.91

Annexure – I.11

STATEMENT OF NON-CURRENT INVESTMENTS AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Clinitech Lab	12.79	12.79	14.00	9.11
Advance for Plot to MIDC	0	189.43	0.00	0.00
HDFC Mutual Fund	0	0	0.00	0.00
Kotak Mutual Fund	0	0.00	0.00	0.00
Total	12.79	202.22	14.00	9.11

Annexure – I.12

STATEMENT OF DEFERRED TAX ASSETS/(LIABILITY) AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Balance at the beginning of the year	15.73	10.79	8.85	7.78
Deferred Tax Asset				
On the Block of Fixed Assets	0.00	4.94	1.92	1.10
On Other Items	0.00	0.00	0.02	0.00
Sub Total	0.00	4.94	1.94	1.10
Deferred Tax Liability				
On the Block of Fixed Assets	0.00	0.00	0.00	0.00
On Other Items	0.00	0.00	0.00	0.03
Sub Total	0.00	0.00	0.00	0.03
Net Deferred Tax Asset / (Liability)	0.00	4.94	1.94	1.07
Closing Deferred Tax Asset / (Liability)	15.73	15.73	10.79	8.85

Annexure – I.13

STATEMENT OF INVENTORIES AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Stock-in-trade	20.07	14.13	15.59	8.91
Total	20.07	14.13	15.59	8.91

Annexure – I.14

STATEMENT OF TRADE RECEIVABLES AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Debts outstanding for more than six months	27.31	16.39	7.67	3.00
Other Debts	39.42	32.50	28.76	52.83
Total	66.72	48.89	36.43	55.83

Annexure – I.15

STATEMENT OF CASH AND CASH EQUIVALENTS AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Balances with banks in current accounts / (Overdraft)	1.12	1.81	1.90	18.00
Balances with banks in Deposit accounts	0.26	0.25	0.24	0.23
Cash on hand	33.78	76.28	8.21	13.80
Total	35.16	78.35	10.36	32.03

Annexure – I.16

STATEMENT OF SHORT-TERM LOANS & ADVANCES AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Advance for Fixed Assets	0.00	0.00	0.00	0.00
Other Advances	5.67	4.32	5.62	9.21
Total	5.67	4.32	5.62	9.21

Annexure – I.17

STATEMENT OF OTHER CURRENT ASSETS AS RESTATED

(₹ in lakhs)

Particulars	30.09.2023	31.03.23	31.03.22	31.03.21
Balances with Revenue Authorities	15.37	0.00	0.12	5.77
Rent Deposits	42.71	38.26	47.06	46.05
Prepaid Expenses	1.98	1.26	1.87	1.16
Others	18.54	11.23	21.31	4.12
IPO related expenses	7.67	0.00	0.00	0.00
Total	86.27	50.75	70.36	57.11

Annexure – II.1

STATEMENT OF REVENUE FROM OPERATIONS AS RESTATED

(₹ in lakhs)

Particulars	For the period / FY ended			
	30.09.23	31.03.23	31.03.22	31.03.21
Clinical Testing Receipts	305.81	631.75	635.28	455.40
Unbilled Revenue	0.00	3.00	3.15	0.00
Total	305.81	634.75	638.43	455.40

Annexure – II.2

STATEMENT OF OTHER INCOME AS RESTATED

(₹ in lakhs)

Particulars	For the period / FY ended			
	30.09.23	31.03.23	31.03.22	31.03.21
Interest on FD	0.01	0.76	0.08	0.01
Discount Received	0.00	0.00	0.19	0.00
Interest on Income Tax refund	0.00	0.00	0.49	0.00
Share of profit/ Salary from Partnership Firm	0.00	0.44	1.09	0.11
Income on Redemption of Mutual Funds	0.00	0.00	0.00	3.02
Others / Writebacks	1.13	0.39	5.42	1.09
Profit on Sale on Plot	1.07	0.00	0.00	0.00
Rent Received	0.10	0.00	0.00	0.00
Total	2.31	1.59	7.27	4.23

Annexure – II.3

STATEMENT OF COST OF MATERIAL CONSUMED AS RESTATED

(₹ in lakhs)

Particulars	For the period / FY ended			
	30.09.23	31.03.23	31.03.22	31.03.21
Opening Stock of Stock in Trade	14.13	15.59	8.91	16.86
Add : Purchases	64.40	115.15	151.44	93.85
Less : Closing Stock of Stock in Trade	20.07	14.13	15.59	8.91
Total	58.46	116.61	144.76	101.80

Annexure – II.4

STATEMENT OF EMPLOYEE BENEFIT EXPENSES AS RESTATED

(₹ in lakhs)

Particulars	For the period / FY ended			
	30.09.23	31.03.23	31.03.22	31.03.21
Directors Remuneration	24.00	48.00	40.00	24.00
Salary, Wages & Bonus and PF/ESIC/Gratuity	88.59	152.18	133.81	87.26
Staff Welfare	3.98	3.01	4.08	5.10
Total	116.58	203.19	177.89	116.36

Annexure – II.5

STATEMENT OF OTHER EXPENSES AS RESTATED

(₹ in lakhs)

Particulars	For the period / FY ended			
	30.09.23	31.03.23	31.03.22	31.03.21
Annual Maintenance Charges	0.95	1.30	0.64	1.36
Bank Charges	0.55	1.16	0.15	0.45
Audit Fees - NABL (Government fees)	0.64	-	-	-
Clinical Waste Management Expenses	0.34	0.51	1.17	0.65
Computer and Internet Charges	0.63	1.88	0.93	0.58
Donation	0.15	0.52	0.31	0.07
Electricity Charges	4.44	8.14	9.16	6.56
Insurance Expenses	0.39	0.71	0.90	0.96
Interest on TDS and Income Tax	0.07	0.08	0.01	0.01
Office Expenses	0.65	1.86	1.03	0.40
Other Expenses	0.90	0.92	2.00	0.76
Printing & Stationery	1.64	5.66	4.77	2.68
Profession Tax Company	-	0.03	0.03	-
Professional Fees	44.58	61.38	68.03	43.78
Rent, Rates & Taxes	27.25	57.18	62.21	49.57
Repairs & Maintenance	0.83	1.23	1.60	0.56
Discount, Bad Debts Written off and Rounding Off	-	2.50	1.51	1.45
Selling & Distribution Expenses	2.17	6.67	11.90	10.32
Society Charges	-	-	0.68	1.43
Telephone Charges	0.68	1.24	0.75	0.53
Travelling & Vehicle Charges	3.33	2.92	3.87	4.09
Water Charges	-	-	-	-
Software Expenses	0.19	-	1.31	0.81
Loss on Sale of Assets	-	-	0.01	-
Stamp Duty & Registration Charges	-	-	0.47	-
Auditor Fees	0.50	1.66	0.86	0.58
Other Expenses	0.07	-	-	-
TOTAL	90.94	157.55	174.30	127.60

Annexure – II.6

STATEMENT OF FINANCIAL CHARGES AS RESTATED

(₹ in lakhs)

Particulars	For the period / FY ended			
	30.09.23	31.03.23	31.03.22	31.03.21
Interest Expenses	3.54	5.74	4.15	7.53
Other borrowing cost	-	0.00	1.47	0.01
Total	3.54	5.74	5.62	7.54

Annexure – V

STATEMENT OF RELATED PARTY TRANSACTIONS AS RESTATED

The company has entered into related party transactions with below mentioned parties and transactions are identified as per accounting standard 18 issued by Institute of Chartered Accountants of India for the periods covered under audit:

As per Accounting Standard 18 on related party disclosure issue by the Institute of Chartered Accountants of India, the Company's related parties are disclosed below:

(i) Key Managerial Personnel and their Relatives

Jagdish Nayak
Jyoti Nayak
Ashutosh Nayak
Balu Laxman Kumbharkar
Ravikant Moreshwar Mhatre
Smita Arjun Patil
Rahul Motilal Patil

(ii) Entities owned and controlled by Directors and their relatives

Clinitech Lab, Partnership Firm

(iii) Particulars of Transactions with Related Parties

Related Party Transactions for the period 01.04.2021 to 30.09.2023

(₹ in lakhs)

Particulars	30.09.23	31.03.23	31.03.22	31.03.21
<i>Remuneration and Salaries</i>				
Jagdish Nayak	12.00	24.00	20.00	12.00
Jyoti Nayak	12.00	24.00	20.00	12.00
Ashutosh Nayak	-	-	5.31	7.08
Rahul Motilal Patil	1.26	-	-	-
<i>Remuneration outstanding at the end of year</i>				
Jagdish Nayak	1.49	3.59	0.06	0.06
Jyoti Nayak	12.12	3.59	0.14	4.54
<i>Unsecured Loans taken / repaid</i>				
<i>Acceptance of Loan</i>				
Jagdish Nayak	35.06	28.56	52.88	3.00
Jyoti Nayak	3.50	35.14	19.50	7.34
<i>Repayment of Loan</i>				
Jagdish Nayak	35.64	33.00	45.76	19.82
Jyoti Nayak	35.49	11.56	9.59	-

<u>Loans Outstanding at the year end - (Receivable) / Payable</u>				
Jagdish Nayak	2.54	3.07	7.51	0.39
Jyoti Nayak	1.50	33.50	9.91	-
<u>Rent paid</u>				
Jagdish Nayak	1.20	1.20	2.40	1.62
Jyoti Nayak	1.20	1.20	2.40	1.62
<u>Rent outstanding at the year end</u>				
Jagdish Nayak	0.05	0.10	0.60	3.38
Jyoti Nayak	1.30	0.10	0.59	3.38
<u>Rent Deposit</u>				
Jagdish Nayak	9.00	9.00	9.00	-
Jyoti Nayak	9.00	9.00	9.00	-
<u>Clinitech Lab, Prtnership Firm</u>				
Investment / (Withdrawal)	-	-1.65	4.90	-3.50
Income from Firm	-	-	1.10	1.20
Closing Balance of Investment at the end of year	12.79	12.79	14.00	14.61
Sales to Firm	1.39	3.41	17.02	17.20
Trade Receivable at the end of year	5.37	4.19	4.21	1.88

Annexure – VI

STATEMENT OF ACCOUNTING RATIOS AS RESTATED

(₹ in lakhs)

Particulars	30.09.23	31.03.23	31.03.22	31.03.21
EBITDA (₹ in Lacs)	29.56	136.69	113.92	86.64
Net Profit as restated after Exceptional item (₹ in Lacs)	6.78	61.31	51.26	40.24
Net Worth (₹ in Lacs)	244.86	238.08	184.81	139.03
Return on Net worth (%)	2.77%	25.75%	27.74%	28.94%
Equity Share at the end of year (in Nos.)	15,00,000	15,00,000	15,00,000	6,66,666
(Face Value ₹ 10)	10.00	10.00	10.00	10.00
Weighted No. of Equity Shares	15,00,000	15,00,000	15,00,000	6,66,666
Basic and Diluted Earnings per Equity Share	0.45	4.09	3.42	6.04
Net Asset Value/Book Value per Equity share (Based on no of share at the end of year)	16.32	15.87	12.32	20.85

Note:- Earnings per share (Rs.) = Profit available to equity shareholders / weighted No. of shares outstanding at the end of the year.

Return on Net worth (%) = Restated Profit after taxation / Net worth x 100

Net asset value / Book value per share (Rs.) = net worth / No. of equity shares

The net worth is considered post elimination of revaluation reserves. The Company does not have any extra- ordinary items.

Annexure – VII

STATEMENT OF CAPITALIZATION AS RESTATED

(₹ in lakhs)

Particulars	Pre-Issue	Pre-Issue	Post Issue*
	As at 30.09.2023	As at 31.03.2023	
Debt :			
Short term debt	56.07	74.70	**
Long term debt	25.52	28.21	**
Total Debt	81.59	102.91	0.00
Shareholders Funds			
Equity Share Capital	150.00	150.00	**
Reserves and Surplus	94.86	88.08	**
Less: Revaluation Reserves	0.00	0.00	0.00
Less: Misc. Expenditure	0.00	0.00	0.00
Total Shareholders' Funds	244.86	238.08	0.00
Long Term Debt/ Shareholders' Funds	0.10	0.12	**
Total Debt / Shareholders Fund	0.33	0.43	**

*Based on the assumption that the Issue will be fully subscribed.

** will be updated at the time of filing of Prospectus with ROC

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion of our financial condition and results of operations together with our restated financial statements included in the Draft Prospectus. You should also read the section entitled “Risk Factors” on page 17, which discusses a number of factors, risks and contingencies that could affect our financial condition and results of operations. The following discussion relates to our Company and is based on our restated financial statements, which have been prepared in accordance with Indian GAAP, the Companies Act and the SEBI Regulations. Portions of the following discussion are also based on internally prepared statistical information and on other sources.

Our financial statements have been prepared in accordance with Indian GAAP, the Companies Act and the ICDR Regulations and restated as described in the report of our auditor dated December 15, 2023 which is included in this Draft Prospectus under “Financial Statements”. The Restated Financial Information has been prepared on a basis that differs in certain material respects from generally accepted accounting principles in other jurisdictions, including US GAAP and IFRS. Our financial year ends on March 31 of each year, and all references to a particular financial year are to the twelve-month period ended March 31 of that year.

Significant Developments Subsequent to the Last Financial Period

In the opinion of the Board of Directors of our Company, other than as mentioned below, since the date of the last financial statements disclosed in this Draft Prospectus, there have not arisen any circumstance that materially or adversely affect or are likely to affect the business or profitability of our Company or the value of its assets or its ability to pay its material liabilities within the next twelve months.

Allotment of Equity Shares:

Following Equity Shares were issued by our Company after the date of last financial statements i.e. September 30, 2023:

Date of Allotment	No. of Equity Shares	Face Value (₹)	Issue Price (₹)	Nature / Reason of Allotment	Nature of Consideration
22-12-2023	1,80,000	10	38	Further Allotment	Cash

COVID 19 Pandemic:

Since the onset of the COVID-19 pandemic in March 2020, our Company has responded swiftly by implementing various processes to ensure our operations continue seamlessly. As we are engaged in diagnostic laboratory services, the same were categorized under the essential goods’ and our operations were not shut down during this pandemic. However, due to limited availability of logistics and other constraints, we were impacted during the initial period of the lockdown. We continued our operation after making arrangements to meet the government’s requirements on sanitization, people movement and social distancing.

We have experienced sustained growth in our business in recent years, including currently during the ongoing outbreak of COVID-19. We consider that our swift response and proactive steps taken have mitigated the impact of COVID- 19 pandemic on our business and personnel thus far. The future impact of COVID-19 or any other severe communicable disease on our business and results of operations depends on several factors including those discussed in “Risk Factors” on page 17 of this Draft Prospectus. For more details, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” – Factors Affecting Results of Operations listed below:

Key factors affecting the results of operation:

Our Company’s future results of operations could be affected potentially by the following factors:

Economic conditions in the markets in which we operate

Our results of operations are dependent on the overall economic conditions in the markets in which we operate, including India. Any change in macro-economic conditions in these markets, including changes in interest rates, government policies or taxation and political, economic or other developments could affect our business and results of operations. The iron and steel market in India may perform differently and be subject to market and regulatory developments that are dissimilar to

the markets in other parts of the world. While stronger macro-economic conditions tend to result into higher demand for our products, weaker macro-economic conditions tend to result into lower demand. Change in demand in the market segments we currently supply or improvement/deterioration in the market or a change in regulations, customs, taxes or other trade barriers or restrictions could affect our operations and financial condition.

Regulatory developments

Our Company is regulated by the Companies Act and some of its activities are subject to supervision and regulation by statutory and regulatory authorities. It is therefore subject to changes in Indian law, as well as to changes in regulation and government policies and accounting principles.

Dependence on third party for our services

Our Company is engaged in providing diagnostic services in healthcare sector. Our Company has no formal supply agreement or contract with our vendors/suppliers for the uninterrupted supply of reagents and other materials required in our business. There can be no assurance that such parties shall continuously provide their products to us and as per our requirements of quantity as well as quality. In the event of any disruption in the supply of products or the non-availability of products, the purchase and distribution schedule may be adversely affected impacting the sales and profitability of the Company.

Our investments in new Diagnostic Centres may not be profitable and may be loss-making

In order to maintain a competitive position, we continue to invest in opening of new Diagnostic Centres. Our investments in new Diagnostic Centres, may be less profitable than what we have experienced historically, may be loss-making, may consume substantial financial resources and/or may divert management's attention from existing operations, all of which could materially and adversely affect our business, results of operations and financial condition.

Changes in Technology

Modernization and technology upgradation is essential for the services that we sell to our customers. Being technology enabled, helps us to gain an understanding of the market trends in the healthcare industry. The landscape of the healthcare industry continues to change in response to technological innovation and evolving consumer trends. New technology is changing the very definition of healthcare service industry. However, if we are unable to respond to changes in technology and evolving industry trends, our businesses may not be able to compete effectively.

RESULTS OF OPERATIONS

Description of the major components of revenue and expense items: -

Our total revenue consists of revenue from sale of products and sale of services and other income.

Revenue

Revenue from Operations

Our revenue from operations primarily accrues from sale of pathology and related healthcare services.

Expenses

Cost of Materials consumed comprised of purchases of reagents and changes in inventories, the same is the major expense head for our Company.

Employee Benefit expense includes, salaries, bonus, Wages, Employee benefits viz. PF/ESIC/Gratuity, Director remuneration and staff welfare expenses.

Other expenses mainly include expenses towards Rent, Rates and Taxes for lease premises, Electricity charges, Professional fees and commission expenses, Selling & Distribution expenses and travelling and vehicle charges etc.

Depreciation and Amortization Expenses

Depreciation and Amortisation Expenses comprised depreciation on fixed assets both tangible and intangible.

Tax Expense

Our tax expense or credit for the period represents the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

DISCUSSION ON RESULTS OF OPERATIONS:

The following discussion on results of operations should be read in conjunction with the audited financial results of our Company for the period ended September 30, 2023 and financial years ended March 31, 2023, 2022 and 2021.

OUR SIGNIFICANT ACCOUNTING POLICIES

For Significant accounting policies please refer *Significant Accounting Policies, "Annexure IV"* beginning under "Auditors' Report and Financial Information of our Company" on page 101.

RESULTS OF OUR OPERATION

For the period ended September 30, 2023

(₹ lakhs)

Particulars	30.09.2023	% of Total Income
Income		
Revenue from Operations	305.81	99.25
Other Income	2.31	0.75
Total Revenue	308.12	100.00
Expenditure		
Cost of Material Consumed	58.46	18.97
Laboratory Testing Charges	12.58	
Employee Benefit Expenses	116.58	37.83
Other Expenses	90.94	29.52
Total (B)	278.56	86.32
Profit Before Interest, Depreciation and Tax	29.56	13.68
Depreciation and Amortization Expenses	18.98	6.16
Profit Before Interest and Tax	10.58	7.52
Financial Charges	3.54	1.15
Profit before Taxation	7.05	6.37
Taxes	0.27	0.09
Profit After Tax	6.78	6.28

Revenue from operations

The Revenue from operations was ₹ 305.81 lakhs for the 6 months period ended September 30, 2023. The revenue is generated from sale of laboratory services.

Other income was ₹ 2.31 lakhs the 6 months period ended September 30, 2023. The other income mainly comprises of profit on sale of asset and other miscellaneous income.

Accordingly, the Total Income for the 6 months period ended September 30, 2023 was ₹ 308.12 lakhs.

Expenditure:

The total operating expenditure aggregated to ₹ 278.56 lakhs which was 90.41% of the Total Income.

Cost of Material consumed was ₹ 58.46 lakhs which was 18.97% of the Total Income and Testing charges were ₹ 12.58 lakhs which was 4.08% of the Total Income.

Employee Benefit Expenses stood at ₹ 116.58 lakhs which was 37.83% of the Total Income.

Other Expenses stood at ₹ 90.94 lakhs which was 29.52% of the Total Income.

Financial Charges: We incurred Financial Charges of ₹ 3.54 lakhs, which is 1.15% of our Total Income.

Depreciation and Amortization expenses: We incurred Depreciation cost of ₹ 18.98 lakhs, which is 6.16% of our Total Income.

Tax Expenses: Tax Expenses for the period ended September 30, 2023 is ₹ 0.27 lakhs, which is 0.09% of our Total Income

Profits

Our EBITDA stood at ₹ 29.56 lakhs with the EBITDA margin of 9.59%. We recorded PBT of ₹ 7.05 lakhs and PBT margin stood at 2.29%. We recorded Net Profit of ₹ 6.78 lakhs. Our Net Profit Margin stood at 2.20%.

Comparison of Financial Years ended March 31, 2023, 2022 and 2021

	(₹ lakhs)		
	31.03.23	31.03.22	31.03.21
Income			
Revenue from Operations	634.75	638.43	455.40
Increase/Decrease (%)	-0.58%	40.19%	
Other Income	1.59	7.27	4.23
Total Income	636.34	645.70	459.63
Increase/Decrease (%)	-1.45%	40.48%	
Expenditure			
Cost of Material Consumed	116.61	144.76	101.80
Increase/Decrease (%)	-19.45%	42.20%	
% to Total Income	18.33%	22.42%	22.15%
Laboratory Testing Charges	22.30	34.83	27.23
Increase/Decrease (%)	-35.97%	27.91%	
% to Total Income	19.12%	24.06%	26.75%
Employee Benefit Expenses	203.19	177.89	116.36

Increase/Decrease (%)	14.22%	52.88%	
% to Total Income	31.93%	27.55%	25.32%
Other Expenses	157.55	174.30	127.60
Increase/Decrease (%)	-9.61%	36.60%	
% to Total Income	24.76%	26.99%	27.76%
Total Operating Expenditure	499.65	531.78	372.99
Increase/Decrease (%)	-6.04%	42.57%	
% to Total Income	78.52%	82.36%	81.15%
PBIDT	136.69	113.92	86.64
Increase/Decrease (%)	19.99%	31.49%	
% to Total Income	21.48%	17.64%	18.85%
Depreciation	44.58	38.08	24.53
Increase/Decrease (%)	17.07%	55.24%	
% to Total Income	7.01%	5.90%	5.34%
Profit Before Interest and Tax	92.11	75.84	62.11
Increase/Decrease (%)	21.45%	22.11%	
% to Total Income	14.47%	11.75%	13.51%
Financial Charges	5.74	5.62	7.54
Increase/Decrease (%)	2.14%	-25.46%	
% to Total Income	0.90%	0.87%	1.64%
Profit before Taxation	86.37	70.22	54.57
Increase/Decrease (%)	23.00%	28.68%	
% to Total Income	13.57%	10.88%	11.87%
Tax Effect	25.06	18.96	14.33
Increase/Decrease (%)	32.17%	32.31%	
% to Total Income	3.94%	2.94%	3.12%
Profit After Tax but Before Extraordinary Items	61.31	51.26	40.24
Increase/Decrease (%)	19.61%	27.39%	
% to Total Income	9.63%	7.94%	8.75%
Extraordinary Item	0.00	0.00	0.00
Increase/Decrease (%)	NA	NA	
% to Total Income	0.00%	0.00%	0.00%
Profit After Tax after Extra ordinary Items	61.31	51.26	40.24

Increase/Decrease (%)	19.61%	27.39%	
% to Total Income	9.63%	7.94%	8.75%

Comparison of FY 2023 with FY 2022:

Revenue from operations

The Revenue from operations for the FY 2023 was ₹ 634.75 lakhs as compared to ₹ 638.43 lakhs during the FY 2022 showing a minor dip of 0.58%. This dip is mainly due to decrease in volume of business due to reduction of Covid 19 business in FY 2023 compared to FY 2022.

Other Income for the FY 2023 and FY 2022 was ₹ 1.59 Lakhs and ₹ 7.27 Lakhs respectively includes Interest on FD, share of profit/ remuneration from partnership firm, interest on IT refund and other miscellaneous income.

The Total Income for the FY 2023 and FY 2022 was ₹ 636.34 Lakhs and ₹ 645.70 Lakhs respectively.

Expenditure:

Total Operating Expenses

Total Operating Expenses decreased in an absolute term to ₹ 499.65 lakhs for FY 2023 from ₹ 531.78 lakhs for FY 2022. This decrease was mainly due to reduction in laboratory testing charges for outsourced testings.

Cost of Material Consumed

Cost of Material consumed was ₹ 116.61 lakhs for FY 2023 and ₹ 144.76 lakhs for FY 2022. This decrease was mainly due to decrease in overall business as well as reduction in covid related sanitization costs during FY 2023.

Laboratory Testing Charges

Laboratory Testing charges was ₹ 22.30 lakhs for FY 2023 and ₹ 34.83 lakhs for FY 2022. This decrease was mainly due to decrease in outsourcing of specialised laboratory testing during FY 2023.

Employee Benefit Expenses

Employee Benefit Expenses increased in absolute term from ₹ 177.89 lakhs for the year ended March 31, 2022 to ₹ 203.19 lakhs for FY 2023 showing an increase of 14.22%. This increase was mainly due to increase in Salary & Wages of employees of the Company and Directors remuneration during FY 2023. In % term also there was increase in Employee Benefit Expenses and the same stood at 27.55% and 31.93% of Total income for FY 2022 and FY 2023, respectively.

Other Expenses

Other Expenses decreased to ₹ 157.55 lakhs for FY 2023 from ₹ 174.30 lakhs for FY 2022 showing a decrease of 9.61% mainly due to decrease in Rent Rates & Taxes, Selling & Distribution expenses, Legal & Professional fees, travelling & conveyance etc. Other Expenses was 24.76% of Total income during FY 2023 as against 26.99% during FY 2022.

EBIDTA

EBIDTA increased from ₹ 113.92 lakhs for FY 2022 to ₹ 136.69 lakhs for FY 2023 due to the reasons listed above. During FY 2023, our Company recorded EBIDTA margin of 21.48% of the Total income as against 17.64% during FY 2022.

Depreciation and Amortization Expenses

Depreciation on fixed assets was 7.01% of Total income during FY 2023 as compared to 5.90% during FY 2022. The total depreciation during FY 2022 was ₹ 38.08 lakhs and during FY 2023 it was ₹ 44.58 lakhs.

Financial Charges

Financial Charges was 0.90% of Total income during FY 2023 as compared to 0.87% during FY 2022. The Financial Charges included Interest expenses and other borrowing costs. The total Financial Charges during FY 2022 was ₹ 5.62 lakhs and during FY 2023 it was ₹ 5.74 lakhs, this decrease is mainly due to decrease in other borrowing cost.

Profit after Tax and restatement adjustment but before Extra-ordinary item (PAT before Extra-ordinary item)

PAT before Extra-ordinary item increased from ₹ 51.26 lakhs for the FY 2022 to ₹ 61.31 lakhs in FY 2023. This absolute increase in profits was mainly on account of increase in business volume and other reasons as detailed above. During FY 2023, our Company recorded PAT before Extra-ordinary item margin of 9.63% for FY 2023 as against margin of 7.94% for FY 2022.

Profit after Tax and restatement adjustment and Extra-ordinary item (PAT after Extra-ordinary item)

Since there are no extra ordinary items, PAT after Extra-ordinary remained same as before extra-ordinary item.

Comparison of FY 2022 with FY 2021:**Revenue from operations**

The Revenue from operations for the FY 2021 was ₹ 455.50 lakhs as compared to ₹ 638.43 lakhs during the FY 2022 showing a jump of 40.19%. This huge increase is due to increased health awareness post covid 19 and due to starting of new centres in FY 2022.

Other Income for the FY 2021 and FY 2022 was ₹ 4.23 Lakhs and ₹ 7.27 Lakhs respectively mainly includes Bank Interest and Interest on IT refunds.

The Total Income for the FY 2021 and FY 2022 was ₹ 459.63 Lakhs and ₹ 645.70 Lakhs respectively.

Expenditure:**Total Operating Expenses**

Total Operating Expenses increased in an absolute term from ₹ 372.99 lakhs for FY 2021 to ₹ 531.78 lakhs for FY 2022. This increase was mainly in line with increase in value of sales, however in % term there is fall in operating expenses due to reduction in laboratory testing charges during FY 2022 as compared to FY 2021.

Cost of Material Consumed

Cost of Material consumed was ₹ 101.80 lakhs for FY 2021 and ₹ 144.76 lakhs for FY 2022. This increase was mainly due to increase in overall business as well as extra spend on covid related sanitization costs.

Laboratory Testing Charges

Laboratory Testing charges was ₹ 27.23 lakhs for FY 2021 and ₹ 34.83 lakhs for FY 2022. This increase was mainly due to increase in outsourcing of specialised laboratory testing during FY 2022, however in % term there is fall in laboratory testing charges during FY 2022 as compared to FY 2021.

Employee Benefit Expenses

Employee Benefit Expenses increased in absolute term to ₹ 177.89 lakhs for the year ended March 31, 2022 from ₹ 116.36 lakhs for FY 2021 showing an increase of 52.88%. This increase was mainly due to increase in Salary & Wages of employees of the Company during Covid 19 period and directors remuneration. Employee Benefit Expenses stood at 27.55% and 25.32% of Total income for FY 2022 and FY 2021, respectively.

Other Expenses

Other Expenses increased from ₹ 127.60 lakhs for FY 2021 to ₹ 174.30 lakhs for FY 2022 showing a decrease of 36.60% mainly due to decrease in Rent Rates & Taxes, Selling & Distribution expenses, Legal & Professional fees, travelling & conveyance etc. Other Expenses was 27.76% of Total income during FY 2021 as against 26.99% during FY 2022 showing slight reduction in costs.

EBIDTA

EBIDTA increased to ₹ 113.92 lakhs for FY 2022 from ₹ 86.64 lakhs for FY 2021 due to the reasons listed above. During FY 2021, our Company recorded EBIDTA margin of 18.85% of the Total income as against 17.64% during FY 2022..

Depreciation and Amortization Expenses

Depreciation on fixed assets was 5.34% of Total income during FY 2021 as compared to 5.90% during FY 2022. The total depreciation during FY 2022 was ₹ 38.08 lakhs and during FY 2021 it was ₹ 24.53 lakhs.

Financial Charges

Financial Charges was 1.64% of Total income during FY 2021 as compared to 0.87% during FY 2022. The Financial Charges included Interest expenses and others. The total Financial Charges during FY 2022 was ₹ 5.62 lakhs and during FY 2021 it was ₹ 7.54 lakhs, this decrease is mainly due to lower interest for borrowings due to lower utilisation of credit facilities.

Profit after Tax and restatement adjustment but before Extra-ordinary item (PAT before Extra-ordinary item)

PAT before Extra-ordinary item increased to ₹ 51.26 lakhs for the FY 2022 from ₹ 40.24 lakhs in FY 2021. This increase was mainly on account of reduction in expenditure and other reasons as detailed above. During FY 2021, our Company recorded PAT before Extra-ordinary item margin of 8.75% for FY 2021 as against margin of 7.94% for FY 2022.

Profit after Tax and restatement adjustment and Extra-ordinary item (PAT after Extra-ordinary item)

Since there is no extra ordinary items, PAT after Extra-ordinary remained same as before extra-ordinary item.

Cash Flows

The following table sets forth certain information concerning our cash flows for the periods indicated:

(₹ in lakhs)

Particulars	30.09.2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Net cash flow from operating activities	-13.48	124.75	95.57	37.62
Net cash flow from investing activities	-4.85	-65.32	-146.56	54.37
Net cash flow from financing activities	-24.85	8.56	29.32	-87.79
Net increase in cash and cash equivalents	-43.19	67.99	-21.67	4.20
Add: Balance at the beginning of the year	78.35	10.36	32.03	27.83
Cash and cash equivalents at the end of the year	35.16	78.35	10.36	32.03

FACTORS THAT MAY AFFECT THE RESULTS OF THE OPERATIONS:

1. Unusual or infrequent events or transactions

Since the onset of the COVID-19 pandemic in March 2020, our Company has responded swiftly by implementing various processes to ensure our operations continue seamlessly. As we are engaged in diagnostic laboratory services, the same were categorized under the essential goods' and our operations were not shut down during this pandemic. However, due to limited availability of logistics and other constraints, we were impacted during the initial period of the lockdown. We

continued our operation after making arrangements to meet the government’s requirements on sanitization, people movement and social distancing.

We have experienced sustained growth in our business in recent years, including currently during the ongoing outbreak of COVID-19. We consider that our swift response and proactive steps taken have mitigated the impact of COVID- 19 pandemic on our business and personnel thus far. The future impact of COVID-19 or any other severe communicable disease on our business and results of operations depends on several factors including those discussed in “Risk Factors” on page 17 of this Draft Prospectus.

2. Significant economic changes that materially affected or are likely to affect income from continuing operations.

Our business has been subject, and we expect it to continue to be subject, to significant economic changes arising from the trends identified above in ‘Factors Affecting our Results of Operations’ and the uncertainties described in the section entitled ‘Risk Factors’ beginning on page 17 of the Draft Prospectus. To our knowledge, except as we have described in the Draft Prospectus, there are no known factors which we expect to bring about significant economic changes.

3. Known trends or uncertainties that have had or are expected to have a material adverse impact on sales, revenue, or income from continuing operations.

Apart from the risks as disclosed under Section titled “Risk Factors” on page 17 in the Draft Prospectus, in our opinion there are no other known trends or uncertainties that have had or are expected to have a material adverse impact on revenue or income from continuing operations.

4. Future changes in relationship between costs and revenues, in case of events such as future increase in labour or material costs or prices that will cause a material change are known.

Our Company’s future costs and revenues will be determined by demand/supply situation, government policies and prices quoted by other service providers.

5. Extent to which material increases in net sales or revenue are due to increased sales volume, introduction of new products or services or increased sales prices.

Changes in revenues during the last three fiscal years are explained in “Management’s Discussion and Analysis of Financial Condition & Results of Operations” under the subsection “Comparison of Financial Years ended March 31, 2023, 2022 and 2021” under the respective paragraphs titled “Operating Revenue”.

6. Total turnover of each major industry segment in which the issuer company operated.

For details on the total turnover of the industry please refer to “Industry Overview” on page 67.

7. Status of any publicly announced new products or business segment.

Our Company has not announced any new product or business segment.

8. The extent to which business is seasonal.

Our business is not seasonal in nature.

9. Any significant dependence on a single or few suppliers or customers.

Our customers are patients and accordingly we are not dependent on any of them in terms of the revenue contributed by them to our business. However, our dependence on suppliers is mentioned below:

Particulars	Financial Year ended September 30, 2023	Financial Year ended March 31, 2023	Financial Year ended March 31, 2022	Financial Year ended March 31, 2021
Suppliers’ contribution Top 10 (%)	80.31%	79.76%	92.75%	88.19%

10. Competitive conditions.

Competitive conditions are as described under “*Industry Overview*” and “*Our Business*” on pages 67 and 77, respectively.

FINANCIAL INDEBTEDNESS

Following is a summary of our Company's outstanding borrowings as on September 30, 2023 as per certificate dated January 19, 2024 (UDIN : 24107639BKBEAU8734) issued by our Auditors M/s. E. A. Patil & Associates LLP:

Sr. No.	Nature of Borrowing	Amount (₹ in lakhs)
1.	Secured Borrowings	77.56
2.	Unsecured Borrowings	4.04
	Total	81.60

The details of loans are as under:

There are following secured borrowings as on September 30, 2023:

(₹ in Lakhs)

Particulars	Sanctioned Amount	Outstanding Amount	Rate of Interest (p.a.) (%)	Primary Security	Repayment
Term Loan from Bank of Baroda	36.60	25.52	Presently 9.5%	1) Property Mortgage – Flat No. 902, Plot No. 25, Madhuban Co-op. Housing Society, Sector 6, Airoli, Navi Mumbai 400708, 2) Hypothecation of entire stock, book debts & other movable assets of the Company as a whole to secure all the credit facilities 3) 20% margin on the surrender value of LIC policy no. 884886740 in the name of Mr. Jagdish Umakant Nayak	Rs. 55,240/- monthly installments ending on December 31, 2028
Overdraft from Bank of Baroda	53.40	45.25	Presently 9.5%		On Demand
Current Maturities of loans from Bank of Baroda	36.60	4.00	Presently 9.5%		On Demand
Car loan from Bank of Baroda	10.00	2.79	10.1%	Hypothecation of Vehicle	Rs. 31,153/- monthly installments ending on June 04, 2024
Total		77.56			

Unsecured Loans:

Particulars	Outstanding as on 30.09.23 (₹ in Lakhs)	Rate of Interest (p.a.) (%)	Repayment
Jagdish Umakant Nayak	2.54	Nil	On Demand
Jyoti Jagdish Nayak	1.50	Nil	On Demand
Total	4.04		

SECTION VII – LEGAL AND OTHER INFORMATION

OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS

Except as stated below there is no (i) pending criminal litigation involving our Company, Directors, Promoter or Group Companies; (ii) actions taken by statutory or regulatory authorities involving our Company, Directors, Promoter or Group Companies; (iii) outstanding claims involving our Company, Directors, Promoter or Group Companies for any direct and indirect tax liabilities; (iv) outstanding proceedings initiated against our Company for economic offences; (v) defaults or non-payment of statutory dues by our Company; (vi) material fraud against our Company in the last five years immediately preceding the year of this Draft Prospectus; (vii) inquiry, inspection or investigation initiated or conducted under the Companies Act 2013 or any previous companies law against our Company during the last five years immediately preceding the year of this Draft Prospectus and if there were prosecutions filed (whether pending or not); (viii) fines imposed or compounding of offences for our Company in the last five years immediately preceding the year of this Draft Prospectus; (ix) litigation or legal action against our Promoter by any ministry or Government department or statutory authority during the last five years immediately preceding the year of this Draft Prospectus; (x) pending litigations involving our Company, Directors, Promoter, Group Companies or any other person, as determined to be material by the Company's Board of Directors in accordance with the SEBI (ICDR) Regulations; or (xi) outstanding dues to creditors of our Company as determined to be material by our Company's Board of Directors in accordance with the SEBI (ICDR) Regulations and dues to small scale undertakings and other creditors.

In terms of the Materiality Policy, any pending/outstanding litigation involving the Relevant Parties which exceeds the amount which is 5% of the revenue of our Company as per the Restated Financial Statements for the Financial Year 2023 would be considered material for our Company:

- i) any pending/outstanding litigation involving the Relevant Parties which exceeds the amount which is 5% of the revenue of our Company as per the Restated Financial Statements for the Financial Year 2023 would be considered material for our Company and accordingly disclosed in the Prospectus.*
- ii) As per the Restated Financial Statements for the Financial Year 2023, the revenue of our company is Rs. 634.75 Lakhs and accordingly, any pending/outstanding litigation involving an amount exceeding Rs. 31.74 Lakhs has been considered material for the purposes of disclosures in this section based on the policy approved by our Board in the Board meeting held on January 01, 2024.*

Our Company, our Promoter and/or our Directors, have not been declared as wilful defaulters by the RBI or any governmental authority, have not been debarred from dealing in securities and/or accessing capital markets by the SEBI and no disciplinary action has been taken by the SEBI or any stock exchanges against our Company, our Promoter or our Directors, that may have a material adverse effect on our business or financial position, nor, so far as we are aware, are there any such proceedings pending or threatened.

Unless otherwise stated, all proceedings are pending as of the date of this Draft Prospectus. All information provided below is as of the date of this Draft Prospectus.

None of our Promoters or Directors are Fugitive Economic Offenders under Section 12 of the Fugitive Economic Offenders Act, 2018.

LITIGATION INVOLVING OUR COMPANY: Nil

LITIGATION INVOLVING THE DIRECTORS: Nil

LITIGATION INVOLVING OUR PROMOTERS: Nil

LITIGATION INVOLVING OUR GROUP ENTITIES: Nil

TAX PROCEEDINGS:

There are no pending tax proceedings involving our Company, our Promoter, our Directors, or our Group Companies.

LEGAL NOTICES RECEIVED BY OUR COMPANY, OUR PROMOTER AND OUR DIRECTORS: NIL

MATERIAL FRAUDS AGAINST OUR COMPANY

There have been no material frauds committed against our Company in the five years preceding the year of this Draft Prospectus.

PROCEEDINGS INITIATED AGAINST OUR COMPANY FOR ECONOMIC OFFENCES

There are no proceedings initiated against our Company for any economic offences.

NON-PAYMENT OF STATUTORY DUES

As on the date of the Draft Prospectus there have been no (i) instances of non-payment or defaults in payment of statutory dues by our Company, (ii) over dues to companies or financial institutions by our Company, (iii) defaults against companies or financial institutions by our Company, or (iv) contingent liabilities not paid for.

PAST CASES WHERE PENALTIES WERE IMPOSED

There are no past cases where penalties were imposed on our Company by concerned authorities/courts.

OUTSTANDING LITIGATION AGAINST OTHER PERSONS AND COMPANIES WHOSE OUTCOME COULD HAVE AN ADVERSE EFFECT ON OUR COMPANY

As on the date of the Draft Prospectus, there is no outstanding litigation against other persons and companies whose outcome could have a material adverse effect on our Company.

PAST INQUIRIES, INSPECTIONS, OR INVESTIGATIONS

There have been no inquiries, inspections or investigations initiated or conducted under the Companies Act 2013 or any previous company law in the last five years immediately preceding the year of the Draft Prospectus in the case of Company, Promoters, Directors. Other than as described above, there have been no prosecutions filed (whether pending or not) fines imposed, compounding of offences in the last five years immediately preceding the year of the Draft Prospectus.

Further, there is no legal action pending or taken by any Ministry or Department of the Government or a statutory authority against the promoters during the last five years immediately preceding the year of the issue of the Draft Prospectus and any direction issued by such Ministry or Department or statutory authority upon conclusion of such litigation or legal action.

OUTSTANDING DUES TO CREDITORS

As per the Materiality Policy, our Board has approved that each creditor, to whom our Company individually owes a net aggregate amount that exceeds 5.00% of the revenue of our Company as per the Restated Financial Statements for the most recent financial year, shall be considered as a material creditor of our Company. Our Board has also approved that dues owed by our Company to small scale undertakings as per the Restated Financial Statements for the most recent financial year shall be disclosed in a consolidated manner.

As of September 30, 2023, our Company, in its ordinary course of business, has following amount which is due towards trade creditors. As per the above policy, consolidated information of outstanding dues, as at September 30, 2023, owed to small scale undertakings, material dues to trade creditors separately, giving details of number of cases and aggregate amount for such dues is as under:

<i>(₹ in lakhs)</i>		
Particulars	Number of cases	Amount Outstanding
Dues to small scale undertakings	20	32.38
Material dues to creditors	0	0
Other dues to creditors	33	18.37
Total	53	50.75

Further, our Company has not received any intimation from suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and hence disclosure, if any, in relation to amount unpaid as at the year end together with interest payable as required under the said Act have not been furnished. Our Company does not owe any small-scale industries or any MSMEs any amounts exceeding ₹1 lakh which is outstanding for more than 30 days. There are no disputes with such entities in relation to payments to be made to them.

The details pertaining to net outstanding dues towards our creditors are available on the website of our Company at www.ctllab.in. It is clarified that such details available on our website do not form a part of this Draft Prospectus. Anyone placing reliance on any other source of information, including our Company's website, www.ctllab.in, would be doing so at their own risk.

Material Developments

Except as stated in “*Management’s Discussion and Analysis of Financial Condition and Results of Operation*” on page 140, there have not arisen, since the date of the last financial statements disclosed in the Draft Prospectus, any circumstances which materially and adversely affect or are likely to affect our profitability taken as a whole or the value of our assets or our ability to pay our liabilities within the next 12 months.

GOVERNMENT AND OTHER APPROVALS

We have set out below a list of material approvals, consents, licences, and permissions from the governmental and regulatory authorities obtained by our Company which are considered material and necessary for the purpose of undertaking our business activities and operations. In view of the approvals listed herein, our Company can undertake the Offer and its current business activities. Unless otherwise stated, our Company has obtained all material approvals and the same are valid as of the date of this Draft Prospectus. The material approvals, consents, licenses, registrations, and permits obtained by our Company which enable it to undertake its current business activities are set forth below. Further, as on the date of this Draft Prospectus, our Company does not have any material subsidiaries.

The main objects clause of the Memorandum of Association and objects incidental to the main objects enable our Company to undertake its existing business activities. For further details in connection with the regulatory and legal framework within which we operate, please refer “Key Regulations and Policies” on page 86.

A. Corporate / General Authorizations

Sr. No.	Authorisation granted	Issuing Authority	Registration No./CIN	Date of Issue	Valid up to
1.	Certificate of incorporation in the name of “Clinitech Laboratory Private Limited”	Registrar of Companies, Mumbai	U85195MH2010PTC201078	March 19, 2010	Valid until cancelled
2.	Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company in the name of “Clinitech Laboratory Limited”	Registrar of Companies, Mumbai	U85195MH2010PLC201078	August 25, 2023	Valid until cancelled

B. Issue Related Authorizations

- Our Board of Directors has, pursuant to a resolution passed at its meeting held on December 22, 2023, authorised the Issue subject to the approval by the shareholders of our Company under Section 62(1)(c) of the Companies Act, 2013 and approvals by such other authorities as may be necessary.
- The shareholders of our Company have authorised the Issue, pursuant to a special resolution under Section 62(1)(c) of the Companies Act, 2013, passed at their EGM held on January 16, 2024.
- Our Company has obtained in-principle approval dated [●], 2024 from the BSE Limited.
- Our Company's International Securities Identification Number (“ISIN”) is INE0QMR01015.


C. Tax Related and Other Business Approvals:

Sr. No.	Authorisation Granted	Issuing Authority	Registration No. / Reference No. / License No.	Applicable Act/ Regulation	Valid up to
1.	Permanent Account Number (PAN)	Income Tax Department, GoI	AADCC9485F	Income Tax Act, 1961	Valid until cancelled
2.	Tax Deduction Account Number (TAN)	Income Tax Department, GoI	MUMC17851B	Income Tax Act, 1961	Valid until cancelled
3.	GSTIN Certificate of Registration		NA as Healthcare services Company		
4.	Certificate of Registration	Department of Goods and Services Tax, Maharashtra	27265225486P	Maharashtra State Tax on Professions, Trades, callings and	Valid until cancelled

				Employment Act, 1975	
5.	Employee’s Provident Fund Organisation – Establishment Registration	Government of India and Government of Maharashtra	THVSH1600242000	Ministry of Labour & Employment, Government of India	Valid until cancelled
6.	Employee’s State Insurance Corporation – Establishment Registration	Government of India and Government of Maharashtra	34000412870001403	Ministry of Labour & Employment, Government of India	Valid until cancelled
7.	Combined Consent and Bio-Medical Waste Authorisation (CCA)	Maharashtra Pollution Control Board	MPCB-BMW_AUTH_0000047830	Maharashtra Pollution Control Board	February 12, 2026
8.	Certificate of Accreditation / Scope of Accreditation (ISO 15189:2012)	National Accreditation Board for Testing and Calibration Laboratories (NABL)	MC-5745	NABL	June 25, 2025
9.	Udyog Aadhaar Registration Certificate	Government of India	MH33F0147949	Ministry of Micro, Small and Medium Enterprises	Valid until cancelled
10.	Udyam Registration Certificate	Government of India	UDYAM MH-33-0082699	Ministry of Micro, Small and Medium Enterprises	Valid until cancelled

D. Intellectual Property Registration

As on the date of this Draft Prospectus, Our Company has registered following trademarks with the Registrar of Trademarks.

Particulars of the Mark	TM Registration No.	Date of Issue / Renewal	Issuing Authority	Class	Status	TM in respect of
	3447787	21/06/2017	Trade Marks Registry	44	Registered	Medical Services, Medical Clinic Services, Medical Assistance

E. Approvals applied for but not yet received / Renewals made in the usual course of business:

NIL

F. Material licenses / approvals for which our Company is yet to apply for / Statutory Approvals / Licenses required:

NIL

OTHER REGULATORY AND STATUTORY DISCLOSURES

Authority for the offer

Corporate Approvals

- Our Board has, pursuant to its resolution dated December 22, 2023, authorized the Offer, subject to the approval of the Equity Shareholders of our Company under Section 62(1)(c) of the Companies Act 2013.
- Our Equity Shareholders have, pursuant to a resolution dated January 16, 2024, under Section 62(1)(c) of the Companies Act, authorized the Offer.

We have received in-principle approval from BSE *vide* their letter dated [●], 2024 to use the name of BSE in this Offer Document for listing of our Equity Shares on SME Platform of BSE. BSE is the Designated Stock Exchange.

Prohibition by SEBI, the RBI, or other Governmental Authorities

Our Company, our Promoters, our Directors, the members of the Promoter Group, the persons in control of our Company have not been prohibited from accessing the capital markets and have not been debarred from buying, selling or dealing in securities under any order or direction passed by SEBI or any other regulatory or governmental authority or court, including any securities market regulator in any jurisdiction.

Prohibition by RBI

Neither our Company, our Promoter, our Directors, relatives (as per Companies Act, 2013) of Promoter or the person(s) in control of our Company have been identified as a wilful defaulter or a fugitive economic offender and there has been no violation of any securities law committed by any of them in the past and no such proceedings are pending against any of them.

Neither our Company, our Promoter, our Directors, relatives (as per Companies Act, 2013) of Promoter or the person(s) in control of our Company have been categorized as a wilful defaulter or a fraudulent borrower by any bank or financial institution (as defined under the Companies Act, 2013) or consortium thereof, in accordance with the guidelines on wilful defaulters or fraudulent borrowers issued by the Reserve Bank of India;

None of our Promoters or Directors are Fugitive Economic Offenders under Section 12 of the Fugitive Economic Offenders Act, 2018.

Compliance with the Companies (Significant Beneficial Owners) Rules, 2018

Our Company, Promoter and members of the Promoter Group are in compliance with the Companies (Significant Beneficial Owners) Rules, 2018, as amended (“SBO Rules”), to the extent applicable to each of them as on the date of this Draft Prospectus.

Directors associated with the Securities Market

None of our Directors are, in any manner, associated with the securities market and there has been no action initiated by SEBI against the Directors of our Company in the five years preceding the date of this Draft Prospectus.

Eligibility for this Offer

Our Company has complied with the conditions of Regulation 230 of SEBI (ICDR) Regulations, 2018 for this Offer.

Our Company is an “Unlisted Issuer” in terms of the SEBI (ICDR) Regulations; and this Offer is an “Initial Public Offer” in terms of the SEBI (ICDR) Regulations.

Our Company is eligible for the Issue in accordance with Regulation 229(2) and other provisions of Chapter IX of the SEBI (ICDR) Regulations, 2018 as we are an Issuer whose post issue paid up capital is less than or equal to Rs. 10 crore and we may hence issue Equity Shares to the public and propose to list the same on the Small and Medium Enterprise Exchange (in this case being the “SME Platform of BSE Limited”).

We confirm that:

1. In accordance with Regulation 260 of the SEBI (ICDR) Regulations, this Offer is 100% underwritten and that the LM to the Issue shall underwrite minimum 15% of the Total Issue Size. For further details pertaining to said underwriting please refer to section titled "*General Information -Underwriting*" beginning on page 38.
2. In accordance with Regulation 268 of the SEBI (ICDR) Regulations, we shall ensure that the total number of proposed allottees in the Issue shall be greater than or equal to fifty (50), otherwise, the entire application money will be unblocked forthwith. If such money is not repaid within Two (2) Working Days from the date our Company becomes liable to repay it, then our Company and every officer in default shall, on and from expiry of two (2) Working Days, be liable to repay such application money, with an interest at the rate as prescribed under the Companies Act 2013.
3. In terms of Regulation 246(5) of the SEBI (ICDR) Regulations, our Lead Manager has submitted a soft copy of the Draft Prospectus to SEBI at the time of filing the Draft Prospectus with Stock Exchange. Further, in terms of Regulation 246(2), SEBI shall not issue observation on the Draft Prospectus. In terms of Regulation 246(1) and (3) of the SEBI (ICDR) Regulations, we shall ensure that our Lead Manager submits a copy of the Offer Document along with a Due Diligence Certificate including additional confirmations as required to SEBI at the time of filing the Offer Document with Stock Exchange and the Registrar of Companies. Further, in terms of Regulation 246(2), SEBI shall not issue observation on the Offer Document.
4. In accordance with Regulation 261(1) of the SEBI (ICDR) Regulations, we hereby confirm that we shall enter into an agreement with the Lead Manager and with Market Maker to ensure compulsory Market Making for a minimum period of three (3) years from the date of listing of Equity Shares on the SME Platform of BSE. For further details of the arrangement of market making please refer to section titled "*General Information - Details of the Market Making Arrangements for this Offer*" beginning on page 38.

We further confirm that we shall be complying with all the other requirements as laid down for such an issue under Chapter IX of SEBI (ICDR) Regulations, 2018 as amended from time to time and subsequent circulars and guidelines issued by SEBI and the Stock Exchange.

We confirm that we comply with all the below requirements / conditions so as to be eligible to be listed on the SME platform of BSE:

Incorporation

Our Company was incorporated on March 19, 2010, with the Registrar of Companies, Mumbai under the Companies Act, 1956 in India

Post Issue Paid-up Capital

As on the date of this Draft Prospectus, our Company has a paid-up capital of ₹168.00 lakhs and the Post Issue Paid-up Equity Share Capital will be ₹228.20 lakhs which is less than ₹2,500 lakhs.

Networth

The Networth of the Company as per the restated financials of our Company for the period ended September 30, 2023 and last 3 financial years is more than Rs. 1 crore:

(₹ in Lakhs)

Particulars	30.09.2023	31.03.2023	31.03.2022	31.03.2021
Share capital	150.00	150.00	150.00	66.66
Reserves and surplus	94.86	88.08	34.81	72.37
Total Networth	244.86	238.08	184.81	139.03

Net Tangible Assets

The Net Tangible Assets of the Company as per the restated financials of our Company as at March 31, 2023 (last preceding full financial year) is more than Rs. 300 Lakhs as computed below:

<i>Details</i>	<i>Amount (Rs. In Lakhs)</i>
Total Assets	603.34
Less: Intangible Assets	0.78
Net Tangible Assets	602.56

Track Record

Our Company is incorporated on March 19, 2010 and accordingly it has a track record of at least three years.

Earnings before Interest, Depreciation and Tax

Our company has operating profits on the basis of restated financials (earnings before interest, depreciation and tax) from operations for at least 2 financial years out of preceding 3 financial years, below are the details:

(₹ Lakhs)

Particulars	FY 2023	FY 2022	FY 2021
Profit Before Tax	86.37	70.22	54.57
Add: Interest / Financial charges	5.74	5.62	7.54
Add: Depreciation	44.58	38.08	24.53
Less: Other Income	1.59	7.27	4.23
Positive Cash Accruals (Earnings Before Depreciation and Tax)	135.10	106.65	82.41

Leverage Ratio

Our Leverage Ratio is less than 3 as per restated financial statement is as under:

(₹ in Lakhs)

Particulars	30.09.2023	31.03.2023	31.03.2022	31.03.2021
Share capital	150.00	150.00	150.00	66.66
Reserves and surplus	94.86	88.08	34.81	72.37
Total Networth - A	244.86	238.08	184.81	139.03
Long Term borrowings	25.52	28.21	35.71	48.01
Short Term borrowings	56.07	74.70	52.90	5.66
Total Borrowings - B	81.59	102.91	88.61	53.67
Leverage Ratio – C = B/A	0.33 :1	0.43 :1	0.48 :1	0.39 :1

Disciplinary action

There has been no regulatory action of suspension of trading against the promoter(s) or companies promoted by the promoters by any stock Exchange having nationwide trading terminals.

None of our Promoter(s) or directors have been promoter(s) or directors (other than independent directors) of compulsory delisted companies by the Exchange. Accordingly, there is no applicability of compulsory delisting is attracted. Further, none of our directors are disqualified/ debarred by any of the Regulatory Authority due to the Companies suspended from trading on account of non-compliance.

Default

There are no pending defaults in respect of payment of interest and/or principal to the debenture/ bond/ fixed deposit holders by the applicant company, promoters/ promoting company(ies), Subsidiary Companies.

Name change

In case of name change within the last one year, at least 50% of the revenue calculated on a restated and consolidated basis for the preceding 1 full financial year has been earned by it from the activity indicated by its new name: **Not Applicable**

Other requirements

We have a functional website: www.ctllab.in

100% of Equity Shares held by the Promoters is in dematerialised form.

Our Company has entered into an agreement with both the depositories (CDSL and NSDL) for dematerialisation of its Equity Shares already issued and proposed to be issued.

There has been no change in the promoter/s of the Company in the preceding one year from date of filing application to BSE for listing on SME Platform of BSE.

Our composition of the board is in compliance with the requirements of Companies Act, 2013.

The Net worth computation is computed as per the definition given in SEBI (ICDR) Regulations

The Company has not been referred to NCLT under IBC.

There is no winding up petition against the company, which has been admitted by the court.

Our Company has not been referred to erstwhile Board for Industrial and Financial Reconstruction (BIFR) and no proceedings have been admitted under Insolvency and Bankruptcy Code against the issuer and Promoting companies.

The Draft Prospectus has been filed with BSE and our Company has made an application to BSE for listing of its Equity Shares on the SME platform. BSE is the Designated Stock Exchange.

The entire pre-Issue capital of our Company has shares fully paid-up Equity Shares and the Equity Shares proposed to be issued pursuant to this IPO will be fully paid-up.

The requirement of firm arrangements of finance through verifiable means towards seventy five per cent of the stated means of finance for funding from the Offer Proceeds, excluding the amount to be raised through the proposed public offer or through existing identifiable internal accruals is not applicable to our Company. For details, please refer the chapter “Objects of the Issue” on page 53.

Our Company confirms that the amount for general corporate purposes, as mentioned in objects of the issue in the offer document does not exceed twenty-five per cent. of the amount being raised by our Company from fresh issue of shares.

Further, our Company confirms that it is not ineligible to make the Issue in terms of Regulation 228 of the SEBI ICDR Regulations. The details of our compliance with Regulation 228 of the SEBI ICDR Regulations are as follows:

- (a) Neither our Company nor our Promoters, members of our Promoter Group or our Directors are debarred from accessing the capital markets by the SEBI.
- (b) None of our Promoters or Directors are promoters or directors of companies which are debarred from accessing the capital markets by the SEBI.
- (c) Neither our Company nor our Promoters or Directors is a wilful defaulter.
- (d) Neither our Company nor our Promoters or Directors is a fraudulent borrower.

(e) None of our Promoters or Directors is a fugitive economic offender.

We further confirm that we shall be complying with all other requirements as laid down for such offer under Chapter IX of SEBI (ICDR) Regulations, as amended from time to time and subsequent circulars and guidelines issued by SEBI and the Stock Exchange.

Further, In accordance with Regulation 268(1) of the SEBI (ICDR) Regulations, we shall ensure that the total number of proposed allottees in the Issue shall be greater than or equal to fifty (50), otherwise, the entire application money will be unblocked forthwith. If such money is not repaid within two (2) Working Days from the date our Company becomes liable to repay it, then our Company and every officer in default shall, on and from expiry of two (2) Working Days, be liable to repay such application money, with an interest at the rate as prescribed under the Companies Act 2013. Further, in accordance with Section 40 of the Companies Act, 2013, the Company and each officer in default may be punishable with fine and/or imprisonment in such a case.

DISCLAIMER CLAUSE OF SEBI

IT IS TO BE DISTINCTLY UNDERSTOOD THAT SUBMISSION OF OFFER DOCUMENT TO SECURITIES AND EXCHANGE BOARD OF INDIA (SEBI) SHOULD NOT IN ANY WAY BE DEEMED OR CONSTRUED THAT THE SAME HAS BEEN CLEARED OR APPROVED BY SEBI. SEBI DOES NOT TAKE ANY RESPONSIBILITY EITHER FOR THE FINANCIAL SOUNDNESS OF ANY SCHEME OR THE PROJECT FOR WHICH THE ISSUE IS PROPOSED TO BE MADE OR FOR THE CORRECTNESS OF THE STATEMENTS MADE OR OPINIONS EXPRESSED IN THE OFFER DOCUMENT. THE LEAD MANAGER, FIRST OVERSEAS CAPITAL LIMITED HAS CERTIFIED THAT THE DISCLOSURES MADE IN THE OFFER DOCUMENT ARE GENERALLY ADEQUATE AND ARE IN CONFORMITY WITH THE REGULATIONS. THIS REQUIREMENT IS TO FACILITATE INVESTORS TO TAKE AN INFORMED DECISION FOR MAKING AN INVESTMENT IN THE PROPOSED ISSUE.

IT SHOULD ALSO BE CLEARLY UNDERSTOOD THAT WHILE THE COMPANY IS PRIMARILY RESPONSIBLE FOR THE CORRECTNESS, ADEQUACY AND DISCLOSURE OF ALL RELEVANT INFORMATION IN THIS OFFER DOCUMENT, THE LEAD MANAGER, FIRST OVERSEAS CAPITAL LIMITED IS EXPECTED TO EXERCISE DUE DILIGENCE TO ENSURE THAT THE COMPANY DISCHARGES ITS RESPONSIBILITY ADEQUATELY IN THIS BEHALF AND TOWARDS THIS PURPOSE, THE LEAD MERCHANT BANKER, FIRST OVERSEAS CAPITAL LIMITED HAS FURNISHED TO SEBI, A DUE DILIGENCE CERTIFICATE DATED JANUARY 23, 2024 IN THE FORMAT PRESCRIBED UNDER SCHEDULE V(A) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS), REGULATIONS, 2018.

THE FILING OF THIS OFFER DOCUMENT DOES NOT, HOWEVER, ABSOLVE THE COMPANY FROM ANY LIABILITIES UNDER THE COMPANIES ACT OR FROM THE REQUIREMENT OF OBTAINING SUCH STATUTORY OR OTHER CLEARANCES AS MAY BE REQUIRED FOR THE PURPOSE OF THE PROPOSED ISSUE. SEBI FURTHER RESERVES THE RIGHT TO TAKE UP AT ANY POINT OF TIME, WITH THE LEAD MANAGER ANY IRREGULARITIES OR LAPSES IN THE OFFER DOCUMENT.

All legal requirements pertaining to the Issue will be complied with at the time of registration of the Draft Prospectus with the Registrar of Companies, Maharashtra at Mumbai in terms of sections 26, 32 and 33 of the Companies Act, 2013.

Disclaimer from our Company, our Directors and the Lead Manager

Our Company, our Directors and the Lead Manager accept no responsibility for statements made otherwise than in this Draft Prospectus or in the advertisements or any other material issued by or at our Company's instance and anyone placing reliance on any other source of information, or the website of any affiliate of our Company and its Group Companies, would be doing so at his or her own risk.

The Lead Manager accepts no responsibility, save to the limited extent as provided in the MOU / Issue Agreement entered into between the Lead Manager and our Company dated January 23, 2024 and the Underwriting Agreement dated January 23, 2024 entered into between the Underwriter and our Company and the Market Making Agreement dated January 23, 2024 entered into among the Lead Manager, the Market Maker and our Company.

All information shall be made available by our Company and the Lead Manager to the Applicants and public at large and

no selective or additional information would be available for a section of the investors in any manner whatsoever, including at road show presentations, in research or sales reports, at collection centres or elsewhere.

None among our Company or any member of the Syndicate is liable for any failure in (i) uploading the applications due to faults in any software/ hardware system or otherwise, or (ii) the blocking of the Bid Amount in the ASBA Account on receipt of instructions from the Sponsor Banks on the account of any errors, omissions or non-compliance by various parties involved, or any other fault, malfunctioning, breakdown or otherwise, in the UPI Mechanism.

The Lead Manager and their respective associates and affiliates may engage in transactions with, and perform services for our Company, our Group Entities and our respective affiliates and associates in the ordinary course of business, and have engaged, or may in the future engage in commercial banking and investment banking transactions with our Company or our Group Entities or their respective affiliates or associates for which they have received, and may in future receive compensation.

Disclaimer in Respect of Jurisdiction

This Offer is being made in India to persons resident in India (including Indian nationals resident in India who are not minors, HUFs, companies, corporate bodies and societies registered under the applicable laws in India and authorised to invest in shares, Indian Mutual Funds registered with SEBI, Indian financial institutions, commercial banks, regional rural banks, co-operative banks (subject to RBI permission), or trusts under applicable trust law and who are authorised under their constitution to hold and invest in shares, public financial institutions as specified in Section 2 (72) of the Companies Act, 2013, scheduled commercial banks, mutual fund registered with SEBI, FII and sub-account (other than a sub-account which is a foreign corporate or foreign individual) registered with SEBI, Alternative Investment Fund, multilateral and bilateral development financial institution, venture capital fund registered with SEBI, foreign venture capital investor registered with SEBI, state industrial development corporation, insurance company registered with Insurance Regulatory and Development Authority, provident fund with minimum corpus of ₹2,500 lakhs, pension fund with minimum corpus of ₹2,500 lakhs, National Investment Fund set up by resolution no. F. No. 2/3/2005-DDII dated November 23, 2005 of the Government of India published in the Gazette of India, insurance funds set up and managed by army, navy or air force of the Union of India and Insurance funds set up and managed by the Department of Posts, India, provided that they are eligible under all applicable laws and regulations to hold Equity Shares of the Company this Draft Prospectus does not, however, constitute an invitation to purchase shares offered hereby in any jurisdiction other than India to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. Any person into whose possession this Draft Prospectus comes is required to inform himself or herself about, and to observe, any such restrictions. Any dispute arising out of this Offer will be subject to the jurisdiction of appropriate court(s) in Maharashtra, India only.

No action has been, or will be, taken to permit a public offering in any jurisdiction where action would be required for that purpose, except that this Draft Prospectus has been filed with BSE for its observations and BSE shall give its observations in due course. Accordingly, the Equity Shares represented hereby may not be offered or sold, directly or indirectly, and this Draft Prospectus may not be distributed, in any jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction. Neither the delivery of this Draft Prospectus nor any sale hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of our Company since the date hereof or that the information contained herein is correct as of any time subsequent to this date.

The Equity Shares have not been, and will not be, registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Further, each applicant where required agrees that such applicant will not sell or transfer any Equity Shares or create any economic interest therein, including any off-shore derivative instruments, such as participatory notes, issued against the Equity Shares or any similar security, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable laws and legislations in each jurisdiction, including India.

Disclaimer Clause of the SME Platform of BSE Limited

As required, a copy of the Draft Prospectus has been submitted to the SME Platform of BSE.

" BSE Limited ("BSE") has vide its letter dated [●], 2024 given permission to the Company to use its name in the Offer Document as the Stock Exchange on whose Small and Medium Enterprises Platform ("SME platform") the Company's securities are proposed to be listed. BSE has scrutinized this offer document for its limited internal purpose of deciding on the matter of granting the aforesaid permission to the Company. BSE does not in any manner:

- i. warrant, certify or endorse the correctness or completeness of any of the contents of this offer document; or
- ii. warrant that this Company's securities will be listed on completion of Initial Public Offering or will continue to be listed on BSE; or
- iii. take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;
- iv. warrant, certify or endorse the validity, correctness or reasonableness of the price at which the equity shares are offered by the Company and investors are informed to take the decision to invest in the equity shares of the Company only after making their own independent enquiries, investigation and analysis. The price at which the equity shares are offered by the Company is determined by the Company in consultation with the Merchant Banker (s) to the issue and the Exchange has no role to play in the same and it should not for any reason be deemed or construed that the contents of this offer document have been cleared or approved by BSE. Every person who desires to apply for or otherwise acquire any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against BSE whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever.
- v. BSE does not in any manner be liable for any direct, indirect, consequential or other losses or damages including loss of profits incurred by any investor or any third party that may arise from any reliance on this offer document or for the reliability, accuracy, completeness, truthfulness or timeliness thereof.
- vi. The Company has chosen the SME platform on its own initiative and at its own risk, and is responsible for complying with all local laws, rules, regulations, and other statutory or regulatory requirements stipulated by BSE/other regulatory authority. Any use of the SME platform and the related services are subject to Indian laws and Courts exclusively situated in Mumbai".

Track records of past issues handled by First Overseas Capital Limited

For details regarding the track record of the First Overseas Capital Limited, as specified under Circular reference CIR/MIRSD/1/2012 dated January 10, 2012 issued by the SEBI, please refer to the website of First Overseas Capital Limited at www.focl.in

Listing

The Equity Shares of our Company are proposed to be listed on SME Platform of BSE. Our Company has obtained in-principle approval from BSE by way of its letter dated [●], 2024 for listing of equity shares on SME Platform of BSE.

BSE will be the Designated Stock Exchange, with which the Basis of Allotment will be finalized for the Issue. If the 40 to deal in and for an official quotation of the Equity Shares on the Emerge Platform is not granted by BSE, our Company shall forthwith repay, without interest, all moneys received from the applicants in pursuance of this Draft Prospectus. If such money is not repaid within the prescribed time then our Company becomes liable to repay it, then our Company and every officer in default shall, shall be liable to repay such application money, with interest, as prescribed under the applicable law.

Our Company shall ensure that all steps for the completion of the necessary formalities for listing and commencement of trading at the SME Platform of BSE mentioned above are taken within three (3) Working Days of the Offer Closing Date.

Impersonation

Attention of the Applicants is specifically drawn to the provisions of sub-section (1) of Section 38 of the Companies Act,

2013 which is reproduced below:

“Any person who –

- a) makes or abets making of an application in a fictitious name to a company for acquiring, or subscribing for, its securities, or*
- b) makes or abets making of multiple applications to a company in different names or in different combinations of his name or surname for acquiring or subscribing for its securities; or*
- c) otherwise induces directly or indirectly a company to allot, or register any transfer of, securities to him, or to any other person in a fictitious name, shall be liable for action under section 447.”*

The liability prescribed under Section 447 of the Companies Act, 2013, includes imprisonment for a term of not less than six months extending up to ten years (provided that where the fraud involves public interest, such term shall not be less than three years) and fine of an amount not less than the amount involved in the fraud, extending up to three times of such amount.

Consents

Consents in writing of (a) Our Directors, Our Company Secretary & Compliance Officer, Chief Financial Officer, Our Statutory Auditor, Banker to the Company; (b) Lead Manager, Registrar to the Issue, Banker to the Issue/ Sponsor Bank, Legal Advisor to the Issue, Underwriter to the Issue and Market Maker to the Issue to act in their respective capacities have been obtained and shall be filed along with a copy of the Prospectus with the RoC, as required under Sections 26 of the Companies Act, 2013 and such consents will not be withdrawn up to the time of delivery of the Prospectus for registration with the RoC.

Our Company has received written consent from the Statutory Auditor namely, M/s. E. A. Patil & Associates LLP, Chartered Accountants to include their name as required under Section 26(1)(a)(v) of the Companies Act, 2013 in this Draft Prospectus and as “expert” as defined under section 2(38) of the Companies Act, 2013 in respect of the report of the Peer Reviewed Auditor on the Restated Financial Statements, dated December 15, 2023 and the statement of tax benefits dated January 19, 2024 and such consent has not been withdrawn as on the date of this Draft Prospectus.

Expert Opinion

Except as stated below, our Company has not obtained any expert opinions:

Our Company has received written consent dated January 19, 2024 from the Statutory Auditors, M/s. E. A. Patil & Associates LLP, Chartered Accountants to include their name as required under Section 26(1)(a)(v) of the Companies Act 2013 read with SEBI ICDR Regulations in this Prospectus as an “expert” as defined under Section 2(38) of the Companies Act 2013 to the extent and in its capacity as an independent Statutory Auditor and in respect of its (i) examination report dated December 15, 2023 on our restated financial information; and (ii) other reports and certificates issued in respect of this issue and included in this Draft Prospectus and such consent has not been withdrawn as on the date of this Draft Prospectus.

Previous Rights and Public Issues during the Last Five Years

We have not made any previous rights and/or public issues during the last five years, and are an “Unlisted Issuer” in terms of the SEBI (ICDR) Regulations and this Offer is an “Initial Public Offering” in terms of the SEBI (ICDR) Regulations.

Commission and Brokerage Paid on Previous Issues of our Equity Shares

Since this is the Initial Public Offer of the Company, no sum has been paid or has been payable as commission or brokerage for subscribing to or procuring or agreeing to procure subscription for any of the Equity Shares since inception of the Company.

Previous capital issue during the last three years by listed Group Companies and Subsidiary of our Company

None of the Group Companies of our Company are listed. Further, none of our Group Companies have made any public or rights issue of securities in the preceding three years.

Performance vis-à-vis objects

Our Company is an “Unlisted Issuer” in terms of the SEBI (ICDR) Regulations, and this Offer is an “Initial Public Offering” in terms of the SEBI (ICDR) Regulations. Therefore, data regarding promise versus performance is not applicable to us.

None of the Group Entities has made public issue of equity shares during the period of ten years immediately preceding the date of filing draft offer document with the BSE Limited.

Details of Fees Payable

Fees Payable to the Lead Manager

The total fees payable to the Lead Manager (including underwriting fees) will be as per the Memorandum of Understanding and Underwriting Agreement among our Company and the Lead Manager, copy of which is available for inspection at the Registered Office of our Company.

Fees Payable to the Registrar to the Issue

The fees payable to the Registrar to the Issue will be as per the Agreement signed by our Company and the Registrar to the Issue dated January 23, 2024 a copy of which is available for inspection at our Registered Office.

The Registrar to the Issue will be reimbursed for all out-of-pocket expenses including cost of stationery, postage, stamp duty and communication expenses. Adequate funds will be provided by the Company to the Registrar to the Issue to enable them to send refund orders or allotment advice by registered post/ speed post/ under certificate of posting.

Fees Payable to Others

The total fees payable to the Legal Advisor, Statutory Auditor and Advertisers, etc. will be as per the terms of their respective engagement letters, if any.

Statement on Price Information of Past Issues handled by First Overseas Capital Limited:-

TABLE 1

Sr. No.	Issue Name	Issue Size (Rs. Cr.)	Issue Price (Rs.)	Listing Date	Opening Price on listing date	+/-% change in closing price, [+/-% change in closing benchmark]- 30th calendar days from listing	+/-% change in closing price, [+/-% change in closing benchmark]- 90th calendar days from listing	+/-% change in closing price, [+/-% change in closing benchmark]- 180th calendar days from listing
SME BOARD								
1)	Kore Digital Limited	18.00	180.00	14-06-2023	201.00	-58.10(+4.48)	+48.26(+6.31)	+106.05(+10.60)
2)	Cell Point (India) Limited	50.34	100.00	28-06-2023	100.00	-52.21(+3.51)	-46.74(+3.18)	-54.16(+11.61)
3)	Synoptics Technologies Limited	54.04	237.00	13-07-2023	238.00	-45.05(-0.24)	-45.44(+1.39)	-35.98(+8.89)
4)	Ondoor Concepts Limited	31.18	208.00	01-11-2023	214	-6.20(6.12)	N.A.	N.A.
5)	Shanthala FMCG Products Limited	16.07	91.00	03-11-2023	108	20.44(6.99)	N.A.	N.A.
6)	Graphisads Limited	53.41	111	14-12-2023	111.50	-33.79 (3.99)	N.A.	N.A.
7)	Shree OSFM E Mobility Limited	24.60	65.00	21-12-2023	65.00	N.A.	N.A.	N.A.
8)	Electro Force (India) Limited	80.68	93.00	27-12-2023	100.00	N.A.	N.A.	N.A.
9)	Sameera Agro and Infra Limited	62.64	180.00	01-01-2024	180.00	N.A.	N.A.	N.A.
MAIN BOARD								
10)	Pyramid Technoplast Limited	153.05	166	29-08-2023	187.00	+2.98(+0.66)	23.92(1.69)	N.A.

Note:-

1. The BSE Sensex and Nifty are considered as the Benchmark Index
2. Prices on BSE/NSE are considered for all of the above calculations

3. In case the 30th/90th/180th day is a holiday, closing price on BSE/NSE of the nearest trading day has been considered.
 4. In case 30th/90th/180th days, scrips are not traded then closing price on BSE/NSE of the nearest trading day has been considered.

TABLE 2: SUMMARY STATEMENT OF DISCLOSURE

Financial Year	Total no. Of IPOs	Total amount of funds raised (Rs. Cr.)	No. of IPOs trading at discount-30 th calendar days from listing			No. of IPOs trading at premium-30 th calendar days from listing			No. of IPOs trading at discount-180 th calendar days from listing			No. of IPOs trading at premium-180 th calendar days from listing		
			Over 50%	Between 25-50%	Less than 25%	Over 50%	Between 25-50%	Less than 25%	Over 50%	Between 25-50%	Less than 25%	Over 50%	Between 25-50%	Less than 25%
SME BOARD														
2023-24*	9	390.95	2	1	1	-	-	2	1	1	-	1	-	-
2022-23	10	193.93	-	4	3	3	-	-	2	1	-	3	-	1
2021-22	4	96.13	1	1	-	2	-	-	2	-	-	1	1	-
MAIN BOARD														
2023-24*	1	1530.52	-	-	1	-	-	-	-	-	-	-	-	-

* Upto date of this Draft Prospectus

Outstanding Debentures or Bond Issues or Redeemable Preference Shares

As on the date of this Draft Prospectus, our Company has no outstanding debentures, bonds, or redeemable preference shares.

Partly Paid-Up Shares

As on the date of this Draft Prospectus, there are no partly paid-up Equity Shares of our Company.

Outstanding Convertible Instruments

Our Company does not have any outstanding convertible instruments as on the date of filing this Draft Prospectus.

Option to Subscribe

- a. Investors will get the allotment of specified securities in dematerialization form only.
- b. The equity shares, on allotment, shall be traded on stock exchange in demat segment only.

Stock Market Data for our Equity Shares

Our Company is an “Unlisted Issuer” in terms of the SEBI (ICDR) Regulations, and this Offer is an “Initial Public Offering” in terms of the SEBI (ICDR) Regulations. Thus, there is no stock market data available for the Equity Shares of our Company.

Investor Grievances and Redressal System

The Registrar Agreement provides for retention of records with the Registrar to the Offer for a period of at least eight years from the date of listing and commencement of trading of the Equity Shares to enable the investors to approach the Registrar to the Offer for redressal of their grievances.

All grievances relating to the present Issue may be addressed to the Registrar with a copy to the Compliance Officer, giving full details such as name, address of the applicant, number of Equity Shares applied for, amount paid on application and name of bank and branch. The Company would monitor the work of the Registrar to ensure that the investor grievances are settled expeditiously and satisfactorily.

Further, the Applicants shall also enclose a copy of the Acknowledgment Slip duly received from the concerned Designated Intermediary in addition to the information mentioned hereinabove.

The Registrar to the Offer shall obtain the required information from the SCSBs and Sponsor Banks for addressing any clarifications or grievances of ASBA Applicants. Our Company, the Lead Manager and the Registrar to the Issue accept no responsibility for errors, omissions, commission, or any acts of SCSBs including any defaults in complying with its obligations under applicable SEBI ICDR Regulations. Investors can contact the Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-Issue or post-Issue related problems such as non-receipt of letters of Allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund intimations and non-receipt of funds by electronic mode.

SEBI has launched a centralized web-based complaints redress system “SCORES”. This would enable investors to lodge and follow up their complaints and track the status of redressal of such complaints from anywhere. For more details, investors are requested to visit the website www.scores.gov.in. Our Company shall obtain authentication on the SCORES and comply with the SEBI circular (CIR/OIAE/1/2013) dated April 17, 2013 in relation to redressal of investor grievances through SCORES.

The Board has constituted a Stakeholders Relationship Committee to review and redress the shareholders and investor grievances such as transfer of Equity Shares, non-recovery of balance payments, declared dividends, approve subdivision, consolidation, transfer and issue of duplicate shares. For further details, please refer to the “*Our Management*” on page 95.

Our Company has appointed CS Bharat Kumar Bohra as the Company Secretary and Compliance Officer and he may be contacted at the following address:

Bharat Kumar Bohra

AL-1/545, Sector 16, Airoli,
Opposite Radhikabai Meghe Vidyalaya,
Navi Mumbai, Thane - 400708,
Maharashtra, India
Tel: +91 22 27792281 / +91 9004072223
Fax: Not Available
E-mail: ipo@clinitechlab.com
Website: www.ctllab.in

Investors can contact the Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-Issue or post-Issue related problems such as non-receipt of letters of Allotment, credit of allotted Equity Shares in the respective beneficiary account or refund orders, *etc.*

As on the date of this Draft Prospectus, there are no pending investor complaints. Our Company has not received any investor complaint in the three years prior to the filing of this Draft Prospectus.

Our Company, Lead Manager and the Registrar accept no responsibility for errors, omissions, commission of any acts of the Designated Intermediaries, including any defaults in complying with its obligations under the SEBI ICDR Regulations.

Our Group Companies and our Subsidiaries are not listed on any stock exchange.

Disposal of Investor Grievances by our Company

Our Company estimates that the average time required by our Company or the Registrar to the Issue or the SCSB, for the redressal of routine investor grievances shall be 10 Working Days from the date of receipt of the complaint. In case of nonroutine complaints and complaints where external agencies are involved, our Company will seek to redress these complaints as expeditiously as possible.

SECTION VIII – ISSUE RELATED INFORMATION

TERMS OF THE OFFER

All Applicants should review the General Information Document for Investing in Public Offer prepared and issued in accordance with the circular (CIR/CFD/DIL/12/2013) dated October 23, 2013 notified by SEBI (“General Information Document”) which highlights the key rules, processes and procedures applicable to public issues in general in accordance with the provisions of the Companies Act 2013 (to the extent notified), the Companies Act, 1956 (to the extent not repealed by the Companies Act, 2013), the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957 and the SEBI ICDR Regulations as amended. The General Information Document has been updated to reflect amendments to the SEBI ICDR Regulations and to include reference to the Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2014, SEBI Listing Regulations 2015 and certain notified provisions of the Companies Act, 2013, to the extent applicable to a public issue. The General Information Document is also available on the website of the Stock Exchange and the Lead Manager. Please refer to the relevant portions of the General Information Document which are applicable to this Offer.

Please note that, in terms of SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, all the investors applying in a public Offer shall use only Application Supported by Blocked Amount (ASBA) facility for making payment. Further, pursuant to SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018, Retail Individual Investors applying in public offer may use either Application Supported by Blocked Amount (ASBA) facility for making application or also can use UPI as a payment mechanism with Application Supported by Blocked Amount for making application.

Further vide the said circular Registrar to the Issue and Depository Participants have been also authorized to collect the application forms. Investor may visit the official website of the concerned for any information on operationalization of this facility of form collection by the Registrar to the Issue and Depository Participants as and when the same is made available.

The Offer

The Offer comprises a Fresh Issue by our Company. Expenses for the Offer shall be incurred by our Company in the manner specified in “Objects of the Offer”, beginning on page 53.

Ranking of Equity Shares

The Equity Shares being issued in the Issue shall be subject to the provisions of the Companies Act and the Memorandum and Articles of Association and shall rank *pari-passu* with the existing Equity Shares of our Company including rights in respect of the rights to receive dividends and other corporate benefits, if any, declared by us after the date of Allotment. The Allottees in receipt of Allotment of Equity Shares under this Offer will be entitled to dividends and other corporate benefits, if any, declared by our Company after the date of Allotment. For further details, please refer “Main Provisions of Articles of Association” on page 199.

Authority for the Issue

This Offer has been authorized by a resolution of the Board passed at their meeting held on December 22, 2023 subject to the approval of shareholders through a special resolution to be passed pursuant to section 62 (1) (c) of the Companies Act, 2013. The shareholders have authorized the Issue by a special resolution in accordance with Section 62 (1) (c) of the Companies Act, 2013 passed at the EGM of the Company held on January 16, 2024.

Mode of Payment of Dividend

The declaration and payment of dividend will be as per the provisions of Companies Act, 1956 and Companies Act, 2013, Article of Association, the provision of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 any other rules, regulations or guidelines as may be issued by Government of India in connection to recommendation by the Board of Directors and the Shareholders at their discretion and will depend on a number of factors, including but not limited to earnings, capital requirements and overall financial condition of our Company. We shall pay dividend, in cash as per the provisions of the Companies Act and our Articles of Association.

Face Value and Offer Price per Share

The face value of the Equity Shares is ₹10.00 each and the Offer Price is ₹ 96.00 per Equity Share.

The Issue Price is determined by our Company in consultation with the Lead Manager and is justified under “*Basis for Offer Price*” on page 58. At any given point of time there shall be only one denomination for the Equity Shares.

Compliance with SEBI (ICDR) Regulations

Our Company shall comply with all requirements of the SEBI (ICDR) Regulations. Our Company shall comply with all disclosure and accounting norms as specified by SEBI from time to time.

Rights of the Equity Shareholders

Subject to applicable laws, rules, regulations and guidelines and the Articles of Association, the Equity shareholders shall have the following rights:

- Right to receive dividend, if declared;
- Right to attend general meetings and exercise voting rights, unless prohibited by law;
- Right to vote on a poll either in person or by proxy;
- Right to receive offer for rights shares and be allotted bonus shares, if announced;
- Right to receive surplus on liquidation subject to any statutory and preferential claim being satisfied;
- Right of free transferability subject to applicable law, including any RBI rules and regulations; and
- Such other rights, as may be available to a shareholder of a listed public limited company under the Companies Act, the terms of the listing agreements with the Stock Exchange(s) and the Memorandum and Articles of Association of our Company.

For a detailed description of the main provisions of the Articles of Association relating to voting rights, dividend, forfeiture and lien and/or consolidation/splitting, please refer “*Main Provisions of Articles of Association*” on page 199.

Jurisdiction

Exclusive jurisdiction for the purpose of this Offer is with the competent courts/authorities in Mumbai, India.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

The above information is given for the benefit of the Applicants. Our Company and the Lead Manager are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Draft Prospectus. Applicants are advised to make their independent investigations and ensure that the number of Equity Shares applied for do not exceed the applicable limits under laws or regulations.

Joint Holders

Where two or more persons are registered as the holders of any Equity Shares, they shall be deemed to hold the same as joint – tenants with benefits of survivorship.

Allotment only in Dematerialised Form

Pursuant to Section 29 of the Companies Act, 2013 and the SEBI ICDR Regulations, the Equity Shares shall be Allotted only in dematerialised form. As per the SEBI ICDR Regulations, the trading of the Equity Shares shall only be in dematerialised form. In this context, two agreements have been signed amongst our Company, the respective Depositories, and the Registrar to the Offer:

- Agreement dated July 26, 2023 amongst NSDL, our Company and the Registrar to the Offer; and
- Agreement dated July 20, 2023 amongst CDSL, our Company and the Registrar to the Offer.

Market Lot and Trading Lot

The trading of the Equity Shares will happen in the minimum contract size of 1,200 Equity Shares and the same may be modified by the SME Platform of BSE from time to time by giving prior notice to investors at large.

Nomination Facility to Investor

In accordance with Section 72 of the Companies Act, 2013 the sole or first Applicant, along with other joint Applicants, may nominate any one person in whom, in the event of the death of sole Applicant or in case of joint Applicants, death of all the Applicants, as the case may be, the Equity Shares Allotted, if any, shall vest. A person, being a nominee, entitled to the Equity Shares by reason of the death of the original holder(s), shall in accordance with Section 72 of the Companies Act, 2013 be entitled to the same advantages to which he or she would be entitled if he or she were the registered holder of the Equity Share(s). Where the nominee is a minor, the holder(s) may make a nomination to appoint, in the prescribed manner, any person to become entitled to Equity Share(s) in the event of his or her death during the minority. A nomination shall stand rescinded upon a sale of Equity Share(s) by the person nominating. A buyer will be entitled to make a fresh nomination in the manner prescribed. Fresh nomination can be made only on the prescribed form available on request at our Registered Office or to the registrar and transfer agents of our Company.

In accordance with Section 72 of the Companies Act, 2013 any person who becomes a nominee by virtue of the provisions of Section 72 of the Companies Act, 2013 shall upon the production of such evidence as may be required by the Board, elect either:

- a) to register himself or herself as the holder of the Equity Shares; or
- b) to make such transfer of the Equity Shares, as the deceased holder could have made.

Further, the Board may at any time give notice requiring any nominee to choose either to be registered himself or herself or to transfer the Equity Shares, and if the notice is not complied with within a period of ninety days, the Board may thereafter withhold payment of all dividends, bonuses or other moneys payable in respect of the Equity Shares, until the requirements of the notice have been complied with.

Since the Allotment of Equity Shares in the Issue will be made only in dematerialized mode there is no need to make a separate nomination with our Company. Nominations registered with respective depository participant of the applicant would prevail. If the investor wants to change the nomination, they are requested to inform their respective depository participant.

Minimum Number of Allottees

Further in accordance with the Regulation 268 of SEBI (ICDR) Regulations, the minimum number of allottees in this Offer shall be 50 shareholders. In case the minimum number of prospective allottees is less than 50, no allotment will be made pursuant to this Offer and the monies blocked by the SCSBs and sponsor bank, shall be unblocked within 2 working days of closure of Offer.

Period of the Subscription list of the Public Issue

Event	Indicative Date
Offer Opening Date	[●]
Offer Closing Date	[●]
Finalization of Basis of Allotment with the Designated Stock Exchange	[●]
Initiation of Refunds	[●]
Credit of Equity Shares to Demat Accounts of Allottees	[●]
Commencement of trading of the Equity Shares on the Stock Exchange	[●]

The above timetable is indicative and does not constitute any obligation on our Company and the Lead Manager. Whilst our Company shall ensure that all steps for the completion of the necessary formalities for the listing and the commencement of trading of the Equity Shares on the Stock Exchange are taken within 3 Working Days of the Issue Closing Date, the timetable may change due to various factors, such as extension of the Issue by our Company or any delays in receiving the final listing and trading approval from the Stock Exchange. The Commencement of trading of the Equity Shares will be entirely at the discretion of the Stock Exchange and in accordance with the applicable laws.

Minimum Subscription

This Offer is not restricted to any minimum subscription level. This Offer is 100% underwritten. If the Issuer does not receive the subscription of 100% of the Offer through this offer document including devolvement of Underwriters within sixty days from the date of closure of the Issue, the Issuer shall forthwith refund the entire subscription amount received. If there is a delay beyond four days after our Company becomes liable to pay the amount, our Company, to the extent applicable, shall pay interest prescribed under the applicable law.

In terms of Regulation 260 of the SEBI ICDR Regulations, 2018, the Issue is 100% underwritten. For details of underwriting arrangement, kindly refer the chapter titled “*General Information – Underwriting*” on page 38.

Further, in accordance with Regulation 267 of the SEBI ICDR Regulations, 2018, the minimum application size in terms of number of specified securities shall not be less than Rupees One Lakh per application.

Arrangements for Disposal of Odd Lots

The trading of the equity shares will happen in the minimum contract size of 1,200 Equity Shares. However, the market maker shall buy the entire shareholding of a shareholder in one lot, where value of such shareholding is less than the minimum contract size allowed for trading on the SME Platform of BSE.

Option to receive Equity Shares in Dematerialized Form

Pursuant to Section 29 of the Companies Act, the Equity Shares in the Issue shall be allotted only in dematerialised form. Further, as per the SEBI (ICDR) Regulations, the trading of the Equity Shares shall only be in dematerialised form on the Stock Exchange.

Migration to Main Board

In accordance with the BSE Limited Circular, our Company will have to be mandatorily listed and traded on the SME Platform of BSE for a minimum period of 3 (Three) years from the date of listing and only after that it can migrate to the Main Board of BSE Limited as per the guidelines specified by SEBI and as per the procedures laid down under Chapter IX of the SEBI (ICDR) Regulations. Our Company may migrate to the main board of BSE from the SME Platform on a later date subject to the following:

- a) If the Paid up Capital of the company is likely to increase above ₹25 crores by virtue of any further issue of capital by way of rights, preferential issue, bonus issue etc. (which has been approved by a special resolution through postal ballot wherein the votes cast by the shareholders other than the Promoters in favour of the proposal amount to at least two times the number of votes cast by shareholders other than promoter shareholders against the proposal and for which the company has obtained in-principal approval from the main board), we shall have to apply to BSE for listing our shares on its Main Board subject to the fulfilment of the eligibility criteria for listing of specified securities laid down by the Main Board.

OR

- b) If the Paid up Capital of the company is more than ₹10 crores but below ₹25 crores, we may still apply for migration to the main board if the same has been approved by a special resolution through postal ballot wherein the votes cast by the shareholders other than the promoters in favour of the proposal amount to at least two times the number of votes cast by shareholders other than promoter shareholders against the proposal.

Market Making

The shares issued and transferred through this Offer are proposed to be listed on the BSE Emerge with compulsory market making through the registered Market Maker of the SME Exchange for a minimum period of three years or such other time as may be prescribed by the Stock Exchange, from the date of listing on the SME Platform of BSE Limited. For further details of the market making arrangement please refer to chapter titled “*General Information*” beginning on page 36 of this Draft Prospectus.

As per the extent Guideline of the Government of India, OCBs cannot participate in this Offer.

The current provisions of the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000, provides a general permission for the NRIs, FPIs and foreign venture capital investors registered with SEBI to invest in shares of Indian companies by way of subscription in an IPO. However, such investments would be subject to other investment restrictions under the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000, RBI and/or SEBI regulations as may be applicable to such investors.

The Allotment of the Equity Shares to Non-Residents shall be subject to the conditions, if any, as may be prescribed by the Government of India/RBI while granting such approvals.

New Financial Instruments

The Issuer Company is not issuing any new financial instruments through this Offer.

Application by Eligible NRI's, FPI's, VCF's, AIF's registered with SEBI

It is to be understood that there is no reservation for Eligible NRIs, FPIs or VCF registered with SEBI. Such Eligible NRIs, FPIs or VCF registered with SEBI will be treated on the same basis with other categories for the purpose of Allocation.

Restrictions, if any on Transfer and Transmission of Equity Shares

Except for the lock-in of the pre-Issue capital of our Company, Promoters' minimum contribution as provided in "*Capital Structure*" on page 43, and except as provided in the Articles of Association there are no restrictions on transfer of Equity Shares. Further, there are no restrictions on the transmission of shares/debentures and on their consolidation/splitting, except as provided in the Articles of Association. For details, please refer "*Main Provisions of Articles of Association*" on page 199.

ISSUE STRUCTURE

This Offer is being made in terms of Regulation 229(2) of Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time, whereby, an issuer whose post issue face value capital does not exceed more than ten crores rupees, shall issue shares to the public and propose to list the same on the Small and Medium Enterprise Exchange ("SME Exchange", in this case being the SME Platform of BSE Limited). For further details regarding the salient features and terms of such an issue please refer "*Terms of the Issue*" and "*Issue Procedure*" on page 169 and 174, respectively.

Following is the Issue structure:

INITIAL PUBLIC OFFERING OF UP TO 6,02,400 EQUITY SHARES OF ₹10 EACH ("EQUITY SHARES") OF CLINITECH LABORATORY LIMITED ("CLINITECH" OR THE "COMPANY") FOR CASH AT A PRICE OF ₹ 96 PER EQUITY SHARE (THE "OFFER PRICE"), AGGREGATING TO ₹ 578.30 LAKHS ("THE OFFER"). OF THE OFFER, 31,200 EQUITY SHARES AGGREGATING TO ₹29.95 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION I.E. OFFER OF 5,71,200 EQUITY SHARES OF FACE VALUE OF ₹ 10.00 EACH AT AN OFFER PRICE OF ₹ 96.00 PER EQUITY SHARE AGGREGATING TO ₹548.35 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET OFFER".

Particulars	Net Issue to Public [^]	Market Maker reservation portion
Number of Equity Shares	5,71,200 Equity Shares	31,200 Equity Shares
Percentage of Issue Size available for allocation	94.82% of the Issue Size (50% for the Retail Individual Investors and the balance 50% for Other than Retail Individual Investors).	5.18% of the Issue Size
Basis of Allotment/Allocation if respective category is oversubscribed	Proportionate subject to minimum allotment of 1,200 Equity Shares and Further allotment in multiples of 1,200 Equity Shares each. For further details please refer to the section titled " <i>Issue Procedure</i> " on page 178.	Firm Allotment
Mode of Application*	All the applicants shall make the application (Online or Physical) through the ASBA Process only (including UPI mechanism for UPI Applicants using Syndicate ASBA).	
Minimum Application Size	<u>For QIB and NII:</u> Such number of Equity Shares in multiples of 1,200 Equity Shares at an Issue price of ₹ 96 each such that the Application Value exceeds ₹2,00,000 <u>For Retail Individuals:</u> 1,200 Equity Shares at an Issue price of ₹ 96 each.	31,200 Equity Shares at an Issue price of ₹ 96 each.
Maximum Application	<u>For QIB and NII:</u> The maximum application size is the Net Issue to public i.e. 5,71,200 Equity Shares, subject to limits the investor has to adhere under the relevant laws and regulations as applicable. <u>For Retail Individuals:</u>	31,200 Equity Shares at an Issue price of ₹ 96 each.

Particulars	Net Issue to Public [^]	Market Maker reservation portion
	1,200 Equity Shares at an Issue price of ₹ 96 each.	
Mode of Allotment	Dematerialized Form	Dematerialized Form
Trading Lot	1,200 Equity Shares	1,200 Equity Shares. However, the Market Makers may accept odd lots if any in the market as required under the SEBI (ICDR) Regulations.
Terms of payment	The entire Application Amount will be payable at the time of submission of the Application Form.	

This Offer is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. For further details please refer 'Terms of the Issue' on page 169.

*As per Regulation 253(2) of the SEBI (ICDR) Regulations, as amended, as present issue is a fixed price offer the allocation in the net offer to the public category shall be made as follows:

- d) Minimum fifty percent to retail individual investors; and
- e) Remaining to:
 - i. Other investors including corporate bodies or institutions, irrespective of the number of specified securities applied for;
- f) The unsubscribed portion in either of the categories specified in (a) or (b) above may be allocated to the applicants in the other category.

If the retail individual investor category is entitled to more than fifty per cent on proportionate basis, accordingly the retail individual investors shall be allocated that higher percentage.

** In case of joint Application, the Application Form should contain only the name of the first Applicant whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such first Applicant would be required in the Application Form and such first Applicant would be deemed to have signed on behalf of the joint holders.*

Withdrawal of the Issue

The Company in consultation with the Lead Manager, reserves the right not to proceed with the Issue at any time before the Offer Opening Date, without assigning any reason thereof. Notwithstanding the foregoing, the Issue is also subject to obtaining the following:

1. The final listing and trading approvals of BSE for listing of Equity Shares offered through this Offer on its SME Platform, which the Company shall apply for after Allotment and,
2. The final ROC approval of the Prospectus after it is filed with the ROC.

In case, the Company wishes to withdraw the Issue after Offer Opening but before allotment, the Company will give public notice giving reasons for withdrawal of Issue. The public notice will appear in two widely circulated national newspapers (One each in English and Hindi) and one in regional newspaper.

The Lead Manager, through the Registrar to the Issue, will instruct the SCSBs to unblock the ASBA Accounts within one Working Day from the day of receipt of such instruction. The notice of withdrawal will be issued in the same newspapers where the pre-Issue advertisements have appeared, and the Stock Exchange will also be informed promptly.

If our Company withdraws the Issue after the Issue Closing Date and subsequently decides to undertake a public offering of Equity Shares, our Company will file a fresh offer document with the stock exchange where the Equity Shares may be proposed to be listed.

Issue Programme

Offer Opening Date	[●], 2024
Issue Closing Date	[●], 2024

Submission of Bids:

Bid/Offer Period (except the Bid/Offer Closing Date)	
Submission and Revision in Bids	Only between 10.00 a.m. and 5.00 p.m. Indian Standard Time (“IST”)
Bid/Offer Closing Date (T day)	
Submission of Bids	<p>Electronic Applications</p> <p>i. Online ASBA through 3-in-1 accounts – Upto 5.00 p.m. IST on T day.</p> <p>ii. Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA etc – Upto 4.00 p.m. IST on T day.</p> <p>iii. Syndicate Non-Retail, Non-Individual Applications – Upto 3.00 p.m. IST on T day.</p> <p>Physical Applications</p> <p>i. Bank ASBA – Upto 1.00 p.m. IST on T day.</p> <p>ii. Syndicate Non-Retail, Non-Individual Applications of QIBs and NIIs – Upto 12.00 p.m IST on T day and Syndicate members shall transfer such applications to banks before 1 p.m. IST on T day.</p>
Revision in Bids	Only between 10.00 a.m. and 5.00 p.m. IST

On the Bid/Offer Closing Date, the Bids shall be uploaded until:

- (i) 4:00 p.m. IST for Bids by QIBs and Non-Institutional Investors; and
- (ii) until 5.00 p.m. IST or such extended time as permitted by the Stock Exchanges, in case of Bids by Retail and reserved category.

Above timelines will be applicable during the Issue Period at the Application Centres mentioned in the Application Form. Applications will be accepted only on Working days i.e. all days excluding Saturdays, Sundays, and public holidays, on which the commercial banks in the city as notified in the offer document are open for business.

On the Bid/Offer Closing Date, extension of time may be granted by the Stock Exchanges only for uploading Bids received from Retail Individual Investors and Eligible Employees Bidding in the Employee Reservation Portion after taking into account the total number of Bids received up to closure of timings for acceptance of Bid cum Application Forms as stated herein and as reported by the BRLMs to the Stock Exchanges.

The Registrar to the Offer shall submit the details of cancelled/withdrawn/deleted applications to the SCSBs on daily basis within 60 minutes of the Bid closure time from the Bid/ Offer Opening Date till the Bid/Offer Closing Date by obtaining the same from the Stock Exchanges. The SCSBs shall unblock such applications by the closing hours of the Working Day and submit the confirmation to the BRLMs and the RTA on a daily basis, as per the format prescribed in SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021.

It is clarified that Bids shall be processed only after the application monies are blocked in the ASBA Account and Bids not uploaded on the electronic bidding system or in respect of which the full Bid Amount is not blocked by SCSBs or not blocked under the UPI Mechanism in the relevant ASBA Account, as the case may be, would be rejected.

Due to limitation of time available for uploading the Bids on the Bid/Offer Closing Date, Bidders are advised to submit their Bids one day prior to the Bid/Offer Closing Date, and are advised to submit their Bids no later than prescribed time on the Bid/ Offer Closing Date. Any time mentioned in this Prospectus is IST. Bidders are cautioned that, in the event a large number of Bids are received on the Bid/Offer Closing Date, some Bids may not get uploaded due to lack of sufficient time. Such Bids that cannot be uploaded will not be considered for allocation under the Offer. Bids will be accepted only during Working Days, during the Bid/Offer Period. Investors may please note that as per letter no. List/smd/sm/2006 dated July 3, 2006 and letter no. NSE/IPO/25101- 6 dated July 6, 2006 issued by BSE and NSE respectively, Bids and any revision in Bids shall not be accepted on Saturdays, Sundays and public holidays as declared by the Stock Exchanges. Bids

by ASBA Bidders shall be uploaded by the relevant Designated Intermediary in the electronic system to be provided by the Stock Exchanges. The Designated Intermediaries shall modify select fields uploaded in the Stock Exchange Platform during the Bid/Offer Period till 5.00 pm on the Bid/Offer Closing Date after which the Stock Exchange(s) send the bid information to the Registrar to the Offer for further processing. In case of any discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical Bid cum Application Form, for a particular Bidder, the details as per the Bid file received from the Stock Exchanges shall be taken as the final data for the purpose of Allotment.

Our Company, in consultation with the Book Running Lead Managers, reserve the right to extend the Bid/Offer Period in accordance with the SEBI ICDR Regulations.

In case of any extension, the Bid/Offer Period will be extended by at least three additional Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, in consultation with the Lead Manager, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of three Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. Any extension of Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice and at the terminals of the Syndicate Member(s) and by intimation to Self-Certified Syndicate Banks (“SCSBs”), other Designated Intermediaries and the Sponsor Bank(s), as applicable.

ISSUE PROCEDURE

All Applicants should review the General Information Document for Investing in Public Issues which highlights the key rules, processes and procedures applicable to public issues in general in accordance with the provisions of the Companies Act 2013 (to the extent notified), the Companies Act, 1956 (to the extent not repealed by the Companies Act, 2013), the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957 and the SEBI ICDR Regulations as amended. The General Information Document is available on the websites of the Stock Exchanges and the Lead Manager. Please refer to the relevant provisions of the General Information Document which are applicable to the Issue. The investors should note that the details and process provided in the General Information Document should be read along with this section.

Additionally, all Applicants may refer to the General Information Document for information in relation to (i) Category of investor eligible to participate in the Issue; (ii) maximum and minimum Application size; (iii) price discovery and allocation; (iv) Payment Instructions for ASBA Applicants; (v) Issuance of CAN and Allotment in the Issue; (vi) General instructions (limited to instructions for completing the Application Form); (vii) designated date; (viii) disposal of applications; (ix) submission of Application Form; (x) other instructions (limited to joint applications in cases of individual, multiple applications and instances when an application would be rejected on technical grounds); (xi) applicable provisions of Companies Act, 2013 relating to punishment for fictitious applications; (xii) mode of making refunds; and (xiv) interest in case of delay in Allotment or refund.

Applicants should not construe the contents of this General Information Document as legal advice and should consult their own legal counsel and other advisors in relation to the legal matters concerning the Issue. For taking an investment decision, the Applicants should rely on their own examination of the Issuer and the Issue, and should carefully read the Draft Prospectus/Prospectus before investing in the Issue.

Our Company and the Lead Manager do not accept any responsibility for the completeness and accuracy of the information stated in this section, and are not liable for any amendment, modification or change in the applicable law which may occur after the date of this Draft Prospectus. Applicants are advised to make their independent investigations and ensure that their applications are submitted in accordance with applicable laws and do not exceed the investment limits or maximum number of the Equity Shares that can be held by them under applicable law or as specified in the Prospectus.

Further, our Company and the Lead Manager do not accept any responsibility for any adverse occurrences consequent to the implementation of the UPI mechanism for application in this Offer.

The lists of Banks that have been notified by SEBI as Issuer Banks for UPI are provided on <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40>. The list of Stockbroker, Depository Participants (DP), Registrar to an Issue and Share Transfer Agent (RTA) that has been notified by BSE Limited to act as intermediaries for submitting Application Forms are provided on <https://www.bseindia.com>.

SEBI through its circular no. (SEBI/HO/CFD/DIL2/CIR/P/2018/138) dated November 1, 2018 read with its circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/50 dated April 3, 2019 and circular no. (SEBI/HO/CFD/DIL2/CIR/P/2019/76) dated June 28, 2019, has introduced an alternate payment mechanism using Unified Payments Interface (—UPII) and consequent reduction in timelines for listing in a phased manner. From January 1, 2019, the UPI Mechanism for RIIs applying through Designated Intermediaries was made effective along with the existing process and existing timeline of T+6 days. (—UPI Phase II). The UPI Phase I was effective till June 30, 2019.

With effect from July 1, 2019, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, read with circular bearing number SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 with respect to Applications by RIIs through Designated Intermediaries (other than SCSBs), issued by SEBI, the existing process of physical movement of forms from such Designated Intermediaries to SCSBs for blocking of funds has been discontinued and only the UPI Mechanism for such Bids with existing timeline of T+6 days will continue for a period of three months or launch of five main board public issues, whichever is later (“UPI Phase II”). The applicability of UPI Phase II was extended from time to time. Thereafter, pursuant to SEBI circular SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 9, 2023, the final reduced timeline of T+3 days using the UPI Mechanism for applications by UPI Bidders (“UPI Phase III”) was implemented by SEBI, voluntarily for all public issues opening on or after September 1, 2023 and has been made mandatory for all public issues opening on or after December 1, 2023. Accordingly, the Offer will be made under UPI Phase III on a mandatory basis, subject to any circulars, clarification or notification issued by the SEBI from time to time. Further, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 has introduced certain additional measures for streamlining the process of initial public offers and redressing investor grievances. This circular shall come

into force for initial public offers opening on or after May 1, 2021 and the provisions of this circular are deemed to form part of this Prospectus. Furthermore, pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/45 dated April 5, 2022, all UPI applicants in initial public offerings (opening on or after May 1, 2022) whose application sizes are up to ₹5.00 lakhs shall use the UPI Mechanism.

Our Company and the Lead Manager do not accept any responsibility for the completeness and accuracy of the information stated in this section and the General Information Document, and are not liable for any amendment, modification or change in the applicable law which may occur after the date of this Draft Prospectus. Applicants are advised to make their independent investigations and ensure that their applications are submitted in accordance with applicable laws and do not exceed the investment limits or maximum number of the Equity Shares that can be held by them under applicable law or as specified in the Draft Prospectus.

Further, our Company and the Lead Manager are not liable for any adverse occurrences consequent to the implementation of the UPI Mechanism for application in the Issue.

Phased implementation of Unified Payments Interface

SEBI has issued a **UPI Circulars** in relation to streamlining the process of public issue of equity shares and convertibles. Pursuant to the UPI Circulars, UPI will be introduced in a phased manner as a payment mechanism (in addition to mechanism of blocking funds in the account maintained with SCSBs under the ASBA) for applications by RIBs through intermediaries with the objective to reduce the time duration from public issue closure to listing from six working days to up to three working days. Considering the time required for making necessary changes to the systems and to ensure complete and smooth transition to the UPI Mechanism, the UPI Circular proposes to introduce and implement the UPI Mechanism in three phases in the following manner:

Phase I: This phase has become applicable from January 1, 2019 and will continue till June 30, 2019. Under this phase, a Retail Individual Applicant would also have the option to submit the Application Form with any of the intermediary and use his / her UPI ID for the purpose of blocking of funds. The time duration from public issue closure to listing would continue to be six Working Days.

Phase II: This phase commenced on completion of Phase I i.e. with effect from July 1, 2019 and was to be continued for a period of three months or launch of five main board public issues, whichever is later. Further, as per the SEBI circular SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019, the UPI Phase II has been extended until March 31, 2020. Further still, as per SEBI circular SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020, the current Phase II of Unified Payments Interface with Application Supported by Blocked Amount be continued till further notice. Under this phase, submission of the Application Form by a Retail Individual Applicant through intermediaries to SCSBs for blocking of funds will be discontinued and will be replaced by the UPI Mechanism. However, the time duration from public issue closure to listing would continue to be six Working Days during this phase.

Phase III: This phase has become applicable on a voluntary basis for all issues opening on or after September 1, 2023 and on a mandatory basis for all issues opening on or after December 1, 2023, vide SEBI circular bearing number SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 9, 2023 ("T+3 Notification"). In this phase, the time duration from public issue closure to listing has been reduced to three Working Days. The Offer shall be undertaken pursuant to the processes and procedures as notified in the T+3 Notification as applicable, subject to any circulars, clarification or notification issued by the SEBI from time to time, including any circular, clarification or notification which may be issued by SEBI.

The Offer is being made under Phase III of the UPI (on a mandatory basis).

All SCSBs offering facility of making application in public issues shall also provide facility to make application using the UPI Mechanism. The Issuers are to appoint one of the SCSBs as a sponsor bank to act as a conduit between the Stock Exchanges and NPCI in order to facilitate collection of requests and / or payment instructions of the Retail Individual Applicants into the UPI mechanism.

SEBI through its circular (SEBI/HO/CFD/DIL2/CIR/P/2022/45) dated April 5, 2022, has prescribed that all individual investors applying in initial public offerings opening on or after May 1, 2022, where the application amount is up to ₹ 500,000, shall use UPI. Individual investors bidding under the Non-Institutional Portion bidding for more than ₹ 200,000 and up to ₹ 500,000, using the UPI Mechanism, shall provide their UPI ID in the Bid-cum-Application Form for Bidding

through Syndicate, sub-syndicate members, Registered Brokers, RTAs or CDPs, or online using the facility of linked online trading, demat and bank account (3 in 1 type accounts), provided by certain brokers.

For further details, refer to the General Information Document available on the websites of the Stock Exchanges and the Lead Manager.

FIXED PRICE ISSUE PROCEDURE

The Issue is being made in compliance with the provisions of Chapter IX of the SEBI (ICDR) Regulations, 2018 and through the Fixed Price Process. As per Regulation 253(2) of the SEBI (ICDR) Regulations, as amended, as present issue is a fixed price issue the allocation in the net offer to the public category shall be made as follows:

- g) Minimum fifty percent to retail individual investors; and
- h) Remaining to:
 - i. Other investors including corporate bodies or institutions, irrespective of the number of specified securities applied for;
- i) The unsubscribed portion in either of the categories specified in (a) or (b) above may be allocated to the applicants in the other category.

If the retail individual investor category is entitled to more than fifty per cent on proportionate basis, accordingly the retail individual investors shall be allocated that higher percentage.

Applicants are required to submit their Applications to the Application collecting intermediaries i.e. SCSB or Registered Brokers of Stock Exchanges or Registered Registrar to the Issue and Share Transfer Agents (RTAs) or Depository Participants (DPs) registered with SEBI. In case of QIB Applicants, the Company in consultation with the Lead Manager may reject Applications at the time of acceptance of Application Form provided that the reasons for such rejection shall be provided to such Applicant in writing.

Subject to the valid Applications being received at or above the Issue Price, allocation to all categories in the Net Issue, shall be made on a proportionate basis, except for the Retail Portion where Allotment to each Retail Individual Applicants shall not be less than the minimum lot, subject to availability of Equity Shares in Retail Portion, and the remaining available Equity Shares, if any, shall be allotted on a proportionate basis. Under subscription, if any, in any category, would be allowed to be met with spillover from any other category or a combination of categories at the discretion of our Company in consultation with the Lead Manager and the Stock Exchange.

Investors should note that according to section 29(1) of the Companies Act, 2013, allotment of Equity Shares to all successful Applicants will only be in the dematerialised form. The Application Forms which do not have the details of the Applicant’s depository account including DP ID, PAN, UPI ID (in case of RIBs using the UPI mechanism) and Beneficiary Account Number shall be treated as incomplete and rejected. In case DP ID, Client ID and PAN mentioned in the Application Form and entered into the electronic system of the stock exchange, do not match with the DP ID, Client ID and PAN available in the depository database, the application is liable to be rejected. Applicants will not have the option of getting allotment of the Equity Shares in physical form. The Equity Shares on allotment shall be traded only in the dematerialized segment of the Stock Exchange.

APPLICATION FORM

Copies of the Application Form and the abridged prospectus will be available at the offices of the Lead Manager, the Designated Intermediaries, and Registered Office of our Company. An electronic copy of the Application Form will also be available for download on the websites of the BSE (www.bseindia.com), the SCSBs, the Registered Brokers, the RTAs and the CDPs at least one day prior to the Offer Opening Date.

ASBA Applicants shall ensure that the Applications are made on Application Forms bearing the stamp of the Designated Intermediary, submitted at the Collection Centres only (except in case of electronic Application Forms) and the Application Forms not bearing such specified stamp are liable to be rejected. Retail Individual Investors using UPI mechanism, may submit their ASBA Forms with Syndicate Members, Registered Brokers, RTA or Depository Participants. ASBA Applicants are also required to ensure that the ASBA Account has sufficient credit balance as an amount equivalent to the full Application Amount which can be blocked by the SCSB.

Category	Colour ⁽¹⁾
Indian Public / eligible NRI’s applying on a non-repatriation basis (ASBA)	White

Non-Residents including eligible NRI's, FPI's, FII's, FVCI's, etc. applying on a repatriation basis (ASBA)	Blue
--	------

(1) Excluding electronic Application Form.

RIIs and other Individual investors using UPI mechanism, may submit their ASBA Forms with Syndicate Members, Registered Brokers, RTA or Depository Participants. ASBA Applicants are also required to ensure that the ASBA Account has sufficient credit balance as an amount equivalent to the full Application Amount which can be blocked by the SCSB.

Further, for applications submitted to designated intermediaries (other than SCSBs), with use of UPI for payment, after accepting the application form, respective intermediary shall capture and upload the relevant application details, including UPI ID, in the electronic bidding system of stock exchange(s).

Applicants shall only use the specified Application Form for the purpose of making an Application in terms of this Draft Prospectus. An Investor, intending to subscribe to this Offer, shall submit a completed application form to any of the following Intermediaries (Collectively called "Designated Intermediaries")

Sr. No.	Designated Intermediaries
1.	An SCSB, with whom the bank account to be blocked, is maintained.
2.	A syndicate member (or sub-syndicate member)
3.	A stock broker registered with a recognized stock exchange (and whose name is mentioned on the website of the stock exchange as eligible for this activity)(‘broker’)
4.	A depository participant (‘DP’)(whose name is mentioned on the website of the Stock Exchange as eligible for this activity)
5.	A registrar to an issue and share transfer agent (“RTA”)(whose name is mentioned on the website of the stock exchange as eligible for this activity)

Retails investors and other Individual Inventors submitting application with any of the entities at (ii) to (v) above (hereinafter referred as ‘Intermediaries’), and intending to use UPI, shall also enter their UPI ID in the application form.

The aforesaid intermediaries shall, at the time of receipt of application, give an acknowledgement to investor, by giving the counter foil or specifying the application number to the investor, as proof of having accepted the application form, in physical form or electronic mode respectively.

The upload of the details in the electronic bidding system of the stock exchange will be done by:

For the applications submitted by the investors to SCSB	After accepting the form, SCSB shall capture and upload the relevant details in the electronic bidding system as specified by the stock exchange and may begin blocking funds available in the Bank account specified in the form, to the extent of the application money specified.
For applications submitted by investors to intermediaries other than SCSBs without use of UPI for payment	After accepting the application form, respective Intermediary shall capture and upload the relevant details in the electronic bidding system of the stock exchange. Post uploading, they shall forward a schedule as per prescribed format along with the application forms to designated branches of the respective SCSBs for blocking of funds within one day of closure of the Issue.
For applications submitted by investors to intermediaries other than SCSBs with use of UPI for payment	<p>After accepting the application form, respective intermediary shall capture and upload the relevant application details, including UPI ID, in the electronic bidding system of stock exchange(s).</p> <p>Stock Exchange shall share application details including the UPI ID with Sponsor Bank on a continuous basis, to enable Sponsor Bank to initiate mandate request on investors for blocking of funds.</p> <p>Sponsor Bank shall initiate request for blocking of funds through NPCI to investor. Investor to accept mandate request for blocking of</p>

	funds, on his / her mobile application, associated with UPI ID linked bank account.
--	---

Stock exchange(s) shall validate the electronic details with depository's records for DP ID/Client ID and PAN, on a real time basis and bring the inconsistencies to the notice of intermediaries concerned, for rectification and re-submission within the time specified by stock exchange.

Stock exchange(s) shall allow modification of selected fields viz. DP ID/Client ID, Bank code and Location code, in the application details already uploaded.

For ASBA Applicants using UPI mechanism, the Stock Exchange shall share the application details (including UPI ID) with Sponsor Bank on a continuous basis to enable the Sponsor Bank to initiate UPI Mandate Request to ASBA applicants for blocking of funds. The Sponsor Bank shall initiate request for blocking of funds through NPCI to RIBs, who shall accept the UPI Mandate Request for blocking of funds on their respective mobile applications associated with UPI ID linked bank account. The NPCI shall maintain an audit trail for every bid entered in the Stock Exchanges bidding platform, and the liability to compensate ASBA applicants (using the UPI Mechanism) in case of failed transactions shall be with the concerned entity (i.e. the Sponsor Bank, NPCI or the Bankers to the Issue) at whose end the lifecycle of the transaction has come to a halt. The NPCI shall share the audit trail of all disputed transactions/ investor complaints to the Sponsor Banks and the Bankers to the Issue. The Lead Manager shall also be required to obtain the audit trail from the Sponsor Banks and the Bankers to the Issue for analysing the same and fixing liability. For ensuring timely information to investors, SCSBs shall send SMS alerts for mandate block and unblock including details specified in SEBI *circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M* dated March 16, 2021.

Who Can Apply?

1. Indian nationals' resident in India, who are not minors (except through their Legal Guardians), in single or joint names (not more than three);
2. Hindu Undivided Families or HUFs, in the individual name of the Karta. The Applicant should specify that the Application is being made in the name of the HUF in the Application Form as follows: —Name of Sole or First Applicant: XYZ Hindu Undivided Family applying through XYZ, where XYZ is the name of the Karta. Applications by HUFs would be considered at par with those from individuals;
3. Companies, Corporate Bodies and Societies registered under the applicable laws in India and authorized to invest in equity shares;
4. Mutual Funds registered with SEBI;
5. Eligible NRIs on a repatriation basis or on a non-repatriation basis subject to applicable laws. NRIs other than Eligible NRIs are not eligible to participate in this Offer;
6. Indian financial institutions, scheduled commercial banks (excluding foreign banks), regional rural banks, cooperative banks (subject to RBI regulations and the SEBI Regulations and other laws, as applicable);
7. FIIs and sub-accounts registered with SEBI, other than a sub-account which is a foreign corporate or foreign individual under the QIB portion;
8. Sub-accounts of FIIs registered with SEBI, which are foreign corporate or foreign individuals only under the Non-Institutional Applications portion;
9. Venture Capital Funds registered with SEBI;
10. Foreign Venture Capital Investors registered with SEBI;
11. Eligible Qualified Foreign Investors;
12. Foreign Nationals and other non-residents (subject to eligibility norms specified in SEBI FPI Regulations, 2014 and other applicable provisions);

13. Multilateral and bilateral development financial institutions;
14. State Industrial Development Corporations;
15. Trusts/societies registered under the Societies Registration Act, 1860, as amended, or under any other law relating to trusts/societies and who are authorized under their respective constitutions to hold and invest in equity shares;
16. Scientific and/or industrial research organizations authorized in India to invest in equity shares;
17. Insurance companies registered with Insurance Regulatory and Development Authority;
18. Provident Funds with a minimum corpus of ₹250 million and who are authorised under their constitution to hold and invest in equity shares;
19. Pension Funds with a minimum corpus of ₹250 million and who are authorised under their constitution to hold and invest in equity shares;
20. Limited liability partnerships;
21. National Investment Fund set up by resolution no. F.NO.2/3/2005-DDII dated November 23, 2005 of the Government of India, published in the Gazette of India;
22. Nominated Investor and Market Maker;
23. Insurance funds set up and managed by the army, navy, or air force of the Union of India and by the Department of Posts, India;
24. Any other person eligible to Apply in this Offer, under the laws, rules, regulations, guidelines, and policies applicable to them and under Indian laws.
25. As per the existing policy of the Government of India, OCBs cannot participate in this Offer. Applicants are advised to ensure that any single Application from them does not exceed the investment limits or maximum number of Equity Shares that can be held by them under applicable law.
26. Applications not to be made by:
 1. Minors (except through their Guardians)
 2. Partnership firms or their nominations
 3. Overseas Corporate Bodies

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Maximum and Minimum Application Size

a) For Retail Individual Applicants:

The Application must be for a minimum of 1,200 Equity Shares and in multiples of 1,200 Equity Shares thereafter, so as to ensure that the Application Amount payable by the Applicant does not exceed ₹2,00,000. In case of revision of the Application, the Retail Individual Applicants have to ensure that the Application Amount does not exceed ₹2,00,000.

b) For Other Applicants [Non-Institutional Applicants and Qualified Institutional Buyer(s) (QIB)]:

The Application must be for a minimum of such number of Equity Shares such that the Application Amount exceeds ₹2,00,000 and in multiples of 1,200 Equity Shares thereafter. Application cannot be submitted for more than the Issue Size. However, the maximum application size by a QIB investor should not exceed the investment limits prescribed for them by applicable laws. **A QIB and a Non-Institutional Applicant cannot withdraw or lower the size of their**

Application at any stage and are required to pay the entire Application Amount upon submission of the Application. Under the existing SEBI regulations, a QIB Applicant cannot withdraw its Application after the Issue Closing Date and is required to pay 100% QIB Margin upon submission of Application.

The identity of QIBs applying in the Net Issue shall not be made public during the Issue Period. In case of revision in Application, the Non-Institutional Applicants, who are individuals, have to ensure that the Application Amount is greater than ₹ 2,00,000 for being considered for allocation in the Non-Institutional Portion.

The above Information is given for the benefits of the Applicants. Our Company and the Lead Manager do not accept any responsibility for the completeness and accuracy of the information stated in this section. Applicants are advised to make their independent investigations and ensure that their Applications do not exceed the investment limits or maximum number of Equity Shares that can be held by them under applicable law or as specified in this Draft Prospectus.

Participation by associates and affiliates of the Lead Manager and the Syndicate Members

The Lead Manager shall not be allowed to subscribe to this Offer in any manner except towards fulfilling their underwriting obligations. However, the associates and affiliates of the Lead Manager may subscribe to Equity Shares in the Issue in non Retail Portion, where the allocation is on a proportionate basis and such subscription may be on their own account or on the behalf of their clients.

Option to subscribe in the Issue

- a) As per Section 29(1) of the Companies Act, 2013, allotment of Equity Shares shall be dematerialized form only. Investors will not have the option of getting of specified securities in physical form. However, they may get the specified securities re-materialized subsequent to allotment.
- b) The Equity Shares, on allotment, shall be traded on the Stock Exchange in demat segment only.
- c) A single application from any investor shall not exceed the investment limit/minimum number of Equity Shares that can be held by him/her/it under the relevant regulations/statutory guidelines and applicable laws.

Applications by Mutual Funds

With respect to Applications by Mutual Funds, a certified copy of their SEBI registration certificate must be lodged along with the Application Form. Failing this, our Company reserves the right to reject the Application without assigning any reason thereof.

Applications made by asset management companies or custodians of Mutual Funds shall specifically state names of the concerned schemes for which such Applications are made.

In case of a Mutual Fund, a separate Application can be made in respect of each scheme of the Mutual Fund registered with SEBI and such Applications in respect of more than one scheme of the Mutual Fund will not be treated as multiple Applications provided that the Applications clearly indicate the scheme concerned for which the Application has been made.

No Mutual Fund scheme shall invest more than 10% of its net asset value in equity shares or equity related instruments of any single company provided that the limit of 10% shall not be applicable for investments in case of index funds or sector or industry specific schemes. No Mutual Fund under all its schemes should own more than 10% of any company's paid-up share capital carrying voting rights.

Applications by Eligible NRIs

Eligible NRIs may obtain copies of Application Form from the Designated Intermediaries. Eligible NRI Applicants applying on a repatriation basis by using the Non-Resident Forms should authorize their SCSB to block their Non-Resident External (NRE) accounts, or Foreign Currency Non-Resident (FCNR) Accounts, and eligible NRI Applicants applying on a non-repatriation basis by using Resident Forms should authorize their SCSB to block their Non-Resident Ordinary (NRO) accounts for the full application amount, at the time of the submission of the Application Form.

Eligible NRIs applying on non-repatriation basis are advised to use the Application Form for residents (white in colour). Eligible NRIs applying on a repatriation basis are advised to use the Application Form meant for Non-Residents (blue in colour).

Application by FPIs (including FIIs)

In terms of the SEBI FPI Regulations, an FII who holds a valid certificate of registration from SEBI shall be deemed to be a registered FPI until the expiry of the block of three years for which fees have been paid as per the SEBI FII Regulations. An FII or sub-account may, subject to payment of conversion fees under the SEBI FPI Regulations participate in the Issue until the expiry of its registration with SEBI as an FII or sub-account, or if it has obtained a certificate of registration as an FPI, whichever is earlier. Accordingly, such FIIs can, subject to the payment of conversion fees under the SEBI FPI Regulations, participate in this Offer in accordance with Schedule 2 of the FEMA Regulations. An FII shall not be eligible to invest as an FII after registering as an FPI under the SEBI FPI Regulations.

In terms of the SEBI FPI Regulations, the purchase of Equity Shares and total holding by a single FPI or an investor group (which means the same set of ultimate beneficial owner(s) investing through multiple entities) must be below 10% of our post-issue Equity Share capital. Further, in terms of the FEMA Regulations, the total holding by each FPI shall be below 10% of the total paid-up Equity Share capital of our Company and the total holdings of all FPIs put together shall not exceed 24% of the paid-up Equity Share capital of our Company. The aggregate limit of 24% may be increased up to the sectoral cap by way of a resolution passed by the Board of Directors followed by a special resolution passed by the Shareholders of our Company and subject to prior intimation to RBI. In terms of the FEMA Regulations, for calculating the aggregate holding of FPIs in a company, holding of all registered FPIs as well as holding of FIIs (being deemed FPIs) shall be included.

FPIs are permitted to participate in the Issue subject to compliance with conditions and restrictions which may be specified by the Government from time to time.

Subject to compliance with all applicable Indian laws, rules, regulations, guidelines and approvals in terms of Regulation 22 of the SEBI FPI Regulations, an FPI, other than Category III foreign portfolio investor and unregulated broad based funds, which are classified as Category II foreign portfolio investor by virtue of their investment manager being appropriately regulated, may issue, subscribe to or otherwise deal in offshore derivative instruments (as defined under the SEBI FPI Regulations as any instrument, by whatever name called, which is issued overseas by a FPI against securities held by it that are listed or proposed to be listed on any recognised stock exchange in India, as its underlying) directly or indirectly, only in the event (i) such offshore derivative instruments are issued only to persons who are regulated by an appropriate regulatory authority; and (ii) such offshore derivative instruments are issued after compliance with 'know your client' norms. Further, pursuant to a Circular dated November 24, 2014 issued by the SEBI, FPIs are permitted to issue offshore derivative instruments only to subscribers that (i) meet the eligibility criteria set forth in Regulation 4 of the SEBI FPI Regulations; and (ii) do not have opaque structures, as defined under the SEBI FPI Regulations. An FPI is also required to ensure that no further issue or transfer of any offshore derivative instrument is made by or on behalf of it to any persons that are not regulated by an appropriate foreign regulatory authority. Further, where an investor has investments as FPI and also holds positions as an overseas direct investment subscriber, investment restrictions under the SEBI FPI Regulations shall apply on the aggregate of FPI investments and overseas direct investment positions held in the underlying Indian company.

Applications by SEBI registered Venture Capital Funds, Alternative Investment Fund (AIF) and Foreign Venture Capital Investors

The Securities and Exchange Board of India (Venture Capital Funds) Regulations, 1996 as amended, (the “**SEBI VCF Regulations**”) and the Securities and Exchange Board of India (Foreign Venture Capital Investor) Regulations, 2000, as amended, among other things prescribe the investment restrictions on VCFs and FVCIs registered with SEBI. Further, the Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012 (the “**SEBI AIF Regulations**”) prescribe, amongst others, the investment restrictions on AIFs.

The holding by any individual VCF registered with SEBI in one venture capital undertaking should not exceed 25% of the corpus of the VCF. Further, VCFs and FVCIs can invest only up to 33.33% of the investible funds by way of subscription to an initial public offering.

The category I and II AIFs cannot invest more than 25% of the corpus in one Investee Company. A category III AIF cannot invest more than 10% of the corpus in one Investee Company. A venture capital fund registered as a category I AIF, as defined in the SEBI AIF Regulations, cannot invest more than 1/3rd of its corpus by way of subscription to an initial public offering of a venture capital undertaking. Additionally, the VCFs which have not re-registered as an AIF under the SEBI AIF Regulations shall continue to be regulated by the VCF Regulation until the existing fund or scheme managed by the fund is wound up and such funds shall not launch any new scheme after the notification of the SEBI AIF Regulations.

All FIIs and FVCIs should note that refunds, dividends, and other distributions, if any, will be payable in Indian Rupees only and net of Bank charges and commission.

Our Company or the Lead Manager will not be responsible for loss, if any, incurred by the Applicant on account of conversion of foreign currency.

There is no reservation for Eligible NRIs, FPIs and FVCIs and all Applicants will be treated on the same basis with other categories for the purpose of allocation.

Applications by Limited Liability Partnerships

In case of Applications made by limited liability partnerships registered under the Limited Liability Partnership Act, 2008, a certified copy of certificate of registration issued under the Limited Liability Partnership Act, 2008, must be attached to the Application Form. Failing this, our Company reserves the right to reject any Application without assigning any reason thereof. Limited Liability Partnerships can participate in the Issue only through the ASBA Process.

Applications by Insurance Companies

In case of Applications made by insurance companies registered with the IRDA, a certified copy of certificate of registration issued by IRDA must be attached to the Application Form. Failing this, our Company reserves the right to reject any Application without assigning any reason thereof. The exposure norms for insurers, prescribed under the Insurance Regulatory and Development Authority (Investment) Regulations, 2000 (“**IRDA Investment Regulations**”), as amended, as amended, are broadly set forth below:

- 1) Equity shares of a company: the least of 10.00% of the investee company’s subscribed capital (face value) or 10.00% of the respective fund in case of life insurer or 10.00% of investment assets in case of general insurer or reinsurer;
- 2) The entire group of the investee company: not more than 15% of the respective fund in case of a life insurer or 15% of investment assets in case of a general insurer or reinsurer or 15% of the investment assets in all companies belonging to the group, whichever is lower; and
- 3) The industry sector in which the investee company belongs to not more than 15% of the fund of a life insurer or a general insurer or a reinsurer or 15% of the investment asset, whichever is lower.

The maximum exposure limit, in the case of an investment in equity shares, cannot exceed the lower of an amount of 10% of the investment assets of a life insurer or general insurer and the amount calculated under (a), (b) and (c) above, as the case may be. Insurance companies participating in this Offer shall comply with all applicable regulations, guidelines and circulars issued by IRDAI from time to time.

Applications under Power of Attorney

In case of applications made pursuant to a power of attorney by limited companies, corporate bodies, registered societies, Mutual Funds, insurance companies and provident funds with minimum corpus of ₹25 Crores (subject to applicable law) and pension funds with a minimum corpus of ₹25 Crores a certified copy of the power of attorney or the relevant resolution or authority, as the case may be, along with a certified copy of the memorandum of association and articles of association and/or bye laws must be lodged with the Application Form. Failing this, our Company reserves the right to accept or reject any application in whole or in part, in either case, without assigning any reason, therefore.

In addition to the above, certain additional documents are required to be submitted by the following entities:

- (a). With respect to applications by Mutual Funds, a certified copy of their SEBI registration certificate must be lodged along with the Application Form. Failing this, our Company reserves the right to accept or reject any application, in whole or in part, in either case without assigning any reasons thereof.

- (b). With respect to applications by insurance companies registered with the Insurance Regulatory and Development Authority, in addition to the above, a certified copy of the certificate of registration issued by the Insurance Regulatory and Development Authority must be lodged with the Application Form as applicable. Failing this, our Company reserves the right to accept or reject any application, in whole or in part, in either case without assigning any reasons thereof.
- (c). With respect to applications made by provident funds with minimum corpus of ₹25 Crores (subject to applicable law) and pension funds with a minimum corpus of ₹25 Crores, a certified copy of a certificate from a chartered accountant certifying the corpus of the provident fund/pension fund must be lodged along with the Application Form. Failing this, our Company reserves the right to accept or reject such application, in whole or in part, in either case without assigning any reasons thereof.

Our Company in its absolute discretion, reserves the right to relax the above condition of simultaneous lodging of the power of attorney along with the Application Form, subject to such terms and conditions that our Company, the lead manager may deem fit.

Our Company, in its absolute discretion, reserves the right to permit the holder of the power of attorney to request the Registrar to the Issue that, for the purpose of printing particulars and mailing of the Allotment Advice / CANs / letters notifying the unblocking of the bank accounts of ASBA applicants, the Demographic Details given on the Application Form should be used (and not those obtained from the Depository of the application). In such cases, the Registrar to the Issue shall use Demographic Details as given on the Application Form instead of those obtained from the Depositories.

The above information is given for the benefit of the Applicants. The Company and the Lead Manager are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of the Draft Prospectus. Applicants are advised to make their independent investigations and ensure that the number of Equity Shares applied for do not exceed the applicable limits under laws or regulations.

Applications by Provident Funds / Pension Funds

In case of Applications made by provident funds with minimum corpus of ₹25 crores (subject to applicable law) and pension funds with minimum corpus of ₹ 25 crores, a certified copy of certificate from a chartered accountant certifying the corpus of the provident fund/ pension fund must be lodged along with the Application Form. Failing this, our Company reserves the right to accept or reject any Application in whole or in part, in either case, without assigning any reason thereof.

Applications by Banking companies

In case of Applications made by banking companies registered with RBI, certified copies of:

- (i) The certificate of registration issued by RBI, and
- (ii) The approval of such banking company's investment committee are required to be attached to the Application Form, failing which our Company reserves the right to reject any Application without assigning any reason, therefore.

The investment limit for banking companies in non-financial services companies as per the Banking Regulation Act, 1949 (the “**Banking Regulation Act**”), and Master Circular – Para-banking Activities dated July 1, 2015 is 10% of the paid-up share capital of the investee company or 10% of the banks' own paid-up share capital and reserves, whichever is less. Further, the investment in a non-financial services company by a banking company together with its subsidiaries, associates, joint ventures, entities directly or indirectly controlled by the bank and mutual funds managed by asset management companies controlled by the banking company cannot exceed 20% of the investee company's paid-up share capital. A banking company may hold up to 30% of the paid-up share capital of the investee company with the prior approval of the RBI provided that the investee company is engaged in non-financial activities in which banking companies are permitted to engage under the Banking Regulation Act.

Applications by Self Certified Syndicate Banks (SCSBs)

SCSBs participating in the Issue are required to comply with the terms of the SEBI circulars dated September 13, 2012 and January 2, 2013. Such SCSBs are required to ensure that for making applications on their own account using ASBA, they should have a separate account in their own name with any other SEBI registered SCSBs. Further, such account shall be used solely for the purpose of making application in public issues and clear demarcated funds should be available in such

account for ASBA applications.

Information for the Applicants

1. Our Company and the Lead Manager shall declare the Offer Opening Date and Issue Closing Date in the Prospectus to be registered with the RoC and also publish the same in two national newspapers (one each in English and Hindi) and in a regional newspaper with wide circulation. This advertisement shall be in prescribed format.
2. Our Company will file the Prospectus with the RoC at least 3 (three) days before the Offer Opening Date.
3. Copies of the Application Form along with Abridged Prospectus and copies of the Prospectus will be available with the Lead Manager, the Registrar to the Issue, and at the Registered Office of our Company. Electronic Application Forms will also be available on the websites of the Stock Exchange.
4. Any applicant who would like to obtain the Prospectus and/ or the Application Form can obtain the same from our Registered Office.
5. Applicants who are interested in subscribing for the Equity Shares should approach Designated Intermediaries to register their applications.
6. Application Forms submitted directly to the SCSBs should bear the stamp of the SCSBs and/or the Designated Branch, or the respective Designated Intermediaries. Application Form submitted by Applicants whose beneficiary account is inactive shall be rejected. The Application Form can be submitted either in physical or electronic mode, to the SCSBs with whom the ASBA Account is maintained, or other Designated Intermediaries (Other than SCSBs). SCSBs may provide the electronic mode of collecting either through an internet enabled collecting and banking facility or such other secured, electronically enabled mechanism for applying and blocking funds in the ASBA Account or alternatively, the Retail Individual Applicants wishing to apply through UPI Channel, may provide the UPI ID and validate the blocking of the funds and the Application Forms that do not contain such details are liable to be rejected.
7. Applicants applying directly through the SCSBs should ensure that the Application Form is submitted to a Designated Branch of SCSB, where the ASBA Account is maintained. Applications submitted directly to the SCSBs or other Designated Intermediaries (Other than SCSBs) , the relevant SCSB , shall block an amount in the ASBA Account equal to the Application Amount specified in the Application Form, before entering the ASBA application into the electronic system.
8. Except for applications by or on behalf of the Central or State Government and the Officials appointed by the courts and by investors residing in the State of Sikkim, the Applicants, or in the case of application in joint names, the first Applicant (the first name under which the beneficiary account is held), should mention his/her PAN allotted under the Income Tax Act. In accordance with the SEBI Regulations, the PAN would be the sole identification number for participating transacting in the securities market, irrespective of the amount of transaction. Any Application Form without PAN is liable to be rejected. The demat accounts of Applicants for whom PAN details have not been verified, excluding persons resident in the State of Sikkim or persons who may be exempted from specifying their PAN for transacting in the securities market, shall be “suspended for credit” and no credit of Equity Shares pursuant to the Issue will be made into the accounts of such Applicants.
9. The Applicants may note that in case the PAN, the DP ID and Client ID mentioned in the Application Form and entered into the electronic collecting system of the Stock Exchange. Designated Intermediaries do not match with PAN, the DP ID, and Client ID available in the Depository database, the Application Form is liable to be rejected.

ISSUE PROCEDURE FOR APPLICATION SUPPORTED BY BLOCKED ACCOUNT (ASBA) APPLICANTS

In accordance with the SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 all the Applicants have to compulsorily apply through the ASBA Process. Our Company and the Lead Manager are not liable for any amendments, modifications, or changes in applicable laws or regulations, which may occur after the date of this Draft Prospectus. ASBA Applicants are advised to make their independent investigations and to ensure that the ASBA Application Form is correctly filled up, as described in this section.

The lists of banks that have been notified by SEBI to act as SCSB (Self Certified Syndicate Banks) for the ASBA Process are provided on <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes>. For details on designated branches of SCSB collecting the Application Form, please refer the above-mentioned SEBI link.

Method and Process of Applications

1. Applicants are required to submit their applications during the Issue Period only through the Designated Intermediaries.
2. The Issue Period shall be for a minimum of three (3) Working Days and shall not exceed ten (10) Working Days. The Issue Period may be extended, if required, by an additional three Working Days, subject to the total Issue Period not exceeding ten (10) Working Days.
3. During the Issue Period, Applicants who are interested in subscribing to the Equity Shares should approach the Designated Intermediaries to register their applications.
4. The Applicant cannot apply on another Application Form after applications on one Application Form have been submitted to the Designated Intermediaries. Submission of a second Application form to either the same or to another Designated Intermediaries will be treated as multiple applications and is liable to be rejected either before entering the application into the electronic collecting system or at any point prior to the allocation or Allotment of Equity Shares in this Offer.
5. The Designated Intermediaries shall, at the time of receipt of application, give an acknowledgement to investor, by giving the counter foil or specifying the application number to the investor, as a proof of having accepted the application form, in physical or electronic mode, respectively. The upload of the details in the electronic bidding system of stock exchange and post that blocking of funds will be done by as given below:

For the applications submitted by the investors to SCSB	After accepting the form, SCSB shall capture and upload the relevant details in the electronic bidding system as specified by the stock exchange and may begin blocking funds available in the Bank account specified in the form, to the extent of the application money specified.
For applications submitted by investors to intermediaries other than SCSBs without use of UPI for payment	After accepting the application form, respective Intermediary shall capture and upload the relevant details in the electronic bidding system of the stock exchange. Post uploading, they shall forward a schedule as per prescribed format along with the application forms to designated branches of the respective SCSBs for blocking of funds within one day of closure of the Issue.

6. Upon receipt of the Application Form, submitted whether in physical or electronic mode, the Designated Intermediaries shall verify if sufficient funds equal to the Application Amount are available in the ASBA Account, as mentioned in the Application Form, prior to uploading such applications with the Stock Exchange.
7. If sufficient funds are not available in the ASBA Account, the Designated Intermediaries shall reject such applications and shall not upload such applications with the Stock Exchange.
8. If sufficient funds are available in the ASBA Account, the SCSB shall block an amount equivalent to the Application Amount mentioned in the Application Form and will enter each application option into the electronic collecting system as a separate application and generate a TRS for each price and demand option. The TRS shall be furnished to the Applicant on request.
9. The Application Amount shall remain blocked in the aforesaid ASBA Account until finalization of the Basis of Allotment and consequent transfer of the Application Amount against the Allotted Equity Shares to the Public Issue Account, or until withdrawal/ failure of the Issue or until withdrawal/ rejection of the Application Form, as the case may be. Once the Basis of Allotment is finalized, the Registrar to the Issue shall send an appropriate request to the Controlling Branch of the SCSB for unblocking the relevant ASBA Accounts and for transferring the amount allocable to the successful Applicants to the Public Issue Account. In case of withdrawal/ failure of the Issue, the blocked amount shall be unblocked on receipt of such information from the Registrar to the Issue.

Terms of payment

The entire Issue price of ₹ 96 per share is payable on application. In case of allotment of lesser number of Equity Shares than the number applied, the Registrar shall instruct the SCSBs or Sponsor Bank to unblock the excess amount paid on Application to the Applicants.

SCSBs or Sponsor Bank will transfer the amount as per the instruction of the Registrar to the Public Issue Account, the balance amount after transfer will be unblocked by the SCSBs or Sponsor Bank.

The applicants should note that the arrangement with Banker to the Issue or the Registrar or Sponsor Bank is not prescribed by SEBI and has been established as an arrangement between our Company, Banker to the Issue and the Registrar to the Issue to facilitate collections from the Applicants.

Payment mechanism for Applicants

The applicants shall specify the bank account number in their Application Form and the SCSBs shall block an amount equivalent to the Application Amount in the bank account specified in the Application Form sent by the Sponsor Bank. The SCSB or Sponsor Bank shall keep the Application Amount in the relevant bank account blocked until withdrawal/rejection of the Application or receipt of instructions from the Registrar to unblock the Application Amount. However Non-Retail Applicants shall neither withdraw nor lower the size of their applications at any stage. In the event of withdrawal or rejection of the Application Form or for unsuccessful Application Forms, the Registrar to the Issue shall give instructions to the SCSBs to unblock the application money in the relevant bank account within one day of receipt of such instruction. The Application Amount shall remain blocked in the ASBA Account until finalization of the Basis of Allotment in the Issue and consequent transfer of the Application Amount to the Public Issue Account, or until withdrawal/ failure of the Issue or until rejection of the Application by the ASBA Applicant, as the case may be.

Please note that, in terms of SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, all the investors applying in a public Offer shall use only Application Supported by Blocked Amount (ASBA) process for application providing details of the bank account which will be blocked by the Self Certified Syndicate Banks (SCSBs) for the same. Further, pursuant to SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018, Retail Individual Investors applying in public offer may use either Application Supported by Blocked Amount (ASBA) facility for making application or also can use UPI as a payment mechanism with Application Supported by Blocked Amount for making application. SEBI through its circular (SEBI/HO/CFD/DIL2/CIR/P/2022/45) dated April 5, 2022, has prescribed that all individual investors applying in initial public offerings opening on or after May 1, 2022, where the application amount is up to ₹ 500,000, may use UPI.

Electronic Registration of Applications

The Designated Intermediary may register the Applications using the on-line facilities of the Stock Exchange. The Designated Intermediaries can also set up facilities for off-line electronic registration of Applications, subject to the condition that they may subsequently upload the off-line data file into the on-line facilities on a regular basis before the closure of the issue.

On the Issue Closing Date, the Designated Intermediaries may upload the applications till such time as may be permitted by the Stock Exchange.

c) Only Applications that are uploaded on the Stock Exchange Platform are considered for allocation/Allotment. In the Phase 1, the Designated Intermediaries are given till 1:00 pm on the day following the Issue Closing Date to modify select fields uploaded in the Stock Exchange Platform during the Issue Period after which the Stock Exchange send the application information to the Registrar to the Issue for further processing.

Other Instructions**Joint Applications in the case of Individuals**

Applications may be made in single or joint names (not more than three). In the case of joint Applications, all payments will be made out in favour of the Applicant whose name appears first in the Application Form or Revision Form. All

communications will be addressed to the First Applicant and will be dispatched to his or her address as per the Demographic Details received from the Depository.

Multiple Applications

An Applicant should submit only one Application (and not more than one) for the total number of Equity Shares required. Two or more Applications will be deemed to be multiple Applications if the sole or First Applicant is one and the same.

In this regard, the procedures which would be followed by the Registrar to the Issue to detect multiple applications are given below:

- i. All applications are electronically strung on first name, address (1st line) and applicant's status. Further, these applications are electronically matched for common first name and address and if matched, these are checked manually for age, signature, and father/ husband's name to determine if they are multiple applications.
- ii. Applications which do not qualify as multiple applications as per above procedure are further checked for common DP ID/ beneficiary ID. In case of applications with common DP ID/ beneficiary ID, are manually checked to eliminate possibility of data entry error to determine if they are multiple applications.
- iii. Applications which do not qualify as multiple applications as per above procedure are further checked for common PAN. All such matched applications with common PAN are manually checked to eliminate possibility of data capture error to determine if they are multiple applications.

In case of a mutual fund, a separate Application can be made in respect of each scheme of the mutual fund registered with SEBI and such Applications in respect of more than one scheme of the mutual fund will not be treated as multiple Applications provided that the Applications clearly indicate the scheme concerned for which the Application has been made.

In cases where there are more than 20 valid applications having a common address, such shares will be kept in abeyance, post allotment and released on confirmation of "know your client" norms by the depositories. The Company reserves the right to reject, in our absolute discretion, all or any multiple Applications in any or all categories.

Permanent Account Number or PAN

Pursuant to the circular MRD/DoP/Circ 05/2007 dated April 27, 2007, SEBI has mandated Permanent Account Number ("PAN") to be the sole identification number for all participants transacting in the securities market, irrespective of the amount of the transaction w.e.f. July 2, 2007. Each of the Applicants should mention his/her PAN allotted under the IT Act. **Applications without this information will be considered incomplete and are liable to be rejected.** It is to be specifically noted that Applicants should not submit the GIR number instead of the PAN, as the Application is liable to be rejected on this ground.

Allocation of Equity shares

1) The Offer is being made through the Fixed Price Process wherein 31,200 Equity Shares shall be reserved for Market Maker. 2,85,600 Equity Shares having face value of ₹10.00 each at a price of ₹ 96 per Equity Share aggregating ₹274.18 lakhs will be available for allocation to Retail Individual Investors. 2,85,600 Equity Shares having face value of ₹10.00 each at a price of ₹ 96 per Equity Share aggregating ₹274.18 lakhs will be available for allocation to other investors including corporate bodies or institutions, irrespective of the number of specified securities applied for.

2) Under-subscription if any, in any category, would be allowed to be met with spill-over from any other category or combination of categories at the discretion of our Company in consultation with the Lead Manager and the Stock Exchange.

3) Allocation to Non-Residents, including Eligible NRIs, Eligible QFIs, FIIs and FVCIs registered with SEBI, applying on repatriation basis will be subject to applicable law, rules, regulations, guidelines, and approvals.

4) In terms of SEBI Regulations, Non-Retail Applicants shall not be allowed to either withdraw or lower the size of their applications at any stage.

5) Allotment status details shall be available on the website of the Registrar to the Issue.

Signing of Underwriting Agreement

Vide an Underwriting Agreement dated January 23, 2024 this Offer is 100% Underwritten.

Filing of the Prospectus with the ROC

The Company will file a copy of the Prospectus with the ROC in terms of 26 of the Companies Act, 2013.

Pre-Issue Advertisement

Subject to Section 30 of the Companies Act, 2013 the Company shall, after registering the Prospectus with the ROC, publish a pre-Issue advertisement, in the form prescribed by the SEBI Regulations, in one widely circulated English language national daily newspaper; one widely circulated Hindi language national daily newspaper and one regional newspaper with wide circulation.

Issuance of Allotment Advice

- 1) Upon approval of the Basis of Allotment by the Designated Stock Exchange.
- 2) On the basis of approved Basis of Allotment, the Issuer shall pass necessary corporate action to facilitate the allotment and credit of equity shares. Applicants are advised to instruct their Depository Participants to accept the Equity Shares that may be allotted to them pursuant to the issue. The Lead Manager or the Registrar to the Issue will dispatch an Allotment Advice to their Applicants who have been allocated Equity Shares in the Issue. The dispatch of Allotment Advice shall be deemed a valid, binding, and irrevocable contract for the Allotment to such Applicant.
- 3) Issuer will make the allotment of the Equity Shares and initiate corporate action for credit of shares to the successful applicants Depository Account within 2 working days of the Issue Closing date. The Issuer also ensures the credit of shares to the successful Applicants Depository Account is completed within one working Day from the date of allotment, after the funds are transferred from ASBA Public Issue Account to Public Issue account of the issuer.

Designated Date

On the Designated Date, the Registrar to the Offer shall instruct the SCSBs or Sponsor Bank to unblock funds represented by allocation of Equity Shares from ASBA Accounts into the Public Offer Account.

GENERAL INSTRUCTIONS

Do's:

- Check if you are eligible to apply;
- Read all the instructions carefully and complete the applicable Application Form;
- Ensure that the details about the Depository Participant and the beneficiary account are correct as Allotment of Equity Shares will be in the dematerialized form only;
- Applicant shall use only his / her own bank account or only his / her own bank account linked UPI ID to make an application.
- Each of the Applicants should mention their Permanent Account Number (PAN) allotted under the Income Tax Act, 1961;
- Ensure that the Demographic Details are updated, true and correct in all respects;
- Ensure that the name(s) given in the Application Form is exactly the same as the name(s) in which the beneficiary account is held with the Depository Participant.
- Ensure that you have funds equal to the Application Amount in the ASBA account or UPI ID linked Bank Account maintained with the SCSB before submitting the Application Form under the ASBA process the SCSBs where the Applicant has a bank account or a UPI ID linked Bank Account, the Registered Broker (at the Broker Centre's), the RTA (at the Designated RTA Locations) or CDP (at the Designated CDP Locations);
- Instruct your respective Banks to release the funds blocked in the ASBA Account/UPI ID linked Bank Account under the ASBA process;
- Ensure that the Application Form is signed by the account holder in case the applicant is not the account holder.

- Ensure that you have mentioned the correct bank account number in the Application Form and in case of Retail Individual Applicants applying through UPI Channel, ensure that you have mentioned the correct UPI ID;
- Ensure that the Application Forms are delivered by the applicants within the time prescribed as per the Application Form and the Prospectus;
- Ensure that you have requested for and receive a TRS;
- Ensure that you request for and receive a stamped acknowledgement of the Application Form for all your application options;
- Ensure that you have correctly signed the authorization/ undertaking box in the Application Form, or have otherwise provided an authorisation to the SCSB via the electronic mode, for blocking funds in the ASBA Account/ UPI ID linked Bank Account, as the case may be, equivalent to the Application Amount mentioned in the Application Form;
- Ensure that you receive an acknowledgement from the concerned Designated Intermediary, for the submission of your Application Form; and
- The Application Form is liable to be rejected if the above instructions, as applicable, are not complied with.

Don'ts:

- Do not apply for lower than the minimum Application size;
- Do not apply for a price different from the price mentioned herein or in the Application Form;
- Do not use third party bank account or third-party UPI ID linked Bank Account for making the Application;
- Do not apply on another Application Form after you have submitted an application to the Designated Intermediary;
- Do not pay the Application Price in cash, cheque, by money order or by postal order or by stock invest;
- Do not send Application Forms by post, instead submit the Designated Intermediary only;
- Do not submit the Application Forms to any non-SCSB bank or our Company
- Do not apply on an Application Form that does not have the stamp of the relevant Designated Intermediary;
- Do not submit the application without ensuring that funds equivalent to the entire application Amount are blocked in the relevant ASBA Account;
- Do not apply for an Application Amount exceeding Rs.2,00,000 (for applications by Retail Individual Applicants);
- Do not fill up the Application Form such that the Equity Shares applied for exceeds the Issue Size and/or investment limit or maximum number of Equity Shares that can be held under the applicable laws or regulations or maximum amount permissible under the applicable regulations;
- Do not submit the GIR number instead of the PAN as the application is liable to be rejected on this ground;
- Do not submit incorrect details of the DP ID, beneficiary account number and PAN or provide details for a beneficiary account which is suspended or for which details cannot be verified by the Registrar to the Issue;
- Do not submit applications on plain paper or incomplete or illegible Application Forms in a colour prescribed for another category of Applicant; and
- Do not make Applications if you are not competent to contract under the Indian Contract Act, 1872, as amended.
- The Bid cum Application Form is liable to be rejected if the above instructions, as applicable, are not complied with.

Further, in case of any pre-issue or post issue related issues regarding share certificates/demat credit/refund orders/unblocking etc., investors shall reach out the Company Secretary and Compliance Officer.

For details of grounds for technical rejections of a Bid cum Application Form, please see the General Information Document.

Further, helpline details of the Lead Manager pursuant to the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 are set forth in the table below:

Name of the Lead Manager	Helpline (email)	Telephone
First Overseas Capital Limited	investorcomplaints@focl.in	+91 22 4050 9999

Names of entities responsible for finalising the basis of allotment in a fair and proper manner

The authorised employees of the Stock Exchange, along with the Lead Managers and the Registrar, shall ensure that the Basis of Allotment is finalised in a fair and proper manner in accordance with the procedure specified in SEBI ICDR Regulations.

Method of allotment as may be prescribed by SEBI from time to time

Our Company will not make any allotment in excess of the Equity Shares offered through the Offer through the offer document except in case of oversubscription for the purpose of rounding off to make allotment, in consultation with the Designated Stock Exchange. The allotment of Equity Shares to applicants other than to the Retail Individual Investors shall be on a proportionate basis within the respective investor categories and the number of securities allotted shall be rounded off to the nearest integer, subject to minimum allotment being equal to the minimum application size.

The allotment of Equity Shares to each Retail Individual Investor shall not be less than the minimum bid lot, subject to the availability of shares in Retail Individual Investor category, and the remaining available shares, if any, shall be allotted on a proportionate basis.

Instructions for Completing the Application Form

The Applications should be submitted on the prescribed Application Form and in BLOCK LETTERS in ENGLISH only in accordance with the instructions contained herein and in the Application Form. Applications not so made are liable to be rejected. Applications made using a third-party bank account or using third party UPI ID linked bank account are liable to be rejected. Application Forms should bear the stamp of the Designated Intermediaries. ASBA Application Forms, which do not bear the stamp of the Designated Intermediaries, will be rejected.

SEBI, vide Circular No. CIR/CFD/14/2012 dated October 04, 2012 has introduced an additional mechanism for investors to submit Application forms in public issues using the stock broker (broker) network of Stock Exchange, who may not be syndicate members in an issue with effect from January 01, 2013. The list of Broker Centre is available on the website of BSE i.e. www.bseindia.com. With a view to broad base the reach of Investors by substantial), enhancing the points for submission of applications, SEBI vide Circular No. CIR/CFD/POLICY CELL/11/2015 dated November 10, 2015 has permitted Registrar to the Issue and Share Transfer Agent and Depository Participants registered with SEBI to accept the Application forms in Public Issue with effect front January 01, 2016. The List of RTA and DPs centres for collecting the application shall be disclosed is available on the website of BSE i.e. www.bseindia.com

For details of instruction in relation to the Application Form, Applicants may refer to the relevant section of GID.

Applicant's Depository Account and Bank Details

Please note that, providing bank account details, PAN Nos, UPI ID (if applicable), Client ID and DP ID in the space provided in the application form is mandatory and applications that do not contain such details are liable to be rejected.

Applicants should note that on the basis of name of the Applicants, Depository Participant's name, Depository Participant Identification number and Beneficiary Account Number provided by them in the Application Form as entered into the Stock Exchange online system, the Registrar to the Issue will obtain front the Depository the demographic details including address, Applicants bank account details, MICR code and occupation (hereinafter referred to as 'Demographic Details'). These Demographic Details would be used for all correspondence with the Applicants including mailing of the Allotment Advice. The Demographic Details given by Applicants in the Application Form would not be used for any other purpose by the Registrar to the Issue.

By signing the Application Form, the Applicant would be deemed to have authorized the depositories to provide, upon request, to the Registrar to the Issue, the required Demographic Details as available on its records.

Submission of Application Form

All Application Forms duly completed shall be submitted to the Designated Intermediaries. The aforesaid intermediaries shall, at the time of receipt of application, give an acknowledgement to investor, by giving the counter foil or specifying the application number to the investor, as a proof of having accepted the application form, in physical or electronic mode, respectively.

Communications

All future communications in connection with Applications made in this Offer should be addressed to the Registrar to the Issue quoting the full name of the sole or First Applicant, Application Form number, Applicants Depository Account Details, number of Equity Shares applied for, date of Application form, name and address of the Designated Intermediary where the Application was submitted thereof and a copy of the acknowledgement slip.

Investors can contact the Compliance Officer or the Registrar to the Issue in case of any pre-Issue or post Issue related problems such as non-receipt of letters of allotment, credit of allotted shares in the respective beneficiary accounts, etc.

Disposal of Application and Application Moneys and Interest in Case of Delay

The Company shall ensure the dispatch of Allotment advice and give benefit to the beneficiary account with Depository Participants and submit the documents pertaining to the Allotment to the Stock Exchange within two working days of date of Allotment of Equity Shares.

The Company shall use best efforts to ensure that all steps for completion of the necessary formalities for listing and commencement of trading at SME Platform of BSE where the Equity Shares are proposed to be listed are taken within 3 working days from Issue Closing Date.

In accordance with the Companies Act, the requirements of the Stock Exchange and the SEBI Regulations, the Company further undertakes that:

1. Allotment shall be made within one (1) day of the Issue Closing Date;
2. Giving of Instructions for refund by unblocking of amount via ASBA not later than 2 (two) working days of the Issue Closing Date, would be ensured; and
3. If such money is not repaid within prescribed time from the date our Company becomes liable to repay it, then our Company and every officer in default shall, on and from expiry of prescribed time, be liable to repay such application money, with interest as prescribed under SEBI (ICDR) Regulations, the Companies Act, 2013 and applicable law. Further, in accordance with Section 40 of the Companies Act, 2013, the Company and each officer in default may be punishable with fine and/or imprisonment in such a case.

Impersonation

Attention of the Applicants is specifically drawn to the provisions of sub-section (1) of Section 38 of the Companies Act, 2013 which is reproduced below:

"Any person who–

- (a) makes or abets making of an application in a fictitious name to a company for acquiring, or subscribing for, its securities; or*
- (b) makes or abets making of multiple applications to a company in different names or in different combinations of his name or surname for acquiring or subscribing for its securities; or*
- (c) otherwise induces directly or indirectly a company to allot, or register any transfer of, securities to him, or to any other person in a fictitious name, shall be liable for action under Section 447 of Companies Act, 2013 and shall be treated as Fraud."*

Mode of Refunds

- a) In case of ASBA Applicants:** Within 2 (two) Working Days of the Issue Closing Date, the Registrar to the Issue may give instructions to SCSBs for unblocking the amount in ASBA Account on unsuccessful Application, for any excess amount blocked on Application, for any ASBA application withdrawn, rejected or unsuccessful or in the event of withdrawal or failure of the Offer
- b)** In the case of Applications from Eligible NRIs and FPIs, refunds, if any, may generally be payable in Indian Rupees only and net of bank charges and/ or commission. If so desired, such payments in Indian Rupees may be converted into U.S. Dollars or any other freely convertible currency as may be permitted by the RBI at the rate of exchange prevailing at the time of remittance and may be dispatched by registered post. The Company may not be responsible for loss, if any, incurred by the Bidder on account of conversion of foreign currency.
- c)** In case of Other Investors: Within two Working Days of the Issue Closing Date, the Registrar to the Issue may dispatch the refund orders for all amounts payable to unsuccessful Investors. In case of Investors, the Registrar to the Offer may obtain from the depositories, the Bidders' bank account details, including the MICR code, on the basis of the DP ID, Client ID and PAN provided by the Investors in their Investor Application Forms for refunds. Accordingly, Investors are advised

to immediately update their details as appearing on the records of their depositories. Failure to do so may result in delays in dispatch of refund orders or refunds through electronic transfer of funds, as applicable, and any such delay may be at the Investors' sole risk and neither the Issuer, the Registrar to the Issue, the Escrow Collection Banks, may be liable to compensate the Investors for any losses caused to them due to any such delay, or liable to pay any interest for such delay.

Mode of making refunds for Applicants other than ASBA Applicants

The payment of refund, if any, may be done through various modes as mentioned below:

(i) NECS - Payment of refund may be done through NECS for Applicants having an account at any of the centers specified by the RBI. This mode of payment of refunds may be subject to availability of complete bank account details including the nine-digit MICR code of the Bidder as obtained from the Depository;

(ii) NEFT - Payment of refund may be undertaken through NEFT wherever the branch of the Bidders' bank is NEFT enabled and has been assigned the Indian Financial System Code ("IFSC"), which can be linked to the MICR of that particular branch. The IFSC Code may be obtained from the website of RBI as at a date prior to the date of payment of refund, duly mapped with MICR numbers. Wherever the Applicants have registered their nine-digit MICR number and their bank account number while opening and operating the demat account, the same may be duly mapped with the IFSC Code of that particular bank branch and the payment of refund may be made to the Bidders through this method. In the event NEFT is not operationally feasible, the payment of refunds may be made through any one of the other modes as discussed in this section;

(iii) Direct Credit – Applicants having their bank account with the Refund Banker may be eligible to receive refunds, if any, through direct credit to such bank account;

(iv) RTGS – Applicants having a bank account at any of the centres notified by SEBI where clearing houses are managed by the RBI, may have the option to receive refunds, if any, through RTGS. The IFSC code shall be obtained from the demographic details. Investors should note that on the basis of PAN of the bidder, DP ID and beneficiary account number provided by them in the Application Form, the Registrar to the Issue will obtain from the Depository the demographic details including address, Bidders account details, IFSC code, MICR code and occupation (hereinafter referred to as "Demographic Details"). The bank account details for would be used giving refunds. Hence, Applicants are advised to immediately update their bank account details as appearing on the records of the Depository Participant. Please note that failure to do so could result in delays in dispatch/ credit of refunds to Applicants at their sole risk and neither the Lead Manager or the Registrar to the Issue or the Escrow Collection Bank nor the Company shall have any responsibility and undertake any liability for the same;

(v) Please note that refunds, on account of our Company not receiving the minimum subscription, shall be credited only to the bank account from which the Bid Amount was remitted to the Escrow Bank. For details of levy of charges, if any, for any of the above methods, Bank charges, if any, for cashing such cheques, pay orders or demand drafts at other centers etc. Bidders may refer to Prospectus.

INTEREST IN CASE OF DELAY IN ALLOTMENT OR REFUND

The Issuer shall make the Allotment within the period prescribed by SEBI. The Issuer shall pay interest at the rate of 15% per annum if Allotment is not made and refund instructions have not been given to the clearing system in the disclosed manner/instructions for unblocking of funds in the ASBA Account are not dispatched within such times as maybe specified by SEBI.

In case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding two Working Days from the Bid/ Issue Closing Date, the Bidder shall be compensated in accordance with applicable law. Further, Investors shall be entitled to compensation in the manner specified in the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 in case of delays in resolving investor grievances in relation to blocking/unblocking of funds.

Undertakings by our Company

We undertake as follows:

- i. That the complaints received in respect of the Issue shall be attended to by us expeditiously and satisfactorily;

- ii. That all steps will be taken for the completion of the necessary formalities for listing and commencement of trading at the Stock Exchange where the Equity Shares are proposed to be listed within the period prescribed by the Board;
- iii. That the funds required for making refunds as per the modes disclosed or dispatch of allotment advice by registered post or speed post shall be made available to the Registrar and Share Transfer Agent to the Issue by our Company;
- iv. Where refunds (to the extent applicable) are made through electronic transfer of funds, a suitable communication shall be sent to the applicant within three Working Days from the Offer Closing Date, giving details of the bank where refunds shall be credited along with amount and expected date of electronic credit of refund;
- v. That no further Issue of Equity Shares shall be made till the Equity Shares issued through the Prospectus are listed or until the Application monies are refunded on account of non-listing, under-subscription etc.;
- vi. That adequate arrangement shall be made to collect all Applications Supported by Blocked Amount while finalizing the Basis of Allotment;
- vii. That if our Company do not proceed with the Issue, the reason thereof shall be given as a public notice to be issued by our Company within two days of the Issue Closing Date. The public notice shall be issued in the same newspapers where the pre-Issue advertisements were published. The stock exchange on which the Equity Shares are proposed to be listed shall also be informed promptly;
- viii. If our Company withdraws the Issue after the Issue Closing Date, our Company shall be required to file a fresh Prospectus with the Stock exchange/RoC/SEBI, in the event our Company subsequently decides to proceed with the Offer;

UTILIZATION OF THE FRESH ISSUE PROCEEDS

The Board of Directors of our Company certifies that:

1. all monies received out of the Issue shall be transferred to a separate Bank Account other than the bank account referred to in Sub-Section (3) of Section 40 of the Companies Act, 2013;
2. details of all monies utilized out of the Issue referred above shall be disclosed and continue to be disclosed till the time any part of the Offer Proceeds remains unutilised, under an appropriate separate head in the balance sheet of our Company indicating the purpose for which such monies have been utilized;
3. details of all unutilized monies out of the Issue, if any, shall be disclosed under an appropriate separate head in the balance sheet of our Company indicating the form in which such unutilized monies have been invested; and

RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES

Foreign investment in Indian securities is regulated through the Industrial Policy, 1991 of the Government of India and FEMA. While the Industrial Policy, 1991 prescribes the limits and the conditions subject to which foreign investment can be made in different sectors of the Indian economy, FEMA regulates the precise manner in which such investment may be made. Under the Industrial Policy, unless specifically restricted, foreign investment is freely permitted in all sectors of the Indian economy up to any extent and without any prior approvals, but the foreign investor is required to follow certain prescribed procedures for making such investment. The RBI and the concerned ministries/departments are responsible for granting approval for foreign investment.

The Government has from time to time made policy pronouncements on FDI through press notes and press releases. The Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India (*earlier known as Department of Industrial Policy and Promotion*) (“**DPIIT**”), issued the FDI Policy, which is effect from October 15, 2020, which subsumes and supersedes all previous press notes, press releases and clarifications on FDI issued by the DPIIT that were in force and effect prior to October 15, 2020. The FDI Policy will be valid until the DPIIT issues an updated circular. FDI in companies engaged in sectors/ activities which are not listed in the FDI Policy is permitted up to 100% of the paid up share capital of such company under the automatic route, subject to compliance with certain prescribed conditions.

The transfer of shares between an Indian resident and a non-resident does not require the prior approval of the RBI, provided that (i) the activities of the investee company are under the automatic route under the FDI policy and transfer does not attract the provisions of the Takeover Regulations; (ii) the non-resident shareholding is within the sectoral limits under the FDI policy; and (iii) the pricing is in accordance with the guidelines prescribed by the SEBI/RBI.

As per the existing policy of the Government of India, OCBs cannot participate in this Offer.

Further, in accordance with Press Note No. 3 (2020 Series), dated April 17, 2020 issued by the DPIIT and the FEMA Non-Debt Instruments Rules, any investment, subscription, purchase or sale of equity instruments by entities of a country which shares land border with India or where the beneficial owner of an investment into India is situated in or is a citizen of any such country, will require prior approval of the Government of India, as prescribed in the FDI Policy and the FEMA Non-Debt Instruments Rules. Further, in the event of transfer of ownership of any existing or future foreign direct investment in an entity in India, directly or indirectly, resulting in the beneficial ownership falling within the aforesaid restriction/ purview, such subsequent change in the beneficial ownership will also require approval of the Government of India. Furthermore, on April 22, 2020, the Ministry of Finance, Government of India has also made similar amendment to the FEMA Rules. Each Bidder should seek independent legal advice about its ability to participate in the Offer. In the event such prior approval of the Government of India is required, and such approval has been obtained, the Bidder shall intimate our Company and the Registrar to the Offer in writing about such approval along with a copy thereof within the Issue Period.

The above information is given for the benefit of the Applicants. Our Company and the Lead Manager are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Draft Prospectus. Applicants are advised to make their independent investigations and ensure that the Applications are not in violation of laws or regulations applicable to them and do not exceed the applicable limits under the laws and regulations.

SECTION IX – MAIN PROVISIONS OF THE ARTICLES OF ASSOCIATION

PRELIMINARY

1. The regulations contained in Table F of the first schedule to the Companies Act, 2013 (hereinafter referred as Table F) shall apply to this Company in so far as are applicable to Public Company and are not amended, modified or substituted by the following Articles, which shall be the regulations for the management of the company.

INTERPRETATION

2. (1) In these Regulations:-
 - (a) "Company" means **CLINITECH LABORATORY LIMITED**.
 - (b) "Office" means the Registered Office of the Company.
 - (c) "Act" means the Companies Act, 2013 and any statutory modification thereof.
 - (d) "Seal" means the Common Seal of the Company.
 - (e) "Directors" means the Directors of the Company and includes persons occupying the position of the Directors by whatever names called.
- (2) *Unless the context otherwise requires, words or expressions contained in these Articles shall have the same meaning as in the Act, or any statutory modification thereof in force at the date on which these Articles become binding on the Company.*

PUBLIC COMPANY

3. The company is a Public Company within the meaning of section 2(71) of the Companies Act, 2013.

SHARE CAPITAL AND VARIATION OF RIGHTS

4. The Authorised Share Capital of the Company shall be such amounts and be divided into such shares as may, from time to time, be provided in Clause V of the Memorandum of Association with power to increase or reduce the capital in accordance with the Company's regulations and legislative provisions for the time being in force in that behalf with the powers to divide the Share Capital, whether original, increased or decreased into several classes and attach thereto respectively such ordinary, preferential or special rights and conditions in such manner as may for the time being be provided by the Regulations of the Company and allowed by law.
- 4.1 The company shall have power, subject to and in accordance with applicable provisions of the Act, to issue further shares and securities, as it may consider appropriate to -
 - (i) person who, at the date of offer, are holders of the equity shares of the company; such offer shall be deemed to include a right exercisable by the person concerned to renounce the shares offered to him or any of them in favour of any other person; or
 - (ii) employees under any scheme of employees' stock option;
 - (iii) any person, whether or not those persons include the persons referred to in sub article (i) and (ii) above.

Subject to and in accordance with the Companies Act 2013 and the rules made thereunder, a further issue of shares including by way of preferential offer or private placement, may be made in the manner and on terms and conditions including imposition of any restrictions on such shares, as determined by the Board or any of its Committee, in case the power is delegated to such Committee.

5. The business of the Company may be commenced soon after the incorporation of the Company as and when the Directors shall think fit notwithstanding that part of the shares have been allotted.
6. The shares shall be under the discretionary control of the Directors who may allot or otherwise dispose of the same.
7. The Board of Directors of the company may decide and approve to issue fully paid up bonus shares to the members of the company as and when they deem fit and expedient to do so.
8. The certificate for shares registered in the name of two or more persons shall be delivered to the first person named in the register and this shall be sufficient delivery to all such holders.
9. (i) Every person whose name is entered as a member in the register of members shall be entitled to receive within two months after incorporation, in case of subscribers to the memorandum or after allotment or within one month after the application for the registration of transfer or transmission or within such other period as the conditions of issue shall be provided,
 - (a) One certificate for all his shares without payment of any charges; or
 - (b) Several certificates, each for one or more of his shares, upon payment of twenty rupees for each certificate after the first.
- (ii) Every certificate shall be under the seal and shall specify the shares to which it relates and the amount paid-up thereon.
- (iii) In respect of any share or shares held jointly by several persons, the company shall not be bound to issue more than one certificate, and delivery of a certificate for a share to one of several joint holders shall be sufficient delivery to all such holders.
10. (i) If any share certificate be worn out, defaced, mutilated or torn or if there be no further space on the back for endorsement of transfer, then upon production and surrender thereof to the Company, a new certificate may be issued in lieu thereof, and if any certificate is lost or destroyed then upon proof thereof to the satisfaction of the Company and on execution of such indemnity as the Company deems adequate, a new certificate in lieu thereof shall be given. Every certificate under this Article shall be issued on payment of twenty rupees for each certificate.
- (ii) The provisions of Articles (9) and (10) shall mutatis mutandis apply to debentures of the Company.
11. Except as required by law, no person shall be recognised by the company as holding any share upon any trust, and the company shall not be bound by, or be compelled in any way to recognise (even when having notice thereof) any equitable, contingent, future or partial interest in any share, or any interest in any fractional part of a share, or (except only as by these regulations or by law otherwise provided) any other rights in respect of any share except an absolute right to the entirety thereof.
12. (i) The company may exercise the powers of paying commissions conferred by sub-section (6) of section 40, provided that the rate per cent or the amount of the commission paid or agreed to be paid shall be disclosed in the manner required by that section and rules made thereunder.
- (ii) The rate or amount of the commission shall not exceed the rate or amount prescribed in rules made under sub-section (6) of section 40.
- (iii) The commission may be satisfied by the payment of cash or the allotment of fully or partly paid shares or partly in the one way and partly in the other.

13. (i) If at any time the share capital is divided into different classes of shares, the rights attached to any class (unless otherwise provided by the terms of issue of the shares of that class) may, subject to the provisions of section 48, and whether or not the company is being wound up, be varied with the consent in writing of the holders of three-fourths of the issued shares of that class, or with the sanction of a special resolution passed at a separate meeting of the holders of the shares of that class.
- (ii) To every such separate meeting, the provisions of these regulations relating to general meetings shall mutatis mutandis apply, but so that the necessary quorum shall be at least two persons holding at least one-third of the issued shares of the class in question.
14. The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking pari passu therewith.
15. Subject to the provisions of section 55, any preference shares may, with the sanction of an ordinary resolution, be issued on the terms that they are to be redeemed on such terms and in such manner as the company before the issue of the shares may, by special resolution, determine.

LIEN

16. The Company shall have a first and paramount lien upon all the shares (not being a fully paid up share) registered in the name of such member (whether solely or jointly with others) and upon the proceeds of sale thereof for his debts, liabilities and engagements (whether presently payable or not) solely or jointly with any other person, to or with the Company, whether the period for the payment, fulfillment or discharge thereof shall have actually alien or not and such lien shall extend to all dividends, from time to time, declared in respect of shares, subject to section 124 and bonuses declared from time to time in respect of such shares under the Act. The Board of Directors may at any time declare any shares to be wholly or in part exempt from the provisions of this clause.

CALLS ON SHARES AND TRANSFER OF SHARES

17. The Directors are empowered to make calls on members of any amount payable at a time fixed by them.
18. Any member desiring to sell any of his shares must notify the Board of Directors of the number of shares, the fair value and the name of the proposed transferee and the Board must offer to the other shareholders the shares offered at the fair value and if the offer is accepted, the shares shall be transferred to the acceptor and if the shares or any of them, are not so accepted within one month from the date of notice to the Board the members proposing transfers shall, at any time within three months afterwards, be at liberty, subject to Articles 19 and 20 hereof, to sell and transfer the shares to any persons at the same or at higher price. In case of any dispute, regarding the fair value of the share it shall be decided and fixed by the Company's Auditor whose decision shall be final.
19. No transfer of shares shall be made or registered without the previous sanction of the Directors, except when the transfer is made by any member of the Company to another member or to a member's wife or child or children or his heirs and the Directors may decline to give such sanction without assigning any reason subject to Section 58 and 59 of the Act.
20. The Directors may refuse to register any transfer of shares (1) where the Company has a lien on the shares or (2) where the shares are not fully paid up shares, subject to Section 58 and 59 of the Companies Act, 2013.
21. Subject to Section 58 and 59 of the Act, the Directors may in their discretion, without assigning any reason, refuse to register the transfer of any shares to any person, whom it shall, in their opinion, be undesirable in the interest of the Company to admit to membership.
22. At the death of any member his or her shares be recognized as the property of his or her heirs upon production of reasonable evidence as may be required by the Board of Directors.

23. The instrument of transfer must be accompanied by the certificates of shares.

TRANSMISSION OF SHARES

24. (i) On the death of a member, the survivor or survivors where the member was a joint holder, and his nominee or nominees or legal representatives where he was a sole holder, shall be the only persons recognized by the company as having any title to his interest in the shares.
- (ii) Nothing in clause (i) shall release the estate of a deceased joint holder from any liability in respect of any share which had been jointly held by him with other persons.
25. (i) Any person becoming entitled to a share in consequence of the death or insolvency of a member may, upon such evidence being produced as may from time to time properly be required by the Board and subject as hereinafter provided, elect, either
- (a) To be registered himself as holder of the share; or
- (b) To make such transfer of the share as the deceased or insolvent member could have made.
- (ii) The Board shall, in either case, have the same right to decline or suspend registration as it would have had, if the deceased or insolvent member had transferred the share before his death or insolvency.
26. (i) If the person so becoming entitled shall elect to be registered as holder of the share himself, he shall deliver or send to the company a notice in writing signed by him stating that he so elects.
- (ii) If the person aforesaid shall elect to transfer the share, he shall testify his election by executing a transfer of the share.
- (iii) All the limitations, restrictions and provisions of these regulations relating to the right to transfer and the registration of transfers of shares shall be applicable to any such notice or transfer as aforesaid as if the death or insolvency of the member had not occurred and the notice or transfer were a transfer signed by that member.
27. A person becoming entitled to a share by reason of the death or insolvency of the holder shall be entitled to the same dividends and other advantages to which he would have been entitled if he were the registered holder of the share, except that he shall not, before being registered as a member in respect of the share, be entitled in respect of it to exercise any right conferred by membership in relation to meetings of the company:

Provided that the Board may, at any time, give notice requiring any such person to elect either to be registered himself or to transfer the share, and if the notice is not complied with within ninety days, the Board may thereafter withhold payment of all dividends, bonuses or other monies payable in respect of the share, until the requirements of the notice have been complied with.

FORFEITURE OF SHARES

28. If a member fails to pay any call, or installment of a call, on the day appointed for payment thereof, the Board may, at any time thereafter during such time as any part of the call or installment remains unpaid, serve a notice on him requiring payment of so much of the call or installment as is unpaid, together with any interest which may have accrued.
29. The notice aforesaid shall:
- (a) Name a further day (not being earlier than the expiry of fourteen days from the date of service of the notice) on or before which the payment required by the notice is to be made; and
- (b) State that, in the event of non-payment on or before the day so named, the shares in respect of which the call was made shall be liable to be forfeited.

30. If the requirements of any such notice as aforesaid are not complied with, any share in respect of which the notice has been given may, at any time thereafter, before the payment required by the notice has been made, be forfeited by a resolution of the Board to that effect.
31. (i) A forfeited share may be sold or otherwise disposed of on such terms and in such manner as the Board thinks fit.
- (ii) At any time before a sale or disposal as aforesaid, the Board may cancel the forfeiture on such terms as it thinks fit.
32. (i) A person whose shares have been forfeited shall cease to be a member in respect of the forfeited shares, but shall, notwithstanding the forfeiture, remain liable to pay to the company all monies which, at the date of forfeiture, were presently payable by him to the company in respect of the shares.
- (ii) The liability of such person shall cease if and when the company shall have received payment in full of all such monies in respect of the shares.
33. (i) A duly verified declaration in writing that the declarant is a director, the manager or the secretary, of the company, and that a share in the company has been duly forfeited on a date stated in the declaration, shall be conclusive evidence of the facts therein stated as against all persons claiming to be entitled to the share.
- (ii) The company may receive the consideration, if any, given for the share on any sale or disposal thereof and may execute a transfer of the share in favour of the person to whom the share is sold or disposed of.
- (iii) The transferee shall thereupon be registered as the holder of the share.
- (iv) The transferee shall not be bound to see to the application of the purchase money, if any, nor shall his title to the share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, sale or disposal of the share.
34. The provisions of these regulations as to forfeiture shall apply in the case of non-payment of any sum which, by the terms of issue of a share, becomes payable at a fixed time, whether on account of the nominal value of the share or by way of premium, as if the same had been payable by virtue of a call duly made and notified.

ALTERATION OF CAPITAL

35. The company may, from time to time, by ordinary resolution increase the share capital by such sum, to be divided into shares of such amount, as may be specified in there solution.
36. Subject to the provisions of section 61, the company may, by ordinary resolution,
- (a) Consolidate and divide all or any of its share capital into shares of larger amount than its existing shares;
- (b) Convert all or any of its fully paid-up shares into stock, and reconvert that stock into fully paid-up shares of any denomination;
- (c) Sub-divide its existing shares or any of them into shares of smaller amount that is fixed by the memorandum;
- (d) Cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person.
37. Where shares are converted into stock

- (a) the holders of stock may transfer the same or any part thereof in the same manner as, and subject to the same regulations under which, the shares from which the stock arose might before the conversion have been transferred, or as near thereto as circumstances admit:

Provided that the Board may, from time to time, fix the minimum amount of stock transferable, so, however, that such minimum shall not exceed the nominal amount of the shares from which the stock arose.

- (b) the holders of stock shall, according to the amount of stock held by them, have the same rights, privileges and advantages as regards dividends, voting at meetings of the company, and other matters, as if they held the shares from which the stock arose; but no such privilege or advantage (except participation in the dividends and profits of the company and in the assets on winding up) shall be conferred by an amount of stock which would not, if existing in shares, have conferred that privilege or advantage.
- (c) Such of the regulations of the company as are applicable to paid-up shares shall apply to stock and the words “share” and “shareholder” in those regulations shall include “stock” and “stock-holder” respectively.

38. The company may, by special resolution, reduce in any manner and with, and subject to, any incident authorised and consent required by law,

- (a) Its share capital;
- (b) Any capital redemption reserve account; or
- (c) Any share premium account.

CAPITALISATION OF PROFITS

39. (i) The Company in general meeting may, upon the recommendation of the Board, Resolve:

- (a) that it is desirable to capitalise any part of the amount for the time being standing to the credit of any of the company’s reserve accounts, or to the credit of the profit and loss account, or otherwise available for distribution; and
 - (b) that such sum be accordingly set free for distribution in the manner specified in clause (ii) amongst the members who would have been entitled thereto, if distributed by way of dividend and in the same proportions.
- (ii) The sum aforesaid shall not be paid in cash but shall be applied, subject to the provision contained in clause (iii) either in or towards
- (a) Paying up any amounts for the time being unpaid on any shares held by such members respectively;
 - (b) Paying up in full, unissued shares of the company to be allotted and distributed, credited as fully paid-up, to and amongst such members in the proportions aforesaid;
 - (c) Partly in the way specified in sub-clause (A) and partly in that specified in sub-clause (B);
 - (d) A securities premium account and a capital redemption reserve account may, for the purposes of this regulation, be applied in the paying up of unissued shares to be issued to members of the company as fully paid bonus shares;
 - (e) The Board shall give effect to the resolution passed by the company in pursuance of this regulation.

40. (i) Whenever such a resolution as aforesaid shall have been passed, the Board shall

- (a) make all appropriations and applications of the undivided profits resolved to be capitalised thereby, and all allotments and issues of fully paid shares if any; and
- (b) generally do all acts and things required to give effect thereto.

- (ii) The Board shall have power
 - (a) to make such provisions, by the issue of fractional certificates or by payment in cash or otherwise as it thinks fit, for the case of shares becoming distributable in fractions; and
 - (b) to authorise any person to enter, on behalf of all the members entitled there to, into an agreement with the company providing for the allotment to them respectively, credited as fully paid-up, of any further shares to which they may be entitled upon such capitalisation, or as the case may require, for the payment by the company on their behalf, by the application thereto of their respective proportions of profits resolved to be capitalised, of the amount or any part of the amounts remaining unpaid on their existing shares;
- (iii) Any agreement made under such authority shall be effective and binding on such members.

BUY-BACK OF SHARES

41. Notwithstanding anything contained in these articles but subject to the provisions of sections 68 to 70 and any other applicable provision of the Act or any other law for the time being in force, the company may purchase its own shares or other specified securities.

GENERAL MEETINGS

42. All general meetings other than annual general meeting shall be called extraordinary general meeting.
43. (i) The Board may, whenever it thinks fit, call an extraordinary general meeting.
- (ii) If at any time directors capable of acting who are sufficient in number to form a quorum are not within India, any director or any two members of the company may call an extraordinary general meeting in the same manner, as nearly as possible, as that in which such a meeting may be called by the Board.

PROCEEDINGS AT GENERAL MEETINGS

44. (i) No business shall be transacted at any general meeting unless a quorum of members is present at the time when the meeting proceeds to business.
- (ii) Save as otherwise provided herein, the quorum for the general meetings shall be as provided in section 103.
45. The chairperson, if any, of the Board shall preside as Chairperson at every general meeting of the company.
46. If there is no such Chairperson, or if he is not present within fifteen minutes after the time appointed for holding the meeting, or is unwilling to act as chairperson of the meeting, the directors present shall elect one of their members to be Chairperson of the meeting.
47. If at any meeting no director is willing to act as Chairperson or if no director is present within fifteen minutes after the time appointed for holding the meeting, the members present shall choose one of their members to be Chairperson of the meeting.
48. (a) The Chairperson may, with the consent of any meeting at which a quorum is present, and shall, if so directed by the meeting, adjourn the meeting from time to time and from place to place.
- (b) No business shall be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place.
- (i) When a meeting is adjourned for thirty days or more, notice of the adjourned meeting shall be given as in the case of an original meeting.
- (ii) Save as aforesaid, and as provided in section 103 of the Act, it shall not be necessary to give any notice of an adjournment or of the business to be transacted at an adjourned meeting.

VOTING RIGHTS AND PROXY

49. Subject to any rights or restrictions for the time being attached to any class or classes of shares
- (a) on a show of hands, every member present in person shall have one vote; and
 - (b) on a poll, the voting rights of members shall be in proportion to his share in the paid-up equity share capital of the company.
50. A member may exercise his vote at a meeting by electronic means in accordance with section 108 and shall vote only once.
51. (i) In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders.
- (ii) For this purpose, seniority shall be determined by the order in which the names stand in the register of members.
52. A member of unsound mind, or in respect of whom an order has been made by any court having jurisdiction in lunacy, may vote, whether on a show of hands or on a poll, by his committee or other legal guardian, and any such committee or guardian may, on a poll, vote by proxy.
53. Any business other than that upon which a poll has been demanded may be proceeded with, pending the taking of the poll.
54. No member shall be entitled to vote at any general meeting unless all calls or other sums presently payable by him in respect of shares in the company have been paid.
55. (i) No objection shall be raised to the qualification of any voter except at the meeting or adjourned meeting at which the vote objected to is given or tendered, and every vote not disallowed at such meeting shall be valid for all purposes.
- (ii) Any such objection made in due time shall be referred to the Chairperson of the meeting, whose decision shall be final and conclusive.
56. The instrument appointing a proxy and the power-of-attorney or other authority, if any, under which it is signed or a notarised copy of that power or authority, shall be deposited at the registered office of the company not less than 48 hours before the time for holding the meeting or adjourned meeting at which the person named in the instrument proposes to vote, or, in the case of a poll, not less than 24 hours before the time appointed for the taking of the poll; and in default the instrument of proxy shall not be treated as valid.
57. An instrument appointing a proxy shall be in the form as prescribed in the rules made under section 105.
58. A vote given in accordance with the terms of an instrument of proxy shall be valid, notwithstanding the previous death or insanity of the principal or the revocation of the proxy or of the authority under which the proxy was executed, or the transfer of the shares in respect of which the proxy is given:
- Provided that no intimation in writing of such death, insanity, revocation or transfer shall have been received by the company at its office before the commencement of the meeting or adjourned meeting at which the proxy is used.

BOARD OF DIRECTORS

59. The number of Directors shall not be less than two and not more than fifteen.
60. The following shall be the First Directors of the Company.

1. Mr. Jagdish Umakant Nayak

2. Mrs. Jyoti Jagdish Nayak

61. The Directors may from time to time, appoint one or more of their body to the office of the Managing Director for one or more of the divisions of the business carried on by the Company and to enter into agreement with him in such terms and conditions as they may deem fit.
62. Subject to the provisions of section 149, the Board of Directors, at any time and from time to time, to appoint any person as additional Director in addition to the existing Director so that the total number of Directors shall not at any time exceed the number fixed for Directors in these articles. Any Directors so appointed shall hold office only until the next following Annual General Meeting but shall be eligible thereof for election as Director.
63. The Managing Director may be paid such remuneration as may, from time to time, be determined by the Board and such remuneration as may be fixed by way of salary or commission or participation in profits or partly in one way or partly in another subject to the provisions of the Companies Act, 2013.
64. The quorum necessary for the transaction, of the business of the Board meeting subject to Section 174 of the Act, shall be one third of the total strength or at least two whichever is higher. The participation of the directors by video conferencing or by other audio visual means shall also be counted for the purpose of quorum.
65. Subject to section 175 of the Act, a resolution in writing signed by the Director except a resolution which the Act specifically required it to be passed at a Board meeting shall be effective for all purposes as a resolution passed at a meeting of Directors duly called, held and constituted.

PROCEEDINGS OF THE BOARD

66. (i) The Board of Directors may meet for the conduct of business, adjourn and otherwise regulate its meetings, as it thinks fit.
- (ii) A director may, and the manager or secretary on the requisition of a director shall, at any time, summon a meeting of the Board.
67. (i) Save as otherwise expressly provided in the Act, questions arising at any meeting of the Board shall be decided by a majority of votes.
- (ii) In case of an equality of votes, the Chairperson of the Board, if any, shall have a second or casting vote.
68. The continuing directors may act notwithstanding any vacancy in the Board; but, if and so long as their number is reduced below the quorum fixed by the Act for a meeting of the Board, the continuing directors or director may act for the purpose of increasing the number of directors to that fixed for the quorum, or of summoning a general meeting of the company, but for no other purpose.
69. (i) The Board may elect a Chairperson of its meetings and determine the period for which he is to hold office.
- (ii) If no such Chairperson is elected, or if at any meeting the Chairperson is not present within five minutes after the time appointed for holding the meeting, the directors present may choose one of their members to be Chairperson of the meeting.
70. (i) The Board may, subject to the provisions of the Act, delegate any of its powers to committees consisting of such member or members of its body as it thinks fit.
- (ii) Any committee so formed shall, in the exercise of the powers so delegated, conform to any regulations that may be imposed on it by the Board.
71. (i) A committee may elect a Chairperson of its meetings.
- (ii) If no such Chairperson is elected, or if at any meeting the Chairperson is not present within five minutes after the time appointed for holding the meeting, the members present may choose one of their members to be Chairperson of the meeting.

72. (i) A committee may meet and adjourn as it thinks fit.
- (ii) Questions arising at any meeting of a committee shall be determined by a majority of votes of the members present, and in case of an equality of votes, the Chairperson shall have a second or casting vote.
73. All acts done in any meeting of the Board or of a committee thereof or by any person acting as a director, shall, notwithstanding that it may be afterwards discovered that there was some defect in the appointment of any one or more of such directors or of any person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such director or such person had been duly appointed and was qualified to be a director.
74. Save as otherwise expressly provided in the Act, a resolution in writing, signed by all the members of the Board or of a committee thereof, for the time being entitled to receive notice of a meeting of the Board or committee, shall be valid and effective as if it had been passed at a meeting of the Board or committee, duly convened and held.

CHIEF EXECUTIVE OFFICER, MANAGER, COMPANY SECRETARY OR CHIEF FINANCIAL OFFICER

75. Subject to the provisions of the Act,
- (i) A chief executive officer, manager, company secretary or chief financial officer may be appointed by the Board for such term, at such remuneration and upon such conditions as it may think fit; and any chief executive officer, manager, company secretary or chief financial officer so appointed may be removed by means of a resolution of the Board;
- (ii) A director may be appointed as chief executive officer, manager, company secretary or chief financial officer.
76. A provision of the Act or these regulations requiring or authorising a thing to be done by or to a director and chief executive officer, manager, company secretary or chief financial officer shall not be satisfied by its being done by or to the same person acting both as director and as, or in place of, chief executive officer, manager, company secretary or chief financial officer.

BORROWING POWERS

77. Subject to section 73 and 179 of the Companies Act, 2013, and Regulations made there under and Directions issued by the RBI the directors may, from time to time, raise or borrow any sums of money for and on behalf of the Company from the member or other persons, companies or banks or they may themselves advance money to the company on such interest as may be approved by the Directors.
78. The Directors may, from time to time, secure the payment of such money in such manner and upon such terms and conditions in all respects as they deem fit and in particular by the issue of bonds or debentures or by pledge, mortgage, charge or any other security on all or any properties of the Company (both present and future) including its uncalled capital for the time being.

OPERATION OF BANK ACCOUNTS

79. The Directors shall have the power to open bank accounts to sign cheques on behalf of the Company and to operate all banking accounts of the Company and to receive payments, make endorsements, draw and accept negotiable instruments, hundies and bills or may authorise any other person or persons to exercise such powers.

DIVIDENDS AND RESERVE

80. The company in general meeting may declare dividends, but no dividend shall exceed the amount recommended by the Board.

81. Subject to the provisions of section 123, the Board may from time to time pay to the members such interim dividends as appear to it to be justified by the profits of the company.
- 82.(i) The Board may, before recommending any dividend, set aside out of the profits of the company such sums as it thinks fit as a reserve or reserves which shall, at the discretion of the Board, be applicable for any purpose to which the profits of the company may be properly applied, including provision for meeting contingencies or for equalising dividends; and pending such application, may, at the like discretion, either be employed in the business of the company or be invested in such investments (other than shares of the company) as the Board may, from time to time, think fit.
- (ii) The Board may also carry forward any profits which it may consider necessary not to divide, without setting them aside as a reserve.
83. (i) Subject to the rights of persons, if any, entitled to shares with special rights as to dividends, all dividends shall be declared and paid according to the amounts paid or credited as paid on the shares in respect whereof the dividend is paid, but if and so long as nothing is paid upon any of the shares in the company, dividends may be declared and paid according to the amounts of the shares.
- (ii) No amount paid or credited as paid on a share in advance of calls shall be treated for the purposes of this regulation as paid on the share.
- (iii) All dividends shall be apportioned and paid proportionately to the amounts paid or credited as paid on the shares during any portion or portions of the period in respect of which the dividend is paid; but if any share is issued on terms providing that it shall rank for dividend as from a particular date such share shall rank for dividend accordingly.
84. The Board may deduct from any dividend payable to any member all sums of money, if any, presently payable by him to the company on account of calls or otherwise in relation to the shares of the company.
85. (i) Any dividend, interest or other monies payable in cash in respect of shares maybe paid by cheque or warrant sent through the post directed to the registered address of the holder or, in the case of joint holders, to the registered address of that one of the joint holders who is first named on the register of members, or to such person and to such address as the holder or joint holders may in writing direct.
- (ii) Every such cheque or warrant shall be made payable to the order of the person to whom it is sent.
86. Any one of two or more joint holders of a share may give effective receipts for any dividends, bonuses or other monies payable in respect of such share.
87. Notice of any dividend that may have been declared shall be given to the persons entitled to share therein in the manner mentioned in the Act.
88. No dividend shall bear interest against the company.

ACCOUNTS

89. (a) The Board shall, from time to time, determine whether and to what extent and at what times and places and under what conditions or regulation the accounts and books of the Company or any of them shall be open to the inspection of members (not being Director).
- (b) No members (not being Director) shall have any right of inspecting any accounts or books of account of the Company except as conferred by law or authorised by the Board or by the Company in General Meeting.
90. The Directors shall in all respect comply with the provisions of Section 128, 134, 137, 206, 207 and 208, of the Act, and Profit and Loss Account, Balance Sheet and Auditors Report and every other document required by law to be annexed or attached as the case may be, to the Balance Sheet, to be sent to every member and debenture holder of the Company and every trustee for the holders of the debentures issued by the Company at least twenty

one days before the date of Annual general meeting of the Company at which they are to be laid, subject to the provisions of section 136 of the Act.

AUDIT

91. (a) The first Auditor of the Company shall be appointed by the Board of Directors within one month from the date of registration of the Company and the Auditors so appointed shall hold office until the conclusion of the first Annual General Meeting.
- (b) At the first Annual General Meeting the Company shall appoint an Auditor to hold Office from the conclusion of the Meeting till the conclusion of its sixth Annual General Meeting and thereafter till the conclusion of every sixth meeting.
- (c) The remuneration of the Auditor shall be fixed by the Company in the Annual General Meeting or in such manner as the Company in the Annual General Meeting may determine. In case of an Auditor appointed by the Board his remuneration shall be fixed by the Board.

WINDING UP

92. Winding up when necessary will be done in accordance with the requirements of the Companies Act, 2013 or statutory modification thereto.

SECRECY

93. Subject to the provisions of law of land and the act, every manager, auditor, trustee, member of a committee, officer, servant, agent, accountant or other persons employed in the business of the company shall, if so required by the Board of Directors before entering upon his duties, sign declaration, pledging himself to observe strict secrecy respecting all transactions of the Company with its customers and the state of account with individuals and in matters relating thereto and shall by such declaration pledge himself, not to reveal any of the matters which may come to his knowledge in the discharge of his duties except when required to do so by the directors or by any court of law and except so far as may be necessary in order to comply with any of the provisions in these presents.

INDEMNITY

94. Every officer of the company shall be indemnified out of the assets of the company against any liability incurred by him in defending any proceedings, whether civil or criminal, in which judgment is given in his favour or in which he is acquitted or in which relief is granted to him by the court or the Tribunal.

SECTION X – OTHER INFORMATION

MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION

The following contracts (not being contracts entered into in the ordinary course of business carried on by our Company or contracts entered into more than two (2) years before the date of filing of this Draft Prospectus) which are or may be deemed material have been entered or are to be entered into by our Company. These contracts, copies of which will be attached to the copy of the Draft Prospectus will be delivered to the RoC for registration and also the documents for inspection referred to hereunder, may be inspected at the Registered Office of our Company located at AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Thane - 400708, Maharashtra, India, from 10.00 a.m. to 5.00 p.m. on working days from the date of the Draft Prospectus until the Issue Closing Date.

Material Contracts

1. Memorandum of Understanding dated January 23, 2024 between our Company and the Lead Manager.
2. Agreement between Bigshare Services Private Limited and our Company dated January 23, 2024 appointing them as the Registrar to the Issue.
3. Underwriting Agreement dated January 23, 2024 between our Company and Underwriter.
4. Market Making Agreement dated January 23, 2024 between our Company, Lead Manager and Market Maker.
5. Tripartite agreement among the NSDL, our Company and Registrar to the Issue dated July 26, 2023.
6. Tripartite agreement among the CDSL, our Company and Registrar to the Issue dated July 20, 2023.
7. Banker to the Issue and Sponsor Bank Agreement dated [●], 2024 between our Company, the Lead Manager, Banker to the Issue and Registrar to the Issue.

Material Documents

1. Certificate of Incorporation of our Company in the name of “*Clinitech Laboratory Private Limited*” dated March 19, 2010 issued by the Registrar of Companies, Mumbai.
2. Fresh Certificate of Incorporation consequent upon conversion in the name of ‘*Clinitech Laboratory Limited*’ dated August 25, 2023 issued by the Registrar of Companies, Mumbai.
3. Certified true copy of the Memorandum and Articles of Association of our Company, as amended.
4. Certified true copy of the resolution passed at the meeting of the Board of Directors dated December 22, 2023 authorizing the Issue.
5. Certified true copy of the special resolution of the Shareholders passed at the Extraordinary General Meeting dated January 16, 2024 authorizing the Issue.
6. Statement of Tax Benefits dated January 19, 2023 issued by our Statutory Auditor, M/s. E. A. Patil & Associates LLP, Chartered Accountants.
7. Report of our Statutory Auditor, M/s. E. A. Patil & Associates LLP, Chartered Accountants dated December 15, 2023, on the Restated Financial Statements included in this Draft Prospectus.
8. Financial Indebtedness Certificate dated January 19, 2023 issued by our Statutory Auditor, M/s. E. A. Patil & Associates LLP, Chartered Accountants.
9. Promoter’s Cost of Acquisition Certificate dated January 19, 2023 issued by our Statutory Auditor, M/s. E. A. Patil & Associates LLP, Chartered Accountants.

10. KPI certificate dated January 20, 2023 issued by our Statutory Auditor, M/s. E. A. Patil & Associates LLP, Chartered Accountants.
11. Deployment certificate dated January 20, 2023 issued by our Statutory Auditor, M/s. E. A. Patil & Associates LLP, Chartered Accountants.
12. Copies of audited financial statements of our Company for Fiscal 2021, 2022, 2023 and period ended September 30, 2023.
13. Certified true copy of the resolution dated September 30 ,2023 passed at the AGM, appointing Jagdish Umakant Nayak as the Chairman and Managing Director of our Company.
14. Certified true copy of the resolution dated September 30 ,2023 passed at the AGM, appointing Jyoti Jagdish Nayak as the Whole Time Director of our Company.
15. Consents of Directors, Chief Financial Officer, Company Secretary and Compliance Officer, Statutory Auditor, Legal Advisor to the Issue, Banker to the Company, the Lead Manager, Registrar to the Issue, Underwriter, Market Maker, Bankers to the Issue, to act in their respective capacities.
16. Due Diligence Certificate dated January [●], 2024 from the Lead Manager to SEBI.
17. Copy of in-principle approval from BSE *vide* letter dated [●], 2024 to use the name of BSE in this document for listing of Equity Shares on SME Platform of BSE.

Any of the contracts or documents mentioned in the Draft Prospectus may be amended or modified at any time if so required in the interest of our Company or if required by the other parties, subject to compliance of the provisions contained in the Companies Act and other relevant statutes.

DECLARATION

We, hereby declare that all the relevant provisions of the Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Draft Prospectus is contrary to the provisions of the Companies Act, 2013 the Securities and Exchange Board of India Act, 1992 or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements are true and correct.

Signed by all the Directors of Clinitech Laboratory Limited

Name and designation	Signature
Jagdish Umakant Nayak <i>Chairman & Managing Director</i>	
Jyoti Jagdish Nayak <i>Whole Time Director</i>	
Ashutosh Jagdish Nayak <i>Non-Executive Director</i>	
Balu Laxman Kumbharkar <i>Non-Executive Independent Director</i>	
Smita Arjun Patil <i>Non-Executive Independent Director</i>	
Ravikant Moreshwar Mhatre <i>Non-Executive Independent Director</i>	

Signed by the – Chief Financial Officer	
Rahul Motilal Patil	

Place: Mumbai

Date: January 23, 2024